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Abstract 
Autosomal dominant optic atrophy (ADOA) is a mitochondrial disorder caused by a nuclear DNA 
mutation. The mutation is within the OPA1 gene, which encodes a 120kDa protein product. The 
protein, OPA1, is a dynamin like GTPase, which is responsible for fusion of mitochondria. It is located 
in the inner mitochondrial membrane and functions in conjunction with outer membrane fission 
proteins to maintain mitochondrial integrity. 
The OPA1 protein is expressed ubiquitously and heterozygous mutations cause atrophy of the optic 
nerve. The variability in human ADOA phenotype may suggest some level of susceptibility to vision 
loss whereas other individuals appear symptom free.  
The Opa1 
Q285STOP 
mouse model of ADOA provides a unique opportunity to examine the disease 
pathology with respect to mitochondrial haploinsufficiency. The tissue specificity of the disease 
suggests local control over the OXPHOS environment.  The bioenergetic activity of Opa1
Q285STOP
 
mouse is currently unestablished. The status of antioxidant activity supporting bioenergetic function 
may be vital in maintaining stability within fusion deficient mitochondria. Mitochondrial stability 
could influence the extent of reactive species, and ultimately, ATP production.  
This thesis combined the study of mitochondrial haploinsufficiency with analysis of OXPHOS and 
antioxidant levels in Opa1
Q285STOP 
mouse where a bioenergetic deficit was identified in all 
mitochondria tested. The addition of a plant derived antioxidant and its potential effects within the 
retinal environment and surrounding central nervous system of Opa1 
Q285STOP
 mouse did not appear to 
influence the extended phenotypic profile observed in this mouse model. The administration of 
resveratrol to the wild type population conferred disadvantages both In Vivo and In Vitro.
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Chapter 1 Introduction 
1.1 Autosomal dominant optic atrophy 
Mitochondrial function is imperative to survival. Any anomaly in the performance of the 
respiratory chain will result in impaired cellular behaviour. Mitochondrial disorders can be due 
to mutations in the nuclear or mitochondrial DNA that encodes the structural proteins required 
for their correct function. Disorders of mitochondrial function can display multiple neurological 
features. This is due to the high energy demands of the central nervous system (CNS). Within 
the CNS, the retina exceeds the energy requirements of the brain (Ames 2000). 
1.1.1 Mitochondrial optic neuropathies 
Retinal disorders due to mitochondrial mutations were first realised in 1988 with the link 
between mitochondrial mutation and Leber’s hereditary optic neuropathy (LHON) (Wallace et 
al. 1988). Since then, dominant optic atrophy has another significant genetically determined 
disease. Respiratory complex dysfunction resulting in reduced energy is also associated with 
other optic neuropathies. 
Chronic progressive external ophthalmoplegia (CPEO) is associated with mutations in 
mitochondrial tRNA and can occur with systemic muscle weakness. Progressive external 
ophthalmoplegia (POLG) is associated with a multitude of phenotypic disorders and relies on 
the presence of one or more mutation in mitochondrial DNA (mtDNA) (Van Goethem et al. 
2001; Horvath et al. 2006). Autosomal dominant optic atrophy (ADOA), is a mitochondrial 
disorder due to a mutation in nuclear DNA that encodes a mitochondrial specific protein. The 
spectrum of disease can include mitochondriopathies (Amati-Bonneau et al. 2005). 
1.1.2 Clinical features of ADOA 
The clinical features in ADOA are bilateral reduction of visual acuity, which is ascribed to loss 
of retinal ganglion cells and degeneration of the optic nerve. ADOA is characterised by a 
painless loss of visual acuity, tritanopia, loss of central visual field, and pallor of the optic, 
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nerve head (Votruba et al. 1998; Ferré et al. 2005). The resting energy reserves in mutant OPA1 
muscle is reduced and a reduced oxidative capacity shows a mitochondrial ATP synthesis 
depletion of 36%. There are no reported mitochondrial myopathic hallmarks such as ragged red 
fibres or deletions in mtDNA to explain these deficits. Patients have a reduced optic nerve head 
size which may be congenital (Barboni et al. 2010). Reduction in the retinal nerve fibre 
thickness (RNFT) found in ADOA may also be associated with age related loss. 
1.1.2.1 Epidemiology and demographics 
The prevalence of ADOA is 3/100,000 in most populations in the world, but can reach 1/10,000 
in Denmark where a founder effect was identified (Thiselton et al. 2002; Yu-Wai-Man P and al 
2010; Yu-Wai-Man et al. 2010) The penetrance of ADOA is about 70% (Ferré et al. 2005) 
1.1.2.2 Visual acuity and electrophysiology in ADOA 
ADOA can be characterized by an insidious onset in early childhood. The wide spectrum of 
visual impairment may result in late diagnosis but visual acuity deteriorates slowly with age. 
Deterioration in visual acuity is a bilateral progressive deterioration with moderate irreversible 
loss of vision usually associated with central visual field deficit (Cohn et al. 2008). A reduction 
in the nerve fiber layer can be identified with Optical Coherence Tomography (OCT)  
Electrophysiology demonstrates visual evoked potentials (VEPs) are typically absent or 
delayed. In subclinical or mildly affected patients, no alternation of the VEPs can be found. 
Pattern electroretinogram (PERG) shows an abnormal N95:P50 ratio, with reduction in the 
amplitude of the N95 waveform suggesting alterations of the ganglion cells layer (Holder et al. 
1998a, b) 
1.1.2.3 ADOA is a ganglion cell disease 
Mitochondrial distribution in the ganglion cell layer shows an uneven distribution between the 
unmyelinated axons and the myelinated optic nerve (Bristow et al. 2002). Haploinsufficiency 
within a high energy cellular field will result in impaired cellular function. As the function of 
the ganglion cell axon is to transport nerve impulses to the lateral geniculate nucleus in the 
thalamus, any interruption to the energy requirements will result in impaired visual processing. 
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Retinal ganglion cells are continually exposed to light which will result in an increase in 
reactive oxygen species (Osborne 2008; Wood et al. 2008). This, combined with impaired 
oxidative phosphorylation may precipitate ganglion cells to an apoptotic pathway. 
In the case of ADOA, the selective targeting of retinal ganglion cells due to disruption in the 
normal physiological mitochondrial gradient at the optic nerve head is the first step in a 
compromised retina (Osborne 2010). 
1.1.3 Clinical features of ADOA plus 
Severe multisystemic disorder may be associated with specific OPA1 GTPase mutations 
(Zeviani 2008). The disorder, called the ADOA ‘plus’ syndrome, associates optic atrophy with 
early onset in childhood, followed by chronic progressive external ophthalmoplegia, ataxia, 
sensorineural deafness, sensorimotor neuropathy, and myopathy in adult life. The energetic 
defect consists of reduced ATP synthesis and a decrease in respiratory function, observed in the 
patient’s fibroblasts compared with fibroblasts from other OPA1 patients or controls. 
Other atypical visual presentations in ADOA include sequential, acute visual loss, occurring late 
during life (Nochez et al. 2009). Some patients harbouring the pathogenic OPA1 mutation can 
be asymptomatic; at the opposite end of the variability spectrum, mutations of the OPA1 gene 
have been reported to enhance only multi systemic deficits, totally sparing the optic nerve 
(Milone et al. 2009). 
1.1.4 Molecular genetics of ADOA  
The gene for ADOA maps to chromosome 3q28-qter (Eiberg et al. 1994). Two independent 
research teams (Alexander et al. 2000; Delettre et al. 2000), identified the OPA1 gene within the 
optic atrophy 1 candidate region that encodes a polypeptide with homology to a dynamin related 
GTPase. The presence of numerous loss-of function heterozygous mutations in affected 
individuals suggests that haploinsufficiency of OPA1 is the pathogenic mechanism involved. 
Homozygous mutations in OPA1 are lethal.  
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OPA1 isoforms in man and mouse
762bp
654bp
600bp
597bp
543bp
489bp
651bp
706bp
N
CCTM 4mts 4b 5b
CCTM 4mts
CCTMmts
CCTMmts 5b
CCTMmts 4b 5b
CCTM 4mts 4b
TMmts 4b CCN
N
CCTM 4mts 5bN
N
N
N
N Tissue Opa1 Expression 
Isoform level
Brain 4 1
4b 1.2
4 4b 1.5
Heart 4 1
4 4b 0.4
4 5b 0.6
4 4b 5b 0.3
Liver 4 5b 2.5
4 4b 5b 1.5
Kidney 4 5b 4
4 4b 5b 2
Thymus 5b 2
4 5b 2
4 4b 5b 1
Levels normalised to Exon 4
           present in all tissues
Conserved sequence between homosapien (Hs) & Mus musculus (Mm)
Domain 4
Hs          KIRKALPNSEDLVKLAPDFDKI-  VESLSLLKDFFTSG
Mm        KIRKALPSSEDLASLAPDLDKI – TESLSLLKDFFTEG
Domain 4b
Hs HKLVSEVIGASDLLLLL
Mm PKLVSEVLEVSEALLLL
Domain 5b
Hs GLLGELILIQQQIQEHEEEARRAAGQYSTSYAQQKRK
Mm GLLGELILIQQQIQEHEEEARRAAGQYSTSYAQQKRK
1.2 OPA1 gene and protein 
1.2.1 OPA1 gene structure and function 
Optic atrophy 1 (OPA1), exists as eight transcript variants encoding different isoforms with 
different chain lengths. The long (L) isoforms activate mitochondrial fusion by interacting with 
Mfns. Short isoforms (S) arrest fusion and generate mitochondrial fragments (Ishihara et al. 
2006). Precursors from all eight mRNA are targeted to the mitochondria by the mitochondrial 
import signal (MIS) which is removed by mitochondrial processing peptidase (MMP) to 
resulting in L Opa1 (Satoh et al. 2003). Proteolysis on the long isoform generates either one or 
two short isoforms (Song et al. 2007).  L-Opa1 anchors to the inner membrane while the s-
isoform is attached peripherally to the IM. 
Mouse Opa1 shares 97% overall identity with the human sequence (Figure 1.1). Divergence 
within the first 200 N-terminal aminoacids results in an 87% homology with human OPA1. 
Sequence analysis of splice variants reveals that exon 4 is highly conserved across species. 
Optic Atrophy 1 (Opa1) is, to date, the only known dynamin related protein within the inner 
retina (Olichon et al. 2002) 
 
Figure 1.1 Opa1 isoforms in 
man and mouse 
Opa1 isoforms in human and 
mouse are the products of post 
translational modification in the 
mitochondria with proteases 
PARL and Yem1l. Tissue 
specificity for each isoform is 
shown 
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1.2.2 Opa1 protein structure and function 
OPA1 is a dynamin like protein within the inner membrane and is associated with cristae 
modelling and inner mitochondrial fusion. Human OPA1 protein expression levels are highest 
in tissues with increased metabolic requirements that include the brain, retina, heart and skeletal 
muscle. Despite ubiquitous expression of OPA1 in mitochondria, the ocular presentation of 
ADOA may be due to the abundant expression in the retinal ganglion cells, nerve fibre layer, 
and both inner and outer plexiform layers. Autosomal dominant optic atrophy may be associated 
with other presentations including deafness or as a multisystemic disorder (ADOA Plus).  
Opa1 isoforms are regulated by a variety of proteases that target Opa1 at specific locations 
under different cellular conditions including membrane potential, mitochondrial DNA loss and 
induction of apoptosis (Griparic et al. 2007; Ehses et al. 2009). Opa1 is cleaved by protease 
presenellin associated rhomboid-like protease (PARL) at the first cleavage site S1 in exon 5 
(Cipolat et al. 2006). Loss of PARL results in a reduction of soluble S-Opa1. Cristae junctions 
widen and accelerate the release of cytochrome c. Matrix localised m-AAA proteases AFG3L1 
and paraplegin regulate the isoforms of Opa1 through peptidase OMA1 because of cellular 
stress. 
Intermembrane space protease Yme1L also regulates Opa1 cleavage on the second 
transmembrane domain S2 at exon b.  
Alternative splicing of exons 4, 4b and 5b result in eight differentially expressed isoforms with 
open reading frames for 960–1015 amino acids (Delettre et al. 2001). Conservation of exon 4 is 
reserved for vertebrate Gnathostomata. Exon 4 is primarily responsible for maintaining the 
mitochondrial membrane and upholding the required membrane potential.  
1.2.3 Function of Opa1 
Opa1 exon 4b is crucial for the maintenance of mtDNA. Figure 1.2 shows a possible way in 
which Opa1 supports mtDNA nucleoids. Mitochondrial nucleoids are anchored to the IMM on 
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the matrix side and replicate autonomously (Gilkerson et al. 2008). The peptide generated from 
the cleavage of OPA1 is a 10kDa hydrophobic 4b isoform (Elachouri et al. 2011) 
Figure 1.2 Opa1 isoform 4b stabilises 
mtDNA nucleoids 
Exon 4b does not contain mtDNA binding 
sites but stabilises nucleoids to the inner 
membrane in an indirect method by 
supporting the nucleoid structure 
surrounding DNA. 
 
Opa1 transcripts correlate with mtDNA copy number. Exon 4b has no DNA binding motif but it 
coimmunoprecipitates with nucleoids possibly through the intermediate loop (Elachouri et al. 
2011). The DNA content of mitochondrial nucleoids could be dependent on the abundance of 
exon 4b without direct binding contact. Exon 4b may provide a membrane bound scaffold to 
anchor nucleoids thus permitting replication. An excess of mtDNA replication could potentially 
induce a bottleneck of nucleoids with negative impact on mitochondrial copy number (Khrapko 
2008). Excessive processing of Opa1 increases the levels of soluble Opa1. Soluble Opa1 is also 
increased with the induction of apoptosis due to decreased membrane potential (Duvezin-
Caubet et al. 2006; Duvezin-Caubet et al. 2007; Song et al. 2007). This fragmentation can be 
reversed with the addition of long isoform Opa1. 
1.2.4 Opa1 and control of apoptosis 
Opa1 isoforms 4 and 5b act as gatekeepers to cristae containing cytochrome c within the IMM. 
By maintaining the structural integrity of cristae, Opa1 controls the amount and duration of 
cytochrome c release in response to caspase dependent apoptotic events. Both exons 4b and 5b 
encode three transmembrane domains and a coiled coil domain predicted to homodimerise 
(Duvezin-Caubet et al. 2007; Wang et al. 2011).  Prohibitins are essential for Opa1-dependent 
formation of mitochondrial cristae (Merkwirth et al. 2008). Deletion of Phb2 leads to a selective 
loss of long isoforms Opa1, resulting in aberrant cristae morphogenesis, impaired cellular 
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L Opa1
S Opa1
Cytochrome c
proliferation, and resistance to apoptosis. Figure 1.3 depicts both isoforms of Opa1maintaining 
cristae structure. 
 
Figure 1.3 Opa1 maintains cristae structure 
Cristae structure is maintained by docking two 
long isoforms and one short isoform. This 
prevents the release of cytochrome c and 
initiation of cell death through the apoptotic 
pathway 
 
1.2.5 Opa1 and stability of electron transport chain  
Opa1 maintains cristae shape and integrity. The electron transport chain is embedded in the 
cristae and relies on an equilibrium allowing fluidity of individual complexes according to 
requirements. The transfer of electrons requires the correct positioning of each complex to 
maintain a homogenous flow through the chain. By exerting a degree of stability in the 
mitochondrial matrix, Opa1 ensures a consistent flow of electrons in the generation of ATP. 
This in turn allows for paired electron transfer to molecular oxygen.  
1.2.6 Opa1 mutations in ADOA 
The mutations associated with OPA1 include both missense and deletions (Alexander et al. 
2000; Delettre et al. 2000). Truncation of OPA1 protein resulting in loss of functional domains 
of GTPase within exons 8 – 15 have also been reported (Delettre et al. 2001). Figure 1.4 is a 
schematic representation of the spectrum of mutations found in the OPA1 gene of ADOA. A 
coupling defect in the electron transport chain in LHON results in a reduction in ATP synthesis 
(Chevrollier et al. 2008). Similar analysis in mutant Opa1 fibroblasts fail to show complex I 
reduction but do demonstrate a complex IV deficit of 25% activity (Milone et al. 2009). OPA1 
is expressed in the inner ear (ADOAD), which may explain some rare cases of optic atrophy and 
deafness occurring in patients with a specific R445H mutation (Amati-Bonneau et al. 2005; 
Amati-Bonneau et al. 2009). 
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Figure 1.4 Mutations associated with ADOA 
There are over 220 confirmed mutations associated with OPA1 in ADOA. 
Approximately 28% are deletions, 68% substitutions and 4% insertions. Frame shift 
mutations with one mutant OPA1 allele result in haploinsufficiency. Missense mutations 
cause loss of function with abnormal OPA1 replication. Mutations within specific 
functional regions include GTPase 32%, dynamin related 32%, basic domain 30% and 
others 6% 
 
1.3 Retinal ganglion cells 
Classification of retinal ganglion cells (RGC) includes the cell size parameters and the extent of 
its stratification within the inner plexiform layer.  
1.3.1 Mammalian retinal ganglion cells 
Human ganglion cell numbers vary from between 1,000,000 to 1,600,000 (Provis and van Driel 
1985) The vertebrate retina has midget ganglion cells which project to the parvocellular layer of 
the lateral geniculate nucleus, which comprise 80% of the total ganglion cell population. They 
are responsible for spatial resolution, visual acuity colour vision, texture and contrast sensitivity.  
Parasols which project to the magnocellular layer of the lateral geniculate nucleus, and provide 
low spatial frequency, depth perception and motion detection.  
Bistratified ganglion cells also known as 'K' ganglion cells which project to the koniocellular 
layer of the lateral geniculate nucleus and are concerned with blue cone processing only. 
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VÖlgyi 2009
Non-image forming melanopsin ganglion cells exist at 1% of the total ganglion cell population 
(Hattar et al. 2002) They are responsible for circadian clock preservation. Mouse RGC 
populations vary from 45,000-75,000 depending on the strain (Williams et al. 1996). The 
distribution of ganglion cells in mouse retina varies between dorsoventral and naso temporal. 
Peripheral nasal retina has higher densities than other peripheral regions (Jeon et al. 1998). Sub 
populations of RGC are divided into alpha large fast transient impulse fields, beta small 
stationary fine detailed fields and motion detection. Each cell type can be ON or OFF centre 
depending on the position of its dendrites within the inner plexiform layer. Even within a 
species as regulated as laboratory mouse, there remains some variation between strains. A study 
of synaptic circuitry in mouse strain C57/Bl6 retina identified twenty-two different retinal 
ganglion cell types (Völgyi et al. 2009). Camera lucida drawings are shown in Figure 1.5. 
Coupling of ganglion cells to neighbouring amacrine cells is found in most ON centre ganglion 
cells. 
 
Figure 1.5 Mouse C57BL/6 RGC subsets 
Camera lucida drawings of representative 
ganglion cells. G1–G22 labels on the top 
represent the name of each ganglion cell subtype. 
Proximally and distally stratifying dendrites of 
bistratified ganglion cells are shown in black and 
gray, respectively. a, axon. Scale bar = 100 μm. 
 
 
Coupling of ganglion cell to ganglion cell only occurs in cells whose dendrites partly stratify 
sub lamina A. This population comprises both ON and OFF centre cells. Ganglion cells with 
dendritic arbors that are restricted to sub lamina B never show homologous coupling. 
Homologous coupling only occurs in bistratified cells. In mouse, this comprises seven of the 22 
ganglion cell types. In this population, both soma and proximal dendrite morphologies are 
identical. This demonstrates that mouse ganglion cells couple to nearby like-type ganglion cells. 
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1.3.2 RGC and stratification within the IPL 
Precise synaptic connections are critical for visual processing. Retinal ganglion cells, amacrine 
and bipolar cells establish this stereotypic pattern within the inner plexiform layer (IPL) of the 
vertebrate retina. The IP is a laminar region divided into five parallel sub lamina layers (Wässle 
2004). Direction of the cellular subsets to exact locations within the retina must account for the 
multiple morphologically distinct properties of these cells. The inner plexiform is divided into 
an upper sub lamina A (OFF) where S1 and S2 strata are located. The lower sub lamina B (ON) 
contains S3, S4 and S5 strata. 
Each drives the ganglion cell dendritic tree response (Sanes and Zipursky 2010). Dopamine 
amacrine cells are restricted to the OFF strata of S1 near the inner nuclear/inner plexiform 
border. These cells synaptically couple to melanopsin ganglion cells in the S1 layer. This allows 
dopamine to generate a diffusible gradient throughout all layers of the IPL. Stratification 
provides a separation mechanism where each cell can respond to input stimuli without loss of 
signal or response from neighbouring cells. The ganglion midget cell pathway is organized into 
ON and OFF centre populations (Devries and Baylor 1997). Invaginating bipolar cells connect 
the cone photoreceptors to the dendrites of cone midget ganglion cells in the sub lamina B of the 
IPL. Flat midget bipolar cells in the OFF pathway connect dendrites of the OFF centre midget 
ganglion cells in the sub lamina A.  
Multiple synapses are the basis and fundamental circuit connections of vision. Each stratum 
exacts a unique pair of excitatory and inhibitory patterns from a visual scene. In most cases, the 
excitatory is derived from the ON system while inhibitory pattern is derived from the OFF 
pathway (Müller and Holländer 1988). In other cases, inhibitory and excitatory patterns derive 
from the same cell (Figure 1.6) 
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S1
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Dopamine 
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S2
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Glycine amacrine
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GABA amacrine
S3
NMDA peptides
Substance P
Bipolar ON type 3
GABA amacrine
Ganglion ON
NO amacrine
S4
Bipolar ON type 4
Ganglion ON
Glycine amacrine
Peptides serotonin
S5
Bipolar ON type5
Rod bipolar
Glycine amacrine
GABA amacrine
GABAc receptors
Serotonin amacrine
 
Figure 1.6  
Organisation within the 
IPL 
Stratification within the 
inner plexiform layer 
permits multiple synapses 
of unique inhibitory or 
excitatory patterns.S1–S2 
contain mostly inhibitory 
OFF systems. S3-S5 
contain excitatory ON 
systems. Dendrites from 
ganglion cells span the 
S2-S5 strata. 
 
1.3.3 The optic nerve 
Within the prelaminar zone, axons are held loosely by glial tissue. Astrocytes segregate the 
nerve fibre into fascicles of approximately 1000 axons. Astrocytes are the only glial cells in the 
prelaminar zone. They provide a nutritional function with stores of glycogen, regulate 
potassium and support axon function. Unmyelinated prelaminar and laminar regions display a 
high concentration of mitochondrial enzyme activity due to the dynamic functional 
requirements. 
In mouse optic nerve (ON), the transition between unmyelinated and myelinated begins 0.6mm 
behind the globe. As the laminar cribrosa (LC), is absent in mouse, axons pass through an 
aperture in the sclera, which is surrounded by a ring of type three and type 1 collagen fibres 
(Hollyfield et al. 1997). Instead of connective tissue beams within the optic nerve, layers of 
elongated astrocytes transverse the ON. The arterial blood supply of the unmyelinated ON 
derives from the retinal artery. There are no choroid blood vessels. Mouse intraocular optic 
nerve is nonmyelinated and astrocytes surround the axon bundles. Oligodendrocyte cells occur 
in the retrobulbar portion where myelination of the nerve fibre begins. The transition zone is not 
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located at the level of the sclera but further posterior. Astrocyte processes transverse the non-
myelinated nerve at the level of the sclera. Distribution of mitochondria actively reflects the 
functional requirements of such a highly specialised tissue as myelinated retro laminar axon and 
unmyelinated prelaminar axon have different bio energetic properties. In mouse, unmyelinated 
regions display a high concentration of mitochondrial enzyme activity due to the dynamic 
functional requirements. Mitochondria are typically about 0.4M in diameter. RGC's must 
transport these mitochondria along their axons to distribute them along strategic, energy 
dependent locations within the optic nerve. Unmyelinated nerve by virtue of its unmyelinated 
state requires more energy to maintain its membrane potential against the plasma membrane. 
The optic nerve travels under considerable mechanical and hydrostatic force.  
Recent findings on the influence of Opa1 mutations on the size of the optic nerve head suggest 
there is a role for Opa1 in the development of the optic nerve size and conformation (Barboni et 
al. 2010). Axon diameter is critical for normal physiological function. If a reduced axon 
diameter can impede the number of mitochondria permitted to travel the length of the axon, 
areas within the nerve will suffer stress. Given that approximately 50% of the mitochondria in 
heterozygous mutant Opa1
 
are functionally compromised, this could result in narrowed axons 
carrying a backlog of mitochondria only half of which can meet the ATP demands of the 
structure. 
Other notable differences in mouse retinal structure include the lack of a macula. Mouse lens 
accounts for almost 80% of the vitreous cavity. Subsequently, the volume of vitreous is small 
compared to human. Mouse ciliary muscle is small and may have little function. The trabecular 
meshwork in mouse has smaller beams and termination in the anterior ciliary differs slightly to 
human. 
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1.4 Mitochondria 
1.4.1 Mitochondrial structure 
The primary function of mitochondria is the production of ATP. They also serve as storage 
depots for calcium required during signalling and apoptosis. Mitochondrial architecture 
determines structure-equating function. The three distinct mitochondrial compartments involved 
in specific function are the intermembrane space, intracristael space and the matrix. The size 
and shape of cristae and cristae number (Mannella 2006), combined with the ratio of ATP 
production part control events within the cell. The junction of cristae can control the movement 
of signalling molecules, enzyme substrates, and metabolites in or out of the inner boundary and 
cristae membranes (Frey et al. 2006). 
1.4.1.1 Outer mitochondrial membrane (OMM) 
The OMM encloses the entire mitochondrion and allows movement of molecules through a 
variety of channels to access the inter membrane space. The OMM is permeable to molecules of 
5000 kDa and smaller (Sorgato et al. 1987). The presence of mitochondrial signal sequence 
translocase permits entry of proteins across the membrane conserved large GTPases, mitofusin 
1 (Mfn1) and mitofusin 2 (Mfn2) are located on the OMM (Chen et al. 2003) et al., 2003). Both 
possess an N-terminal GTPase domain, two transmembrane domains and two coiled-coil motifs 
essential for protein interactions (Rojo et al. 2002) et al., 2002). Both mitofusins interlock the 
coiled coil domains with juxtaposed mitochondria to facilitate fusion. Mutations in the MFN2 
gene are associated with Charcot-Marie-Tooth axonal disease (Cartoni and Martinou 2009), 
canine-fetal neuroaxonal dystrophy (Fyfe et al. 2011) et al., 2011ba), and degenerative axon 
disease in Tyrolean Grey cattle (Drögemüller et al. 2011). 
Dynamin related 1 protein (DRP1/DLP1/DNM1) is responsible for mitochondrial fission 
(Smirnova et al. 1998). Drp1 resides in the cytosol and is recruited to the site of fused 
mitochondria through outer membrane bound Fis1. Drp1 forms polymer rings around the fused 
structures and constricts until the two mitochondria are separated. Homozygous mutations in 
DRP1 gene cause microcephaly and metabolic alterations in glucose metabolism (Waterham et 
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al. 2007). It has significant implications in the progress of Alzheimer’s disease and the presence 
of amyloid  huntingtin oligomers where Drp1 enhances its enzyme activity (Manczak et al. 
2011; Song et al. 2011). 
1.4.1.2 The intermembrane space 
The intermembrane space is the region located between the OMM and inner mitochondrial 
membrane (IMM). Several proteins are located within the intermembrane space. TOM and 
TIM23 complexes (Chacinska et al. 2005) et al., 2005), apoptosis inducing factor 
(AIF),(Lindholm et al. 2004) and copper chaperone for superoxide dismutase (Reddehase et al. 
2009). 
The translocation of proteins from the cytosol to individual mitochondrial compartments 
requires presequences that act as a direct ‘postcode’ to the correct import channels. Nuclear 
encoded proteins destined for the mitochondria are imported through the TOM complex. 
1.4.1.3 Inner mitochondrial membrane 
The IMM contains proteins required for oxidative phosphorylation (OXPHOS) with ATP 
synthase, which generates ATP in the matrix. In addition, the inner membrane is rich in 
phospholipid cardiolipin. The IMM contains porins and is impermeable to all molecules. 
Almost all ions and molecules require special membrane transporters to enter or exit the matrix. 
The IMM is compartmentalised into numerous cristae, which expand the surface area of the 
inner mitochondrial membrane, enhancing its ability to produce ATP. 
1.4.2 Mitochondrial function-the ATP powerhouse 
1.4.2.1 Oxidative phosphorylation 
All nutritionally derived substances are used to power the production of ATP within the 
mitochondria. The initial stage of digestion occurs within the gastrointestinal tract with the 
conversion of aminoacids and fatty acids to simple subunits. Polysaccharides are converted to 
simple sugars in the form of glucose. Within the cell cytoplasm, all subunits are converted from 
glucose to pyruvate through the glycolytic pathway. One molecule of glucose will hydrolyse 2 
molecules of ATP. The conversion of pyruvate and fatty acids into acetyl CoA occurs in the 
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mitochondria. Acetyl groups linked to CoA are oxidised to C02 with the generation of NADH 
and FADH2. The high energy electrons from NADH and FADH2 are transported through the 
electron transport chain to molecular oxygen. This generates a proton gradient, which drives the 
ATP synthase proton pump. Oxidative phosphorylation drives ATP synthesis from the 
phosphorylation of adenine diphosphate (ADP). 
1.4.3 Mitochondrial control of cell signalling 
Mitochondria communicate with other organelles of the cell, such as the nucleus, through a 
process called retrograde signalling to maintain cellular homeostasis and adapt to changing 
metabolic requirements within the cell (El Zein et al. 2010; Passos et al. 2010; Shah and Iqbal 
2010). Reactive oxygen species (ROS) contribute significantly to the regulation of activity of 
various signal transduction pathways and transcription factors. ROS activates members of the 
MAP kinase pathway. ROS play a role in growth factor receptor activation through oxidative 
deactivation of protein tyrosine phosphatases that maintain the growth factor receptors in an 
inactive state. Multiple transcription factors, including NF-κB (Foncea et al. 2000), AP-1 
(Martínez-Salgado et al. 2005) TGF- (Lee et al. 2007) and p53 (Preta et al. 2010) are sensitive 
to ROS. Altered activation of these signalling pathways and transcription factors results in 
changes in gene expression and initiation of different cellular events, including cell 
proliferation, senescence, apoptosis, angiogenesis, and autophagy. 
1.4.3.1 Mitochondrial control of apoptosis 
The intrinsic pathway of apoptosis is sealed by mitochondrial membrane permeability (MMP) 
(Kroemer and Blomgren 2007). MMP leads to the loss of  transmembrane potential, cession of 
ATP production and the release of several cytotoxic proteins into the cytosol (Green 2005). The 
presence of voltage gated anion channels (VDAC) is implicit in the pathway (Baines et al. 
2007) but not ultimately as responsible as was previously thought  (Adachi et al. 2004; Marin et 
al. 2007; Martin et al. 2011). VDAC isoforms may regulate Bax-Bak mediated MMP. 
Mitochondrial fission is an early trait of apoptosis, occurring simultaneously to BAX 
translocation from the cytosol and prior to caspase activation (Frank et al. 2001). 
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Within the intrinsic pathway of apoptosis, a normal cell has free anti apoptotic Bcl2, which 
binds to and sequesters proapoptotic Bax/Bak. When stressed, proapoptotic BH3 is up regulated 
and binds to anti apoptotic Bcl2 thus freeing proapoptotic Bax/Bak to promote cytochrome c 
release  (Kim et al. 2009; Mérino et al. 2009). Bax/Bak oligomerise and form pores on the outer 
mitochondrial membrane to facilitate cytochrome c release 
The morphological changes associated with early stages of apoptosis include opening and 
widening of cristae junctions within the matrix. Mobilisation of cytochrome c from open cristae 
to the IMS promptly follows its release into the cytosol  (Scorrano et al. 2002). Regulation of 
cristae opening and remodelling of cristae shape is specifically designated to particular exons 
within the Opa1 isoforms. The highly conserved exons 4 and 5b are paramount in restricting the 
extent of apoptosis by sequestering cytochrome c within the cristae under strict control of 
junctions within the cristae structures. Opa1 protein is the gatekeeper to imminent cell death. 
Once released into the cytosol, cytochrome c binds to apoptotic protease activating factor 
(APAF-1). This complex has high affinity for ATP, which forms apoptosome complexes of 
cytochrome c, APAF-1 and ATP. The apoptosome recruits executioner caspases via caspase 9 
cysteine protease that cleaves intracellular substrates inducing chromatin condensation, DNA 
fragmentation, and reduction of the nuclear membrane and formation of apoptotic cell bodies. 
Figure 1.7 summarises the combined functions of mitochondria with respect to membrane 
potential of the matrix ultimately responsible for their survival. 
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Figure 1.7 Mitochondrial function 
Dietary conversion to ATP is determined by the coupling efficiency between respiration 
and OXPHOS. If ETC is efficient at pumping hydrogen out of the matrix, and ATP 
synthesis is converting hydrogen re-entry, then the negative membrane potential is 
maintained at -240mV and there is maximum ATP with minimum heat per calorie 
consumed. Uncoupled mitochondria generate heat rather than ATP due to a reduced 
membrane potential. Maintaining a core temperature despite environmental conditions 
is critical. Coupled mitochondria in the presence of excess calories and reduced 
cytoplasmic ADP have reduced hydrogen re-entry. The membrane potential increases 
until migration of electrons through the ETC is suspended. Accumulated non-oxidised 
electrons interact with molecular oxygen to generate reactive oxygen species. 
Maintaining a healthy mitochondrial membrane potential through calorific reduction 
and increasing OXPHOS through exercise thus ensuring adequate cytoplasmic ADP 
can alleviate stress in mitochondria. 
 
1.4.4 Mitochondrial dynamics: fusion and fission 
Mitochondria are responsible for the provision of ATP, which is a fundamental requirement of 
every cell. They are also regulators of thermogenesis, oxidative phosphorylation, apoptosis and 
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a storage depot for calcium. Mitochondrial dynamics ensure quality control through fusion, 
fission and mitophagy. They are semiautonomous structures, which depend on the expression of 
both nuclear and mitochondrial DNA. Fusion and fission dynamics ensure only healthy 
mitochondria fuse. Fission acts by separating out mitochondria that are not part of the 
mitochondrial network, but exist in separate fragmented isolation. Elimination of these 
functionally deficient structures by mitophagy ensures a healthy population in each cell. 
Mitochondrial function is dependent on fission and fusion to affect change in shape according to 
their environment. Dynamin are ubiquitous enzymes that hydrolyse GTP to regulate fusion, 
fission, tubulation and elongation of cellular membranes (McNiven et al. 2000) 
1.4.4.1 Mitochondrial fusion 
Fusion is mediated by outer membrane Mfn1 and Mfn2 and inner membrane Opa1. Fusion 
facilitates the exchange of mtDNA and other vital components between mitochondria for the 
maintenance of functional mitochondria. Unbalanced fusion leads to elongation of 
mitochondria. 
Two distinct forms of mitochondrial fusion exist-transient and complete (Liu et al. 2009b). 
Transient fusion is for exchange of mitochondrial contents while maintaining mitochondrial 
morphology describes this part fusion as 'Kiss and Run' whereby only the minimal requirements 
of fusion occur. In normally functional mitochondria, complete fusion is followed by fission. 
Transient fusion is Opa1 concentration dependent. When the levels of Opa1 are too low to 
support complete fusion, transient fusion occurs. The separation phase of transient fusion 
depends on Drp1. If fusion is not complete, Drp1 binds to the fusion site and initiates fission 
promptly. Mitochondria are operating under a force generated by motor proteins and mediated 
by the anchorage to microtubules. This tension may promote scission ring formation of Drp1 as 
is described in dynamin (Roux et al. 2006). Re separation of the mitochondrial membranes 
restores the original shape and prompts recovery of movement activity. Transient fusion 
provides an efficient recharging mechanism by allowing rapid equilibrium of soluble inner 
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mitochondrial matrix proteins. Transient fusion can operate with a compromised membrane 
potential (Mattenberger et al. 2003). A summary of fusion event is shown in Figure 1.8. 
 
Figure 1.8 Fusion and 
fission 
Mitochondrial fusion of 
both outer and inner 
mitochondrial membranes 
facilitated by Mfn1/Mfn2 
and Opa1 is followed by 
Drp1 induced fission 
resulting in mitochondria 
with preserved essential 
component. 
 
 
 
1.4.4.2 Mitochondrial fission 
Fission is mediated by dynamin related protein Drp1, which is located in the cytosol. Drp1 
translocates to the outer mitochondrial membrane by the surface receptor Fis1 (James et al. 
2003).  Drp1 acts by mechanically constricting and severing mitochondria. Mitochondrial 
fission factor (Mfi) may also recruit Drp1 (Otera et al. 2010). Mitochondrial fission contributes 
to the correct distribution of mitochondria in response to the local demand for ATP and the 
elimination of damaged mitochondrial fragments through mitophagy. Anterograde transport 
(kinesin) is responsible for the correct delivery of functional mitochondria to synapses of 
neurones (Chang and Blackstone 2007). Dysfunctional mitochondria return to the soma by 
retrograde transport (dynein) (Li et al. 2004; Russo et al. 2009). 
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1.5 Animal models of Opa1 dysfunction 
1.5.1 Drosophila melanogaster 
Homologues of human OPA1 are present in Drosophila melanogaster (Yarosh et al. 2008) 
Exploiting Drosophila genetics, an enhancer trap under Eyeless promoter permitted a viable 
homozygous mutant. The dOpa1 mutation results in a dual disease phenotype- ‘rough eye’ and 
‘glossy eye’. Rough eye is the result of excess interommatidial cell apoptosis, which is 
unchecked due to reduced dOpa1. Glossy eye is due to lens depleted cone cells. Reversal of the 
phenotype was possible with the addition of ‘therapeutic’ SOD 1000units to the feed. The 
Mitosox staining signal was dramatically reduced. The addition of Vitamin E to the diet of D. 
Melanogaster enhanced the effect. These experiments demonstrated the dual pathogenic effect 
of homozygous dOpa1 mutation and the rescue of phenotype with the addition of antioxidant 
therapy. 
1.5.2 C elegans 
In C.elegans, the gene Eat-3 is homologous to human OPA1 (Kanazawa et al. 2008). Eat-3 
mutations cause fusion defects in the inner mitochondrial membrane. The 964 amino acid 
protein plays a pivotal role in pharyngeal pumping hence the name Eat. Clearly because of the 
nature of the animal, Opa1 has no role in ophthalmic conditions, however the animal model 
does provide some significant detail on the role Opa1 has in other physiological systems. The 
importance of intestinal motility in ADOA recently identified in compound heterozygous 
offspring (Schaaf et al. 2011)  might not have otherwise been associated as a function of Opa1. 
1.5.3 Mouse 
Currently there are four published mouse models of Opa1 dysfunction. Three models focus on 
ADOA. They are summarised in Table 1.1. 
1.5.3.1 Mouse Opa1mBEWI 
Mouse model Opa1
M1BEWI
 is an ENU induced single point mutation with G→A transition in 
intron 10. These amino acids are an integral part of the GTPase domain. The mutation causes a 
50% reduction in endogenous protein levels in heterozygous mice. 
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Heterozygous mutants are viable but exhibit an age-dependent loss of RGCs that eventually 
progresses to a severe degeneration of the ganglion cell and nerve fibre layer. The optic nerves 
of mutant mice showed a reduced number of axons, swelling and abnormal shape of the 
remaining axons. Mitochondria in these axons showed disorganized cristae structures (Alavi et 
al. 2007). 
ERG responses in optic nerve of two-year-old mutant Opa1
mBewi
 mice are normal. Visually 
evoked potentials (VEP), measurements reveal a significantly reduction in amplitudes indicating 
a reduction of RGC. Retrograde labelling demonstrates a significant reduction in the numbers of 
RGC in Opa1
mBewi 
mice. Long-term experiments reveal the presence of microglial cells with 
ingested fluorescent dye (Heiduschka et al. 2010). 
1.5.3.2 Mouse Opa1Q285STOP 
A truncated protein due to ENU induced C to T transition at 1051bp results in the Q285STOP 
substitution in exon 8, immediately before the central dynamin-GTPase. The heterozygous 
mutation B6; C3-OPA1Q285STOP leads to about a 50% reduction of protein in retina and all 
tissues. The mutation corresponds to several human OPA1 mutations including C→T at 868bp 
resulting in an arginine to tryptophan at 290, and G→T at 869bp causing arginine to glutamine 
at 290 mm (Ferré et al. 2005). Figure 1.9 shows a model of the Opa1
Q285STOP 
mouse gene 
structure. The homozygous mutation is embryonic lethal by 13.5 dpc. Heterozygous mutants 
show a slow onset of degeneration in the optic nerve as determined by electron microscopy. 
There is evidence of mitochondrial dysfunction with Opa1
Q285STOP 
mouse muscle fibroblast in 
culture, displaying punctuated mitochondria, with an abnormal ‘powdered’ appearance (Davies 
et al. 2007). 
Ganglion cell populations remain intact in this Opa1 model with reported increase in the 
number of autophagosomes in the RGC layer in heterozygous mutants compared with wild type 
at 24 months (White et al. 2009). Axonal degeneration is observed in both wild type and mutant 
Opa1 at 24 months, which would suggest an age related reduction in myelin.  
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Ultra structure of the optic nerve in heterozygous mutants and wild-type littermate controls at 
six, nine, and 24 months using electron microscopy demonstrate increased autophagosomes in 
the RGC layer. Signs of optic nerve degeneration are confirmed as early as 9 months in 
Opa1
Q285STOP
, with more severe degeneration by 24 months. The number of opaque 
mitochondria in the Opa1
Q285STOP
 increase at 6 and 24 months (White et al. 2009). Opa1
Q285STOP
 
mouse shows late onset pruning in the dendritic branches of ON centre RGC (Williams, Morgan 
and Votruba, 2010).The ON centre ganglion cell population are specific to sub lamina B of the 
IPL. Glutamatergic ON centre ganglion cells are non-homologous coupling cells (Völgyi et al. 
2009). As such, this may mean they can reduce the impact of impaired mitochondrial fusion by 
association with more competent dendrites. 
 
Figure 1.9 Opa1
Q285STOP
 mouse model of ADOA 
Exon 8 pre central dynamin GTPase domain C → T transition at 1051bp results in a 
premature STOP codon. Haploinsufficiency leads to 50% reduction of protein in retina 
and all tissues. 
Electrophysiological deficits OPA1
Q285STOP
 mouse model show no detectable difference in the 
major ERG components ( wave and wave) from wild type in the amplitude or time of dark-
adapted electroretinogram (ERG). Light-adapted ERG responses reveal a significant reduction 
in the photopic negative response (PhNR) amplitude in the mouse model when compared to 
wild types at the brighter intensities tested. Elements of the light-adapted VEP display 
functional deficits in electrophysiology that is consistent with ganglion cell dysfunction. The 
reduction of retinal nerve fibre layer thickness (RNFLT), combined with a PhNR below the 
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lower limits of normal does not necessarily mean visual abilities are impaired (Gowrisankaran 
et al. 2011). There are no obvious anomalies seen in 6–month Het organs when compared to 
wild type littermates(Davies et al. 2007). They demonstrate increased transfer arousal, when 
compared to wild type littermates of the same genetic background. Of equal significance, there 
is no clutch reflex anomaly in the Opa1
Q285STOP
 mouse model (personal observation). Clutch 
reflex is imperative if normal mating is to occur. 
1.5.3.3 Mouse Opa lil 
The mouse model Opa1
lil2
 was generated by chemically induced (ENU) insertion mutation with 
nucleotide substitutions (Moore et al. 2010). The mutation leads to a A to G transition in intron 
19 which results in a stable but mislocalized cytosolic protein. Homozygous Opa1
lil3
 survive 
through mid-gestation and die at E11.5. These mutants display growth retardation, 
encephalopathy, and abnormal patterning along the anterior-posterior axis, although the A-P 
axis itself remains intact. Mouse Opa1
lil3
 demonstrates mitochondrial retention of Opa1 protein 
which is essential for normal embryogenesis (Moore et al. 2010). 
1.5.3.4 Mouse Opa1delTTAG 
The most recent arrival to the ADOA mouse model array, mouse Opa1
delTTAG
 is a knock-in 
carrying the recurrent C.2708_2711delTTAG mutation (Sarzi et al. 2012). By deleting the four 
conserved base pairs in exon 27 and replacing them with a neomycin cassette. The subsequent 
recombinant stem cells were injected into 3.5 blastocysts of C57Bl6/J mice. By crossing the 
chimeras with a creatine expressing mouse line, thereby removing the neomycin cassette but 
resulting in a constitutive Opa1 knock-in mouse. This mouse model would appear to 
demonstrate all the significant hallmarks of age related decline in mitochondrial function. 
Tissue specific haploinsufficiency results in visual and auditory loss, encephalomyopathy, 
ataxia, peripheral neuropathy and cardiomyopathy. 
The authors refer to this mouse model as an accelerated aging mouse model of ADOA. 
Although the human version of ADOA may harbour multiple mitochondrial mutations as a 
direct result of impaired mitochondrial function, the vast spectrum of disorders presented in the 
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Opa1 
mBEWI
Opa1
Q285STOP
Opa1 
delTTAG
Opa1
 lil3
Mutation G → A Intron 10 C→ T Intron 8 Del exons 29-31 A→ G Intron 19
DNA c1065+ 5G>A c1051 C>T c1616splice site
GTPase domain Central dynamin Middel domain GED domain
Hom Lethal E8.5 Lethl E13.5 Lethal E10.5 Lethal E11.5
Het 50% reduction 50% reduction Developmental 
defects
Retinal Age dep  RGC RGC unaltered RGC loss Cell migration
morphology loss  periphery 11 months Cell organisation
Optic nerve Axon loss No  axon loss Axon loss  
 by 8 months by 5 months
ERG Latency normal Latency normal Latency increase
VEP normal VEP normal Reduced Amp
Reduced PNR
response
Neuro Reduced Reduced Reduced
locomotion Clutch reflex Increased Sensoneural 
Reduced body fat transfer deafness
Reduced weight  arousal Siatic nerve 
COX RFF -ve demyelination
CNS Dilated 
4th ventricle
Cardiac Cardiomyopathy Cardiac 
anomalies
with myofibrils
Ref: Moore et al., 2010, Alavi et al., 2007, Alavi et al., 2009, Heiduschka et al.,2010, Davies et al.,
White et al 2009, Yu-Wai-Man et al., 2009, Barnard et al., 2011,  Williams et al., 2011
mouse model Opa1
delTTAG
 is happily not necessarily present in Homo sapien. Electron complex 
destabilisation seen as a result of the aging process identified solitary sub complexes within the 
mitochondria. 
Table 1.1 Mouse models of 
ADOA 
 
A comparative summary of 
mouse models of ADOA with 
a summary of disease 
pathologies associated with 
each model 
 
 
 
 
 
 
1.5.4 Summary of pathophysiology of Opa1 dysfunction in animal models 
In summary, the availability of different species in the study of Opa1 has provided some 
significant information about the function of the mitochondrial GTPase in development and 
disease pathology. The generation of a viable homozygous mutant with Drosophila shows the 
dual pathologies due to a complete lack of Opa1 in the retina. The increase in ROS and response 
to exogenous addition of dietary antioxidants provides a potential therapeutic avenue. Based on 
these findings, it may be possible to reduce excess production of ROS, which may cause 
dendropathy of the IPL by the administration of antioxidant therapy. 
C.elegans provides a significant link between the pathology of Opa1 mutation and a hitherto 
unrecognised gastrointestinal disorder. Reduced gastrointestinal motility in an adult human can 
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be relieved by dietary modification before it can develop into a pathological disorder. Presence 
of the condition in a very young child could ultimately prove fatal with severe electrolyte 
imbalance in a physiology that is too immature to cope. In the field of ophthalmology, 
C.elegans may have little input, but demonstrates that tissue specific ATP level maintenance 
requires the full quota of Opa1. 
The wide variation in phenotypes as seen in both the Opa1
M1BEWI
 and in Opa1
Q285STOP
 models of 
disease would suggest there are some post translational modifications responsible for Opa1 
function. Mouse Opa1
Q285STOP
 represents the GTPase domain where there are nine registered 
point mutations, which lead to ADOA, thus making Opa1
Q285STOP
 a significantly more relevant 
mouse model for the study of ADOA. This unique feature puts Opa1
Q285STOP
 at the pinnacle in 
the study of inherited dominant optic atrophy. 
1.6 Reactive oxygen  
The term reactive oxygen species (ROS) is used to describe both oxygen free and non-radical 
derivatives of molecular oxygen. The human brain is estimated to produce 1011 free radicals a 
day (Perry et al. 2002). Any disturbance in the oxidant homeostasis can generate both radical 
and non-radical species that participate in the radical chain reactions. The reduction of oxygen 
by four one-electron steps progressively generate superoxide(O2
-
), hydrogen peroxide( H2O2), 
and the hydroxyl radical OH

 plus water.  An excess of O2
-
can damage nucleic acids and 
proteins. Reduction of this excess is by dismutation which is catalysed by superoxide dismutase 
(SOD), and produces H2O2 and water. 
1.6.1 Function of ROS 
Superoxide (O2
●-
) is a single electron oxidant and formed as a by-product within the electron 
transport chain (ETC) with one electron reduction of oxygen mediated by enzymes such as 
NAPH oxidase or circulating xanthine oxidase. The half-life of O2
●-
 depends on pH and the 
availability of SOD within the different cellular compartments. A decrease in ROS production 
will deactivate the redox sensitive signalling pathways and have deleterious effects on cell cycle 
regulation.  
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The activity of ROS during embryological development is necessary for proliferation, 
differentiation and apoptosis. Embryological control over the specific activity of ROS is vital. 
The function of ROS in primary brain-derived neural progenitors maintains a high ROS status 
and is highly responsive to ROS stimulation. 
1.7 Reactive nitrogen species 
RNS are derived from nitric oxide (NO) with O2
●-
 to form peroxynitrite (ONOO-) and nitrogen 
dioxide (NO2
●
) (Castro et al. 2011). NO2
●
 can denature DNA, proteins and fats, and are 
potentially more damaging due to their non-selective targets.  
Cellular sources of RNS are the enzyme catalysed formation of nitric oxide from arginine: NO
●
 
and O2
●-
 combine to form the oxidizing agent ONOO
-
. Peroxynitrous acid breaks down to form 
additional ROS/RNS in the form OH
●
 and NO2

 (Berski et al. 2011; Mòdol et al. 2011). 
1.7.1 Function of RNS 
There are tissue-specific NO synthases- neuronal (nNOS or NOS1) which are responsible for 
cell communication and are found within the central nervous system and skeletal muscle type II 
(Bradley et al. 2010; Hervera et al. 2010; Wisor et al. 2011). Inducible iNOS or NOS II is found 
within the immune system and cardiovascular system. It is induced on presentation of 
pathogenic lipopolysaccharide and certain cytokine subsets (Zheng and Kern 2009; Shin et al. 
2010; Zhao et al. 2010). 
1.7.2 Relevance of ROS 
While ROS are important for normal cellular activities, aberrant production of ROS, or 
diminished capacity to scavenge excessive ROS, leads to an imbalance in the redox 
environment of the cell. ROS contributes to a wide field of disease states. (Lee et al. 2002; Duan 
et al. 2003; Yang and Hekimi 2010; Jiang et al. 2011; Lee et al. 2011). ROS-scavenging enzyme 
systems are in place to detoxify mitochondrial ROS. Manganese superoxide dismutase 
(MnSOD) (Yuyama et al. 2003) is the major ROS scavenger of the mitochondria catalyzing the 
dismutation of superoxide radicals.  
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Cu2
+ Fe2
++e =
H2O
+
SOD =
OH•
OH•
CAT
= H2O O2+
H2O2
O2
- O2
-
The target of ROS is of equal significance. ROS cause loss of essential cellular functions or gain 
of toxic functions. Essential targets during ROS stress include membrane lipid integrity 
(Colquhoun 2010), and activity of ROS-susceptible proteins, including proteins required for 
translation of mRNA (Jeong et al. 2010). Protein oxidation also triggers accumulation of toxic 
protein aggregates or apoptosis. 
1.7.2.1 Superoxide anion 
O2
- is highly reactive but due to its limited lipid solubility, cannot travel far. It can generate a 
more reactive hydroxyl and hydroperoxyl radical (HO

2) by reacting with H2O2 in the Haber-
Weiss reaction. This reaction is pH dependent at acidic environment within the lysosomes. H2O2 
is a weak oxidiser but can generate OH
-
. Transition metals such as ferrous iron (Fe
2+
) and 
copper (Cu
2+
) catalyse the formation of OH
-
 with H2O2 in the Fenton reaction as depicted in 
Figure 1.10. O2
●-
 can oxidise iron sulphur (Fe-S) and release iron (Bhattacharya et al. 2011; 
Krätzer et al. 2011). O2
●- 
can also react with thiols (in vitro) but due to its negative charge is 
unable to diffuse through the membrane making it a poor signalling molecule. 
Figure 1.10 Reactive oxygen species 
 
Superoxide anion (O2
-
)is dismutated to 
H2O2 and water. It can also react with 
H2O2 to form hydroxyl radicals(OH

) in 
the Haber Weiss reaction. In the 
presence of transition metals, H2O2 can 
generate OH

 in the Fenton reaction. 
Catalase can reduce H2O2 and prevent 
hydroxyl formation. 
 
1.7.2.2 Hydrogen peroxide 
Hydrogen peroxide (H2O2) is formed from the spontaneous dismutation of O2
- 
or the action of 
SOD on O2
●-
. H2O2 is a weak oxidant and can diffuse through membranes and lipid bilayer 
possibly via aquaporin (Conde et al. 2010). DNA is a highly charged anion capable of binding 
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both Cu
2+
 and Fe
2+
 ions (Zheng et al. 2009; Zheng et al. 2010a). The catalysis by metal ions of 
H2O2 reduces it to OH
●-
. Scavengers cannot intercept OH
●-
 once it is formed directly on DNA. 
1.7.2.3 Hydroxyl radicals 
The hydroxyl radical, OH
●
, is the radical form of the hydroxide ion (OH
–
). Hydroxyl radicals 
are highly reactive and consequently short-lived. OH
●
 are produced from the decomposition of 
hydro peroxides (ROOH) (Kadiiska et al. 2005). 
Hydroxyl radical scavengers cannot intercept OH
●
 as it is formed directly on the DNA strand. 
Base pair mutations are increased with RNS (Chandor-Proust et al. 2008). Abasic sites are 
mutagenic and act to block DNA transcription and replication. The reaction of O2
-
 with 
hypochlorus acid (HOCl) and ONOOH results in further OH
●
 production (Tretyakova et al. 
2000). 
1.8 Endogenous antioxidants and defence 
Because of their potentially harmful effects, excessive ROS must be promptly eliminated from 
the cells by a variety of antioxidant defence mechanisms. Antioxidants include both hydrophilic 
and lipophilic molecules for metabolizing ROS (Pavlica and Gebhardt 2010; Rodrigo et al. 
2011; Sun et al. 2011). There are several endogenous defence mechanisms, which normally act 
in synchronicity with ROS/RNS. The up regulation of a particular ROS may be due to a 
reduction of a particular antioxidant. An overload of ROS may deplete antioxidant levels, which 
can result in further increases in ROS. The balance between ROS/antioxidant once lost, can be 
detrimental not just to the cellular environment, but to whole organs. The antioxidant system 
consists of enzymes and small antioxidant molecules. The enzymes comprise of superoxide 
dismutase enzymes (CuZnSOD and MnSOD) catalase, glutathione peroxidases, the thioredoxin, 
thioredoxin reductase pair, haem oxygenase and heat shock proteins. Small antioxidant 
molecules are glutathione, uric acid, bilirubin, glucose, vitamins A, C, E, ubiquinone, 
carotenoids and flavonoids. 
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1.8.1 Superoxide dismutase 
There are three mammalian isoforms of SOD. SOD 1 is located in the cytoplasm. The human 
form of CuZnSOD is a dimeric enzyme, which is negatively charged except for the copper 
binding site which directs O2
-
 by electrostatic facilitation. Copper ions mediate the dismutation. 
Zinc stabilises the enzyme. CuZnSOD is inhibited by cyanide. Extracellular CuZnSOD (SOD 3) 
is a tetrameric glycoprotein and exists in several forms. Most EC SOD is bound to cell surface 
proteins especially lung and blood vessel walls.  
MnSOD Manganese SOD (SOD 2) is found primarily in the mitochondria and unlike 
CuZnSOD, is pH dependent with reduced activity at alkaline pH. MnSOD of neurons serves to 
detoxify the effects of ROS, which involve catabolizing glutamate and scavenging superoxide 
anions, respectively (St-Pierre et al. 2006).  Both CuZnSOD and MnSOD enzymes catalyze one 
electron dismutation of superoxide anion to generate O2 and H2O2.  
1.8.2 Catalase 
All oxygen utilising organisms have catalase. The enzyme consists of four polypeptide chains 
each over 500 aminoacids long. It has four iron groups – porphyrin haem that allow interaction 
with H2O2 and decompose it to water and oxygen. Catalase activity is versatile at pH 6.8-7.5. 
Catalase is located in the peroxisomes of cell and the liver has the highest concentration. 
1.8.3 Glutathione peroxidase 
Glutathione peroxidase (GPx) is a selenium dependent scavenging enzyme that reduces lipid 
and hydrogen peroxides with concomitant oxidation of glutathione. Glutathione peroxidase 
(GSH-PO), is localised in both the mitochondria and cytosol (Utsunomiya et al. 1991). There 
are tissue specific glutathione peroxidases each performing individual antioxidant activities 
pertaining to their environment. GPx1 is located in the cytoplasm of virtually all cells of the 
body. It specifically targets H2O2 as its substrate. Gpx2 is found primarily in the gastrointestinal 
tract. Gpx4 is associated with lipid hydroperoxides. Mouse GPx1 knockouts are viable but 
develop cataracts early in life. Knockout for GPx4 are lethal indicating the importance of 
removal of lipid hydroperoxides (Ran et al. 2007). 
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1.9 Emerging therapies for human ADOA 
In humans, the variability of phenotype with ADOA means that it is impossible to target pre-
clinical mutant carriers before they develop symptoms. With age related disease onset, the use 
of antioxidants prior to pathology may have some application. The application of specific 
therapies targeted to individual complexes of the electron transport chain has been used in 
retinal disorders of mitochondrial origin. 
1.9.1 Co enzyme Q10 derivatives 
The first randomized controlled trial in a mitochondrial disorder of Leber’s hereditary optic 
neuropathy (LHON), used Idebenone as a therapy(Klopstock et al. 2011) Idebenone acts by 
increasing the complex I driven respiration by balancing electron fluxes between complex I and 
complex II. However not all individuals derive benefit from this. In a study of 9 LHON 
individuals, 16% showed an increase in complex I activity, whereas 42% showed a reduction 
(Angebault et al. 2011). More recently reports of a clinical trial with Idebenone in ADOA 
reported a positive outcome in 5 out of seven patients. Four of the five individuals, reported 
bilateral subjective improvement in visual function (Barboni et al. 2013). 
EPI-743 is a third generation quinone with 1000 time’s greater activity compared to Idebenone. 
EPI-743 is a ‘digital biochemical information transfer & sensing compound’ (D-BITS).and acts 
by regulating metabolic control and replenishing glutathione pools. It has been used in a variety 
of mitochondrial disorders with overall improvement in skeletal/motor coordination and 
cognitive skills (Enns et al. 2012). Phase 2 of an on-going trial continues with four in five 
individuals with LHON were successfully treated as part of a clinical trial (Sadun et al. 2012). 
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1.10 Potential therapies for Opa1Q285STOP mouse 
1.10.1 Resveratrol 
1.10.1.1 Introduction 
Resveratrol is a polyphenolic phytoalexin and a derivative of stilbene. It is produced in plants as 
a defence mechanism against fungal pathogens. The substrate for stilbene is present in most 
plants however the enzyme stilbene synthase (STS) is only in a selected few. It is found in 
peanuts, red grape and pine nuts. 
1.10.1.2 Pharmacological properties 
Resveratrol displays several pharmacological actions including non-steroid anti-inflammatory 
(Song et al. 2013) antioxidant (Goldberg 1996; Bellaver et al. 2014; Liu et al. 2014)   
chemopreventive (Jang et al. 1997; Kma 2013) cardiovascular (Mokni et al. 2013) and platelet-
inhibitory actions (Rotondo et al. 1996). The action of resveratrol in ophthalmic applications 
includes protection of the human lens from H2O2 induced oxidative stress (Zheng et al. 2010b) 
light induced damage on mouse retina (Kubota et al. 2010) inhibits diabetic induced activation 
of ganglion cell death (Kim et al. 2010) and inhibits endotoxin induced uveitis by inhibition of 
oxidation  (Kubota et al. 2009)  
1.10.1.3 Mode of action 
Resveratrol is a competitive inhibitor of phosphodiesterases (PDE). PDE are a group of 
enzymes that regulate second messengers by controlling their degradation. PDE’s are 
ubiquitously expresses with each tissue having a specific subtype. Glucagon stimulates the 
cAMP response through adenylate cyclase 1. In response to glucagon signalling, PDE-4 
degrades cAMP. Inhibition of PDE4 results in the activation of Epac1, a cAMP effector protein 
which elevates calcium levels and triggers calcium/calmodulin dependent protein kinase AMPK 
pathway (CaMKK). This protein kinase activates peroxisome proliferator-activated receptor co 
activator  PGC-1 which acts as a transcriptional co activator regulating the genetic response to 
energy metabolism. PGC1is activated during cellular stress, hypothermia and stimulates 
mitochondrial biogenesis (Liang and Ward 2006). Resveratrol induces its antioxidant properties 
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through PGC1activation. PGC1 is expressed in regions of high metabolic demand including 
heart, brain, retina, and brown adipose tissue (BAT). The tissue with highest gene expression is 
retina (Egger et al. 2012). PGC-1expression is up regulated in response to light induced 
retinal damage. Loss of function studies show increased apoptosis in PGC-1knockout mice. 
In the retina, PDE6 is restricted to the PRL where it facilitates cGMP hydrolysis following light 
stimulation (Fung et al. 1981). PDE1 is activated by calmodulin found in the OPL photoreceptor 
terminals and the IPL synaptic terminals of bipolar cells and in the dendrites of ganglion cells 
(Cooper et al. 1985). PDE 4 is the most abundant PDE expressed in the CNS  (Bolger et al. 
1996). The presence of PDE4 in RGC may suggest a direct target for transcription factor CREB 
(cAMP response element binding protein) which is down regulated in axon damage (Fernandes 
et al. 2007). A schematic representation of resveratrol mode of action is shown in Figure 1.11. 
 
Figure 1.11 Resveratrol mode of action 
Glucagon stimulates metabolic activity 
through adenylate cyclase 1.  PDE-4 in 
the presence of glucagon degrades cAMP. 
Resveratrol competitively inhibits cAMP 
degradation through the inhibition of 
PDE-4.This activates the 
CaMKKpathway. PGC-1a is responsible 
for mitochondrial biogenesis and anti-
oxidant properties associated with 
resveratrol 
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Hypothesis 
The course of disease pathology may be due to impairment in one or several aspects of 
mitochondrial activity in Opa1
Q285STOP
 mouse. The precise nature of mitochondrial impairment 
in Opa1
Q285STOP
 mouse is unknown.  Late onset ADOA may be due to a bioenergetic deficit. 
This may result in reduced tissue specific ATP quota.  
The current available literature supports the presence of excess ROS in a fusion deficient 
environment. This excess ROS may result in a reduction of endogenous antioxidant thus a 
potential trigger for disease progression. To support this hypothesis, Opa1
Q285STOP 
mouse was 
administered the phytoalexin Resveratrol with the aim of exploiting its antioxidant properties 
and investigating its potential as a therapeutic agent in the treatment of late onset ADOA 
pathology.  
By investigating several mitochondrial parameters the precise nature of disease onset may be 
determined. This study aims to compare Opa1
Q285STOP 
mouse model of ADOA with wild type 
C57BL/6 for the following investigation 
 Explore to precise physiological effects that reduced mitochondrial fusion may have in 
the phenotypic function of Opa1
Q285STOP
 mouse 
 Examine the functional activity of the electron transport chain and the presence of ATP. 
 Review the endogenous antioxidant functions in mouse model Opa1Q285STOP including 
enzyme assays for SOD and catalase activities. 
 Consider other factors which may have a direct effect on OXPHOS including any 
compensatory mechanisms to overcome fusion deficits due to Opa1 haploinsufficiency 
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Chapter 2 Chapter 2 Materials and methods 
2.1 Live mouse maintenance 
The implementation of the three ‘R’s’ (refinement reduction and replacement), is currently in 
practice and where possible an animal was culled only when necessary with forward planning of 
experimental procedures. Tissue retrieval of as many organs as possible at time of culling 
provided adequate supply of experimental material for most of  the planned experiments. 
2.1.1 Origins of Opa1Q285STOP mouse  
ENU mutagenized male C3H mouse donors were used for in vitro fertilization of female 
C57Bl/6J to generate ‘founder’ heterozygous  hybrid (B6 : C3 Opa1Q285STOP mousse line). 
Founder mice were crossed to C57Bl/6J (Charles River, East Lothian, UK) to generate a pure 
C57Bl/6J background. 
The Opa1 colony of mice was maintained by selective breeding and genotyping. With the 
assistance of the animal technicians, maintaining a healthy population of mice ensured 
continued high quality research data. Mice were maintained on a twelve-hour light cycle in 
average 10 lux intensity (max 9.3 minimum 2.66 Details of readings in Appendix A). 
Temperature and humidity were constant at 20 °C and 45% humidity.  
Enrichment is an imperative part of animal maintenance (Cancedda et al. 2004; Sale et al. 2004; 
Landi et al. 2007; Sale et al. 2007; Maruoka et al. 2009; Baroncelli et al. 2010; Sparling et al. 
2010).  This study required that the mice were aged to at least 15 months. The provision of a 
running ‘saucer’ was also a preventative measure against osteoporosis. 
 
  Mouse saucer, which provided enrichment for animals 
housed in larger mouse boxes. It was also beneficial in the 
prevention and treatment of osteoporosis by increasing bone 
density and muscle mass. This wheel allowed up to three mice at 
any one time without any risk of spinning out or damaging their 
tails.  
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2.1.2 Breeding 
Female mice were introduced to a single male for a period of five days. Male mice with good 
‘nest building’ abilities had a clear advantage over non-nest builders. Females were from the 
same litter, as this helped to synchronise their breeding cycles. 
2.1.3 Mouse genotyping 
2.1.3.1 Mouse ear punch protocol 
Following sexing, females were ear punched in rotation (L1,R1 which corresponded to left 1, 
right 1 etc., (see Figure 2.1), by scruffing gently. Ear punch tissue samples were placed in sterile 
1.5ml tubes with the corresponding mouse identity number and mouse was returned to its 
mother. 
 
Figure 2.1 Genotyping ID 
Mice were ear punched for 
identification purposes at day 
16-20.L1,R1 corresponds to 
left 1 right 1etc. 
 
 
2.1.4 DNA extraction 
Mouse ear punch samples were lysed with 50 l of 50mM sodium hydroxide ensuring the tissue 
was fully submerged in solution. Samples were transferred to a pre heated block at 95 
o
C, for 
five minutes. Following lysis, tissue was neutralised with 10l of 1M Tris-HCl pH 6.0. Samples 
were centrifuged for 5 minutes and 1l of solution was used to perform PCR reaction. 
2.1.5 Mouse Opa1 PCR 
Mouse genotyping was performed using custom primers targeting exon 8 of mouse Opa1 
sequence (Sigma Genosys)  
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Opa1 forward strand WT  TCTCTTCATGTATCTGTGGTCTTTG and  
Opa 1reverse strand WT-TTACCCGTGGTAGGTGATCATG or  
Opa 1 reverse strand Het-TTACCCGTGGTAGGTGATCATA.  
The reaction was initiated with the addition of 12.5l of Biomix to 1l of mouse DNA. 
Denaturation at 92 
o
C was followed by annealing at 56 
o
C for 1 minute and extension at 72 oC 
for 1 minute. Final extension was 72 
o
C for five minutes and kept on 4 
o
C hold until run on a 1% 
agarose gel (TC512-PCR). Products were run with a 1kb molecular marker on ethidium gel at 
~70v and bands with wild type forward and reverse primers at 180bp identified in all mice. Het 
DNA had bands with forward WT primer and reverse Het primer at the same 180bp location. 
Figure 2.2 shows a typical PCR product size following amplification with both primers. 
Figure 2.2 Opa1 DNA PCR 
Mouse ear punch DNA amplified primers specific 
to Opa1. The WT primer produced bands of 180bp 
in both phenotypes. The Het primers, amplified a 
same size DNA band but in Het DNA only. 
 
2.2 Mouse phenotyping 
2.2.1 SHIRPA analysis 
Phenotype screening procedure according to the MRC Harwell standard operating procedure, 
SHIRPA is an acronym for SmithKlein Beecham, Harwell, Imperial College, Royal London 
hospital Phenotype Assessment. It is an observational record of mouse in three stages: within a 
viewing jar, within and above the arena (Rogers et al. 1997). 
The primary screen consisted of behavioural observation. Mice were transferred in their home 
cages to the procedure room where following a period of acclimatization, were transferred 
individually to a Perspex viewing tube measuring 14cm in diameter and 18cm in height. Here, 
the mouse was analysed for body position including activity on transfer, the presence of any 
tremor, general coat appearance and the presence of any piloerection, the presence of a full 
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complement of whiskers, and whether defecation and urination occurred. The secondary screen 
assessed locomotor activity.  Mouse was transferred to the arena and observed for transfer 
arousal, gait tail elevation and touch escape response. An IHR click box was used to record the 
startle response at 30cm above the arena. The final screen assessed sensory function. Above the 
arena, handling responses to tail and scruffing and supine positioning were recorded. The 
presence of trunk curl and limb grasping was recorded on tail hold. Reflexes were examined 
including corneal, pinna and contact righting inside a Perspex tube. Any attempt at biting and 
vocalization during the screen was noted and recorded. Data was recorded on a SHIRPA test 
sheet where results were scored from ‘0’ to ‘2’ depending on the result (Appendix E contains 
test procedure sheet). 
2.2.2 Rotarod 
The rotarod procedure was carried out according to the standard operation procedure 
(http://empress.har.mrc.ac.uk/). Rotarod is a test of balance and coordination. The rotarod is a 
rotating drum with a grooved rubber surface to facilitate grip. For training of the mice, the 
rotarod was set to ‘run’ mode with a maximum speed of 8 revolutions per minute (RPM) for a 
maximum duration of 1 minute. There were three training sessions with a fifteen-minute 
interval between each test. For the test, mice were placed on the drum in ‘accelerate’ mode 
where the speed of the drum increased from 8rpm to a maximum of 40rpm within 5 minutes. 
This was a fixed acceleration of 0.133 revolutions per second for 300 seconds.  Each test lasted 
a maximum of one minute with a fifteen-minute rest session between tests. 
 
Figure 2.3 Rotarod analysis in 
mouse 
Up to five mice were tested on 
rotarod simultaneously. The test 
recorded acceleration from 0-
40rpm in 5 minutes with a 0.133 
revolution per second increase.  
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Mean Day1 Day2 Day3
RR score 1.66 1.50 1.94
D2-D1 D3-D2 D3 -D1
-0.16 0.44 0.28
D2-D1 D3-D2 D3 -D1
-0.16 0.44 0.28
On three consecutive days, a total of three rotarod trials were performed each day. Any mouse 
that fell from the rod was returned to his cage for a fifteen minute rest period before the next 
trial. Mouse body weight was recorded prior to the test. During this test, no mouse completed a 
full passive rotation. Any aberrant behaviour was recorded on the test sheet. Figure 2.3 shows 
mice performing a rotarod test. 
2.2.2.1 Mouse learning 
As many of the phenotypic tests required some learning skills, the rotarod was taken as an 
example of increased learning ability. The mean score on day 1 was subtracted from the mean 
score on day 2 as described in the schematic Figure 2.4.  It was anticipated that there may be a 
slight reduction in this value as seen in latency values in WT mice. The final score on day three 
represented the maximum trained latency a mouse can achieve and this was expected to show 
some level of improvement from day 1.   
 
Figure 2.4 Mouse learning in 
training trials 
Calculated from increased learning 
skills over a three day training 
period 
 
 
2.2.3 Tight rope test 
The rope grip test has been replaced by an instrumental analysis. (Bioseb or TSE grip strength 
meter apparatus). An automated grip strength meter measures the strength in hind and fore 
limbs. The measurements are a record of the force required in Newtons. The guidelines in the 
SOP for grip strength (http://empress.har.mrc.ac.uk/) were adhered to as far as appropriate. 
Mice were placed on a suspended rope 1cm in diameter. The tight rope was taut and not mobile. 
They were encouraged to either cling on with their front paws or to balance on both hind and 
fore paws with tester support until they gained balance. The tight rope test was placed over a 
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large tank filled with cotton wool to avoid any injuries on falling. Mice were then encouraged to 
move along the tight rope by tilting it at a 15 degree 
 
incline. Mice will travel up rather than 
down in these circumstances. With the use of all four limbs and tail, balance and coordination 
are required before movement along the rope can be performed. The speed with which the task 
is performed depends on the ability of the animal to right itself on the rope thereby facilitating 
running. Analysis of the distance travelled and whether mice gained an upright position were 
analysed. Figure 2.5 shows sequential images from the rope test. The test has been applied to 
several mouse models of disease (Hall et al. 1987; Kashiwabuchi et al. 1995; Peled-Kamar et al. 
1997; Heck et al. 2008). 
 
Figure 2.5 Tight rope testing in mouse 
Rope 1cm in diameter secured between two weighted objects. There was no slack in the 
rope which provided a firm solid base for mouse to grip. It was suspended 30cm from 
the ground which was covered with cotton wool to reduce impact on falling (A) Mice 
suspended by two limbs were observed for incorporation of (B) 4 limbs and (C) 
distance travelled on the rope plus (D) a righting ability and (E) maintaining righting 
resulting in (F) a faster exit from the rope. 
In order to optimise the tightrope test, it was observed in wild type mice that 60cm was too great 
a distance to travel on the tight rope. Mice were placed at a mid-point of the rope (at 30cm 
position), and they selected whether to move up or down hill from their position. Once they 
were confident of their balance, using all four limbs and tail, they began to travel. 
 
1cm


24cm
Tight rope Test
A B C D E F
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2.2.4 Narrow beam testing  
Traversing an elevated narrow beam suspended between platforms is a method of assessing hind 
limb motor coordination. The use of the narrow beam test can help to distinguish the difference 
between an animal who is having difficulty performing a task due to weight, vision, balance or 
lethargy. There was no physical exertion involved. Mice with reduced vision were expected to 
require a longer time to initiate crossing (freeze). Analysis of the time taken to initiate crossing 
and distance travelled across the beam were recorded. Animals with balance and coordination 
issues could be observed clearly without any other immediate stress factor to consider, such as 
falling with the provision of a step. Figure 2.6 shows the beam and sequential images taken 
from a test. 
 
Figure 2.6  Narrow beam testing in mouse 
The beam was held in position at the widest end (2.5cm) where mouse was placed on. 
The beam narrowed at 10cm with gradual reduction of width to 1cm. The platform on 
either side of the beam provided a step to stabilize balance and a visual cue of beam 
width reduction. 
The wooden beam was 60cm in length and 2.5cm wide at the nearest end tapering to 1cm width 
towards the farthest end. As the beam narrowed, provision was made for this adjustment with a 
0.6cm step, which allowed a mouse to regain his balance but required a certain amount of 
dexterity. The furthest end of the beam rested on a platform where upon reaching it, mouse was 
returned to his home cage. The surface of the beam was scored diagonally at 1cm intervals to 
aid movement along the surface. A drop tank filled with cotton wool provided a soft landing for 
any casualties. Measurements of the distance travelled and the number of paw faults (using the 
platform) were used as a gauge of balance, gait and spatial awareness. (Carter et al. 2001). 
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In order to permit all mice irrespective of weight to participate in the test, the platform was 
incorporated 10cm from the start of the beam. This permitted mouse to correct for speed his fall 
from the beam. It required that his peripheral senses were intact and that he could interpret the 
platform as a means of maintaining his position. The narrowing of the beam required the use of 
visual cues in order to realize that the space in which to walk was gradually reducing. The 
platform helped to provide these cues. At the furthest end, the beam tapered to a 1cm width. The 
test was performed once as this was adequate to provide the required information without 
learning association (Allbutt and Henderson 2007). 
2.3 Cognitive function analysis in Opa1Q285STOP mouse 
2.3.1 T maze testing 
Habituation of exploration can be induced by exposure to spatial location. The use of a T maze 
can demonstrate spontaneous alternation. Mice are started from the base of the maze and have 
free access to one of two arms of the maze. The repeat trial is carried out within one minute of 
the previous trial where the animal is given free access to both arms of the maze. Normal rodent 
behaviour suggests the animal will select the previously unvisited arm of the maze. This reflects 
an intact short term memory. The selection choice (novel/ unexplored) is called spontaneous 
alternation. The protocol was followed according to the Eumorphia Standard operating 
procedure method (www.europhenome.org). (Youn et al. 2012).The walls of the T maze were 
clear Perspex which will induce anxiety in animals and affect their performance. The floor of 
the T maze was matt wood colored coating.  
For T maze testing, mice were maintained in their home cages during acclimatisation to the 
location. Once testing began, mice were kept in a holding tank with one minute intervals 
between tests. Once the final test was complete, mouse was returned to his home cage and left 
undisturbed. In grouped cages, only the test mouse was transferred to the holding cage. The 
training period allowed the mouse to enter the T maze for a period of one minute to explore his 
surroundings. Once familiar with the surroundings, mouse was returned to his holding cage. 
Training sessions were extended over a five minute period so that when the tests began, mouse 
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was familiar with the routine. Mice were started from the base of the maze and had free access 
to one of two arms of the maze. The repeat trial was carried out within one minute of the 
previous trial where the animal was given free access to both arms of the maze. 
The time spent in the novel arm and time spent in the original arm were analyzed as functions of 
cognitive novelty recognition. A total of seven trials were performed. Figure 2.7 shows a T 
maze test in progress. Video recordings were made with a Canon Ixus 100IS 12MP 720p HD 
movie stabilized on a tripod and attached directly to a laptop to permit accurate analysis of each 
test and provide a record of analysis.  
The investigation ratio (IR) was calculated by dividing the time in seconds spent in the novel 
arm by the time spent in both the novel and original arm. 
The discrimination ratio (DR) was calculated by dividing the time in seconds spent in the novel 
arm minus time in original by time in novel arm plus original arm. 
 
Figure 2.7 T Maze testing  
He who hesitates... Mouse score based on the 
selection of the correct novel side, time spent in the 
novel arm and time spent in the original arm. 
 
 
 
The only limit to the experiment was the time taken to acclimatise (10 minutes in the home 
cage), train (5 minutes), and test (20 minutes with a 1 minute interval between tests).The 
investigation ratio (IR) was calculated by dividing the time in seconds spent in the novel arm by 
the time spent in both the novel and original arm. The discrimination ratio (DR), was calculated 
by dividing the time in seconds spent in the novel arm minus time in original by time in novel 
arm plus original arm. 
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2.3.2 Novel object testing (NOR) 
The basis of the novel object recognition test was described by Ennaceur (Ennaceur and 
Delacour 1988),where they showed that in a familiar environment, rodents show an affinity 
towards new or novel objects. It assumes the rodent has a retention capacity for the familiar 
object. In the original experiments, rats were the subject animal. The protocol was performed 
with modifications (Akkerman et al. 2012a; Akkerman et al. 2012b). 
Mice were given an acclimatisation period prior to the test, where they were free to explore the 
Perspex tray containing two identical novel objects. This ‘training’ period lasted 10 minutes. 
Following training, mouse was returned to his home cage for a period not exceeding 2 hours. 
Following the T maze data where C57BL/6 mice demonstrated laterality for the left side, novel 
objects were randomly placed in either left of right sides of the arena.  
The test began with the return of the mouse to the arena following a one hour interval with the 
placement of an identical item seen during the training period and a new item previously 
unseen- the novel item. Each test was conducted from the time mouse was placed in the arena 
for a period of one minute. A total of seven novel objects were used in the experiment so at no 
time was mouse exposed to non-novelty item in any test.  
Analysis of the raw data established the IR and DR for NOR. The time spent exploring the 
novel object divided by the time spent exploring either object yielded ‘Investigation ratio’. The 
discrimination ratio was defined as the difference in exploration time for the objects divided by 
the total exploration time can be used for analysis of discrimination of normal exploration not 
necessarily associated with novelty.  
Optimization of NOR testing included the provision of seven absolute novel duplicate items 
allowed for six individual tests of novelty recognition were performed at one session (Dere et al. 
2007). One trial contained the selection of novel items suggested by Dere with variations in 
shape colour and texture. The duplicate item ensured the mouse initially approached the 
‘known’ object with the same degree of curiosity as for the novel object. It was assumed that 
recognition of the ‘known’ object occurred with a combination of visual, tactile and olfactory 
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contact. In the Het mice, it was considered that due to their impaired visual status, their 
olfactory memory may be enhanced. Also it was important to determine the difference in mouse 
ability to recognise based on visual cues and those of olfactory and tactile. To this end, 
duplicate identical items ensured the mouse did not ignore the ‘known’ object because he 
identified his own scent on the object and assumed he was familiar with it. 
Novel object recognition was analysed according to the investigation ratio and discrimination 
ratio generated from the data collected during the test. The time to discover the novel object, the 
time spent with novel object and the time spent with the original object were measured in all 7 
items in each mouse. Het mice who did not discover the novel object either because they  did 
not leave the location they were placed in or did not move from the original familiar object were 
scored as 60 seconds in time to novel object. As each mouse had a specific time period of one 
minute (Dix and Aggleton 1999) to locate the item, or identify the original item before 
exploring the novel item, mice who didn’t explore obtained higher time scores. Figure 2.8 
shows the items used for OR testing. 
 
Figure 2.8  Items for NOR testing 
The novelty items were made of plastic, metal, resin, silicone, wood, fabric, slate and 
glass. All objects were in duplicate. All items were cleaned with 70% alcohol prior to 
any testing, and evaporated with a bench top fan. All colour items were paint safe. 
On the final test, mouse was returned to his home cage. The arena was cleaned with 70% 
ethanol, allowed to evaporate, and then wiped down with warm water. As each item was 
cleaned with 70% ethanol on removal from the arena and air dried with the use of a fan, the 
provision of ‘clean’ items for each mouse was ensured. 
ED
CA/B
F G IH
ID MaterialSize (cm) Color
A/B Plastic 5 x 5 Orange
C Metal 10x10x4.5 Black
D Resin 6x6x1.5 Multi
E Silicone 7x4 Lime
F Wood 8.5x5x9 Tan/Mix
G Fabric 13x4 Blue
H Slate 10x7 Grey
I Glass 3x3x3 Clear
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2.4 Thermal imaging in Opa1 Q285STOP mouse 
A thermal imaging camera was used to determine whether there was any difference in the core 
heat production in Opa1
Q285STOP
 mouse compared to his wild type littermates. A high resolution 
320 x 320 pixel camera with thermal sensitivity of <0.05
o
C and temperature sensitivity from -
20
o
C to +120
o
C was used to obtain images (FLIR E60). Measurements were corrected for 
reflected temperature, optic transmission and atmospheric transmission. Image processing was 
performed using FLIR Tools 2011 software. Measurement mode was in ‘isotherm’ and spot 
mode for precise temperature readings. Data was analysed from the same physical location in 
each animal. The head, tail base and flank region were selected to represent core, peripheral   
and central body temperatures. Mice were transferred to an arena as cage groups to reduce 
anxiety which may result in a rapid increase in temperature as an autonomic response to stress. 
Once acclimatised, the mice were identified by means of ear punch and isolated individually by 
means of a Perspex tube 20cm in diameter and 20cm in height. This allowed visual access to the 
mouse without the need to make physical contact. Because the mouse still had visual and 
olfactory cues to his surroundings, there were no immediate physiological alternations during 
the imaging process. Once an image was obtained, the Perspex tube was lifted, and mouse re-
joined his cage mates in the arena. 
2.5 Tissue retrieval 
All procedures were performed in accordance with the Home Office Animals in Scientific 
Procedures Act. Mice were killed by cervical dislocation and tissue retrieval carried out as 
rapidly as tissue type permitted.  
Mouse brain was removed by cutting along the coronal and sagittal suture. The parietal bones 
were folded back and the interparietal bone removed completely to gain access to the spinal 
canal. Using a broad ended forceps, the whole brain was scooped out of the cranial cavity as an 
intact organ. The tissue was placed in ice-cold 0.9% saline and any excess blood washed away. 
The brain was severed at the corpus callosum and both halves were placed on sterile gauze to 
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absorb excess saline then transferred to a pre labelled cryo vial for immediate submersion in 
liquid nitrogen.  
Mouse eye was removed with as much optic nerve intact as possible. Removal of the brain 
facilitates the complete removal of the orbit with intact optic nerve. If fixed retinal tissue was 
required, the orbit was washed in 0.9% saline and transferred to the appropriate fixative. Further 
resection of extra ocular muscle was performed following fixation. 
The vertebrate column was resected at the lumbar region and vertebral muscles removed. The 
whole spinal column was washed in ice-cold 0.9% saline and using a blunt ended cannula, 
saline was introduced into the lumbar vertebrae to facilitate washing out the cord. This method 
worked well in young animals however, older mice with more tenacious spinal cords usually 
required further resection directly into saline. Tissue handling was kept to a minimum, and snap 
frozen immediately.  
All internal organs were removed with an intact major blood vessel to facilitate blood washout 
in ice cold saline. Removal of blood was imperative for accurate analysis of SOD and other 
enzyme related assays. Larger organs were divided into two aliquots for storage at -80 
o
C. 
Perfusion in normal saline was considered for complete removal of residual blood, but prolongs 
total tissue retrieval time by over twenty minutes. As it was imperative to remove tissue as 
expediently as possible, it was decided to continue with organ retrieval as described. 
2.6 Immunohistochemistry  
2.6.1 Tissue fixation 
Whole mouse eye was removed and submerged in 4% paraformaldehyde (PFA), pH 7.4 for a 
minimum of four hours at room temperature. All but the superior rectus were removed. The 
rectus muscle was used to handle tissue and orientate prior to embedding. Tissue was 
cryopreserved in 30% sucrose and embedded in FSC 22 compound (Leica). Tissue sections 
were cut on a Leica CM1850 cryostat and left overnight to air dry. All sections were stored at -
20 
o
C until required. 
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Retina were cut as vertical 7M serial sections on electrostatic charged slides. Where possible, 
sections pertaining to regions numbered 2-4 were used for analysis. See Figure 2.9 for details.  
 
Figure 2.9 Cryostat sectioning 
Numbered sections from vertical orientated block. 
 
 
Whole brain from was divided at the corpus collusum, fixed, cryopreserved and 10m sagittal 
sections placed on electrostatic microscope slides. 
2.6.2 Immunohistochemistry controls 
2.6.2.1 Antibody controls 
Positive primary antibody controls were employed to determine the specificity of the 
primary antibody on a range of different tissue types known to express the antigen of 
interest. This also demonstrated the staining pattern of the epitope of interest. Titrations 
of the primary antibody were performed to determine the optimum concentration 
required to detect a positive signal. This was applied for each antibody as part of the 
experimental set up. Positive controls for each antibody are available in Appendix U. 
Table 2.1 shows the primary antibodies used, the concentration and tissue specific positive 
control tissue used for this. 
The secondary antibody control was determined by incubating the section in parallel with the 
test sections but in the absence of the primary antibody.  This was performed to confirm that 
any fluorescence detected in the test sections was due to the binding of the conjugated antibody 
the Fc region of the primary antibody only.  The presence of staining with the secondary 
fluorescence conjugated antibody in the absence of the primary antibody would indicate the 
availability of Fc receptors on the cell surface. This control was run in parallel with each 
experiment  
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2.6.2.2 Tissue controls 
Sections were examined by fluorescence microscopy following cutting prior to any 
antibody staining to detect the presence of any autofluorescence inherent to the tissue. 
Initial testing determined the presence of endogenous tissue background by incubating 
sections in all buffers but without primary and secondary antibodies.  Any staining with 
detection reagents in the absence of primary antibody was considered to be non-
specific.  Each run included sections run in parallel without the primary antibody 
Table 2.1 Antibodies for IHC and Western blotting 
 
Primary antibodies used for IHC. Specificity was confirmed on tissue specific substrates. 
Antigen localisation is shown. Dilutions are shown for IHC and Western blotting (WB). 
Secondary antibodies for Western blotting were HRP conjugated. Secondary antibodies for IHC 
were conjugated to green fluorophore 488 
2.6.3 IHC staining method  
Slides from -20
o
C were allowed to equilibrate to room temperature and were immersed in 
phosphate buffered saline (PBS), pH 7.4, blocked with 10% heat inactivated normal goat serum 
for 30 minutes at room temperature and endogenous peroxidases removed with freshly prepared 
3% hydrogen peroxide. Primary antibodies were incubated at stated dilutions at room 
temperature (21
o
C) for 4 hours. Secondary antibody was applied for 2 hours. Sections were 
counterstained with Hoechst 33342 nuclear stain applied for 4 minutes at a dilution of 1:1000. 
Sections were mounted using ProLong Gold (Life Technologies). 
 
Antigen Species Iso  + Con Geno Localisation Company Dil IHC Dil WB Band
(cat no) (cryo) kDa
Opa1 Mouse IgG1 Liver C57Bl/6 Mitochondrial BD 612607  1:500  1:1000 80-100
VDAC Rabbit IgG Brain C57Bl/6 Mitochondrial Sigma V2139  1:500  1:1000 30
Neuroglobin Goat IgG Cerebrum C57Bl/6 Mitochondrial Santa Cruz 22001  1:500  1:4000 17
MnSOD Rabbit IgG Liver C57Bl/6 Mitochondrial Abcam 13533  1:500  1:5000 25
PSD95 Goat IgG Brain C57Bl/6 Cell membrane Abcam 12093  1:500  1:5000 105
Preli Mouse IgG1k Cardiac C57Bl/6 Mitochondrial SigmaWH0027166M1  1:500  1:5000 25
NF H Goat IgG Brain Python Cytoplasmic Santa Cruz 22909  1:500  1:1000 200
NF L Goat IgG Brain Python Cytoplasmic Santa Cruz 12966  1:500  1:4000 80
3'Nitro Rabbit IgG Kidney C57Bl/6 Sigma N0409  1:250  1:4000
Actin Mouse IgG Sigma A1978 NA  1:5000 42
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2.6.4 IHC Image analysis 
Sections were viewed with a fluorescent microscope (Leica Wetzlar DM6000) using 10x and 
20x objectives and a 10x eyepiece which provided a total magnification of 100x and 200x, 
using filters for Hoechst (excitation/emission maxima 352/461nm) and Alexafluor 488 
(excitation/emission maxima 495/519nm). Fluorophore saturation was avoided by setting the 
threshold, gains and exposure to the same setting in both channels for all images within the 
density histogram. The image acquisition parameters were set so that no detection channel 
showed pixels reading zero or saturated levels. This was visualized in histogram settings for 
each image. 
The quantification of fluorescence was calculated using Image-J software. Figure 2.10 
summarizes the method used for subtraction the background fluorescence from the test section. 
Briefly, the control section (with no primary antibody) was converted to 8-bit TIFF to preserve 
the linear relationship between photons and image intensity values  (Staal et al. 2004). Using the 
threshold tool the autofluorescence was determined. This threshold was applied to the layers 
that were analyzed: PRL-IS,ONL,OPL,INL,IPL and GCL and applied to the test section.  
 
Figure 2.10 Determination of autofluorescence using control section 
(A)Control section with no primary threshold was set which (B) identified 
autofluorescence in the PRL OS and OPL. (C) The test section before background 
correction (D) After background correction. 
Pixel density was measured for threshold intensity within the selected areas (PRL, ONL, INL 
etc.). Measurements of area, mean and integrated density were obtained. Specifically for the 
analysis of PRL-IS, the inner segment only was used to calculate the fluorescence intensity as 
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the outer segments frequently autofluoresces resulting in inaccurate reporting. Each genotype 
included control sections for each test run. 
Using Image J, the regions of interest were selected using polygon tool and area, mean and 
integrated density values selected.  The corrected cell fluorescence was calculated by 
subtracting the mean fluorescence background multiplied by the area selected (Abramoff et al. 
2010; Rasband 2014). 
Retinal images reported AFU of each layer from the photoreceptor inner segment layer (PRL 
IS) to ganglion cell layer (GCL). Brain sections were orientated to permit maximum exposure to 
the hypothalamic region. In the absence of a tissue specific marker, brain sections were analysed 
as total RGB count minus background staining. IHC are reported as arbitrary fluorescent units 
(AFU). 
2.7 Western blotting 
2.7.1 Tissue homogenisation 
Tissue was defrosted on ice and washed briefly in ice-cold 0.9% saline to remove any remaining 
blood. Wet weights were recorded and tissue divided into equal aliquots. Aliquots were 
suspended in ice-cold homogenisation buffer at a ratio of 1:4 W/V in 1.5 ml tube. The tissue 
was homogenised using a Teflon pestle on ice to reduce degradation of contents. Balanced 
homogenates were centrifuged at 4
o
C at 500 x g for 20 minutes and the pellet was resuspended 
in buffer with protease inhibitor cocktail (Sigma protease inhibitor cocktail), at manufacturers 
recommended dilution. The supernatant was transferred to a fresh pre chilled tube. Protein was 
measured by bicinchoninic acid (BCIP), mitochondrial extractions were diluted in 2% TritonX-
100 and assays were performed in triplicate with the results recorded as the average of three 
results. 
Approximately 20g protein supernatant was applied to each well. Protein samples were 
resolved on 14% SDS–polyacrylamide gels and transferred to nitrocellulose membranes 
(Biorad). The membranes were blocked for 1 hour at room temperature with blocking solution 
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(5% skimmed milk). Primary antibodies were incubated overnight at 4
o 
C on a rocking platform 
with the antibodies shown in Table 2.1. 
Following washing, the membrane was incubated with HRP conjugated secondary antibody. 
Further washing was followed by incubation with enhanced chemiluminescent (ECL) substrate 
and exposure to clear blue X-ray film for development.  
2.7.2 Analysis of Western blot by densitometry 
X Ray film of blotted proteins were acquired as .tiff files by flatbed scanner (Canon) and 
imported into Image J 1.47v software where they were converted to 8 bit  image and processed 
for densitometry using the Gel Analysis according to established methods (Abramoff and 
Magalhaes 2004; Gassmann et al. 2009; Taylor et al. 2013). Briefly, each lane was selected 
individually and a plot of the profile obtained (See Figure 2.11). The plots represented the 
relative density of the contents of the selected lane. Background noise was eliminated using the 
straight line tool to close off the end of each plot. The ‘area’ measurement represented the pixel 
density value of the band and the percentage value was relative to the total size and density of 
bands for any given image. Each blot had  actin as a loading control. For each blot, one 
sample was selected to be the standard e.g.: WT was selected in blots of WT and Het, 
untreated Het was selected in blots of Het and res treated Het. The percentage value was 
divided by the percentage value in the standard. This gave a measure of the relative density 
of each peak.  
Figure 2.11 Western blot profile plots of an individual band 
 Images show the two-dimensional 
graph of pixel intensity along a line 
within the selected band. The x axis 
represents the distance along the line 
and the y axis represents the 
intensity. (A) profile plot (B) plot 
minus the background (C) and the 
percentage. 
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This process was repeated for the loading controls. The relative density of the loading control 
represented the total protein loaded for each sample. The value obtained for the relative density 
of each test band was divided by the relative density of its corresponding actin loading 
control. This gave the adjusted relative density value relative to the total amount of protein 
examined. Western blot are reported as relative density (RD). Results are presented according to 
the primary antibody used.  
2.8 BCIP protein assay 
Protein concentrations of both mitochondria and tissue homogenates were measured using a 
commercial protein assay kit (Thermo Scientific BCA protein assay kit (cat# 23225) 
BSA standards were plated in triplicate in a flat bottomed 96-well plate and incubated for 30 
minutes at room temperature. The plate was read at 540nm wavelength. The average of each 
absorbance reading was plotted on the y axis  against the known protein concentration of the 
standard on the x axis. The BCA method is compatible with up to 5% Triton X-100 in protein 
samples (Thermo Scientific Tech Tip #68) 
2.9 Mitochondrial isolation 
Mitochondria were isolated from tissue stored at -80 
o
C using a commercial mitochondrial 
isolation kit (Sigma Mitochondrial Isolation Kit (cat# MITOISO1).The kit was designed for the 
isolation of viable mitochondria in animal tissue of 10-20g wet weight. Isolation of 
mitochondria was by differential centrifugation in sucrose. The mitochondria were re suspended 
in an OXPHOS support storage buffer which contained 10mM HEPES pH 7.5, 250mM sucrose,  
1mM ATP, 0.08mM ADP, 5mM sodium succinate and 2mM phosphate.  The kit also included a 
JC-1 stain for measurement of electrochemical proton gradient (ΔΨ) of the inner mitochondrial 
membrane.  
For each assay, tissue was defrosted on ice and washed in extraction buffer. The average of 
three weights was used as wet weight of tissue. Tissue was chopped into fragments on a glass 
dish. Tissue was homogenised using a Teflon pestle. The homogenate was transferred to a fresh 
pre chilled 2ml tube and centrifuged at 600xg at 4 
o
C for 5 minutes. (Sigma 1-15pk). The 
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supernatant was transferred to a fresh pre chilled tube and centrifuged at 11,000xg for 10 
minutes at 4
o
C. The supernatant was removed and the pellet was resuspended in extraction 
buffer followed by further centrifugation at 600xg and 11,000xg as before with final pellet 
resuspended in storage buffer at 40l per 100mg of the original tissue weight. Mitochondria 
were resuspended in storage buffer which supports OXPHOS and diluted in phosphate buffer to 
1mg/ml in preparation for analysis following protein assay. The mitochondrial populations in 
the Het tissues were considered to have potentially more lysozyme activity however the 
isolation of lysosomes requires centrifugation at speeds in excess of 20,000 x g. The population 
of isolated Het mitochondria was considered to be as close to In vivo environmental conditions 
as possible. Mitochondria were maintained at 4
0
C in storage buffer containing 5mM sodium 
succinate for a period not extending 30 minutes prior to spectrophotometric analysis which did 
not impact on the analysis performed. It was considered important to provide support to 
mitochondria prior to dilution in the appropriate phosphate buffer. 
2.10 Mitochondrial staining 
2.10.1 JC1 for m 
JC-1 (5,5,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenz-imidazolcarbocyanine iodide) is a cationic 
carbocyanine dye. The stain stock (1mg/ml) in DMSO was vortexed vigorously prior to use. 
The stock solution was diluted to 0.2mg/ml in DMSO and kept at room temperature in a dark 
amber tube to protect it from light according to the manufacturers instructions. Mitochondria 
were diluted to a final protein concentration of 0.020mg/ml with storage buffer. The suspension 
was gently pipetted to resuspend mitochondria. JC1 stain was added at 40g/ml to the diluted 
mitochondria and mixed thoroughly but gently. The mitochondrial suspension was incubated 
with JC1 at room temperature in the dark for 7 minutes and analysed immediately using a 
disposable haemocytometer. Chambers were visualised using a 20x objective with a 10x 
eyepiece giving a 200 times magnification with a 470nm +/- 40 nm excitation and 525 nm +/-50 
nm  emission wide band pass filter and 546 nm +/-12 nm excitation and 600 +/- 40 nm emission 
band pass filter using a Leica Wetzlar DM6000 microscope equipped with a DFC 350 FX 
digital camera. Fluorescence was pseudocolored and third channel merge was a combined dual 
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immunofluorescence from both filter cubes. Counts were performed using Image J plug-in for 
tricolour cell count with split channel analysis of individual fluorescence. The ratio of viable red 
and reducing potential green is an indicator of membrane potential. For simultaneous 
visualisation, excitation at 488 nm and 568 nm were used. The reduction of membrane potential 
is associated with H2O2 production and subsequent mitochondrial death. 
2.10.2 Mitotracker staining 
Mitotracker stain (Mitotracker Red CMXRos MW 531.53 (M7512 Life Technologies) was 
resuspended in 940.6l anhydrous dimethylsulfoxide (DMSO) to give a stock concentration of 
100M. DMSO. For mitochondrial staining, mitochondria were diluted to 1mg/ml in storage 
buffer containing Mitotracker Red at a concentration of 20nM. Stock Mitotracker was diluted to 
20nM by adding 1l of stock to 5ml of storage buffer containing 10mM HEPES pH 7.5, 
250mM sucrose,  1mM ATP, 0.08mM ADP, 5mM sodium succinate and 2mM phosphate 
Mitochondria from WT and Het tissues were incubated with Mitotracker Red in 1.5ml tubes and 
protected from light. Tubes were incubated at 37
o
C in a rotating incubator to ensure adequate 
mixing of contents. Following incubation, tubes were kept in the original dark container and the 
contents analysed on PTFE welled slides at 5l/well. Wells were visualised using a x100 
objective under oil immersion with a x10 eyepiece (x1000 magnification) and visualised with 
580nm excitation and 600 +/- 40nm emission on a Leica Wetzlar DM6000 microscope with a 
DFC Fx digital camera. 
2.11 Spectroscopy for electron transfer analysis 
Age matched wild type and Het mice were killed by cervical dislocation according to approved 
schedule one UK Home Office guidelines (Scientific Procedures Act, 1986). Tissues of the 
central nervous system (brain, spinal cord and retina), were rapidly snap frozen and stored at -
80
o
C until processed for mitochondrial extraction. Mitochondrial preparations were kept on ice 
throughout analysis. Statistical analysis was performed using SPSS. A normality test for 
distribution using Shapiro-Wilk was used and univariate ANOVA with post hoc Tukey HSD 
where a value of <0.05 was considered significant. 
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2.11.1 Fluorescence spectroscopy for complex I analysis 
The specific activity of NADH ubiquinone oxidoreductase - complex I was investigated by the 
oxidation of NADH. NADH passes electrons to complex I that are then passed to the synthetic 
ubiquinone Coenzyme Q1 (CoQ1) as the electron acceptor. Using a fluorometric assay, with 
excitation of 340nm and emission 460nm, complex I activity was monitored by the decrease in 
absorbance of NADH at 460nm as a function of time (Starkov et al. 2004). The assay was 
performed in 20mM phosphate buffer pH7.4 at room temperature (21-23
o
C) in a final volume of 
1ml. Buffer contained 100M NADH, 1mM KCN and 40M CoQ1. Specificity of the assay 
was conformed using rotenone at a concentration of 2M.  Mitochondria were diluted to 
1mg/ml and added at a concentration of 30g/ml. The expected absorbance of 100M NADH 
was calculated from the absorption coefficient of NADH at 340nm  6200 M
-1
 x cm
-1
 (McComb 
et al. 1976). A standard curve was used to calculate NADH concentration from 30-160 M at 
340nm and repeated using fluorescence at 460nm. The equation for the line from the 
fluorescence standard was used to calculate NADH concentration in the kinetic assay. Figure 
2.12 shows the fluorescence spectrum of NADH from 350-700nm at 30-160M and the 
standard curve generated from fluorescence spectrophotometry.  
Figure 2.12 Standard curve 
NADH 
Fluorescence spectrum of 30-
160M NADH from 
wavelengths 350-700nm and 
standard curve from 
fluorescence absorbance at 
460nm used to calculate the 
oxidation of NADH for 
complex 1. 
 
The data was expressed as mol/mg mitochondrial protein/ml. Magnetic stir bars were included 
in the cuvette to ensure adequate mixing of reagents. All reagents were supplied by Sigma. All 
buffers were treated with Chelex overnight to eliminate transition metals. 
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2.11.2 UV spectrophotometry for complex II analysis 
Complex II activity was analysed using the oxidation of succinate with an artificial electron 
acceptor 2,6 dichlorophenol indophenols (DCPIP) resulting in a reduction of DCPIP turning it 
from blue to colourless. This resulted in an increase in light transmittance, which was measured 
spectrophotometrically. The assay was performed at 30
o
C in 20mM phosphate buffer pH 7.8 
containing 10mM succinate, 100M decylubiquinone and 2mM potassium cyanide (KCN). 
DCPIP was prepared fresh at a concentration of 16mM. This was diluted to 16M (1:10), with 
the addition of buffer containing 100M decylubiquinone and 2mM KCN. The expected 
absorbance of 16mM DCPIP at 600nm was calculated from the extinction coefficient of DCPIP 
22 x 10
3
 M
-1
- cm 
-1
 (Arrigoni and Singer 1962). This was calculated to be 0.352. A standard 
curve was generated with concentrations from 0.6-20mm (Figure 2.13). 
Figure 2.13 DCPIP 
Standard curve 
Absorbance spectrum of 0.6-
20M DCPIP from 
wavelengths 550-700nm and 
standard curve from 
absorbance at 600nm. 
 
Mitochondria were diluted to 
1mg/ml and 50g used for each assay of brain and spinal cord. Retinal mitochondria were used 
at a concentration of 30g/ml.  Buffer containing 100M decylubiquinone, 2mM KCN and 
16M DCPIP was followed with the addition of 30g mitochondria.  The rate of reduction of 
DCPIP was expressed in mol/mg/ml. 
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2.11.3 UV spectrophotometry for complex IV analysis 
Complex IV activity was analysed by measuring the change in absorbance at 550nm of reduced 
cytochrome c. 2mm cytochrome c was reduced with the addition of 1ml of 100mM ascorbate 
and was purified by Sephadex G-25 chromatography. In order to determine the concentration of 
reduced cytochrome c in each preparation, the isosbestic point of equine cytochrome c was 
determined.  
2.11.3.1 Isosbestic point of equine cytochrome c 
The isosbestic point of equine cytochrome c was determined using 30M oxidised cytochrome c 
incubated with 30M ascorbate. The spectrum was read from 500-730nm at 1 minute intervals 
for 24 minutes. The reduction of 30M cytochrome c  in the presence of 30M ascorbate was 
followed for 24 minutes. The reduction plateaued at 7 minutes without further addition of 
ascorbate (Figure 2.14). 
The wavelength which showed the least difference in absorbance between oxidised and reduced 
cytochrome c was determined. This was identified at 542nm which agreed with  the  published 
isosbestic point at  541.75 nm (Margoliash and Frohwirt 1959). 
 
Figure 2.14 Spectra of 
30M cytochrome c  
during incubation with 
30M ascorbate 
 
 
The absorption coefficient at the wavelength corresponding to the isosbestic point was obtained 
from three independent preparations of 1.99mM oxidised cytochrome c from which seven 
concentrations of 100M, 80M , 60M, 40M,20M,10mM and 5M were prepared.  The 
absorption coefficient at 542nm which corresponded to the isosbestic point e iso  was calculated 
using the formula 1: 
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Formula 1: eiso  = Aiso /cL  
where A
iso
 was the absorbance at the isosbestic point of 542nm, c was the concentration of 
cytochrome c  and L was the optical pathlength of 1cm. The eiso was 9.056 ± 0.010 x103 x M-1 x 
cm
-1
. Figure 2.15 A shows the absorbance of oxidised cytochrome c from 450-700nm and B 
shows a graph of absorbance at 542nm with corresponding concentrations of cytochrome c 
 
Figure 2.15Absorbance of cytochrome c as a function 
of concentration  
(A) Representative absorbance spectra of cytochrome c 
at indicated concentrations (B) Absorbance of 
cytochrome c  at 542nm as a function of concentration. 
The absorbance was calculated from A0 of 0.0006 
±0.0002 and the extinction from 9.030, 9.050 and 9.053 
x 10
3 
M
-1
 cm
-1
. 
 
 
For complex IV assays, the spectrum of reduced 
cytochrome c was recorded prior to the assay. The 
concentration of total cytochrome c was calculated from the absorbance of reduced cytochrome 
c at 542nm using Formula 1:  eiso  = Aiso /cL 
The concentration of reduced cytochrome c was calculated using the following formula 2: 
Formula 2:  Cred = (A
550
 - eox
550
A
iso
/eiso) / (( ered
550
 -  eox
550
)L) 
Where A
550 
was the absorbance at 550nm 
eox
550
 was the extinction coefficient of oxidised cytochrome at 550nm which was 8.4 x 10
3 
M
-1
 x 
cm 
-1
 (Van Gelder and Slater 1962). 
A
iso
 was the absorbance at isosbestic point of 542nm and  
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eiso was the absorption coefficient at the wavelength corresponding to the isosbestic point at 
542nm equal to 9.056 x 10
3
 x M
-1
 x cm
-1
. 
e red
550
 was the absorption coefficient of reduced cytochrome c at 550nm equal to 29.5 x 10
3
 x 
M
-1
 x cm
-1
 (Van Gelder and Slater 1962) and L was the optical pathlength of 1cm. 
The absorbance corresponding to the lowest concentration of reduced cytochrome c used in the 
analysis of complex IV was calculated using the formula 3: 
Formula 3: A
550 
= ( ered
550
 -  eox
550
) Cred L  +  eox
550
A
iso
/eiso 
Where e red
550
 - eox
550
 was the absorption coefficient of reduced cytochrome c at 550nm (equal to 
29.5 x 10
3
 x M
-1
 x cm
-1 
) minus the absorption coefficient of oxidised cytochrome at 550nm  
(8.4 x 10
3 
M
-1
 x cm 
-1
) which was 21.1 x10
3 
M
-1
 cm
-1
. 
The absorbance calculated using formula 3 was used to determine the absorbance at 550nm 
which was the start of exponential decay fittings at the same initial concentration of reduced 
cytochrome c  
For the assay of complex 4 activity, reduced cytochrome c was aliquoted under Argon gas and 
stored at -80
o
C. The assay was performed at 30
o
C using a water bath to control temperature in 
10mM phosphate buffer pH 7.4  a final volume of 600l containing 100M cytochrome c and 
0.025% n-Dodecyl β-D-maltoside. Mitochondria were added at a tissue specific concentration 
of 50g/ml for brain, spinal cord and muscle and 30g/ml for retina. 
Mitochondria were mixed well with stir sticks (Fisher #NCO116097), before the lid was closed. 
The reaction was recorded by measuring the absorbance at 550nm as a function of time. The 
linear slope of the kinetic reaction was obtained.  
2.12 ATP determination 
Recombinant firefly luciferase and its substrate D-luciferin was used to determine ATP in 
isolated mitochondria. Luciferase requires ATP to produce light (emission at maximum 560nm 
at pH 7.8) from the reaction 
 
Luciferase +Lucirerin+ATP→Luciferase-Luciferly-AMP+Ppi
Luciferase-Luciferyl-AMP+O2 → Luciferase+Oxyluciferin+AMP+CO2
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Measurement of the light produced in the reaction was monitored with a BMG Labtech 
FLUOstar Omega plate reader using a black clear bottomed 96 well microtitre plate (Costar). 
Background luminescence intensity was accounted for. 
Due to the extreme sensitivity of the assay, all exogenous sources of ATP were eliminated by 
the application of GLP. This included the use of sterile tubes and pipette tips and MilliQ water. 
For each assay, a standard curve of ATP from 1nM to 1M was prepared. The final volume of 
standard and mitochondria was no more than 10% of the total assay volume (of 100l). Plate 
loading was the same as directional analysis of the plate reader to ensure the same luminance 
development in all wells. Initial analysis using a 5l volume of both standards and mitochondria 
yielded low luminescence levels. The optimum temperature for analysis was 25
o
C. 
Mitochondria were isolated from fresh tissue. In cryopreserved tissue, ATP production can be 
enhanced and may reflect an inaccurate base level (Barksdale et al. 2010). Each reaction was 
performed in triplicate and contained 0.5mM D-luciferin, 1.25g/ml firefly luciferase, 25mM 
tricine buffer pH 7.8, 5mM MgSO4, 100M EDTA and 1mM DTT. All products were protected 
from direct light source. Firefly luciferase was mixed by gently inversion due to the easily 
denatured structure of the product. The light intensity of the assay and its effective linear range 
was proportional to the luciferase concentration from 10
-20
 to 10
-13
 moles of ATP. Dilution of 
mitochondria in storage buffers yielded increased background signals. For the purpose of these 
assays, an aliquot of mitochondria was diluted in isolation buffer which reduced background 
levels of luminance. Owing to the speed of the reaction, it was necessary to load mitochondria 
with the plate on the plate carriage to ensure a rapid read. 
2.13 Endogenous antioxidant assays 
2.13.1 SOD assay 
SOD assay was performed using a commercial kit (Sigma SOD Assay Kit (cat# 19160-1KT-F). 
Bovine superoxide dismutase was obtained from Sigma (cat# S9697).One unit of enzyme 
activity was defined as the amount required to inhibit the reduction of cytochrome c by 50% in a 
coupled system with xanthine and xanthine oxidase at pH 7.8 at 25°C.  A 96 well plate assay 
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(Fisher-Scientific), was used to measure superoxide dismutase activity by colorimetric assay. 
Reagents were diluted according to the manufacturer guidelines. The absorbance at 450nm was 
proportional to the amount of O2
-
. Superoxide dismutase (SOD) catalyzes the dismutation of 
O2
-
 into hydrogen peroxide (H2O2) and molecular oxygen (O2). Indirect measurement using 
Dojindo’s water soluble tetrazolium salts was performed. WST-1 produces a water-soluble 
formazan dye absorbing at 450nm on reduction with O2
-
 . SOD scavenges the O2
•- 
and inhibits 
the formation of formazan. IC50 refers to 50% inhibition of the rate of formazan formation. SOD 
activity as an inhibitor was quantified by measuring the rates of colour development at 450nm. 
Tissue homogenate was diluted to 1mg/ml in SOD dilution buffer.  
The inhibition of formazan formation due to SOD activity (inhibition rate %) was calculated 
using the following equation: Inhibition (((S1-S3) – (SS – S2)) / (S1-S3)) x100 where S1 
contained enzyme, WST, and no homogenate which acted as an uninhibited formation of 
formazan in the absence of SOD. S2 contained homogenate, WST dilution buffer and no 
enzyme which acted as test blank for homogenate without the presence of enzyme and S3 
contained WST, dilution buffer no enzyme and no homogenate which was the background 
absorbance as detected at 450nm. Figure 2.16 shows a summary of the test controls run with 
each assay. 
For MnSOD inhibition in tissue homogenates samples were resuspended in SOD buffer 
containing 2% SDS. For CuZnSOD inhibition in tissue homogenates, samples were incubated in 
a final concentration of 5mM of potassium cyanide for 45 minutes at room temperature (Geller 
and Winge 1983). Results for SOD activity are presented as units of SOD activity per mg tissue 
in total SOD, CuZnSOD and MnSOD. Statistical analysis was performed using SPSS ANOVA 
multivariate analysis with significance of <0.05 followed by Post hoc Tukey. 
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Figure 2.16 SOD assay analysis 
(A)SOD inhibition of formazan formation as a function of concentration in units/ml. Formazan 
produced a yellow colour which absorbed light at 450nm causing an increase in absorbance. 
Increased SOD units inhibited the formation resulting in reduced absorbance. (B)Blanks 
included were uninhibited formazan formation in the absence of SOD, homogenate without the 
presence of enzyme and background absorbance from dilution buffer. (C) Standard curve of 
SOD units/ml against percentage inhibition of formazan showing the formula used to determine 
SOD units in tissue homogenate. 
 
2.13.2 Catalase assay 
The application of Amplex red for the measurement of catalase activity was considered for this 
assay however, Amplex red is unstable in the presence of instrumental excitation light and can 
generate the fluorescent resorufin in the absence of H2O2 and HRP. The generation of the 
superoxide radical and H2O2 are artefacts of photooxidation (Zhao et al. 2012), Therefore, the 
method of Aebi (Aebi 1984), and Beers  (Beers and Sizer 1952) was employed to calculate the 
catalytic activity of tissue homogenates.  The method measured the decomposition of a known 
concentration of H2O2 using the change in absorption at 240nm. The assay employed 10.3mM 
H2O2 which was critical because there is direct proportionality between the substrate 
concentration and the rate of decomposition. A concentration of 10.3mM H2O2 also prevents 
inactivation of catalase and reduces the formation of air bubbles due to the liberation of O2.  
H2O2 at concentrations in excess of 0.1M results in rapid inactivation of catalase (Aebi). 
Age matched WT and Het mice were killed by cervical dislocation according to approved 
schedule one UK Home Office guidelines (Scientific Procedures Act, 1986). Tissue samples 
stored at -80
o
C were defrosted on ice and homogenised in 50mM phosphate buffer pH 7.0 using 
a hand held homogeniser with Teflon pestle. Tissue homogenates were centrifuged at 600g at 
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4
o
C for five minutes. This yields a pellet consisting of unbroken tissue, whole cells, cell nuclei, 
and large debris. The supernatant was used to quantify protein concentration by BCIP. 
Supernatants were diluted to 1mg/ml and following optimisation, a concentration of 80g/ml 
was used to assay the catalytic activity of brain, spinal cord and retina in WT and Opa1
Q285STOP
 
mouse tissue. As the optical density of tissue homogenate was expected to be considerably 
higher than the absorption of hydrogen peroxide, (absorbance values up to 0.727) the UV 
spectrophotometer was blanked with 50mM phosphate buffer containing tissue homogenate. 
The assay was followed as a kinetic reaction over 600 seconds. All buffers were treated with 
Chelex to remove transition metals. 
As the assays were performed in a quartz cuvette, this was rinsed twice with MQ water between 
samples. As the kinetic assay followed H2O2 prior to addition of catalase, any alternation in 
absorption could be detected indicating extraneous catalytic activity. To validate each assay, a 
positive control was incorporated in each test run. The positive control was 1 unit of bovine 
catalase (Sigma #C1345) in phosphate buffer pH 7.0. One unit of catalase will decompose 
1Mole of H2O2/min at pH7.0. The application of a standard curve was not employed as the rate 
of H2O2 decomposition reaction using pure catalase was not comparable to the rates obtained 
using tissue homogenate. Thus the slope of a standard reaction obtained within 120 seconds of 
addition to a known concentration of H2O2 was not comparable to the same slope generated over 
a ten minute period using tissue samples. 
The catalase assay was performed using UV spectrophotometer measuring the change in 
absorbance of the substrate H2O2 in the presence of catalase. The kinetics of H2O2 
decomposition was followed for 600 seconds. The reaction is first-order in both enzyme and 
substrate therefore the amount of peroxide decomposition is directionally proportional to the 
concentration of catalase. The concentration of H2O2 was determined from absorbance at 240nm 
using a quartz cuvette with the absorption coefficient e240mM= 0.0436mM-1 x cm-1  (Beers 
and Sizer, 1952). The reaction was performed in 1ml of 50mM phosphate buffer pH 7.0 with 
10.3mM HO2 and 80g tissue homogenate protein. Straight line fitting was applied to kinetic 
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3 Armed trial
     No Treatment
WT 34
F WT 24
M WT 10
Het 47
F Het 24
M Het 23
      Resveratrol 
 13.5mg/Kg (219.06M)
WT 26
F WT 14
M WT 12
Het 33
F Het 22
M Het 11
           Vehicle
Ethanol 0.1% (17mM)
WT 12
F WT 6
M WT 6
Het 19
F Het 11
M Het 8
reaction to calculate catalase activity in units/mg tissue homogenate. The difference in 
extinction e240 per unit of time is a direct measure of catalase activity.  
Statistical analysis was performed using SPSS with multivariate analysis ANOVA. Statistically 
significant values are given with the F value followed by the p value where p=<0.05 was 
considered significant. 
2.14 Antioxidant therapy trial 
2.14.1 Introduction 
2.14.2 Experimental design of resveratrol study 
The resveratrol study was performed as a three armed trial. Each arm consisted of age matched 
WT and Het mice. Arm one consisted of untreated WT and Het mice. There were a total of 34 
untreated WT and 47 untreated Het mice. The resveratrol arm had 26 WT and 27 Het mice. The 
vehicle arm had 12 WT and 19 Het mice. Table 2.2 summarises these participants. A detailed 
trial design is shown in Appendix C. 
Table 2.2 Resveratrol three armed 
trial design 
The table shows a summary of the 
design of a 3 armed trial of resveratrol 
administration to both WT and Het mice 
over a 15 month period. Arm 1 
consisted of no treatment in WT and 
Het, arm 2 was resveratrol treated and 
arm 3 was vehicle treated. 
 
 
In order to increase the number of participating animals, a cohort of 3 month old WT and Het 
mice were commenced on resveratrol for 1 month. Following intensive health screening, these 
mice were crossed to produce the first round of off spring for treatment beginning in utero. This 
cohort consisted of 3 WT and 6 Het for resveratrol therapy and 4 mice for vehicle treatment.  
The inclusion criteria for the initial set up was that the females were of breeding age and that 
they had not been crossed before. The male mice were all housed as solitary animals none of 
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whom had been crossed. The subsequent crosses were performed at six, fourteen and twenty six 
weeks from starting the trial. The inclusion criteria for these mice were that they were matched 
WT for Het. There was a concerted effort to sex match the babies so that both male and female 
WT and Het mice could be studied. 
2.15 Statistical analysis 
Results are expressed as a mean ±SD. Statistical analysis was performed with SPSS software 
(V20).  Data was analyzed for distribution using Shapiro-Wilk where all data above 0.05 was 
considered normally distributed. Parametric t test were performed where Levene’s test for 
equality of variance was observed. Parametric data demonstrating a significant difference was 
further analyzed using multivariate analysis of variance with post hoc Tukey or Dunnett for 
unequal sample numbers. Where data was not normally distributed, Mann –Whitney U test or 
Kruskall –Wallis H test for multiple groups was performed with Bonferroni adjustment. Data 
where the null hypothesis was rejected are indicated with asterisks where *p<0.05, **p<0.010 
and ***p<0.001.The F value in ANOVA is the between group variability divided by the within 
group variability. 
2.16 Presentation of data 
Unless otherwise described, bar graphs show the mean with error bars showing ±SD. Box plot 
graphs show all data with the upper and lower boxes representing the first and third quartile. 
The dividing line between the two boxes is the median. The upper whisker represents the 
maximum range and the lower whisker represents the minimum range. Graphs of IHC show the 
mean ± SEM.  Line graphs showing mean ± SD include the WT value for reference. Kinetic 
graphs are explained in the text.
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Chapter 3 Chapter 3 Neuromuscular & cognitive dysfunction in 
Opa1
Q285STOP
   mouse 
3.1 Introduction 
As Opa1 is ubiquitously expressed in all tissues, it was considered that tissues exerting a high 
demand on available ATP may be influenced by impaired mitochondrial fusion. The skeletal 
and cardiovascular system of Opa1
Q285STOP
 mouse was analyzed for endurance performance in a 
selection of tests designed to demonstrate any impairment in gait, balance and coordination. 
Peripheral neuropathy is associated with impaired oxidative phosphorylation.  
3.1.1 Osteoporosis in C57Bl/6 mouse population 
Bone density is maintained through the balanced activity of osteoblast and osteoclasts.  
Osteoblasts synthesize bone and regulate osteoclast number and activity. Osteoclast cells 
reabsorb bone tissue and are responsible for bone remodelling. In C57Bl/6 mouse, bone density 
peaks at 4-8 months followed by a gradual decline (Perkins et al. 1994; Cao et al. 2003; 
Ferguson et al. 2004). The loss of balanced blast clast activity results in expanded bone 
reabsorbing osteoclasts. Age related osteoporosis can be associated with reduced levels of 
circulation oestrogen which enhances bone reabsorption (Silberberg and Silberberg 1970; 
Ambrus et al. 1984). Diet can influence bone mass including proanabolic supplements (Halloran 
et al. 2010). Vertebrate osteoporosis responds well to moderate physical exercise (Wu et al. 
2003; Kesavan and Mohan 2010; Thongchote et al. 2014; Yamada et al. 2014). The provision of 
a running wheel was designed to alleviate the discomfort and potential effects of reduced bone 
density in aged inactive mice.  
C57Bl/6 mouse is predisposed to develop osteoporosis (Ambrus et al. 1978; Massie et al. 1989; 
Akhter et al. 1998; Judex et al. 2002). The provision of a running saucer (Small & Furry) was 
considered appropriate in the alleviation of this age related onset. As Opa1
Q285STOP
 mouse was 
required to reach the minimum age of 15 months, saucers were provided for at least the last 
eight months of life. The speed of learning in Het mouse was dependant on whether they shared 
a mixed genotype cage. In one particular Het cage, the skill was mastered in aged 18 month old 
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Het males who continued to use their saucer until 28 months of age. Figure 3.1 shows a female 
mouse at 6 months and at 12 months following use of a running saucer, which demonstrates a 
reduction in vertebrate scoliosis. 
  
Figure 3.1 C57Bl/6 at 6 months and 15 months following use of running saucer 
(A)Male C57Bl/6 mouse at 6 months was living in a shared cage without a running 
wheel. Mouse spinal vertebrae are pronounced with scoliosis (green arrow). (B) Male 6 
months following use of wheel showing less curvature in vertebrate. 
Owing to the somewhat sedentary lifestyle of the average laboratory mouse, the presence of 
osteoporosis can reduce physical performance of exertion based exercises. As the Opa1 mice 
were observed to have a degree of osteoporosis, the provision of running saucers provided them 
with an adequate means of daily exercise and a means of improving their bone density. By the 
completion of this thesis, there was a significant improvement in the bone density with a 
reduced incidence in osteoporosis. As it was considered to be a cage induced lack of exercise, 
the provision of saucers improved the overall skeletal frame of all mice. 
3.2 Neuromuscular impairment in Opa1Q285STOP mouse 
3.2.1 Experimental design of SHIRPA analysis 
SHIRPA testing was performed as described in Chapter 2 Methods section2.2. 
There were some limitations of the SHIRPA protocol. Mice that were accustomed to handling 
produced a more accurate representation of the phenotype that was not influenced further by 
fear or intimidation. Spontaneous activity in mice was preserved due to familiarity with the 
handler. Many of the observations noted during SHIRPA testing were originally observed 
during routine testing with rotarod, tight rope and narrow beam testing. Vigilance and an 
B: C57Bl/6 12 months post  wheel use  A: C57Bl/6 6 months prior to wheel use  
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accurate record of all activities in all animals can help to detect the more significantly affected 
mice in the Het population. Interpretation of SHIRPA results were examined by dividing each 
behavioral or physical trait into one of five categories: lower motor function, cerebrospinal 
function, sensory function, neuropsychiatric function and autonomic function. As several of the 
observations belonged to more than one category, there was more than one test to determine the 
extent of anomalous behavior. Detailed below are the observations of SHIRPA 
The SHIRPA protocol is a three staged measurement of physical and neurological health body 
condition sensory and motor function. The purpose of SHIRPA is to identify any anomalies in 
neurological motor  sensory and autonomic function. 
The primary test incorporates measurements of body and coat condition, gait, posture and motor 
function. The secondary tests include motor function, spontaneous locomotion and open field 
observations. The tertiary assessment includes tests of neuropsychiatric and cognitive function, 
grip strength, trunk curl and limb clasping. Automatic responses including pinna pinch and  self 
righting. Environmental induced variations must be accounted for. Mouse maintenance, noise, 
housing conditions light intensity and the time of testing (light cycle) can all influence the 
observed phenotype. The individual observations of SHIRPA are detailed. Before removal from 
the cage, a healthy mouse should respond to open cage with curiosity. This is normal mouse 
behaviour. Familiarity with the handler eases this process and reduced stress induced aberrant 
behaviours. 
3.2.2 In viewing jar: 
Observations were made over a minimum of five minutes and maximum of 15 minutes. 
Prolonged testing time can influence the results. 
 Body: General physical condition including mouse stance. Use of all four paws flat on 
the surface is normal mouse stance. Mouse body weight recorded.  
 Body position: On transfer to the viewing jar, mouse normally maintains a flat position 
with all four paws in position for rapid movement. Any prone position where legs are 
Chapter 3 Neuromuscular and cognitive dysfunction in Opa1
Q285STOP 
mouse 
 
69 
 
visible is abnormal. Stereotypic behaviours observed include mouse rearing on hind 
legs with or without repeated vertical leaping or continuous circling (Waltzer). 
 Coat: Includes coat colour and condition. The mouse coat should be well groomed. 
Colour density may depend on the age of the mouse. Regions of discolouration or 
‘damp’ looking regions require further examination. Matted fur is unusual in short 
haired rodents but is indicative of reduced grooming. Coat can appear ‘spiky’ as though 
standing on end. This is piloerection and indicative of prolonged stress. Regions of 
alopecia may be indicative of in cage fighting, underlying injury or wound, allergies or 
excessive grooming. Whiskers should be symmetrical straight and twitching in response 
to their environment. Mouse with whiskers that have been chewed by another cage mate 
should be transferred to another cage as barbering including whiskers is an aggressive 
behaviour. Whiskers are required for texture discrimination balance and orientation.  
 Defecation: Mouse response to transfer to the viewing jar should be done in a calm 
efficient manner. Mice that are used to handling will not exhibit aberrant behaviour 
associated with fear. The presence of defecation and the amount produced correlates 
directly to anxiety in mouse (Kalueff and Tuohimaa 2004; Savignac et al. 2011; Muñoz-
Castañeda et al. 2014) 
 Urination: Mouse urination in a strange environment is normal behaviour. Mouse will 
intentionally lift the tail and not allow it to become wet.  Incontinence is abnormal 
behaviour suggesting neurological motor or autonomic disturbances.  
 Tremor: Any involuntary repetitive cyclical movements of the mouse or mouse parts 
when at rest or which manifests in response to movement is abnormal. Very fine tremor 
can be observed in mouse ears. The environmental temperature and mouse room 
temperatures should not differ more than 2 degrees. 
 Palperbral closure: Mouse eyes should be wide open giving a round appearance. The 
inability to maintain an open eyed position may indicate impaired motor control, 
neurological disorder, injury, infection. Microphtalmia can be associated with 
hydrocephalus.  
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 Lacrimation:  Mouse eye is large globe structure slightly protruding on side profile. It 
should appear shiny and moist without discharge or excess tearing. Excessive tearing in 
mouse eye is abnormal. It may be indicative of excessive tear production or a blockage 
in the tear duct. 
3.2.3 In the arena:  
Observations over a period of five minutes not exceeding 15 minutes comprised of body 
positions, touch escape and startle response. 
 Transfer arousal: On transfer to the viewing jar, latency to move is observed. Normal 
mouse behaviour on transfer to the viewing jar is to remain inactive for several seconds 
and then move into the central space to begin investigating. Abnormal transfer arousal 
include inactivity or hyperactivity. Thigmotaxis and digging in response to transfer are 
considered abnormal behaviours.   
 Gait: Mouse normal gait is sleek and smooth with no variation in body height as 
movement progresses. Mouse uses the front pad of the paw when walking. At least two 
mouse paws are in contact with the surface at all times. Impaired mobility and abnormal 
gaits can be indicative of impaired lower motor function, cerebrospinal function sensory 
dysfunction or autonomic function. Unbalanced gait due to physical injury because of in 
cage fighting should be investigated. Mouse paw pads should be examined for condition 
colour and sensitivity (toe pinch). Mouse toes should be bent at a soft angle of 5 
degrees. All nails should be visible on examination but not excessively long.  
 Tail elevation: Normal mouse tail is straight and held parallel to the ground.  An 
elevated or straub tail is rigid dorsiflexed and is abnormal. Tail dragging is also 
abnormal and ay be indicative of impaired sensory cerebrospinal function.  
 Pelvic elevation: Normal pelvic elevation in mouse is approximately 2mm from the 
floor (dependant on age and sex of mouse). Normal elevation is less than 5mm.  
Elevation more than 5mm is abnormal and may indicate pain or distress because this 
position is anatomically difficult to maintain. 
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 Startle response: The startle response is a stereotyped motor response to sudden intense 
stimulus. Using a IHR click box held above the arena which elicits the Preyer reflex. 
The Preyer reflex is the backwards flick of the ears in response to the noise. On repeat 
testing, the Preyer reflex is absent. This is a normal conditioned response. 
 Touch escape: Mouse response to increased stroke pressure is to escape. As well 
handled mice are responsive to stroking, a gradual increase in the pressure will elicit 
alarm and they will try to flee. The extent to which mouse attempts to flee is measured 
as mild struggle to increased pressure (normal), moderate struggle to escape a light 
stroke and a vigorous struggle to escape the approach of the handler. 
3.2.4 Above the arena:  
Tests comprised of manual handling, reflexes biting and vocalisation 
 Trunk curl: When suspended by the base of the tail a healthy mouse will position the 
hind legs in a ‘V’ shape and stretch the front limbs towards the floor. After several 
seconds, mouse will then attempt to right himself and grip onto the handlers hand.  
Mice with impaired vestibular function will curl their hind limbs towards their abdomen 
in a trunk curl.  
 Limb grasping: A test of grip strength measures the muscle strength of the forelimbs 
and coordination of fore and hind limbs. Mouse is suspended above a grid and allowed 
to grip with the front paws. When they make contact with the grid, the handler attempts 
to dislodge the grip by pulling back with sustained gently pressure. How easily the 
mouse lets go of the grip depends on the amount of exertion required to dislodge him.  
 Corneal reflex: When the cornea is touched gently with a cotton bud mouse reaction is 
to blink. This is a normal autonomic response to a foreign object in the cornea. Impaired 
autonomic function may reduce this blink reflex. 
 Pinna reflex: Mouse is gently restrained and the auditory meatus is touched lightly with 
the tip of a cotton bud minus the cotton. This elicits a rapid ear retraction or head 
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movement. Impaired autonomic function may result in an impaired or absent pinna 
reflex response. 
 Contact righting: Mouse is placed in a Perspex tube which is slowly inverted. Intact 
proprioreceptors on the mouse paw with normal vestibular function sense body position 
and rotate back to their original position. Impaired vestibular apparatus in mouse rely on 
paw pressure only and remain inverted in the Perspex tube. 
 Evidence of biting: Provoked biting is a normal response in mouse. A wooden dowel is 
placed to one side of mouse mouth between the teeth. Mouse response will be to 
withdraw his head back slightly and grip the dowel between his teeth. This is normal 
mouse behaviour. Mouse attempting to bite the handler when picked up is a fear 
response and can be eliminated with regular careful gently handling. 
 Vocalisation: Mouse normally vocalises when he is highly anxious or in pain. Vocal 
mice are usually frightened but with practice will soon adapt to handling especially 
when there are no procedures carried out. Mouse in pain must be carefully examined for 
the site of damage. Chronic pain is usually identified in mouse sitting hunched and 
alone in their shared cage.. Vocalisation in mouse with chronic pain should be dealt 
with as humanly and quickly as possible. 
Table 3.1 summaries the observational data recorded and the number of specific functional 
observations made pertaining to function. 
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SHIRPA
F WT 3 M WT 3
F Het 5 M Het 3
Table 3.1SHIRPA observational profiles for specific function 
 
Multiple observations of mouse from in the viewing jar to above the arena were used to compile 
a functional assessment of specific systems with graded data from zero (normal) to 3 
(impaired/reduced/abnormal). The number of observations for each function is shown in the 
insert 
3.2.4.1 Results of SHIRPA 
Table 3.2 Summary of test numbers for SHIRPA analysis in WT 
and Het 
 
As previously described, SHIRPA categories of mouse behavior were divided into 5 main 
functions. Figure 3.2 shows a summary of the values obtained and the statistical difference 
between both male and female WT and Het. 
 
  
 
 
Location Measure Function
Viewing Jar Body position A B lower motor  cerebrospinal
Coat D E neuropsychiatric autonomic 
Defecation B D E cerebrospinal neuropsychiatric autonomic 
Urination B D E cerebrospinal neuropsychiatric autonomic 
Tremor AD E lower motor  neuropsychiatric autonomic
Palpebral closure C E sensory autonomic
Lacrimation C E sensory autonomic
In Arena Transfer Arousal A B D lower motor cerebrospinal neuropsychiatric
Gait A B lower motor  cerebrospinal
Tail elevation A B E lower motor  cerebrospinal autonomic
Pelvic elevation A B E lower motor  cerebrospinal autonomic
Startle response C D E sensory neuropsychiatric  autonomic A B C D E
Touch escape C D E sensory neuropsychiatric  autonomic Viewing jar 2 3 2 4 6
Position A B E lower motor  cerebrospinal autonomic Arena 4 5 2 3 4
Above Arena Trunk curl A B E lower motor  cerebrospinal autonomic Above Arena 5 5 3 1 7
Limb grasping A B E   lower motor  cerebrospinal autonomic 11 13 7 8 17
Pinna reflex A B E lower motor  cerebrospinal autonomic A lower motor function
Corneal reflex C E sensory autonomic B cerebrospinal function
Contact righting A B E lower motor  cerebrospinal autonomic C sensory function
Evidence biting C E sensory autonomic D neuropsychiatric function
Vocalisation C D sensory neuropsychiatric  E autonomic function
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Figure 3.2 SHIRPA analysis in WT & Het 
Graph showing the average SHIRPA  observational values  for all functions in female 
and male WT  (n6) and Het(n8) at 12 months. 
3.2.4.2 Discussion of SHIRPA analysis in WT and Het mouse 
The phenotype analysis using SHIRPA was designed to test several functions: Muscle and 
lower motor function, cerebrospinal function, sensory, neuropsychiatric and autonomic function 
through a combination of test parameters. Body position which was a test of lower motor 
function cerebrospinal and neuropsychiatric function was present in all Het mice and absent in 
all but one WT mouse suggested Het mice had some impairment involving all three functions. 
Tremor was present in eight of nine Het mice tested and absent in all wild type mice. Gait 
anomalies were identified as ‘other’ on the score sheet and were described as ‘jerky’ or ‘tip-toe’ 
which suggested lower motor sensory and cerebrospinal function impairment. Figure 3.3 shows 
typical Het stance where foot placement is asymmetrical. 
Autonomic function in tail elevation was observed in all Het mice. Vocalization was another 
factor present in Het mice that was absent in WT mice. Although sensory function was within 
normal limits in the Het mice, this demonstrates the application of visual cues to mouse in 
bright light (47.8 lux compared to an average 10.4 lux in the mouse room). Mice rely primarily 
on their olfactory senses especially in an unfamiliar territory where all visual cues are unknown. 
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A:Lower Motor B:Cerebrospinal C:Sensory D:Neuropsychiatric E:Autonomic
FWT FHet MWT MHet FWT FHet MWT MHet FWT FHet MWT MHet FWT FHet MWT MHet FWT FHet MWT MHet
Ave 0.36 0.57 0.39 0.46 0.28 0.60 0.28 0.53 0.00 0.17 0.00 0.02 0.21 0.61 0.27 0.60 0.12 0.41 0.06 0.33
SEM 0.09 0.07 0.03 0.06 0.05 0.08 0.05 0.12 0.00 0.10 0.00 0.00 0.03 0.06 0.00 0.04 0.00 0.06 0.00 0.07
n A B C D E
FWT 3 FWT:FHet 0.042 0.009 0.019 0.001 0.001
FHet 5 MWT:MHet 0.502 0.032 0.988 0.001 0.001
MWT 3 F(3,11) 2.238 F(3,11) 5.512 F(3,11) 4.518 F(3,11) 24.718 F(3,11) 14.918
MHet 3 *p<0.05**p<0.010***p<0.001 ±SD
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Figure 3.3 Het mouse phenotype 
above the arena 
Female Het grooming required 
balancing on two hind paws but the 
right paw does not make contact with 
the floor. (Opa1
Q285STOP
 mouse was 
previously back crossed into CH3 
strain and occasional CH3 coat colour 
occurred.)   
 
 
3.2.5 Rotarod analysis in Opa1Q285STOP mouse 
3.2.5.1 Experimental design of rotarod testing 
Mice remained in their original cages and were transferred to the test room for a period of 
fifteen minutes to acclimatise. Each test required that mouse began with the rod rotating at 
8rpm. Once the mice were balanced, the ‘acceleration’ mode was selected. This was 0-40 rpm in 
5 minutes. This was achieved by an increase of 0.133 revolutions per second for 300 seconds.  
Individual floor sections were elevated to initiate the built in timer device which recorded the 
time in seconds that individual mice remained on the rod. When the mouse fell onto the floor 
panel, the timing device stopped recording and a record was made of the latency. Mouse was 
returned to his cage for a 15-minute rest period before repeat testing. Three tests were 
performed. During this test, no mouse completed a full passive rotation. Any aberrant behaviour 
was recorded on the test sheet. 
Housing conditions were considered where 12 month old mice had been housed for at least nine 
consecutive months as a group where the minimum number of mice was three or housed as 
solitary. Some male mice were housed as solitary for breeding purposes or for in cage fighting. 
No female mice were caged solitary.  
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   Rotarod Analysis
F WT 11 M WT 8
F Het 13 M Het 15
sMWT 4 gMWT 5
sMHet 5 gMHet 10
    s:solitary g:group
In order to optimise rotarod analysis, a test run was performed to give the mice an opportunity 
to familiarise themselves with the slowly rotating rubber grip rod. This test was carried out on 
‘run’ setting, which maintains the rate and speed of acceleration. Mice demonstrated a 
preference for an 8rpm speed. Mice were retained in a holding cage between tests so that they 
were prepared for the next stage of testing. Mouse weight can have a limiting effect on their 
ability to perform this procedure.  Male WT mice who weighed in excess of 34g appeared to 
have more difficulty with synchronised hind limb movement compared to their lighter cage 
mates 
3.2.5.2 Results of rotarod testing 
 Table 3.3Summary of test numbers for rotarod analysis in WT 
and Het 
 ‘s’ denotes solitary housed and ‘g’ denotes group housed as explained 
in the text 
 
Female WT had a latency of 114±4 seconds. Female Het latency was 82±4 seconds /sec which 
was significantly reduced compared to female WT (F (3,42) 3.897 p=0.004). 
 Male WT latency was 70±5 seconds. Male Het latency was 71±5 seconds which was not 
significantly different compared to male WT  (p=0.744). Figure 3.4 A shows this data. 
As one of the conditions that differed between male and female mice was housing, latency in 
solitary and paired male mice was examined. Housing conditions can influence rotarod 
performance (Abramov et al. 2008).  As there were no solitary housed females, the analysis was 
performed in male mice only. 
Solitary housed male mice had significantly increased latencies compared to group housed 
males regardless of phenotype. Solitary male WT had a latency of 103±6 seconds. Group 
housed male WT latency was 50±5 seconds which was significantly reduced compared to 
solitary housed WT males (F(3,20) 2.727 p=0.013). 
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Rotarod p
FWT 11 FWT:FHet 0.004
FHet 13 FWT:MWT 0.006
MWT 8 MWT:MHet 0.744
MHet 15 FHet:MHet 0.263
F(3,42) 3.897
*p<0.05**p<0.001***p<0.001
Latency/Housing
sMWT 4 sMWT:sMHet 0.972
sMHet 5 sMWT:gMWT 0.013
gMWT 5 gMWT:gMHet 0.760
gMHet 10 sMHet:gMHet 0.020
F(3,20) 2.727
s:solitary g:group
Solitary Het male latency was 108±3 seconds and group housed latency was 34±7 seconds 
which was also significantly reduced compared to solitary housed Het males (F(3,20) 2.727 
p=0.020). Solitary housed male WT and Het mouse latencies were not significantly different 
(p=0.934). Group housed male WT and Het latencies were not significantly different (p=0.898). 
Figure 3.4 B shows a graph of these findings. 
 
Figure 3.4 Rotarod latency 
to fall analysis in WT & Het 
mouse 
Bar graphs show the mean 
±SD latency to fall from 
rotarod in (A) WT and Het 
female & male (B) Latency in 
male WT and Het solitary 
housed and latency in WT and 
Het group housed  
 
The possible effects of weight were considered. As 34g was the maximum weight at which no 
difficulties in synchronising hind leg movement was observed, this was selected as the value at 
which to examine latencies. No female WT or Het mice weighed in excess of 34g. Two male 
Het mice weighed in excess of 34g and so were excluded from the analysis. Male WT weight 
versus latencies was examined. Male WT weighing less than 34g had a latency of 76±5/sec and 
male WT who weighed more than 34g had a latency of 61±6/sec which was not significantly 
different to male WT who weighed led than 34g (p=0.076). 
3.2.5.3 Discussion of rotarod test in WT and Het mouse 
Female WT mice had significantly increased latency to fall compared to female Het mice 
(p=0.001). This represented a 28% reduction in latency in the female Het mice. In the male 
population, the Het mice had a 2% increase in latency compared to WT males. On further 
investigation, it was considered that many of the Het males were housed in solitary conditions 
for breeding purposes. WT males were usually housed in groups. Further rotarod analysis 
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   Rope/Beam
WT 10 Het 15
F WT 5 M WT 5
F Het 7 M Het 8
revealed the statistical difference seen in rotarod performance which directly correlated to 
housing conditions. The solitary housed WT males had a  significant 107% increase in latency 
compared to group housed male WT  (F(7,205) 21.433 p=0.001). Solitary housed Het males had 
a 221% increase in latency compared to group housed male Het (p=0.001). Latency to fall in 
solitary housed male WT and male Het was not significantly different (p=0.134). Latency to fall 
in group housed WT and Het was not significantly different (p=0.480). 
WT male group housed latency was 52% less than solitary housed WT.  In the Het population, 
the group housed latency was 69% less than solitary housed male Het. As there were no solitary 
housed female mice and it was considered more stressful to separate a group of cohabitating 
mice the investigations on housing completed here. 
3.2.6 Tightrope testing in Opa1Q285STOP mouse 
3.2.6.1 Experimental design of tight rope testing 
The object of the tight rope test was to observe symmetrical coordination and balance.  There 
were some limitations to the tightrope test. Individual testing on the tight rope test required mice 
to be observed carefully for signs of exhaustion. Any mouse seen to be distressed at any time 
during the test was carefully given a platform by way of an open palm on which to drop. Mice 
frequently wire hang from their cage roofs and were familiar with this method of collection. 
Analysis of the tightrope test included latency to fall from the rope with a maximum time of 60 
second duration. 
3.2.6.2 Results of tight rope testing 
  
Table 3.4 Summary of test numbers for rope and beam analysis in 
WT and Het 
  
The total distance travelled down the rope was the first parameter analysed. The total distance 
travelled was calculated from the maximum time (1 minute) that mouse was suspended from the 
rope in either direction. Female WT mice travelled 7.4 ±1.7cm. Female Het travelled 4.7±1.2cm 
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which was not significantly different compared to female WT (p=0.082). Male WT travelled 
9.9cm±0.4 and Het males 3.6±0.6 which was significantly reduced compared to male WT 
(F(3,21) 1.498 p=0.026). These results are shown in Figure 3.5A. 
3.2.6.3 Discussion of tight rope testing in WT and Het mouse 
Other observations included in this test were the ability to obtain and maintain an upright 
position on the rope. As this was dependent on weight, female Het mice performed well, 
however as this was also considered an extremely stressful test, it was decided not to pursue it. 
As the lifestyle of the Het mouse does not involve any gross exertion, it was considered that 
their cardiac function may not have coped well with the challenge (Chen et al. 2012). Instead, a 
less physical test was employed using the narrow beam. 
3.2.7 Narrow beam testing in Opa1Q285STOP mouse 
3.2.7.1 Experimental design of narrow beam testing 
The narrow beam test was a measure of mouse balance, gait and spatial awareness while 
walking a wooden beam towards a platform.  
The limits of the narrow beam experiment were that visually impaired mice may not see the 
platform or realize its intention. It was anticipated that mice would require the platform at least 
once during the trial and avail of it again as the beam narrows. Mice whose gait was not 
synchronized were encouraged to continue uphill by tilting the beam at a 150 angle against 
gravity. Measurements analyzed were the time to initiate movement along the beam and 
distance travelled along the beam measured in cm. 
3.2.7.2 Results of narrow beam testing 
The time to initiate movement along the beam was analyzed. In female WT the time to initiate 
movement along the beam was 2.0±0.5 seconds. In the female Het mice, this was 45±8 seconds 
which was significantly increased compared to female WT (F (3,21)5.725 p=0.003). In the male 
WT initiation was 7.4±2 seconds. In the Het males, initiation was 39.2±8.0 seconds which was 
significantly increased compared to male WT (p=0.007). The second parameter measured was 
the distance travelled down the beam. It was observed that once Het mouse moved, he ran the 
Chapter 3 Neuromuscular and cognitive dysfunction in Opa1
Q285STOP 
mouse 
 
80 
 
0
10
20
30
40
50
60
FWT FHet MWT MHet
In
it
ia
ti
o
n
(s
ec
)
****
0
2
4
6
8
10
12
FWT FHet MWT MHet
D
is
ta
n
ce
 (
cm
)
*A B
n Beam p
FWT 5 FWT:FHet 0.003
FHet 7 FWT:MWT 0.432
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n Rope p
FWT 5 FWT:FHet 0.082
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MHet 8 FHet:MHet 0.097
F(3,21) 1.498
*p<0.05**p<0.001***p<0.001
length of the beam to return to his home cage. WT mice travelled an average distance of 42 ±20 
cm. However, wild type mice stopped on route to investigate the beam and their surroundings, 
including walking back the way they had travelled. As a result the distance travelled by both 
genotypes was not comparable. While the Het mice were clearly looking for an escape from the 
beam, the WT were busy investigating the experimental design.  Figure 3.5 B shows a summary 
of these findings. 
 
Figure 3.5 Tight rope and narrow 
beam testing in WT and Het mouse 
Graph showing means ±SD (A) 
Tightrope distance travelled in cm  in 
WT and Het and (B) Narrow beam 
initiation time in seconds in WT and 
Het 
 
 
3.2.7.3 Discussion of narrow beam testing in WT and Het mouse 
The narrow beam test was used to identify imbalance and uncoordinated behavior in mice who 
manage to perform the rotarod test successfully. The sensitivity of the rotarod can be reduced 
through training and practice. The aim of the narrow beam was to give mouse a novel 
environment without any immediate threat, and a means of escaping. Time to initiate travel 
down the beam showed a significant difference between WT and Het mice with Het mice taking 
an average 550% more time to initiate travel.  
Female Het mice showed a 42 fold increase in time to initiate compared to female WT. Male 
Het showed a 32 fold increase compared to male WT.  
In the WT population, female mice were 265% quicker to initiate travel and travelled 21% 
further  compared to male WT. This may indicate that the female WT were more anxious to 
return to their home cage. Male WT explored their surroundings.  
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In the Het population, females were 13% slower to initiate travel and travelled 16% less 
compared to male Het. 
The innate curiosity of healthy mice may have led to some curious data but for the observations 
of what constitutes normal behavior in mouse behavior. The extended freeze seen in the Het 
mouse was also observed on placement into the arena during SHIRPA analysis resulted in 
increased initiation times which were not present in WT mice thus significant observations seen. 
The ability to complete the task in WT males resulted in a reduced distance in the WT 
population. Again, some individual mice performed the task with the skill and dexterity of 
practiced animals while others seemed disorientated and hesitant once the travel was initiated. 
Figure 3.6 shows an image of female WT and Het on completion of the narrow beam test. 
Female WT appears bright eyed and curious. The Het mouse is demonstrating poor spatial 
awareness (right rear toes are overhanging the beam). Unlike female WT, the Het fur is spiky 
and appears to be standing on end. She appears nervous and not paying attention to her 
surroundings. On returning to their home cage these physical appearances were less obvious. 
 
Figure 3.6 Cage mates–and Opa1Q285STOP and C57Bl/6 WT at 12 months 
Opa1 
Q285 STOP
 mouse sitting beside WT on the narrow beam awaiting return to home 
cage.  Note Het rear right paw overhanging the beam. Lack of eye contact and slightly 
ruffed fur (piloerection) indicative of distress. 
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3.2.8 Mouse learning in training trials 
3.2.8.1 Introduction 
Rotarod was a learning trial where the mean latency from three individual tests were compared 
over three consecutive days. The final score on day three represented the maximum trained 
latency a mouse can achieve and was expected to show some level of improvement from day 1.   
3.2.8.2 Results of mouse learning 
Table 3.5 shows a summary of learning scores from three consecutive days testing in female 
and male WT and Het. There was no statistical difference in learning between solitary and 
group housed male WT (p=0.099). Solitary housed male Het learning was significantly different 
compared to group housed Het males (p=0.036). Figure 3.7 shows line graphs of learning in WT 
and Het 
Table 3.5 Mouse learning in training trials 
Table shows (A) the mean score from learned training trial from three consecutive days with the 
statistical difference between groups. (B) Housing associated learning in solitary and group 
housed male WT and Het. 
 
 
 
 
 
 
A D1 D2 D2-D1 D3 D3-D2D3-D1 B D1 D2 D2-D1 D3 D3-D2D3-D1
FWT 1.72 1.70 -0.02 2.28 0.58 0.56 sMWT 1.42 1.80 0.38 1.99 0.18 0.56
SEM 0.13 0.12 0.10 SEM 0.04 0.13 0.06
FHet 1.01 1.16 0.16 1.34 0.18 0.34 sMHet 1.53 1.82 0.29 1.54 -0.28 0.01
SEM 0.17 0.29 0.02 SEM 0.16 0.21 0.19
FWT:FHet F(3,41)4.725 0.088 sMWT:sMHet F(3,20) 4.747 0.151
MWT 1.30 1.31 0.01 1.52 0.21 0.22 gMWT 0.75 0.77 0.02 0.95 0.18 0.20
SEM 0.09 0.09 0.01 SEM 0.21 0.35 0.33
MHet 1.35 1.22 -0.13 1.15 -0.07 -0.20 gMHet 1.26 0.92 -0.34 0.96 0.04 -0.30
SEM 0.20 0.16 0.01 SEM 0.28 0.14 0.14
MWT:MHet F(3,41)4.725 0.018 gMWT:gMHet F(3,20) 4.747 0.071
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Figure 3.7 Learning in training trials  
Line graphs showing mean learning trends over three sequential days in (A) female and male 
WT and Het.(B) Male solitary housed and group housed learning. 
 
3.2.8.3 Discussion of mouse learning in training trials 
There was no significant difference in female Het learning compared to female WT (p=0.088). 
Male Het learning was significantly recued compared to male WT (F(9,70) 2.554 p=0.018). 
This was examined with respect to housing conditions Solitary housed male Het learning was 
not significantly different to solitary housed male WT (p=0.151). Group housed male Het 
learning was significantly reduced compared to group housed male WT (F(3,17) 4.747 p=0.007) 
showing a 2.5 fold reduction. 
3.3 Thermal imaging of Opa1Q285STOP mouse 
3.3.1 Introduction 
A thermal imaging camera was used to determine whether there was any difference in the core 
heat production in Opa1
Q285STOP
 mouse compared to his wild type littermates. The metabolic rate 
is influenced by core body temperature. Oxidative stress can be influenced by temperature, and 
cooling of core temperature can reduce the accumulation of reactive species through the 
reduction of energy expenditure (Lane et al. 1996). Calorific restriction which has been 
established as a means of reducing oxidative stress (Alemany 2012; Jang et al. 2012; Lee and 
Wei 2012) has the secondary effect of reducing the body core temperature (Weindruch et al. 
1988). This reduction in core temperature can have beneficial effects in controlling the effects 
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Thermal
yWT 9 yHet 4
oWT 8 oHet 9
of oxidative stress and increased oxygen demand. By reducing the tissue oxygen requirements, 
fusion deficient mouse may be demonstrating an adaptive mechanism through reduced thermal 
conductance.  
3.3.1.1 Experimental design of thermal imaging 
Thermal imaging data was designed to be a provisional experiment to support the hire of a 
thermal camera. As this did not come to fruition, it was decided to present this provisional data 
as it shows a significant finding in younger Het mice which does not extend into aged Het when 
compared to WT. Mice were divided according to age into two groups. Young mice were 
between 2-6 months of age. Old mice were between 12-15 months of age. All wild type and Het 
mice were analysed within 1 hour of the start of a dark phase of the 12 hour light-dark cycle. 
A limiting factor of thermal imaging experiment was the spatial resolution of the camera which 
was 1.36mrad with an image frequency of 60Hz and a minimum focussing distance of 0.4 
meters. As a result, the time delay from shutter activation and image acquisition was increased. 
This resulted in several ‘missed’ shots as mice were not manually restrained at any point. 
Although the camera was sensitive, it was unable to detect the heat transferred from mouse paw 
to the floor of the arena, and thermal imaging of potential gait anomalies were not realised. 
3.3.1.2 Data analysis of thermal imaging in WT and Het mouse 
 
Table 3.6 Summary of test numbers for thermal imaging analysis in 
WT and Het 
‘y’ denotes young and ‘o’ denotes old 
Following image acquisition, three regions of the mouse were used for interpretation of data. 
Mouse head was targeted between the frontal and occipital region. This represented mouse 
central temperature. As this region is located directly between the cooling influence of the ears, 
it was considered an appropriate location in which to analyse core brain temperature 
measurement. For the sake of clarity, this reading was called the head temperature. Tail base 
readings were taken from the base of the tail where residual heat was visible in the first third. 
This represented peripheral temperature. Flank readings were taken from both left and right side 
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where possible. This represented a mean central temperature readings in the mouse. Figure 3.8 
shows representative images taken with the thermal camera and Figure 3.9 shows graphs of 
head, flank and tail reading in young and older WT and Het mice. 
 
Figure 3.8 Thermal imaging in young & old WT & Het 
Thermal images of young (2-6 months) and older (12-15 month) WT and Het mice in the arena. 
The thermal camera was set to detect temperatures within the range of 25
o
C-35
o
C. No manual 
handling or restriction of mouse movement was done.  In each image, the ‘Sp’ denotes spot 
metering where temperature measurement was analysed. SP1 Head, SP 2 tail end, SP3 flank 
3.3.1.3 Results of thermal imaging in WT and Het 
The results were analysed as groups of ‘young’ (2-6 months), ‘old’ (12-15 months) head, flank 
and tail. Table 3.7 shows a summary of these data. 
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n Head p Tail p Flank p
yWY 4 yWT:yHet 0.001 yWT:yHet 0.024 yWT:yHet 0.006
yHet 5 yWT:oWT 0.321 yWT:oWT 0.371 yWT:oWT 0.112
oWT 6 oWT:oHet 0.004 oWT:oHet 0.287 oWT:oHet 0.130
oHet 6 yHet:oHet 0.797 yHet:oHet 0.439 yHet:oHet 0.072
F(3,26) 38.542 F(3,26) 2.502 F(3,26) 2.077
*p<0.05**p<0.010***p<0.001 ±SD
Table 3.7 Summary of thermal results WT and Het 
Table shows the mean ±SEM of thermal readings taken from head, tail and flank regions of 
young and old WT and Het. The statistical difference between groups is shown. 
 
 
Figure 3.9 Thermal 
analysis in WT and Het 
mouse 
Graphs showing the mean 
±SD temperature  in degrees 
Celsius in (A) Head, (B) Tail 
and (C) flank in young and 
old WT and Het. ‘y’ denotes 
young and ‘o’ denotes old. 
 
3.3.1.4 Discussion of thermal imaging in WT and Het mouse 
Heat preservation in the mouse presents a challenge because of the high surface to volume ratio. 
The large surface area presents a source of heat loss and requires an increased metabolic rate to 
maintain core body temperatures. In Opa1
Q285STOP
 mouse, the average body temperature was 
reduced in both young and older aged mice.  
3.3.1.4.1  Young WT and Het mice thermal analysis 
In the young Het mice, there was a significant reduction in body temperatures compared to 
young WT. The head reading was a significant 9% less than WT (F(3,26) 38.542 p=0.001).  Tail 
temperature was also reduced by 9% which was significantly different to WT (F(3,26) 2.502 
p=0.024). Flank temperature in Het mouse was 5% less than WT which was also statistically 
different to WT (F(3,26) 2.077 p=0.006). 
Young n Age(m) Head Tail Flank Old n Age(m) Head Tail Flank
yWT 8 4 32.8 29.4 33 oWT 8 12 32.2 27.7 32.5
SEM 2 0.9 1.6 1.1 SEM 2 1.4 1.4 1
yHet 4 4 30 26.9 31.4 oHet 9 12 30.2 28.3 31.9
SEM 2 1.2 0.8 0.4 SEM 1 1.6 2.4 11.4
yWT:yHet 0.001 0.024 0.006 oWT:oHet 0.004 0.287 0.130
F F(3,26) 38.542 F F(3,26) 2.077
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3.3.1.4.2 Older WT and Het thermal analysis 
In the older aged mice, the Het head temperature was reduced by a mean 2%. This temperature 
reduction was significantly different in Het head recording which had a 6% reduction compared 
to WT (F(3,26) 2.077 p=0.004). Tail and flank temperatures in older Het were not significantly 
different to older WT. 
As mice aged, the differences between WT and Het mice with respect  thermal readings was 
less pronounced possibly due to age related decline in core temperatures. 
The reduction in temperature with age observed in the WT population demonstrated a reduction 
of 3% compared to young WT.  There was a 2% reduction in head temperature with a 6% 
reduction in tail and 2% reduction in flank region. In the Het population, the age related 
reduction in temperature was not observed. The head temperature showed an increase of 0.6%, 
the tail temperature showed a 5% increase and the flank region showed a 2% increase compared 
to young Het temperatures. This represented a mean 2.4% increase in temperature in old Het 
mouse compared to young Het mouse.  In summary, young Het mice had a 7% reduction in 
thermal readings compared to young WT. In older mice, the percentage difference in Het was a 
2% reduction compared to older WT mice.  
A variety of causal factors may result in a reduced surface body temperature including social 
housing and dietary input. Calorific restriction reducing oxidative damage also reduces body 
core temperatures (Merry 2004). The reduction in core temperature associated with uncoupling 
protein 2 results in an elevated hypothalamic temperature causing a reset of the internal 
thermostat (Conti et al. 2006). The heat generation observed in older Het may a by-product of 
inefficient mitochondrial ATP production. Might the reduced temperatures seen in the young 
Het mice be a compensatory mechanism for reduced OXPHOS function?  
Findings of thermal imaging and the role of Opa1 as a fusion protein in mitochondrial dynamics 
may be interpreted as a functional maintenance role in mitochondrial activity. The generation of 
heat in WT mice was considered a response to the environmental temperature of the procedure 
room (23
o
C) compared to the mouse stock room (20
o
C).WT mice demonstrated a healthy 
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response to a transient increase in environmental temperature. In the Het population, the 
increase in ambient temperature was not sufficient to alter the body surface temperature seen in 
these mice. A recent paper discussing the obliteration of a mitochondrial protease OMA results 
in a reduction of short isoform Opa1. These mice demonstrated increased body weight and 
defective thermogenesis due to defective brown adipose fat (BAT) oxidation (Quirós et al. 
2012).In Opa1
Q285STOP
 mouse, it was not the reduction of short isoform but the reduction of 
Opa1 that may result in reduced BAT oxidation. An age related reduction in thermoregulation 
may also signify the replacement of BAT for adipose fat (Sellayah and Sikder 2014). At 15 
months of age, the core temperature of mice can be reduced regardless of pathology (Gonzales 
and Rikke 2010) . 
Both WT and Het mice were caged in groups of 4 where they had free access to the same diet 
(Teklad Global 14% protein maintenance diet). Mouse thermo neutral zone is between 26
o
C and 
34
o
C. Studies in C57BL/6 mice demonstrate a preference for warmer ambient temperatures 
(Gaskill et al. 2012)in order to maintain optimum health. Mice whose mitochondria are 
compromised have even greater need for basic provision of heat. If  these provisions are not 
met, might this inadvertently prolong the mitochondrial  life span of these mice? 
Temperature homeostasis is regulated by neurones of the preoptic area (POA) of the anterior 
hypothalamus. The core body temperature is set within narrow range and is dependent on 
feedback from both the local and peripheral temperatures.  The presence of mitochondrial 
uncoupling protein 2 (UCP-2) expression in the preoptic area  (Horvath et al. 1999) can alter the 
core thermostat. UCP-2 is an inner mitochondrial membrane protein that uncouples oxidative 
phosphorylation from respiration by leaking hydrogen ions from the intermembrane space to the 
matrix, thereby dissipating the proton gradient energy in the form of heat. This will produce an 
increase in the local preoptic area temperature and result in a thermostat reset of the core 
temperature. Reduced mitochondrial fusion in the POA could initiate UCP-2 resulting in 
reduced core temperatures observed in Opa1
Q285STOP 
mouse.  
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Temperature governs the metabolic rate. A cold defence reaction will result in increased 
metabolic rate to generate heat in place of ATP or a cold induced reduction of metabolism 
(induced hypothermia). The reduction in core temperature confers protection by reducing the 
requirements for ATP while maintaining the membrane potential in high energy demand tissues 
(Zeevalk and Nicklas 1996). The loss of electrons and concomitant ROS production depend 
maintenance of the inner membrane potential. 
Adaptive thermogenesis has been identified in C elegans  (Zhao and Wang 2012)  where the 
hypothermic induced longevity conferred increased lifespan while reducing resistance to 
oxidative stress. This suggests that ROS play a positive role in survival. 
3.4 Cognitive impairment in Opa1Q285STOP mouse 
3.4.1 Introduction 
The ability to investigate cognitive function in mammals employs the use of particular tests 
designed to highlight specific retentive functions of the hypothalamus. A test of spontaneous 
alternation employs the T maze. Habituation of exploration can be induced by exposure to 
spatial location. The use of a T maze can demonstrate spontaneous alternation. Normal rodent 
behaviour suggests the animal will select the previously unvisited arm of the maze. This reflects 
an intact short term memory. The selection choice (novel/ unexplored) is called spontaneous 
alternation. 
The basis of the novel object recognition test was described by Ennaceur (Ennaceur et al. 1997) 
where they showed that in a familiar environment, rodents show an affinity towards new or 
novel objects. It assumes the rodent has a retention capacity for the familiar object. In the 
original experiments, rats were the subject animal. The method has been modified for mouse 
with variations on the procedure and the parameters analysed including repeat testing within a 
24 hour period (Ferguson et al. 2004; Arqué et al. 2008). Studies in sleep deprivation in mice 
(Palchykova et al. 2006) and the effects of housing can alter the outcome of the performance 
(Võikar et al. 2005) A recent study on the effects of reactive oxygen species (ROS), in the 
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    T Maze 
WT 13 Het 16
F WT 6 F Het 7
M WT 7 M Het 9
brains of aged mice determined the impaired novel object recognition seen in some aged mice 
was due to NOX induced synaptic ROS (Ali et al. 2011). 
3.4.2 T Maze analysis in WT and Het mouse 
3.4.2.1 Experimental design of T maze testing 
Rewards in the form of food treats were not included in this trial. Mice showed spontaneous 
alternation pattern as an intrinsic behaviour and not as a food motivated response. Treat and 
reward trials can produce reverse results if the anticipated reward was less than expected. This 
can result in contrast reward where the mouse loses motivation to continue the test  (Youn et al. 
2012).  
Habituated mice who performed the test under stress less conditions learned the routine quickly. 
Their ability to recall events from one minute previous can be adversely affected if the animal is 
removed from the maze in a hurried fashion. Allowing the mouse to climb onto the testers hand 
will ensure a rapid turn round of repeat tests. Therefore, the only limit to the experiment was the 
time taken to acclimatise (10 minutes in the home cage), train (5 minutes), and test (20 minutes 
with a 0.5 minute interval between tests). 
3.4.2.2 Results of T maze testing in WT and Het mouse 
Table 3.8 Summary of test numbers for T maze testing in WT 
and Het 
 
Mice were analysed according to shared cages. Alternate female/male grouped cages were 
tested to eliminate any confounder effect initiated by the stress of new location. Mice were 
analysed alternately WT and Het. The T maze was cleaned with 70% ethanol followed by warm 
water between each mouse regardless of their phenotype. The data collected from the time in 
seconds before the novel arm was located, the time in seconds spent in the novel arm and the 
time in seconds spent in the original familiar arm was used to generate the investigation ratio 
and discrimination ratio for the test. The mean time to novel arm was in female WT was 10.2 
±2.4 seconds. Female Het time to novel was 31±3.9 seconds which was significantly increased 
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FWT 7 FWT:FHet 0.001 FWT:FHet 0.001 FWT:FHet 0.741
FHet 7 MWT:MHet 0.005 MWT:MHet 0.530 MWT:MHet 0.021
MWT 6
MHet 9 F(3,25)6.675 F(3,25)4.455 F(3,25)6.675
compared to WT (F(3,25)6.675 p=0.001).Time to novel in male WT was 11.9±2.6 seconds and 
33.1±3.2 seconds in male Het which was significantly increased compared to male 
WT(p=0.005). Time in novel arm in female WT was 33.1±3.2 seconds and in female Het 
16±2.8 seconds which was significant reduced compared to WT (F(3,25) 4.455 p=0.001). Time 
in novel arm in male WT was 23.8±2.2 seconds and 21.4±1 seconds in male Het which was not 
significantly different to WT (p=0.530). Time in the original arm in female WT was 11.5±2.6 
seconds and 11.5±2.6 seconds in female Het which was not significantly different to WT 
(p=0.741). Time in original arm in male WT was 11±1.5 seconds and 15.1±1.4 seconds in male 
Het which was significantly increased compared to WT (F(3,25) 6.675 p=0.021). Figure 3.10 
shows a summary of these data. 
 
Figure 3.10 T maze 
testing parameters in 
WT and Het 
Graph  showing mean 
±SD of  T maze 
spontaneous alternation 
testing parameters in 
female and male WT and 
Het. 
  
The investigation ratio (IR) female WT was 0.66 ±0.06 and in female Het was 0.41±0.07 which 
was significantly reduced compared to WT (F(3,25)10.619 p=0.006). The IR in male WT was 
0.68±0.04 and in male Het was 0.56±0.04 which was not significantly different compared to 
male WT (p=0.144). The discrimination ratio (DR) in female WT was 0.40±0.10 and in female 
Het was 0.12±0.01 which was significantly reduced compared to WT (F(3,25) 11.741 p=0.002). 
The DR in male WT was 0.66±0.08 and in male Het was 0.51±0.05 which was not significantly 
different compared to male WT (p=0.096). Figure 3.11 shows a summary of these ratios. 
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Figure 3.11 T Maze IR and DR in WT and 
Het 
Graph of mean ±SD of the investigation ratio 
and discrimination ratio for T maze 
spontaneous alternation in WT and Het at 15 
months 
 
 
The selection of the correct novel arm in repeat 
tests reflects a degree of recall and learning. The average correct selection of the novel arm 
provides an indication of participation in the population (Whishaw and Tomie 1996; Wolfer et 
al. 1998). For example, selection in test number 10 often resulted in mouse remaining between 
both arms and selecting neither. This was interpreted as inertia due to lack of motivation. The 
novel arm was exactly the same as the original arm except that it was on the opposite side. As 
far as structure and lighting levels were concerned there was very little novelty. Spontaneous 
alternation testing did not include reward and so it was important to discover what the boredom 
threshold for WT mouse was and apply it across the range of animals tested. The number of 
repeat tests was 7. Female WT scored the correct selection in 74% of tests. Female Het scored 
40% correct which was significantly reduced compared to WT (F(3,25) 10.832p=0.001). Male 
WT scored 66% correct selections and male Het scored 51% correct which was not statistically 
different compared to male WT (p=0.454). Figure 3.12 shows a summary of these findings and 
shows details of test participation. 
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Figure 3.12T maze learning trends and score in WT and Het 
Line graphs show the mean ±SD participation of female and male WT and Het in the 
total repeat tests. Graph (A) shows female WT and Het repeat test and (B) male WT 
and Het repeat tests showing participation was reduced by test number 7. The bar 
graph represents the mean ±SD correct choice selection across all the repeat tests 
performed. 
The learning pattern of the T maze in WT and Het mice was examined. The combined correct 
choice selection and time spent in the novel arm was used to calculate a learning score for each 
test. The mean of 53 independent experiments in WT showed an initial reduction in motivation 
in both male and female WT on the second test. The trend in learning continued until the 6th 
test where motivation began a slow decline. In the Het population, the average of 85 
independent tests again showed a decline in the second test. The trend in learning was erratic in 
female Het mice compared to male Het. By test number 5, the female Het population appear to 
have reduced participation unlike male Het who were still actively participating in the test. 
Enthusiasm for the test began to evaporate at test 6 indicating that the number of repeat tests of 
7 was the correct choice. 
3.4.2.3 Discussion of T maze in WT and Het mouse 
This protocol was based on timed investigations where mouse had one minute to ‘discover’ the 
novel arm and score further points by remaining in the novel arm, Het mice who were reluctant 
to explore the environment may not have accessed both sides of the T maze. If Het mouse did 
not ‘discover’ the previous arm then both arms represented a novel arm and he should have been 
awarded accordingly. This discrepancy remains unresolved. 
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Time spent in the novel arm was statistically different in male and female WT and Het mice. 
Male WT took 17% longer time to investigate the novel arm compared to female WT and spent 
28% less time in it.  Male WT spent 12% less time in the original arm compared to female WT. 
Male Het were 45% quicker to explore and spent 34% more time compared to female Het. They 
spent 32% more time in the original arm compared to female Het indication their discrimination 
for novel over original was impaired.  
The investigation ratio in male WT was 4% higher compared to female WT and their 
discrimination ratio was 13% less than female WT. Male Het IR was increased 35% compared 
to female Het and the DR was 20% higher compared to female Het suggesting that the reduced 
investigation ratio in female Het may have been due to an enhanced fear response. Female Het 
had a 200% increase in time to novel compared to female WT which suggests that this was an 
exaggerated response to novel.  The enhanced discrimination ratio in male Het reflected the 
reduced exploratory activity of female Het. 
The DR revealed that female Het mice showed 69% less discrimination in novel arm 
identification compared to female WT. DR required investigation of both sides and the selection 
of one arm over the other. The Het mice that did explore the novel arm were unlikely to select 
the novel arm for its novel properties but selected it based on which side it was on. Het mice 
appeared to have a preference for right sided (personal observation). Despite attempts to 
demonstrate this, moving the direction the T maze altered the amount of light flooding the maze 
thus altering the investigational parameters of the experiment. Reduced visual cues appeared not 
to influence the results obtained with the T maze. As mice are primarily olfactory driven in 
bright light, and their tactile senses were intact, both of these functions were in evidence in the 
wild type population.  
In conclusion, the spatial testing of Opa1
Q285STOP
 mouse by T maze showed that female Het mice 
were very reluctant to explore a territory that should have been familiar after thirty minutes of 
testing. When they did locate the novel arm, the female Het mice spent significantly less time in 
it compared to female wild type mice. Male Het reluctance to explore was not as profound as 
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female Het, but discrimination of novel was reduced. Laterality in C57BL/6 mouse is an already 
established finding (Watanabe et al. 2004; Goto et al. 2010; Apostolova et al. 2012), however it 
would appear to be reduced in Opa1
Q285STOP
 mouse. 
3.4.3 Novel object testing in Opa1 Q285STOP mouse 
3.4.3.1 Optimization of NOR testing 
The handling and training of animals is imperative if accurate analysis is to be performed 
(Powell et al. 2004).  The technique is based on normal behaviour in mouse and conditions must 
be as ‘normalised’ as possible. Other factors that require consideration are sex of the mice. Male 
C57BL/6 mice were identified as having an enhanced NOR score compared to female animals 
(Frick and Gresack 2003). However it has been established that co-learning in females can 
enhance their NOR skills (Lipina and Roder 2012). In rats, single housed animals have better 
object recognition skills compared to group housed (van Goethem et al. 2012). 
Other factors which required attention included the precise nature of the test and testing 
parameters including training period, data collection and analysis, and repeat testing interval. A 
factor of trial retention intervals can affect performance. As the delay between training and test 
increases, so performance can deteriorate. A short retention interval is considered to be less than 
three hours (Obinu et al. 2002; Schiapparelli et al. 2006). All mice were tested within the short 
retention maximum of three hours 
3.4.3.2 Results of NOR testing in WT and Het mouse 
  
Table 3.9 Summary of test numbers for NOR testing in WT and 
Het 
  
Novel object recognition was analysed according to the investigation ratio and discrimination 
ratio generated from the data collected during the test.  
The time to novel object in female WT was 9.7±2.4seconds Female Het took 25.7 ±4.4 seconds 
/sec which was significantly increased compared to female WT (F(3,24) 10.129 p=0.001). Male 
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WT time to novel was 11±0.9 seconds and male Het 29.9±4.4 seconds which was significantly 
increased compared to male WT (p=0.001). Time with novel object in female WT was 26.4±3.9 
seconds and female Het was12.4±3.9 seconds which was significantly reduced compared to 
female WT (F(3,24) 8.188 p=0.004). Male WT time with novel object was 26.2±1.1 seconds 
and Het male was 13.5±2.2 seconds which was significantly reduced compared to male WT 
(p=0.001). Time with original object in female WT was 4.72±1.1 seconds and female Het 
6.6±2.5 seconds (p=0.823). Male time with original object was 6.5±0.45 seconds and male Het 
was 14.2±2.5 seconds which was significantly increased  compared to male WT (F(3,24) 1.880 
p=0.021).Figure 3.13 shows a summary of the raw data used to generate the IR and DR of novel 
object recognition. 
 
Figure 3.13Novel object 
testing parameters in WT 
and Het 
Graph showing the mean 
±SD testing parameters of 
novel object recognition in  
WT and Het  
 
 
The IR in female WT was 0.65±0.04 and female Het was 0.52 ±0.06 which was significantly 
reduced compared to female WT (F(3,24) 6.926 p=0.005). The IR in male WT was 0.81 ±0.02 
and 0.45±0.05 in the male Het which was significantly reduced compared to male WT 
(p=0.004). The DR in female WT was 0.46±0.05 and in female Het was 0.28±0.05 which was 
significantly reduced compared to female WT (F(3,24) 7.634 p=0.004). The DR in male WT 
was 0.59±0.04 and male Het was -0.01 ±0.18 which was significantly reduced compared to 
male WT (p=0.002). Figure 3.14 shows these data. 
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Figure 3.14 NOR IR and DR in WT 
and Het 
Graphs showing the mean ±SD of (A) 
IR and (B)DR as calculated from the 
observations of NOR in male and 
female WT and Het. 
The learning trend in NOR between 
WT and Het mice was examined. 
Unlike T maze where there was no 
diversity in each arm, the novel object recognition test provided a novel item to examine. In the 
series of seven novel items, the mean score for each item was placed on a scale of correct or 
incorrect. As it was presumed that Opa1
Q285STOP
 mouse had no olfactory deficit, the objects were 
anticipated to generate some curiosity in both WT and Het mice. The female WT score was 
0.66±0.06 and female Het score was 0.50±0.11 which was not significantly different compared 
to female WT (p=0.144). The learning score for male WT was 0.57±0.13 and for male Het was 
0.43±0.06 which was not significantly different compared to male WT (p=0.200). The 
identification of preference in WT and Het was examined. Female Het spent significantly less 
time with resin compared to female WT (F(3,23) 1.807 p=0.032) and male Het spent 
significantly less time with glass compared to male WT (F(3,23) 2.071 p=0.025). The learning 
trend observed in both female and male Het was reduced but not significantly different 
compared to WT. 
As seen in Figure 3.15, both WT and Het demonstrated a reduction in time with novel on the 
second test. This was mice displaying an acclimatization period where the time spent doing 
anything appropriate was lost. This is possibly a part of learning where the test parameters are 
being processed by mouse brain. In both T maze and NOR, both WT and Het mouse sit between 
novel and original for longer periods than at any other time in the assays. The response seen in 
the Het mice demonstrated that they appeared not to have impaired vibrissae activity. Mice use 
single whiskers to investigate the texture which results in a characteristic whisker vibration or 
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kinetic signature. This allows sensory discrimination (Hutson and Masterton 1986; Diamond et 
al. 2008) . The single item to illicit avoidance in WT and Het mice was slate. The composition 
and texture of slate was cold and hard. As the exploratory mode of activity (whiskering without 
contact) (Ferezou et al. 2006), was clearly in use by both WT and Het mice they both elected to 
avoid slate. Observation of the trend in Het mice showed that they spent a greater time before 
becoming accustomed to the test and by test 5 had begun to demonstrate some interest in their 
environment. The ability to make an informed choice with preference in some Het mice 
indicated that their innate curiosity was depressed compared to WT. Figure 3.15 shows the 
learning trend and correct choice selection of NOR testing. 
 
Figure 3.15 NOR learning trends in WT and Het 
Line graphs show the mean ±SD participation of female and male WT and Het in NOR 
testing.  Graph (A) shows female WT and Het time with novel and (B) male WT and Het 
time with novel showing full participation in all tests. The bar graph represents the 
mean ±SD correct choice selection across all the repeat tests performed. 
Finally, the response to one particular item (fabric) suggested that Het mice were preserving 
their energy. The response towards this item that was not just novelty but usefulness suggested 
that the issue of nesting material might be addressed. As previously shown, the core temperature 
of Het mice was reduced by a mean 7%. Any opportunity to preserve and maintain body 
temperature was evidently worth investigating. 
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3.4.3.3 Discussion of NOR in WT and Het mouse 
The time taken to explore the novel items in female Het mice was 165% longer than female WT 
and 173% percent longer in male Het compared to male WT.  Once the novel item was located, 
female Het mice spent an average 51% less time compared to wild type females. The time spent 
with the original object was increased by 42% in female Het compared to female WT and 
increased by 116% in male Het compared to male WT.  The selection of items for this test was 
expected to generate the natural curiosity of mice. In the wild type population, on investigating 
the original item, many mice returned more than once for a very brief time as though to confirm 
they had investigated it before returning to the novel item. Both WT and the Het mice, who did 
explore, climbed onto objects and approached from different directions in the course of their 
explorations, both investigating initially by mystacial vibrissae. It demonstrated an intact 
whisker mediated texture discrimination. Further investigation was usually followed by both 
forepaw investigations. Recent discrimination task development has incorporated this testing 
parameter into novel screening methods(Wu et al. 2013). Detection of impaired somatosensory 
systems may be indicative of axonal damage. A sub population of individual axons representing 
whisker movement in the brain stem trigeminal nuclear complex is responsible for interpretation 
of this sensory information in mouse (Wu et al. 2011). Any sensory or motor system that has a 
high demand for ATP may be impaired in the Opa1
Q285STOP
 mouse model and tactile 
investigation using all senses was therefore considered noteworthy. The male Het mice who 
spent extensive time with the original item were not doing so because it was familiar to them as 
it was a replacement item, but the tactile sensation or shape was known. The reluctance to 
explore may have been associated with fear; however the female Het mice demonstrated that 
they were able to overcome their initial trepidation. Some male Het mice appeared to be 
disorientated and sat in the middle of the arena.  
The investigation ratio showed the male Het mice investigated 13% less compared to female 
Het mice and 45% less compared to male wild type mice.  The discrimination ratio (DR) 
demonstrated that some of the male Het mice were unable to discriminate between novel and 
original objects; the mean reduction in DR score was 102% in male Het mice and a 40% 
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reduction in Het females. However this may also be due to some Het mice not investigating 
either object, thus not contributing any valid information to the test. The analysis suggests that 
Opa1
Q285STOP
 mice were memory impaired, with male Het mice more impaired compared to 
female Het mice. These are summarized in Figure 3.16. 
Figure 3.16 Summary of cognitive impairment in Opa1
Q285STOP
 mouse  
Different cognitive tests reveal the same 
cognitive defects. The graph shows the 
reduction in IR, DR and correct choice 
selection in T maze and NOR testing 
compared to WT (represented by green 
line).The box shows the percentage 
reduction for IR and DR in NOR and T 
maze. 
 
A further observation of the experiment was confirmed where it was shown that male C57BL/6 
mice demonstrate enhanced NOR performance (Frick and Gresack 2003).  Male WT C57BL/6 
had enhanced IR compared to WT females with a 26% increase. The male WT DR also showed 
a 28% increase compared to female WT. This was clearly not so in the male Het mice.  
Housing conditions in solitary, paired and group housed mice was examined for evidence of 
enhanced performance in solitary housed animals (van Goethem et al. 2012).  As there were no 
solitary housed female mice, analysis was restricted to male mice only. In wild type mice, there 
was no significant difference observed between solitary (n3) and paired (n2) mice. With Het 
male mice, there was no significant difference identified in solitary (n6) compared to paired 
male (n3) or grouped male (n3) mice for IR (p=0.759) or DR (p=0.255). 
Co learning in female C57BL/6 mice was examined in group housed female mice. There were 
12 wild type females and sixteen Het females sharing a collective six cages. It may explain how 
the Het females outperformed the Het males.   
3.4.4 Discussion of cognitive decline in Opa1Q285STOP mouse 
Both the T maze and novel object recognition imparted valuable information about the impact 
fusion deficiency had on memory recall and spatial habituation. The T maze test showed a 45% 
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deficit of function in Het. T maze identified that female Het mouse had significant impairment 
of IR and DR that was greater than male Het compared to WT female and male respectively. 
Because the investigation ratio was reduced, the ability to discriminate between novel and 
original was impaired. Observations of WT mouse showed that for both T maze and NOR tests, 
male WT IR and DR exceeded female WT by 15% and 7 % respectively. If the reference 
sample was WT then it was expected that Het male scores would exceed female Het. For IR, 
male Het scores exceeded female Het by 11%. The DR score in male Het was 20% higher than 
female Het for T maze only.  The discrimination required in novel object recognition was 
reduced by 95% compared to female Het. 
The NOR test revealed a 52% deficit of function in Het compared to WT. NOR revealed that 
male Het demonstrated a significant reduction in IR and DR Male Het deficit was 66% greater 
than female Het when compared to WT counterparts. As the novel object recognition test 
included many aspects of the T maze including initiation of investigation and identity of the 
novel, NOR offered an increased opportunity to succeed because unlike T maze, there was a 
novelty to be discovered. Female Het mice appeared to grasp the concept but Het males scored a 
negative DR. Their inability to tell novel from original was demonstrated by the time spent with 
novel and original. 
T maze required self-motivation without any clear advantage in locating the novel arm. In this 
respect the female Het mice conserved their ATP levels with many remaining in the arm of the 
maze not venturing down either arm of the maze. As these experiments were performed on the 
same cohort of mice, direct comparisons with respect to T maze and NOR was possible. Het 
females spent 5% less time with the original item compared to WT females demonstrating 
ability to learn and remember.  
At 15 months of age, these mice were mature but not elderly; therefore the results were not due 
to age related deterioration. This phenotype variation is seen in humans with dominant optic 
atrophy where the same mutation in different individuals can produce different severity of 
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n Body Brain Cardiac
weight(g) weight(g) Ratio
eFWT 25 28.2 ±1.7 0.58 ± 0.18 0.62 ± 0.14
eF Het 17 28.2±1.3 0.48 ± 0.03 0.63 ± 0.03
E F Het 4 23.0±1.7 0.57 ± 0.06 0.74 ± 0.05
N eFWT:eFHet 0.833 0.013 0.96
R eFHet:FHet 0.009 0.020 0.009
I F(3.79) 14.03 2.647 1.164
C eMWT 4 28.2 ±1.3 0.47 ± 0.06 0.68 ± 0.05
H eM Het 7 29.0±1.3 0.44 ± 0.04 0.70 ± 0.04
M eMWT:eMHet 0.729 0.688 0.781
E eMWT:MWT 0.001 0.846 0.287
N eMHet:MHet 0.008 0.534 0.004
T F(3.79) 10.469 1.369 1.681
M WT 6 35.4 ±1.3 0.49 ± 0.03 0.61 ± 0.04
M Het 16 33.1±0.8 0.47 ± 0.03 0.60 ± 0.03
H S M WT:M Het 0.154 0.839 0.866
O O F(5,37) 5.372 1.65 1.186
U L sMWT 4 34.0 ±2.6 0.49±0.08 0.52±0.08
S O sMHet 14 32.6 ±1.0 0.49±0.03 0.60±0.03
I sMWT:sMHet 0.634 0.963 0.343
N G sMWT:gMWT 0.624 0.009 0.012
G R sMHet:gMHet 0.247 0.015 0.129
P F(5,37) 5.372 1.65 1.186
gMWT 7 32.5±1.2 0.48±0.04 0.66±0.03
gMHet 9 30.7±1.25 0.42±0.04 0.68±0.09
gMWT:gMHet 0.317 0.288 0.779
F(5,37) 5.372 1.65 1.186
e enrichment s=solitary housed  g-group housed
disease. Although the Opa1
Q285STOP
 mouse originates from the same original stock and this 
might be expected to reduce the variability in their extra ocular phenotype. 
3.4.4.1 Tissue weights at 15 months 
At 15 months, full tissue retrieval was performed in order to continue with the analysis of Het 
mouse. Body weight, brain weight and cardiac weight ratio was obtained for all animals. There 
was no significant difference observed between the body weights of female WT (n=25) and 
female Het (n=25) (p=0.427 or between male WT (n10) and male Het (n23) (p=0.272). Female 
Het (n25) brain weight was 0.53±0.04g was significantly reduced compared to female WT 
(n=25) 0.59±0.02g (F(3,79) 2.647p=0.013). There was no significant difference observed 
between male WT and male Het brain weight (p=0.839).  
Housing conditions and enrichment can affect brain weight (Mazarakis et al. 2014). There were 
no solitary housed female mice. Analysis was confined to male WT and Het only. Table 3.10 
summarises the body brain and cardiac weight ratio in WT and Het at 15 months. Enrichment 
was provided with a running saucer (Small n 
Furry) in all multiple occupancy cages. Mice 
housed in smaller cages were prevented from 
having saucer enrichment due to cage size 
limitations.   
Table 3.10 Body brain and cardiac weight 
ratio at 15 months in WT and Het 
Table showing a summary of weight in WT 
and Het body, brain and cardiac weight 
ratios at 15 months.   The effect of 
enrichment (e) on body weight was 
significant in all phenotypes examined. 
Enrichment had a significant effect on Het 
cardiac ratios. Housing conditions had a 
significant impact on both WT and Het male 
WT brain weight.  
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n Body weightBrain weightCardiac ratio
(g) (g)
E M WT 10 ↓20% ↓4% ↑12%
N eMWT:MT 0.001 0.846 0.287
R M Het 23 ↓12% ↓6% ↑17%
I eMHet:MHet 0.008 0.534 0.004
C F Het 21 ↑23% ↓16% ↓15%
H eFHet:FHet 0.009 0.020 0.009
F(5,50) 10.469 0.408 2.467
H sMWT 4 ↑5% ↑2% ↓21%
O sMWT:gMWT 0.624 0.909 0.012
U sMHet 14 ↑6% ↑18% ↓12%
S sMHet:gMHet 0.247 0.015 0.129
E F(5,37) 1.202 1.323 3.534
e-enrichment e =no enrichment  s=solitary  g-group
Enrichment had a positive effect on body weight in male WT. Compared to no saucer male WT  
there was a significant  20% reduction in enriched male WT weight (F(5,50) 10.469 p=0.001). 
Body weight in enriched male Het was also significantly reduced by 12% (p=0.008) compared 
to male Het without saucer. Body weight in enriched female Het increased by a significant 23% 
F(3,79) 14.03 p=0.009) compared to female Het without saucer. 
Brain weight in enriched male WT weighed 4% less than non-enrichment male WT (p=0.846). 
Enriched male Het brain weight was 6% less than non-enrichment male Het (p=0.534). 
Enriched female Het brain weight was significantly reduced by 16% (F(3,79) 2.647 p=0.020) 
compared to non-enriched female Het. 
Cardiac weight ratio in enriched male WT was increased by 12% (p=0.287) compared to non-
enriched male WT. Cardiac weight ratio in enriched male Het was significantly increased by 
17% (F (5,79) 1.681 p=0.004) compared to non-enriched male Het. Enriched female Het cardiac 
weight ratio was reduced by a significant 15% (p=0.009) compared to non-enriched female Het. 
Housing conditions in male mice showed that solitary housed male WT body weighed 5% 
(p=0.624) more than group housed male WT. Solitary housed male WT brain weighed  2% 
(p=0.909)  more than group housed and cardiac weight ratio was significantly  reduced by 21% 
(F(5,37) 1.186 p=0.012) compared to group housed male WT. 
Table 3.11 Effects of enrichment and 
housing on tissue weights in WT and Het 
Table summarising the effects of enrichment in 
male WT and Het showing a significant 
reduction in body weight and in male Het an 
increase in cardiac weight ratio. Female Het 
showed a significant increase in body weight 
with a significant reduction in both brain and 
cardiac weight ratio. Compared to group 
housed, solitary housed male WT had a 
significant reduction in cardiac weight ratio. 
Solitary housed male Het had a significant 
reduction in brain weight. 
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3.4.5 Discussion of tissue weights at 15 months 
Solitary housed male Het weighed 6% more (p=0.247) than group housed male Het. Solitary 
housed male Het brain weight was a significant 18% (F(5,37) 1.65 p=0.015) more than group 
housed and cardiac weight ratio was 12% (p=0.129) less than group housed male Het. Table 
3.11 summarises these data. 
The advantages of physical exercise on brain function are well documented (Kohman et al. 
2012; Nishijima et al. 2013; Waters et al. 2013; Meek et al. 2014). A change in regional specific 
brain activity due to a reduction in tissue mass may result in subtle behavioural alternations 
(Burke and Barnes, 2006) but is unlikely to cause an alternation in weight. The increase in 
cardiac weight in the enriched population has been documented (Stones et al. 2009; Sultanova 
2010; Aufradet et al. 2012). It is associated with the altered morphological and mechanical 
properties of cardiac myocytes (Allen et al. 2001; Natali et al. 2002). 
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3.4.6 Summary of Chapter 3: Neuromuscular and cognitive dysfunction in Opa1Q285STOP 
mouse 
3.4.6.1 Significant neuromuscular dysfunction in Opa1Q285STOP mouse 
Opa1
Q285STOP
 mouse showed significant physiological impairment of lower motor function with 
impaired gait, balance, and coordination as tested by rotarod, rope, and narrow beam.  
Autonomic dysfunctions were also observed. Het mice showed a reduction in core temperature 
which was more significant in younger aged mice. SHIRPA revealed neuropsychiatric 
disturbances with increased extended freeze and initiation.  Other phenotypic findings included 
reduced learning skills in the Het population. Some of these findings were influenced by the 
housing conditions of both WT and Het mice.     
3.4.6.2  Significant reduction in cognitive function in Opa1Q285STOP mouse  
Opa1
Q285STOP
 mouse showed a significant reduction in short term retentive memory as observed 
in spontaneous alternation testing.  Regional impairment of specific functions associated with 
prefrontal cortex were observed with increased initiation times in Het mice. The specific object 
recognition function of the perirhinal cortex was especially reduced in male Het mice as 
determined by NOR testing.  Co learning in Het females was more evident than in male Het 
mice. 
3.4.6.3 Post mortem body organ weight 
Enrichment had a significant effect on body weight in WT and Het. Male WT and Het showed a 
significant reduction in weight and female Het showed a significant increase.  Brain weight was 
significantly reduced in female Het and cardiac weight ratio was increased in male Het but 
reduced in female Het. Housing conditions affected brain weight in male Het but not male WT. 
The extended phenotype found in Opa1
Q285STOP 
mouse would suggest that the Opa1 mutation 
resulted in functional impairment that extended beyond the retina. Because of these data, it was 
decided to extend the tissue range of mitochondrial assays to include the spinal cord and skeletal 
muscle. This was anticipated to provide a broader picture of the effects of Opa1 
haploinsufficiency on the mitochondrial environment. 
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Chapter 4 Bioenergetic impairment in Opa1Q285STOP mouse 
4.1 Introduction 
In the previous chapter the extended phenotype of Opa1
Q285STOP
 mouse was investigated using 
several phenotypic techniques which highlighted the extent of impairment in this mouse model. 
Despite this, the overall health of mouse at 15 months was intact. His appetite was healthy and 
he appeared to enjoy the use of a running saucer for a few hours each day. At 15 months, it was 
not considered that this was an especially aged animal but in order to investigate the 
mitochondrial profile it was important to eliminate age as a confounder from the analysis. 
Opa1
Q285STOP
 mouse was culled at 15 months for full tissue retrieval. WT cage mates were 
culled at the same time to permit age matched analysis.  All central nervous system tissue was 
employed in the following investigations 
4.1.1 Morphology of mitochondrial in Opa1Q285STOP mouse 
4.1.1.1 Experimental design of mitochondrial morphology 
Mitochondrial staining with Mitotracker Red CMXRos was performed as discussed in Chapter 
2 Methods (2.10.2). Mitochondria were freshly isolated from three WT and Het brain and four 
WT and Het retina and diluted to 1mg/ml. A volume of 5l was used for analysis of Mitotracker 
staining. 
4.1.1.2 Results of mitochondrial morphology in WT and Het 
Mitochondria were isolated from brain of three WT and three Het mice and were stained with 
Mitotracker red. Mitochondria were also isolated from retina of four WT and four Het mice. 
The purpose was to measure a range of parameters using Image J. Table 4.1 shows a summary 
of the number of mitochondria analyzed from both WT and Het brain and retina. In the interest 
of studying the complete mitochondrial profile of Het mice, it was considered that the isolated 
mitochondria included an accurate representation of all populations and sizes. If this population 
did contain structures other than mitochondria, then this was the environment that Het 
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mitochondria survived in. However as previously addressed, isolation of lysosomes would 
require more intensive centrifugation at greater speeds. 
Data analysis was performed in SPSS by ANOVA followed by Tukey’s post hoc test where 
p<0.05was considered  statistically significant and as non-parametric Mann-Whitney U test 
followed by Kruskal -Wallis H test. 
Table 4.1 Summary of mitochondrial properties in brain and retina of WT and Het 
 
The table shows the total number of events from each (A)brain and (B)retina and the mean size 
of each category. The p value indicates the statistical difference between groups. (A)Brain 
mitochondrial size: A total of 2165 mitochondria (events) were recorded from WT brain. In the 
Het brain, 6453 were recorded. There was a significant difference in the minimum size of 
mitochondria between WT and Het (p=0.045) and the medium sized mitochondria (p=0.006) 
but not the maximum sized (p=0.855). (B) Retinal mitochondrial size: WT (n2896) events and 
Het (n2873) events. There was a significant difference between the minimum sized mitochondria 
(p=0.009)and the medium sized (p=0.048) but not the maximum (p=0.971).  
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A n Brain Min Med Max Total Brain
WT 1 684 1.032 1.325 6.051 n p
2 756 0.587 1.326 4.045 WT Min 727 WT:Het 0.007
3 725 0.587 1.321 6.625 Het Min 4757 F(5,12) 26.391
Ave M/ 5g 0.735 1.324 5.573
STDEV 0.257 0.302 0.742 WT Med 495 WT:Het 0.007
Het 1 1489 0.587 0.981 4.602 Het Med 1095 F(5,12) 26.391
2 3783 0.587 0.660 6.960
3 1181 0.580 0.917 4.558 WT Max 764 WT:Het 0.855
Ave M/ 5g 0.585 0.853 5.373 Het Max 1947 F(5,12) 26.391
STDEV 0.254 0.170 0.375
B n  Retina Min Med Max Total Retina
WT 1 664 1.165 1.486 7.491 n p
2 755 1.174 1.394 4.193 WT Min 2794 WT:Het 0.009
3 735 1.173 1.321 4.193 Het Min 2394 F(5,18) 23.307
4 742 1.174 1.380 4.300
Ave M/ 5g 1.172 1.395 5.044 WT Med 454 WT:Het 0.048
STDEV 0.244 0.682 0.623 Het Med 168 F(5,18) 23.307
Het 1 754 0.567 1.394 3.061
2 698 0.587 1.321 4.548 WT Max 343 WT:Het 0.971
3 704 0.587 1.380 7.472 Het Max 307 F(5,18) 23.307
4 717 0.587 0.660 5.045
Ave M/ 5g 0.582 1.189 5.031
STDEV 0.100 0.354 0.880
*p<0.05**p<0.010***p<0.001 ±SD
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Measurements of mitochondria included area and perimeter. Both the perimeter and area 
measurements were dependent on image magnification.  The aspect ratio reports the change in 
length but using a formula based on both area and perimeter which was Formfactor.  The 
Formfactor was (Pm2)/4Am)  (Koopman et al. 2006; Koopman et al. 2010) where Pm2 is the 
perimeter squared, Am is area and  (3.1415) is the ratio between the circumference and the 
diameter of a circle which has a minimal value of 1 corresponding to a circular mitochondria.   
This allowed the Formfactor to report the length of individual mitochondria.   
Brain mitochondrial size was calculated using the equation (Pm2)/4Am). The median size in 
WT (n2165) brain mitochondria was 1.321m±0.324 with the minimum size 0.735m±0.257 
and the maximum size 5.57m±0.742. In Het (n=6453) brain mitochondria the median size was 
0.853m±0.170 which was significantly reduced compared to WT (F5,12) 26.391  p=0.007).  
The minimum size was 0.585m±0.254 which was significantly smaller than WT (F5,12) 
26.391 p=0.007). The maximum size in Het brain was 5.37m±0.375 which was not statistically 
different compared to WT (p=0.855). 
Isolated retinal mitochondria were analysed from WT (n=2896) which showed a range from the 
minimum 1.171m ±0.244, median 1.395m±0.682 to the maximum 5.044m ±0.623. Het 
(n=2873) retinal mitochondrial measured from the minimum 0.582m±0.100 which was 
significantly smaller compared to WT (F(5,18) 23.307 p=0.009). The median size was 1.189m 
±0.354 which was statistically different compared to WT (F(5,18) 23.307 p=0.048). The 
maximum size was 5.031m ±0.880 which was not statistically different to WT (p=0.971). 
Table 4.1 shows the range sizes in brain and retina for WT and Het with the statistical difference 
between groups and a graphical representation of these findings showing the range of sizes in 
WT and Het brain and retina and a table. Figure 4.1 shows a bar and whisker plot demonstrating 
the range of size in WT and Het brain and retina. Figure 4.2 are representative images of 
mitochondria from both WT and Het brain and retina.   
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Figure 4.1 Size variation in isolated 
mitochondria in WT and Het 
Box graphs show all the range of size  
of mitochondria in brain (A) and retina 
(B) in WT and Het with the upper and 
lower boxes representing the first and 
third quartile. The dividing line between 
the two boxes is the median. The upper 
whisker represents the maximum range 
and the lower whisker represents the 
minimum range. 
 
 
Figure 4.2 Mitotracker staining of 
isolated mitochondria from WT and 
Het  
Mitotracker Red CMXRos   staining of 
isolated mitochondrial from brain of WT 
brain (A) and Het (B), and retina of WT 
(C) and Het (D).Scale bar 5m 
 
 
 
The range of mitochondrial sizes was plotted in a histogram and sorted according to size. This 
allowed a direct overlay of both histograms from WT and Het. Figure 4.3 shows double plotted 
Mann-Whitney histograms and the results for statistical test (Mann-Whitney U test, Kruskal-
Wallis H test). 
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Figure 4.3 Histogram of brain and retinal mitochondrial size in WT and Het 
Graphs show non parametric analysis of mitochondrial size in WT and Het. Histogram 
of mitochondrial size as calculated by area and perimeter readings and plotted 
according to size. (A) Brain mitochondria in WT (green) and Het (blue) plotted as a 
function of size. WT size range from 0.735m to 5.573m Het size range from 0.580m 
to 5.373m which was significantly different (U 22.3 p=0.001) 
 (B)Retinal mitochondria in WT and Het plotted as a function of size. WT size range 
from 1.172m to 5.044m. Het retinal mitochondrial size range from   0.582m 
to5.031m which was significantly different to WT (U 15.6 p=0.001).  
  
4.1.1.3 Discussion of mitochondrial morphology in WT and Het 
The aim of these experiments was to confirm that the whole range of available mitochondria 
were being isolated. A range of sizes from 0.5m to 5.3m is in agreement with previous 
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findings (Munn 1974; Schwerzmann et al. 1986; Cereghetti and Scorrano 2006; Scheffler 2007; 
Youle and van der Bliek 2012). However as the aim of isolating mitochondria was to perform 
functional studies, it was important to include the whole available range. The mitochondria in 
brain of Het mouse showed that there were higher proportions of smaller sized mitochondria. 
The mean reduction in size was 20% compared to WT. The larger sizes mitochondria in WT 
were 5.573m In Het brain they were 5.37m. This represented a 4% reduction in larger size. 
The median range in WT brain was 1.321m and in Het brain was0.853m which represented a 
reduction of 36% in mitochondrial size.  The smallest sized mitochondria in WT brain were 
20% bigger than the smallest size in Het brain. 
In the retina, there was a significant difference in the smaller sized mitochondria. WT retinal 
mitochondria were 1.17m. Het smallest sized retinal mitochondria were 0.587m which was 
50% smaller than WT. In contrast, the larger sized mitochondria in WT and Het showed less 
than 1% difference in size. 
This might suggest that to compensate for such a high population of possible inadequate 
mitochondria, Het mouse retinal mitochondria that have fused with adjoining mitochondria 
remain in this fused state, thus avoiding mitophagy and elimination. The mean of median size in 
WT retina was 1.380m and in Het retina was 1.189m which represented a 15% reduction in 
mitochondrial size throughout the retina. The 50% reduction in smaller sized brain mitochondria 
is possibly below the threshold for pathological effects, however with much physical 
phenotyping, the threshold may be approaching in several animals. The retina of Het mouse 
would appear to be home to a very large population of very small mitochondria. If these 
mitochondria have a reduced membrane potential then it would seem advisable to eliminate 
them as this will ultimately result in ROS mediated damage. The size threshold for mitophagy 
induced elimination may be adjusted in Het mouse to incorporate smaller sized mitochondria 
but the function threshold must remain the same. The presence of larger sized mitochondria 
would suggest there was some damage limitation in the retina, however it must be reminded that 
most mitochondria reside in the photoreceptor layer and what percentage of isolated 
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mitochondria originate from the ganglion cell layer would require more sophisticated methods 
for examination.   
Mitochondrial fragmentation due to fusion imbalance results in bioenergetic impairment. The 
initiation of mitochondrial fragmentation is due to reduced membrane potential.  A reduction in 
membrane potential will trigger mitophagy (McBride et al. 2006; Carlucci et al. 2008). Reduced 
transport of electrons  (Ishihara et al. 2004) with subsequent reduction in ATP (Legros et al. 
2002).are insufficient to trigger mitophagy (Westermann 2003)   
 Mitophagy serves to eliminate non-functional mitochondria and is important in the prevention 
of excessive ROS generation and the reduction of potential mtDNA mutations. 
4.1.2 Mitochondrial membrane potential inOpa1Q285STOP mouse 
4.1.2.1 Experimental design of JC1 staining 
JC-1 is a cationic dye that accumulates in energised mitochondria. JC-1 remains as a monomer 
within the cytoplasm and fluoresce green. When in the mitochondria, the dye aggregates into 
red fluorescent molecules provided the membrane potential of the mitochondria remains 
hyperpolarised. 
On at least three separate occasions, JC1 staining was performed on freshly isolated 
mitochondria from WT and Het brain and retina to determine if the membrane potential differed 
between the two populations. Mitochondria were diluted to a final protein concentration of 
0.20g/ml with storage buffer. The mitochondrial suspension was incubated with JC-1at room 
temperature for 7 minutes and analysed immediately using a disposable haemocytometer. 
Viable healthy mitochondria with intact membrane potential fluoresced red, mitochondria with 
reduced membrane potential were green and mitochondria that were in the process of losing 
membrane potential termed ‘transition’ were fluorescent yellow. 
4.1.2.2 Results of JC1 staining 
In WT brain (n5), a total of 60122 mitochondria were analysed. The percentage of red 
fluorescence representing intact membrane potential was 89%±4%. Green fluorescent 
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representing reduced membrane potential was 4%±3% and mitochondria in transition (yellow) 
was 7%±2%. In Het brain (n5), a total of 45930 mitochondria were analysed. Mitochondria with 
intact membrane potential was 85%±2% which was not significantly different to WT (p=0.011), 
reduced membrane potential was 5%±3% which was not significantly different to WT 
(p=0.226) and in transition was 9%±2% which was not statistically significant (p=0.254) 
In WT(n5) retina, a total 69388 mitochondria were analysed. The intact population was 80% 
±3%, and the reduced was 12%±2with 8%±3% in transition.  The total number of retinal 
mitochondria from Het (n5) was 61311 which had 82%±4% intact membrane potential which 
was not significantly different to WT (p=0.120), 5%±5% reduced potential which was not 
statistically different to WT (p=0.560) and 12%±4% in transition which was not statistically 
different to WT (p=0.329).  Figure 4.4 shows a representation of JC-1 stained mitochondria in 
WT and Het brain and retina. 
 
Figure 4.4 JC1 staining for m in WT and Het brain and retinal mitochondria. 
Representative images of freshly isolated mitochondria which were stained with JC-1 to 
determine the membrane potential in brain and retina of WT and Het. (A)In WT brain (n5), a 
total of 60102 mitochondria were analysed . In Het brain(n5), in a total of 45930 mitochondria 
were analysed., where there was no statistical difference in any population observed between 
WT and Het brain mitochondria. (B) In the WT retina (n5) a total of 69388mitochondria were 
analysed. In Het retina (n5) a total of 138309 mitochondria showed no statistical difference in 
any population observed between WT and Het retinal mitochondria. 
Het Brain  WT  BrainA
Brain n Total Intact Red Trans p
WT 5 60102 55586 2037 2480 Intact 0.245
% 89% 4% 7% Red 0.226
Het 5 45930 41944 1649 2337 Trans 0.254
% 85% 6% 9% F(5,189)159.743
Het Retina
WT Retina
WT  RetinaB
Retina n Total Intact Red Trans p
WT 5 69388 55493 7080.26 6815 Intact 0.120
% 80% 12% 8% Red 0.560
Het 5 61311 55646 2598 3067 Trans 0.329
% 82% 5% 12% F(5,183) 247.049
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Brain n SC n Retina n
F WT 3 F WT 3 F WT 3
M WT 4 M WT 4 M WT 3
F Het 6 F Het 6 F Het 5
M Het 4 M Het 4 M Het 4
4.1.2.3 Discussion of membrane potential in WT and Het brain and retina 
There was no statistical difference observed between WT and Het brain or retina in intact, 
reduced or mitochondria in transition. 
4.2 Determination of ATP in Opa1Q285STOP mouse 
4.2.1 Introduction 
The central nervous system consumes about 20% of inspired oxygen at rest, thus has vast 
metabolic demand. This demand is met by oxidative phosphorylation within mitochondria. Any 
impairment in the mitochondrial population serving the tissue specific requirements will result 
in dysregulation of function. Maintenance of ionic gradients ensuring excitability of neuronal 
cells requires 60-80% of ATP consumption (Ames 2000). Mitochondria with impaired fusion 
may harbour damaged matrix content but owing to the Opa1 mutation, cannot exchange their 
content. This results in reduced oxidative phosphorylation and available ATP (Kanazawa et al. 
2008; Van Bergen et al. 2011; MacVicar and Lane 2014). Recombinant firefly luciferase and its 
substrate D-luciferin was used to determine ATP in freshly isolated mitochondria. 
4.2.1.1 Experimental design of ATP measurements 
For the measurement of ATP in the central nervous system of Opa1
Q285STOP
 mouse, brain, spinal 
cord and retinal mitochondria were examined.  Mitochondria were isolated from fresh tissue. In 
cryopreserved tissue, ATP production can be enhanced and may reflect an inaccurate base level 
(Barksdale et al. 2010). Each reaction was performed in triplicate and were protected from 
direct light source.  
4.2.1.2 Results of ATP measurement in WT and Het 
Table 4.2 Summary of sample numbers for analysis of 
ATP in WT and Het 
 
 
ATP in brain of female WT was 6.25±0.18nmol/mg. Female Het brain had 6.26 ±0.50 nmol/mg 
which was not significantly different to F WT (p=0.859). Male WT had 6.76 ±0.64 nmol/mg 
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and male Het had 7.97±1.05 nmol/mg which was not significantly different compared to male 
WT (p=0.349). 
ATP in spinal cord of female WT was 7.78±0.92nmol/mg. Female Het had 8.48 ±0.69 nmol/mg 
which was not statistically different to female WT (p=0.218). Male WT spinal cord ATP was 
8.42±0.73 nmol/mg and male Het SC was 8.01±1.05 nmol/mg which was not statistically 
different to male WT (p=0.737).  
Retinal ATP in female WT was 8.41±1.08 nmol/mg and 7.40±0.90 nmol/mg in female Het 
which was not significantly different to female WT (p=0.171). Retinal ATP in male WT had 
9.34±0.26 nmol/mg and male Het had 9.28±0.19 nmol/mg which was not significantly different 
to M WT (p=0.969). Figure 4.5 shows a summary of these findings. 
 
Figure 4.5 ATP measurements in freshly isolated mitochondria of WT and Het 
Graph of mean ±SD ATP in isolated mitochondria of WT and Het (A) ATP in brain  
(B) Spinal cord (SC) and (C)ATP in retina (D) ATP in all WT and Het brain, SC and retina. 
 
The ATP in male Het brain was 18% higher than in male WT brain which was significantly 
increased (p=0.023). Female Het had less than 1% more compared to female WT. Spinal cord 
ATP in female Het was 9% higher than in female WT (p=0.029). Male Het spinal cord ATP was 
reduced by 5% compared to male WT.  
Retinal ATP was reduced in female Het who showed 12% reduction although not statistically 
significant compared to female WT (p=0.118), it was significantly different to male Het 
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(p=0.006) which might suggest that female Opa1 mutation carriers may be more susceptible to 
impaired ATP production.  
The total ATP in female WT was 7.44±1.21 nmol/mg and 7.53±1.15 nmol/mg in female Het 
which was not significantly different (p=0.860). Total ATP in Male WT was 8.16±1.22 
nmol/mg and 8.17 ±1.37 nmol/mg in male Het which was not significantly different (p=0.897). 
In WT, the male mice had an average 9% more ATP compared to female. In the Het population, 
the male mice had an average 25% more ATP compared to female Het. The exception in Het 
tissue was spinal cord where male Het had 6% less ATP compared to female Het spinal cord 
mitochondria. 
4.2.1.3 Discussion of ATP determination in WT and Het mouse 
ATP determination in specific tissues of the central nervous system of both wild type and 
Opa1
Q285STOP
 mouse demonstrated several potentially important findings.  
The enhanced ATP in the retina of male Het would suggest that the presence of oestrogen may 
modulate ATP synthase activity in a tissue specific manner (Moreno et al. 2013).  In a WT 
environment, the presence of oestrogen in retinal specific cell types confers protection (Onishi 
et al. 2010; Prokai-Tatrai et al. 2013; Wang et al. 2014), however it may offer less advantage in 
a fusion deficient environment.   
Compensatory mechanisms may also influence the effects of fusion deficiency. Up regulation of 
neuroglobin may confer protection in Opa1 deficient retinal ganglion cells, this may result in 
increased ATP production within the retina as a direct response to oxidative stress (Lechauve et 
al. 2012), The association of neuroglobin with cytochrome c in the mitochondrial matrix 
prevents the apoptotic cascade associated with cytochrome c release into the cytosol  (Fiocchetti 
et al. 2013). Compensatory mechanisms can override ATP reduction by altering specific cellular 
expression. As previously discussed, Opa1
Q285STOP 
mouse had reduced core temperature. This 
can initiate uncoupling protein 4 (UCP4) transcription (Yu et al. 2000). As UCP4 is found 
almost exclusively in mitochondria of neuronal cells (Smorodchenko et al. 2009) and can 
enhance ATP levels (Ho et al. 2012; Ramsden et al. 2012). 
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The ATP synthase enzyme consists of F0-F1 ATP synthase subunits.  Oestrogen can bind to a 
subunit of the F0-F1 subunit and modulate its activity (Zheng and Ramirez 1999; Massart et al. 
2002).  This binding results in the uncoupling of  the ATP synthase (Moreno et al. 2013).  The 
presence of oestrogen can confer protection to cerebrovascular mitochondria by increasing their 
capacity for ATP production (Kemper et al. 2013). The presence of oestrogen receptors on the 
surface of retinal ganglion cells (Munaut et al. 2001; Kumar et al. 2005; Real et al. 2008) can 
confer a protective role   (Giordano et al. 2011; Hao et al. 2015). Specific oestrogen receptor 
activity is associated with different functions. The presence of estrogen receptor – (ERG-) 
impairs exercise induced skeletal muscle repair  (LaBarge et al. 2014). The reduction of ERG- 
can promote metabolic and inflammatory responses in hepatic tissue  (Hong et al. 2013).  
Activation  of ERG-is associated with impaired OXPHOS  (Manente et al. 2013) and a variety 
of malignancies  (Thomas et al. 2011). 
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4.3 Electron transport analysis in Opa1Q285STOP mouse 
4.3.1 Introduction 
Electron transport is the final step in cellular respiration. In the presence of oxygen, electrons 
are passed by redox reaction along a series of protein units in the lipid membrane of 
mitochondria. Redox reactions are coupled with the transfer of protons across the membrane 
which generate a proton gradient in the intermembrane space. The proton gradient provides the 
proton motive force that drives ADP and inorganic phosphates to ATP via ATP synthase. 
Complex I or NADH-Coenzyme Q reductase is the first point of entry of electrons into the 
electron transport chain.  Complex I is made up by 45 different subunits  (Lazarou et al. 2007). 
A total of seven of the subunits of the complex are encoded by mitochondrial DNA, while the 
remainder subunits are nuclear encoded (Carroll et al. 2006) Complex I oxidises NADH to 
NAD+ by using flavin mononucleotide (FMN) which is an absolute requirement for activity. 
FMN accepts two electrons and donates them to CoQ. Each electron is passed to coenzyme Q 
which acts as an electron acceptor. The process allows 4 hydrogen atoms to pass across the 
membrane into the inter membrane space where they accumulate generating a proton motive 
force due to the positive change. 
Complex II or succinate dehydrogenase complex is composed of four nuclear encoded subunits 
containing flavin. Complex II binds FAD to generate FADH2 which acts as the electron donor 
passing two electrons individually to coenzyme Q. No protons are transported across the 
membrane during complex 2 oxidation because the change in energy of the whole reaction is 
too small to drive protons across the inner membrane.   
Complex III is also known as coenzyme Q- cytochrome c oxidoreductase. The complex 
contains 11 different subunits, one of which is cytochrome c1. Electrons from complex I or 
complex II are passed to the mobile iron-sulphur protein in complex III called the Rieske 
protein. This mobile carrier transfers electrons to cytochrome c1. Cytochrome cI donates these 
electrons to the mobile carrier cytochrome c. This generates energy for the production of 1 
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molecule of ATP from ADP plus Pi. Four protons are released into the intermembrane space in 
this reaction. 
Cytochrome c is a mobile electron carrier that shuffles between complexes III and  IV carrying 
electrons from complex III and depositing them to the copper binding sites of complex 4.  
Complex IV or cytochrome c oxidase is the electron acceptor for cytochrome c. Cytochrome c 
contains two haem groups (cytochrome a and cytochrome a3) and two copper proteins (CuA 
and CuB). The copper sites act as the electron acceptor and carry electrons one at a time to 
cytochrome a and a3 respectively. Cytochrome a and a3 reduce molecular oxygen to water by 
the addition of electrons. Two protons transvers from the matrix to the inter membrane space 
and four protons move from the intermembranes space into the matrix 
Complex V – ATP synthase catalyses the phosphorylation of ADP in a reaction driven by 
proton movement across the inner membrane. This causes the synthase motor to spin releasing 
ATP in exchange for ADP and Pi. Generation of a proton motive force is maintained by the 
continual transfer of negatively charged hydrogen atoms into the positively charged 
intermembrane space. The result is an electrochemical gradient of both membrane potential and  
pH  (Mitchell 1974).  The pH of the mitochondrial matrix is pH8 and the intermembrane space 
is pH 7.2.  The pH gradient provides the gradient to drive pyruvate import. The voltage gradient 
drives ADP-ATP exchange and permits the release of ATP. Figure 4.6 shows a schematic 
version of the electron transport chain.  
From a functional aspect the electron chain is organised into supercomplexes where the relevant 
components reside in close proximity of each other which serves to enhance activity and 
conserve energy   (Hochman et al. 1982; Schäfer et al. 2006; Althoff et al. 2011). The presence 
of an assembly protein SCAFI (SC) in supercomplex formation of complexes I,III and IV where 
all three complexes are bound (Lapuente-Brun et al. 2013) is not present in C57Bl/6 mouse 
strain. ATP production in SC- phenotypes is higher than in SC+. This suggests that by allowing 
complex IV to act in free form would allow for more diverse functional control in tissues of 
different metabolic rates (Genova and Lenaz 2013). 
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Figure 4.6 Representation of electron transport in the mitochondrial matrix 
Schematic of electron flow through the electron transport chain. Complex 1 NADH initiates the 
reaction by donating two electrons to NADH dehydrogenase. Simultaneously, two protons are 
pumped out from the matrix to the intermembrane space (IMS). The electrons are passed via 
coenzyme Q to complex III which transfers them one by one to cytochrome c. Complex III also 
transfers protons out to the IMS. Complex II donates electrons from FADH2
+
 and passes them 
to cytochrome c. Cytochrome c is fully mobile and occupies the space between CII and CIII. It 
passes single electrons to copper sites of complex IV which reduces molecular oxygen to water. 
A further 4 protons are pumped to the IMS.  Complex V F1F0-ATP synthase transfers protons 
from the IMS which initiates the conversion of ADP+Pi to ATP.  The red line denotes the path 
travelled by electrons as they pass through the chain. 
 
Determining the functional ability of individual complexes in Opa1
Q285STOP
 mouse was 
considered vital to the relevance of potential therapy. 
4.3.1.1 Experimental design of ETC assays 
As analysis of each electron complex required a specific buffer in order to enhance the kinetic 
performance, mitochondrial were resuspended in a minimum volume of storage buffer (see 
methods section 2.8), and diluted to the required concentration in the required buffer according 
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to the assay. In order to perform assays for complex I, II and IV on the same samples, a 
maximum of eight animals were analysed in any one session. This may have prolonged the final 
analysis, however it was determined that mitochondria analysed within 14 hours of isolation 
demonstrated little variation in kinetic performance. 
The decision to select complex’s I, II and IV and not complex III were two fold. One considered 
the availability of mitochondria to include in a test run where possible all complex activity 
would be included. Secondly, the function of complex III is to transfer electrons from ubiquinol 
to complex IV. Therefore the activity of complex III relies on the functional ability of complex I 
and complex II. If  both complexes I and II were fully functional, complex III might have been 
considered. 
Abbreviations: ETC: electron transport chain, CI, CII, CIV: complex I, complex II complex IV.  
Data is shown according to the individual complex presenting brain, spinal cord retina and 
skeletal muscle from aged matched wild type and Het mice. Each assay is shown with a table of 
sample sizes, mouse numbers and observations obtained, as one mouse contributed multiple 
observations in more than two tissue types.  
Isolated mitochondria were maintained in storage buffer from the time of isolation throughout 
the duration of protein analysis which did not exceed 30 minutes. However storage buffer 
contained 5mM succinate which may have had an adverse effect on complex I activity. 
Individual rates of activity were plotted against succinate concentrations which did not exceed 
0.08028mM in any one sample. There was no significant difference observed for succinate 
concentration and rate of complex I activity in any samples. Graphs and statistical analysis are 
in Appendix H. Calculations of substrate oxidation are shown in Appendix H. 
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C1 Brain C1 Retina
WT 8 WT 9
Het 11 Het 9
C1 SC C1 Muscle
WT 10 WT 5
Het 10 Het 5
4.3.1.2 Results of ETC activity in WT and Het 
4.3.1.2.1 Complex I activity in WT and Het 
 
Table 4.3Summary of sample numbers for complex I analysis in 
WT and Het 
  
In order to confirm that the assay was specifically testing the function of NADH oxidation, 
mitochondria from brain of WT and Het were first analysed for oxidation activity and then the 
activity of complex I in the presence of 2M rotenone which was a specific inhibitor of 
complex I (Horgan et al. 1968) and the assay repeated.  
Complex I activity in brain of WT (n=3) mouse oxidised 357±30 nmol/mg. When inhibited with 
2M rotenone WT brain oxidised 32.1±1.5nmol/mg which meant that 91% of the activity was 
specific to complex 1 and 9% was mediated by other complexes. Het mouse brain (n=3) 
oxidised 139±6 nMol/mg and when inhibited with rotenone, oxidised 36±2nmol/mg which 
meant that 74% of the activity observed was specific to complex 1 and 26% was due to other 
ETC activity. 
WT brain oxidised 263±33 nmol/mg. Het brain oxidised 108±6 nmol/mg which was statistically 
reduced compared to WT (F(7,55) 25.123 p=0.001).   
WT spinal cord oxidised 341±54 nmol/mg. Het spinal cord oxidised 83±9nmol/mg which was 
significantly reduced compared to WT (F (7,55) 89.435, p=0.001). WT retinal mitochondria 
oxidised 289±14nmol/mg Het retinal mitochondria oxidised 52±17nmol/mg which was 
significantly reduced compared to WT (F (7,55) 60.655 p=0.001). WT Muscle oxidation of 
NADH was 155 ±36 nmol/mg.. Het muscle oxidised 95±10nmol/mg which was significantly 
reduced compared to WT (F (7,55) 66.350  p=0.011). 
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C2 Brain C2 Retina
WT 9 WT 9
Het 8 Het 9
C2 SC C2 Muscle
WT 7 WT 5
Het 7 Het 5
4.3.1.2.2 Complex II activity in WT and Het 
 
Table 4.4 Summary of sample numbers for complex II analysis 
in WT and Het 
 
In order to confirm that the assay was testing the function of succinate dehydrogenase, repeat 
assays including the complex II inhibitor TTFA (Tapel 1960)  at a concentration of 100M was 
included in the assay. Complex II activity was analysed for the reduction of DCPIP which acted 
as an electron acceptor in the presence of succinate. The reaction was followed at 600nm using 
a UV spectrophotometer. Table 4.4 shows a summary of sample sizes used for the complex II 
assay. 
WT brain (n=3) reduced 47±9mol/mg. When inhibited with 100M TTFA, WT brain  reduced 
0.084±0.036mol/mg.  This meant that 99.8% of the activity observed was specific to succinate 
dehydrogenase activity and 0.18% was due to other ETC activity. Het brain (n=3) reduced 
20±2.5mol/mg In the presence of TTFA, Het reduced 0.0836±0.014mol/mg. which meant 
that 99.6% of the activity was succinate dehydrogenase specific and the remaining 0.42% due to 
other activity. 
Brain mitochondria in WT reduced 50±13mol/mg. Het brain mitochondria reduced 21 
±6mol/mg. which was statistically different compared to WT (F(7,48) 55.804, p=0.001). WT 
spinal cord mitochondria reduced 54±3mol/mg. Het spinal cord mitochondria reduced 
19±7mol/mg. which was statistically reduced compared to WT (F (7,48) 54.260 p=0.001). 
WT retinal mitochondria reduced 128±27mol/mg. Het reduced 58.3±14mol/mg was 
considered significantly reduced compared to WT (F(7,48) 45.570 p=0.001). Muscle 
mitochondria in WT reduced 39±13 mol/mg and Het muscle reduced 25±6 mol/mg which 
was significantly different compared to WT (F (7,48) 4.374  p=0.025) 
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C4 Brain C4 Retina
WT 10 WT 8
Het 11 Het 8
C4  SC C4Muscle
WT 9 WT 4
Het 10 Het 5
4.3.1.2.3 Complex IV activity in WT and Het 
 
Table 4.5 Summary of samples numbers for complex IV analysis in 
WT and Het 
 
Reduced cytochrome c was followed at 550nm and the change in absorbance was observed from 
reduced to oxidized cytochrome c. Reduced cytochrome c was prepared in batches on at least 
five separate occasions concurrent with tissue availability. All efforts were made to prevent re-
oxidation of reduced cytochrome c by treating buffers with Chelex and saturating solutions with 
argon gas. Batches of reduced cytochrome c showed variation in the ratio between the oxidized 
and reduced form. The analysis of kinetics was performed starting from the same concentration 
of reduced cytochrome c. The initial rate of cytochrome c oxidation by complex IV was used in 
the analysis. 
To confirm that the assay was examining the activity of cytochrome oxidase, inhibition of the 
complex with 20mM potassium cyanide was performed in each assay.  
WT brain (n=3) oxidised 689±174mol/mg of reduced cytochrome c. When inhibited with 
20mM KCN, oxidised 0.0506±0.0109mol/mg which meant that 99.9% of the activity observed 
was specific to cytochrome oxidase. Het brain (n=3) oxidised 926±36mol/mg and in the 
presence of KCN oxidised 0.0569±0.0001 which meant that less than 0.007% was due to 
activity other than cytochrome oxidase.  
WT brain mitochondria oxidized cytochrome c at 3.26±0.17mol/mg. Het brain mitochondria 
oxidized 2.80±0.13mol/mg which was significantly different to WT (F(7,53) 27.562 p=0.017). 
Spinal cord mitochondria in WT oxidised 2.50±0.11 mol/mg. Het spinal cord mitochondria 
oxidized 2.68±0.18 mol/mg which was not significantly different compared to WT (p=0.203). 
Retinal mitochondrial oxidation of cytochrome c in WT was 2.39±0.09 mol/mg and Het retinal 
mitochondria oxidised 0.968 ±0.06 mol/mg which was considered statistically different to WT 
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(F(5,34) 8.631 p=0.001). Muscle oxidation of cytochrome c in WT was 2.56±0.06 mol/mg. 
Het muscle oxidised 1.63±0.34 mol/mg which was statistically different compared to WT (F 7, 
53) 13.864  p=0.001). Figures 4.7-4.9 show the kinetics of these reactions. Figure 4.10 shows a 
graphical representation of the results. 
 
Figure 4.7 Kinetic activity of complex I in isolated mitochondria of WT and Het  
Representative kinetics of complex I activity in isolated mitochondria of WT and Het  
(A) Complex I activity was followed at 460nm using fluorescence spectrophotometry. Inhibition 
of complex I in the presence of 30g/ml mitochondria with 100M NADH, 1mM KCN, 40M 
CoQ1 and 20mM rotenone confirmed the specificity of the assay for NADH dehydrogenase 
activity. In the presence of 100M NADH, 1mM KCN, and 40M CoQ1 and 30g/ml of 
mitochondrial proteins, the reduction in NADH fluorescence from brain, SC, retina and skeletal 
muscle in WT and Het was fitted with a straight line. 
 
Figure 4.8 Kinetic activity of complex II in isolated mitochondria of WT and Het 
Representative kinetics of complex II succinate dehydrogenase activity in WT and Het 
(B) Complex II reduction of DCPIP: complex II in the presence of 100M TTFA confirmed that 
99.8% of the reaction was specific to the activity of succinate dehydrogenase. Complex II was 
followed at 600nm in the presence of 10mM succinate, 100M decylubiquinone, 2mM KCN and 
16M DCPIP. The reduction in absorbance in the presence of mitochondrial protein from 
50g/ml brain, SC, retina and skeletal muscle in WT and Het. was fitted with a straight line.  
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Figure 4.9 Kinetic activity of complex IV in isolated mitochondria of WT and Het 
Representative kinetics of complex IV cytochrome oxidase activity in WT and Het 
(C) Complex IV oxidation of reduced cytochrome c: complex IV in the presence of 20mM KCN 
confirmed that 99.9% of the reaction was specific to the activity of cytochrome oxidase. 
Complex IV activity was followed in samples equilibrated with air at room temperature (21-
23
o
C) by monitoring absorbance at 550nm in the presence of reduced cytochrome c at 
concentrations close to 100 M. The rate of absorbance decay in the presence of mitochondrial 
protein from 50g/ml brain, SC, retina and skeletal muscle in WT and Het was fitted by an 
exponential decay starting from 29.9-31.9mM concentration of the reduced form of cytochrome 
c. The initial rate of oxidation was used in the analysis of complex IV. 
 
Figure 4.10 Bioenergetic assays in isolated mitochondria of WT and Het 
Graphs showing the mean ±SD of bioenergetic assays performed in isolated mitochondria of 15 
month WT and Het brain, spinal cord (SC), retina(Ret) and skeletal muscle(Mus) showing (A) 
Complex I activity using 30g mitochondria/ml compared the oxidation of NADH in WT and 
Het. (B) Complex II activity in 50g/ml of isolated mitochondria compared the rate of reduction 
of DCPIP. (C) Complex IV activity compared the rate of oxidation of reduced cytochrome c in 
50g/ml of isolated mitochondria from WT and Het. 
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Brain SC Ret
CI WT8 Het11 WT10 Het10 WT9 Het9
Ave 29±8 45±5 38±7 33±6 33±7 22±6
WT:Het 0.017 0.685 0.597
F(5,48)2.144
CII WT9 Het8 WT9 Het9 WT9 Het9
Ave 21±3 21±5 23±5 19±6 56±10 60±1
WT:Het 0.675 0.626 0.779
F(4,40)45.389
CIV WT10 Het11 WT9 Het10 WT8 Het8
Ave 41±6 43±4 30±5 42±6 29±2 15±2
WT:Het 0.278 0.001 0.001
F(5,46)38.685
As the Het population demonstrated a reduction in activity across the range, the ratio of 
complex activity between tissues was examined in brain spinal cord and retina. The total 
oxidation for each complex was calculated and the ratio of each according to tissue type 
calculated. Table 4.2 summarises these findings.  
Table 4.6 Ratio of complex activity in mitochondria of CNS in WT and Het 
 
The table shows the ratio of the percentage of total 
activity for each complex in the CNS of WT and Het. 
The p value represents the statistical significance 
between pairs. 
 
 
In mitochondria from the CNS, the ratio of complex I activity in WT was highest in the spinal 
cord at 38%. Het complex I ratio in spinal cord mitochondria did not differ significantly 
compared to WT with 33% (p=0.578). The ratio of complex II activity was highest in both WT 
with 56% and Het with 60% in retinal mitochondria. The ratio of complex IV activity in WT 
was highest in brain with 41% and in Het was 43% which was not significantly different 
(p=0.822). 
4.3.1.3 Discussion of ETC activity in WT and Het 
In Het mouse, there was a 54% reduction of mitochondrial complex I activity compared to WT. 
Het brain mitochondria had a 48% reduction, spinal cord mitochondria 69%, and retinal 
mitochondria 77% and skeletal muscle mitochondria 22%. 
Compared to WT, complex II activity in Het mitochondria was reduced by 53%. Brain showed 
a reduction of 54%, spinal cord of 65%, and retina of 55% and skeletal muscle of 35%.  
Compared to WT, complex IV activity in Het CNS mitochondria was reduced by 26%.  Het 
brain mitochondria had a 14% reduction, retina had 60% and skeletal muscle 36% reduction. 
Spinal cord showed a 7% increase.    
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Mitochondrial tissue specific changes were observed for ETC activity compared to WT where 
brain had a 40% reduction; spinal cord showed a 42% reduction, retina a 64% reduction and 
skeletal muscle a 31% reduction.  These findings are summarised in Figure 4.11 with a 
summary of percent reductions in each complex. 
Figure 4.11 ETC and tissue specific changes 
in Het mouse 
Line graph showing Het percent changes of 
electron transport in individual complex’s and 
in specific tissues. The green line represents 
WT values. All complex’s showed a significant 
reduction in activity. All three CNS tissues 
showed reduced ETC activity with retina 
showing the biggest loss. The lower box shows 
the percentage reduction in each complex for 
each tissue type. 
The net function of electron transfer is to generate sufficient ATP to maintain cellular function. 
How this is maintained will depend on the requirements of the cell and the environment it 
survives in. The mitochondrial threshold effect suggests that cells have the ability to challenge a 
reduction in ETC activity up to their threshold. When this is reached, the viability of the cell is 
compromised (Letellier et al. 1994; Rossignol et al. 1999). The value of the threshold for any 
given complex depends on the tissue type and the metabolic demand. For example, the 
threshold value in rat brain for complex I activity is 50.3±7. The skeletal muscle of rat for 
complex I is 74.5±5. Complex IV threshold in rat brain is 87.8±4 and 66.8 ±4 in skeletal muscle 
(Rossignol et al. 1999). Considering the physical activity of the average laboratory rat, the 
threshold values in skeletal muscle appear high. This might suggest a genetic component is 
responsible for setting the threshold value during development (Faustin et al. 2004).The 
threshold values in specific cell types may be adjusted to circumvent the bioenergetic deficits 
before they become established (Rocher et al. 2008).  
The ratio of complex specific activity in skeletal muscle for WT and Het showed that WT had 
the same ratio of complex I, complex II and complex IV. Het skeletal muscle maintained this 
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Skeletal muscle Ratio
CI CII CIV
WT 5 Het5 WT 5 Het5 WT 4 Het5
25±1 20±2 25±4 20±3 25±2 20±1
0.022 0.036 0.255
F(5,17) 11.87 F(5,17)1.87 F(5,16) 13.55
same ratio albeit at a reduced percentage. Table 4.7 shows a summary of the ratio of complex 
activity in skeletal muscle mitochondria 
Table 4.7 Ratio of complex activity in skeletal muscle mitochondria in WT and Het 
The table shows the ratio of the percentage of 
total complex activity for isolated skeletal muscle 
mitochondria in WT and Het. The same ratio of 
activity was present in both WT and Het except the 
ratio of complex I and complex IV was 
significantly reduced in Het muscle 
 
The bioenergetic activity of Het cardiac muscle was shown to have a significant reduction in 
complex I and complex IV activity with complex II not demonstrating any significant difference 
(Chen et al. 2012). Considering the bioenergetic threshold for both cardiac and skeletal muscle 
the difference in complex II mediated activity can be explained.  
Both cardiac and skeletal muscle are striated however cardiac muscle is involuntary and under 
the control of the medulla. Cardiac mitochondria fill about 25% of the cell and use aerobic 
respiration exclusively. The metabolic by-products are CO2 and water which do not adversely 
affect function.  
Skeletal muscle is under voluntary control and the bioenergetic demands will depend on the 
amount of physical activity. Skeletal muscle mitochondria reside between sarcomeres fill about 
2% of the cell. As skeletal muscle contains different myosin isoforms, and each has its own 
oxidative potential, both high and low oxidative potentials exist in the same tissue. They utilise 
a combination of oxidative phosphorylation and anaerobic oxidation resulting in an 
accumulation of lactic acid which imposes restrictions on function. Finally, the examination of 
cardiac mitochondrial function in Opa1
Q285STOP
 mouse may have been influenced by the use of 
inhalation anaesthetic. Het mouse underwent a surgical procedure (thoracotomy for 
haemodynamic measurement) requiring general anaesthetic. Inhalation anaesthetics commonly 
used in mouse surgery are ketamine/xylazine and isoflurane. The activity of these anaesthetics 
has been shown to cause reduced complex I activity (Yan and Sohal 1998; Schenkman and Yan 
2000; Hanley et al. 2002). Post anaesthetic mitochondrial recovery is delayed due to alternations 
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of the biosensor function in mitochondria. Alternations in calcium flux can occur (Branca et al. 
1988). This can be induced by altered lipid composition (Dekutovich and Kargapolov 1986).  
Tissue retrieval in both WT and Het did not employ any anaesthetic agents and the activities of 
all mitochondria were considered to reflect an accurate analysis of true function at 15 months.  
Opa1
Q285STOP 
mouse demonstrated a 54% reduction in complex I activity. Tissue specific 
reduction was observed in retina, spinal cord, brain and skeletal muscle in order of ascending 
reduction. Because complex I is central to energy production in the cell, its malfunction results 
in a wide range of disorders in cells with increased ATP requirements.  Both neurological and 
neuromuscular impairment were observed during phenotyping.  It would appear Het mouse had 
reached a critical threshold for complex I activity.  
Acquired complex I dysfunctions are associated with many disorders. Unlike inherited disorders 
of complex I where particular mutations result in specific disease, acquired complex I 
dysfunction can be the cause or the result of a host of disorders. The mitochondrial threshold 
effect possibly determines whether symptoms arise from such impairment. 
Aging can contribute to reduced activity. In aged rats, reduced complex I activity was associated 
with poor neuromuscular performance. This in turn was associated with changes in 
mitochondrial size where the percentage of small mitochondria in brain was higher in young 
than in old animals, whereas the opposite occurred for large mitochondria (Sastre et al. 1998). 
Mitochondrial morphology helps to support the requirements of threshold maintenance. 
Impaired mitochondrial dynamics lead to defects in oxidative phosphorylation (Parone et al. 
2008). In an Opa1 knockout, brain mitochondria exhibited a dose-dependent reduction in 
oligomeric OPA1 which was accompanied by parallel increases in non-oligomeric OPA1 
isoforms. There were morphological alternations in mitochondrial sizes where increased 
mitochondria with a length of >3M considered as elongated were identified and no change in 
mitochondria smaller than 0.5 M considered as fragmented (Ramonet et al. 2013). 
Reduced electron transport function may initiate a pro survival response to stress in impaired 
mitochondria resulting in hyperfusion (Gomes et al. 2011; Rolland et al. 2013). If the fusion 
machinery is impaired, then other mechanism may intervene.  
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The formation of supercomplexes within healthy mitochondria may help to support the 
necessary requirements in fusion deficient mice. A form of mitochondrial hypertrophy has 
recently been suggested as a compensatory mechanism (Sgarbi et al. 2014).  In a different  
mouse model of ADOA, Opal deltag  mouse,  it was observed at 5 months that an accumulation 
of complex III and IV monomers coincided  with a reduction in  supercomplexes (Sarzi et al. 
2012). As the absence of SCAF1 protein in C57Bl/6 has already been established, the ‘loss’ of 
supercomplexes would not be associated with disease pathology in this mouse model.  
The bioenergetic deficits observed in Opa1
Q285STOP
 mouse were compared to the previous 
literature on Opa1 reduction. Lymphocytes isolated from human ADOA showed reductions in 
complex I and complex II  (Van Bergen et al. 2011). In mouse models of ADOA, skeletal 
muscle mitochondria showed a combined reduction in both complexes I and IV. (Sarzi et al. 
2012). However this is an accelerated age onset disorder. Complex I deficiencies were also 
observed in fibroblast cultures of ADOA patients (Chevrollier et al. 2008). 
A significant finding was that despite the reduction in Het bioenergetic activity, the ratio of 
electron transfer within complexes was preserved for all tissue of the CNS. Considering that 
individual complexes are part of a chain, maintaining the correct ratio of activity between 
complexes may be more important than the preservation of individual complex activity. As 
C57Bl/6 mouse has the versatility of SCAF- mitochondrial environment it may confer the 
advantage of mobility (Lapuente-Brun et al. 2013). 
Dietary intake may influence electron transport. Polyunsaturated n-3 fatty acids are prone to 
oxidative damage. Investigating a mouse model that can synthesize its own n-3 fatty acid 
revealed impaired complex 1 activity with reduced H2O2 production which was due to a 
decrease in ROS production from ETC complex I (Hagopian et al. 2010). As Opa1
Q285STOP 
mouse received a daily intake of 2.1% polyunsaturated (3:6 ratio of 1:5) this could 
potentially put them at risk of oxidative damage. 
In a type II diabetic mouse model ob/ob mouse, both the activity and gene expression of 
mtDNA complex I components are reduced. Peroxynitrite induced degradation of complex I 
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subunits or reduced synthesis of complex I subunits was ascribed to be the cause (García-Ruiz 
et al. 2010).  
In Parkinson Disease (PD) there is a profound reduction of complex I activity (Schapira et al. 
1990) which has been linked to the kinase domain Pink 1 which  is responsible for the 
phosphorylation status of the complex (Morais et al. 2009).  
The role of electron transfer in the  neuropsychiatric disorder autism has demonstrated reduced 
complex 1 activity by 31% (Gu et al. 2013). Stress can also influence complex I activity 
(Madrigal et al. 2001). 
Reactive nitrogen species (RNS) may also have a significant impact on complex I activity. The 
conversion of nitric oxide (NO) to a more reactive derivative (RNS) can have major 
implications on electron transfer function. NO can cause reversible inhibition of cytochrome 
oxidase by competing with oxygen (Brown and Borutaite 2001). Peroxynitrite can inhibit 
complex I, (Brown and Borutaite 1999), complex II, and complex IV and  MnSOD  (Cassina 
and Radi 1996).  
ATP production depends on the efficiency of OXPHOS energy conservation (Cocco et al. 
2009). How efficient the ETC chain is depends on the permeability of the inner membrane and 
the pumping efficiency of complexes. Peroxynitrite can also induce the mitochondrial 
permeability transition pore (Packer and Murphy 1994; Borutaite et al. 1999).  The precise 
mechanism for complex I inhibition could be nitration of tyrosine residues, modification of 
NADH or FMN (Gadelha et al. 1997).  
 The compensatory mechanisms that may override a complex mediated deficiency would by 
nature of the electron transfer chain be limited to the extent of the deficiency. As complex IV 
requires electron donations from either complex I or II, a reduction in one or both will 
eventually impact complex IV activity. Cellular compensation may attempt to reduce the ATP 
requirement by minimising function. The inability to adapt would ultimately result in cell death. 
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4.4 Mitochondrial related proteins in Opa1Q285STOP mouse 
4.4.1 Introduction to mitochondrial related proteins 
The data from extracted mitochondria may only be considered a version of the events that are 
occurring within the cell. Tissue handling and processing although kept to minimum will alter 
the final result. Homogenization of tissues results in the release of proteases and apoptotic 
caspases, with the final event yielding reduced protein content. Immunohistochemistry is a 
method designed to avoid excess structural alternation and maintain the integrity of cellular 
content. Tissue sections of retina and brain can be probed using a variety of established 
antibodies which can then be quantified according to immunofluorescence intensity. This also 
permits the localization of proteins of interest within the tissue architecture. The antibodies that 
were used in this study are detailed. 
4.4.1.1.1 VDAC expression 
Voltage gated anion channel 1 (VDAC) is a global regulator of mitochondrial function 
(Lemasters and Holmuhamedov 2006). It provides permeability between the inner membrane 
space and the cytoplasm and permits the transport of small hydrophilic molecules including 
substrates for respiration (Maldonado and Lemasters 2014).  At reduced m VDAC remains 
in an open state (Mannella and Kinnally 2008). VDAC can also participate to mitochondrial 
membrane permeabilization, an apoptotic checkpoint in stress and pathological conditions. By 
altering its conductance, VDAC can inhibit apoptosis (Duan et al. 2003; Shoshan-Barmatz et al. 
2010) It is an important regulator of mitochondrial calcium. 
4.4.1.1.2 Neuroglobin expression 
Neuroglobin is a member of the oxygen carrying  globin family that has a higher affinity for 
oxygen than haemoglobin (Kiger et al. 2011).  It is found throughout the CNS including the 
CSF (Casado et al. 2005) and retina (Schmidt et al. 2003; Lechauve et al. 2012).  Complex I 
impaired Harlequin mouse recently were shown to have a twofold reduction in neuroglobin 
expression with optic atrophy and RGC loss. Intravitreal injections of  a Neuroglobin construct 
returned complex I activity and prevented RGC and axon loss   (Lechauve et al. 2014). 
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Neuroglobin can inhibit apoptosis by interacting with cytochrome c preventing its release to the 
cytoplasm (Fiocchetti et al. 2013). 
4.4.1.1.3 Preli expression 
The Preli gene encodes a member of the late embryogenesis abundant (Lea) motif-containing 
protein family. The encoded protein is localized to mitochondria (Sesaki et al. 2006). Preli 
ensures the accumulation of cardiolipin by acting as a transporter of phosphatidic acid (PA) 
which is a requirement for cardiolipin synthesis (Hall et al. 1987; Potting et al. 2010). The 
cellular adaptive response through cristae remodelling is due to the  interaction of preli with 
Opa1 (McKeller et al. 2010). This interaction is responsible for maintaining the negative 
curvature of the membrane especially at sites of membrane fusion (Renner and Weibel 2011; 
Chan and McQuibban 2012) (See Figure 4.12).  Opa1 regulation of cristae is independent of 
fusion function. Substrate availability determines the mitochondrial architecture which is 
determined by Opa1 (Patten et al. 2014).  
Figure 4.12 Preli associated Opa1 maintenance of cristae 
structure 
Preli enhances Opa1 sequestration of cytochrome c by 
allowing tight curvature in the membrane. This also enhances 
fusion.  
 
The interaction of Preli with Opa1 upholds mitochondrial ΔΨ 
and enhances respiratory chain function. The increased 
cardiolipin content increases the fluidity of the inner mitochondrial membrane (Verstraeten et 
al. 2005; Unsay et al. 2013). This permits respiratory complexes to move into closer proximity 
to each other enhancing function (Mileykovskaya and Dowhan 2014; Paradies et al. 2014). 
Figure 4.13 summarises  some of the known functions of these proteins. 
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Figure 4.13 Mitochondrial related protein activity in mitochondria 
Schematic summarises some of the known functions of VDAC, Neuroglobin and Preli 
proteins and the impact of expression on mitochondrial size shape function 
bioenergetics and control of apoptosis. 
4.4.1.1.4 PSD95 expression 
PSD95 is a scaffold protein found at post synaptic glutamate receptors where it provides 
anchorage and support to the vertical filaments at the post synaptic domain. PSD95 interacts 
with the cytoplasmic tail of NMDA receptor subunits and shaker-type potassium channels 
(Eldstrom et al. 2002). PSD95 is involved in synaptic plasticity (Meyer et al. 2014). 
Overexpression or depletion of PSD95 changes the ratio of excitatory to inhibitory synapses in 
neurons. The pruning of dendritic branches is paralleled by a significant elevation in synaptic 
expression of PSD95 (Bustos et al. 2014). This inverse correlation has also been seen in RGC of 
both rabbit and mouse (Jakobs et al. 2008; Chen and Chiao 2014). 
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4.4.1.1.5 Neurofilament expression 
Neurofilaments (NF) are a neuronal cytoskeleton proteins with a diameter of 10nm and are 
abundant in the axons of neurons. They are essential for the maintenance of axon calibre and the 
transmission of electrical impulses along axons (Eyer and Peterson 1994; Yum et al. 2009). NF-
H is present in brain but not in all retinal ganglion cell axons (Ruiz-Ederra et al. 2004).  
An excess of NF-H can result in a reduction of dendritic branching  (Sánchez et al. 1996). A 
pathological accumulation of neurofilament has been implicated in several diseases including 
Charcot-Marie-Tooth (CMT) (Abe et al. 2009), Spinal muscle atrophy (SMA) (Perrot and Eyer 
2009; Liu et al. 2011), Alzheimer and Parkinson’s disease (Szaro and Strong 2010). 
4.4.2 Experimental design of mitochondrial related proteins4 
Using a variety of antibodies, mitochondrial proteins were investigated. In order to evaluate the 
significance of staining intensity, profiles were established where specific functions were 
considered- mitochondrial specific, compensation, and damage mediated. Mitochondrial 
specific antibodies were Opa1 and VDAC; compensatory proteins were Preli and Neuroglobin. 
Damage mediated proteins were PSD95 and neurofilament. 
4.4.3 Results of mitochondrial related protein expression in the retina  
Table 4.8 shows a summary of AFU in retinal layers for Opa1, VDAC and Preli.  Table 4.9 
shows a summary for Neuroglobin, PSD95 and NF L expression in WT and Het. Figure 5.6 and 
Figure 5.7 shows graphs representing AFU in retinal layers of WT and Het.  
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PRL ONL OPL INL IPL GCL
A Opa1 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 192 96.4 256 98.8 258 130 224 71.1 281 89 187 77.7
SEM 39.3 26.8 52.6 37.6 73 26.3 79.2 11.9 41.8 29.2 30.5 10.3
WT:Het 0.241 0.024 0.006 0.177 0.022 0.008
F ( 5,15) 3.865 F (5,15) 4.390 F (5,15) 2.751 F (5,15)5.463 F (5,15) 9.729 F (5,15) 3.971
PRL ONL OPL INL IPL GCL
B VDAC WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 91.9 555 273 944 184 526 215 890 181 747 404 798
SEM 15.9 88 25.1 23.5 19.6 81.9 26.5 66.1 25.7 67.6 30.6 65.8
WT:Het 0.005 0.769 0.023 0.008 0.010 0.031
F ( 5,15) 10.470F (5,15) 1.380 F (5,15) 6.747 F (5,15)1.028 F (5,15)1.146 F (5,15)0.441
PRL ONL OPL INL IPL GCL
C Preli WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 366 255 17 186 194 144 110 120 122 215 213 99
SEM 120 71 4 113 63 58 16 43 37 106 61 30
WT:Het 0.386 0.520 0.004 0.898 0.027 0.003
F ( 5,21) 21.466 F (5,21) 1.843 F (5,15) 5.851 F (5,15)4.645 F (5,15) 1.132 F (5,15) 3.626
 
Table 4.8 Opa1,VDAC and 
Preli expression in retinal 
sections of WT and Het 
Table shows the mean (±SEM) 
of (A) Opa1, (B) VDAC and 
(C) Preli, expression in retinal 
layers of WT and Het. 
Statistical difference between 
groups is represented by the  p 
value 
 
 
 
Figure 4.14 Retinal mitochondrial related protein expression: Opa1, VDAC and Preli 
Graphs show the mean ±SEM AFU of (A) Opa1, (B) VDAC and (C) Preli expression in 
retinal sections of WT and Het. 
 
Retinal protein expression in Het was compared to WT. Het Opa1 protein expression was 
reduced by 59% compared to WT. The INL showed the highest reduction of protein expression 
with a 68% reduction which was statistically different compared to WT (F(5,13) 1.191 
p=0.002). VDAC expression was increased by 277% in Het retina. The PRL had the highest 
percentage increase with 504% which was statistically increased compared to WT(F(5,12) 6.623 
p=0.001). 
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PRL ONL OPL INL IPL GCL
D Neuro WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 228.1 250.5 218.1 349.2 170.2 129.8 163.3 259.3 180.9 90.4 71.3 64.8
SEM 52.3 38.1 99.9 39.0 54.2 20.8 81.3 21.3 80.6 35.0 36.4 23.2
WT:Het 0.384 0.722 0.701 0.634 0.846 0.503
F ( 5,20) 1.530 F (5,20) 0.784 F (5,20) 0.969 F (5,20)0.896 F (5,20) 1.654 F (5,20) 0.838
PRL ONL OPL INL IPL GCL
E PSD95 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 90.5 267.0 37.8 162.0 84.4 239.0 24.5 82.8 40.3 211.0 34.0 92.9
SEM 10.2 24.2 10.3 32.0 24.6 2.3 11.3 11.2 18.1 15.8 26.4 15.6
WT:Het 0.314 0.292 0.75 0.272 0.122 0.346
F ( 5,28) 1.900 F (5,28) 1.176 F (5,28) 4.913 F (5,28)2.091 F (5,28)2.78 F (5,28) 1.762
PRL ONL OPL INL IPL GCL
F NF L WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 112.0 128.0 165.0 168.0 99.2 182.0 57.1 140.0 195.0 173.0 443.0 405.0
SEM 13.2 56.5 87.1 54.8 3.6 70.4 11.7 42.0 28.3 54.7 37.6 105.0
WT:Het 0.020 0.536 0.059 0.452 0.740 0.038
F ( 5,23) 8.530 F (5,23) 1.280 F (5,23) 4.219 F (5,23)3.493 F (5,23) 7.706 F (5,23) 2.512
Table 4.9 Neuroglobin, 
Neurofilament and 
PSD95 expression in WT 
and Het retina 
Table shows the mean 
(±SEM) of (D) 
Neuroglobin, (E) PSD95  
and (F) Neurofilament 
expression in retinal layers 
of WT and Het. Statistical 
difference between groups 
is represented by the  p 
value. 
 
 
Figure 4.15 Retinal mitochondrial related protein expression untreated WT and Het 
Graphs show the mean ±SEM AFU of (D) Neuroglobin (E) PSD95 and (F) NF L 
expression in retinal sections of WT and Het. 
Het retina showed Preli expression was reduced by 3% compared to WT. The GCL had a 
significant 54% reduction which was statistically reduced compared to WT (F(5,14) 0.561 
p=0.026). Neuroglobin expression in Het retina was increased by 8%. The ONL had the highest 
percentage increase with 59 % (p=0.133). 
PSD95 expression in Het retina was increased by 257% compared to WT. The IPL showed a 
significant 423% increase (F(5,12) 2.052 p=0.039) compared to WT. Neurofilament light chain 
expression was increased by 37% compared to WT. The OPL had a significant increase with 
83% more than WT (F(5,12) 5.578 p=0.031). 
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A Mito PRL ONL OPL INL IPL GCL
WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 637 985 556 383 498 379 411 355 691 663 702 458
SEM 85.3 140 97.9 67.8 63 54.8 65.7 63.2 124 148 118 87.4
p 0.366 0.044 0.531 0.090 0.067 0.683
F(5,69) 5.364 F(5,69) 3.036 F(5,69) 2.201 F(5,69) 1.791 F(5,69) 3.187 F(5,69) 3.187
B Comp PRL ONL OPL INL IPL GCL
WT Het WT Het WT Het WT Het WT Het WT Het
Ave 414 500 344 403 333 391 198 378 288 395 298 362
SEM 57.6 58.1 62.9 53.8 58.2 54.3 33.7 55.1 63.4 69.8 55.8 73.7
p 0.074 0.002 0.250 0.005 0.014 0.376
F(5,78) 2.133 F(5,78) 0.851 F(5,78) 0.705 F(5,78) 2.759 F(5,78) 1.570 F(5,78) 0.961
C Dam PRL ONL OPL INL IPL GCL
WT Het WT Het WT Het WT Het WT Het WT Het
Ave 342 571 253 232 307 378 160 203 264 313 278 392
SEM 47.4 50.7 24.9 45.4 34.9 45.2 28.6 51.8 34.5 58.6 37.6 56.2
p 0.046 0.370 0.006 0.001 0.110 0.485
F(5,81) 0.741 F(5,81) 2.097 F(5,81) 0.948 F(5,81) 1.660 F(5,81) 1.198 F(5,81) 1.321
In order to identify which retinal layers were specifically targeted for the activities examined, 
the combined AFU were re-examined. Table 4.10 shows a summary of these data and Figure 
4.16 shows graphs representing the AFU from all mitochondrial, compensatory and damage 
related proteins in WT and Het retinal layers. 
Table 4.10 Targets in the Het retinal layer 
 
The table shows the 
mean ±SEM of AFU for 
all (A) mitochondrial 
(B)compensatory and 
(C)damage mediated 
protein activities in 
retina of WT and Het.  
The statistical difference 
between groups is 
represented by the p 
value. 
 
 
Figure 4.16 Retinal profile of protein expression of WT and Het 
Graphs show the mean ±SEM AFU of (A) mitochondrial, (B) compensatory and (C) 
damage mediated protein expression in the retinal layers of WT and Het. 
 
Mitochondrial related protein expression was increased by a mean 62% in Het retina. The ONL 
showed a significant 135% increase (F(5,54) 1.909 p=0.044) compared to WT. No other retinal 
layers were significantly different compared to WT. Compensation protein expression in Het 
retina showed a mean 96% increase compared to WT. All retinal layers showed an increase in 
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protein expression compared to WT.  Het ONL showed a significant 185% increase compared 
to WT (F(5,52)1.883 p=0.002). The INL had a significant 150% increase (F(5,52) 2.253 
p=0.005).  The IPL had 39% increase (F(5,52) 2.695 p=0.014). Damage mediated protein 
expression in Het retinal layers was increased by 89%. The specific layers targeted were the 
INL with a 178% increase (F(5,48) 2.548 p=0.001), the OPL with a 131% increase (F(5,48) 
3.380 p=0.006).  
Considering that compensatory protein expression was significantly increased in both the outer 
and inner nuclear layer and that damage mediated protein expression was significantly increased 
in the corresponding plexiform layers might suggest that the compensation effects were 
insufficient, however, the activity of compensatory proteins within the inner plexiform layer 
were 92% higher than that of WT.  
The ratio of compensatory to damage protein (C:D) expression was examined. Table 4.11 shows 
a summary of these findings.  
Table 4.11 Ratio of compensation to damage protein expression in retina of WT and Het 
 
Table shows the ratio of compensation to damage mediated protein expression in WT and Het 
retinal layers. A ratio of less than 1 suggested that the activity of compensation was exerting a 
positive effect on damage mediated protein expression. In WT retinal layers, there was a 
positive compensation to damage ratio in all layers. In Het retinal layers all but the RGC layer 
showed a positive compensation to damage mediated ratio. The percentage difference between 
groups is shown. 
 
Figures 4.17- 4.21 show representative images of these protein expression in retinal sections of 
WT and Het. 
 
 
C:D 1: PRL ONL OPL INL IPL GCL
WT 0.42 0.64 0.50 0.25 0.74 1.12
Het 0.57 0.36 0.86 0.28 0.54 0.84
% WT 36 -44 72 12 -27 -25
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Figure 4.17 Opa1 expression in retina of WT and Het 
Representative images of Opa1 expression in WT and Het retina (A-B) with RGC 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and 
(F) Het were processed without the primary antibody. 
 
A WT Opa1 WT merge WT Hoechst
B Het Opa1 Het merge Het Hoechst
C WT RGC Opa1 WT merge WT Hoechst
D Het RGCOpa1 Het merge Het Hoechst
E WT Control WT merge WT Hoechst
F Het Control Het merge Het Hoechst
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Figure 4.18 VDAC expression in retina of WT and Het 
Representative images of VDAC expression in WT and Het retina (A-B) showing RGC 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and 
(F) Het were processed without the primary antibody. 
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Figure 4.19 Preli expression in retina of WT and Het 
Representative images of Preli  expression in WT and Het retina (A-B) showing RGC 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and 
(F) Het were processed without the primary antibody. 
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Figure 4.20 Neuroglobin  expression in retina of WT and Het 
Representative images of Neuroglobin expression in WT and Het retina (A-B) showing RGC 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and (F) Het 
were processed without the primary antibody. 
 
 
A WT  Neuroglobin WT merge WT  Hoechst
B Het Neuroglobin Het merge Het Hoechst
C WT RGC Neuro WT merge WT  Hoechst
D Het RGC Neuro Het merge Het Hoechst
E WT Control WT merge WT Hoechst
F Het Control Het merge Het Hoechst
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Figure 4.21 PSD95 expression in retina of WT and Het 
Representative images of PSD95 expression in WT and Het retina (A-B) showing OPL 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and 
(F) Het were processed without the primary antibody. 
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Figure 4.22 NF L expression in retina of WT and Het 
Representative images of NF L expression in WT and Het retina (A-B) showing RGC 
regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for WT and 
(F) Het were processed without the primary antibody. 
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4.4.4 Results of mitochondrial related protein expression in brain of WT and Het 
Table shows a summary of AFU in brain for mitochondrial Opa1 VDAC, Neuroglobin, Preli, 
PSD95 and NF H expression in brain of WT and Het.  Figure 5.9 shows graphs representing 
AFU in protein expression of WT and Het brain. 
Table 4.12 Summary of mitochondrial related protein expression in brain of WT and Het 
 
Table shows the mean (±SEM) of brain 
mitochondrial (A) Opa1, (B) VDAC (C) 
Neuroglobin, (D) Preli (E)PSD95 and (F) 
NF H proteins expression in brain of WT 
and Het. difference between groups is 
represented by p value. 
 
 
 
 
Figure 4.23  
Mitochondrial protein 
expression in brain of 
WT and Het 
Graphs show the mean 
±SEM of AFU for (A) 
Opa1, VDAC and Preli 
proteins (B) 
Neuroglobin,PSD95 and 
NF H  protein expression 
in brain of WT and Het. 
 
 
Mitochondrial related protein expression in Het brain showed a 32% reduction in Opa1 protein 
expression (p=0.492) compared to WT. VDAC expression was increased by 105% which was 
significantly increased compared to WT (F(5,24) 2.223 p=0.005). 
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Het brain had a significant 87% increase in preli expression compared to WT (F(5,26) 1.615 
p=0.008). Neuroglobin expression was increased by 148% which was statistically significant 
compared to WT (F(5,19) 5.086 p=0.003). 
Het brain showed a 74% reduction in PSD 95 expression compared to WT which was not 
statistically different to WT (p=0.112). Neurofilament expression in Het brain was increased by 
725% which was significantly increased compared to WT (F(5,25) 6.683 p=0.001). p=0.001). 
4.4.5 Western blotting of brain homogenate in WT and Het 
Western blotting of WT and Het  brain homogenate Opa1 expression in WT brain homogenate 
had 1.30±0.24 RD and Het had 0.97±0.07 which was significantly reduced compared to WT 
(F(3,12) 2.267 p=0.047). Preli expression in WT brain homogenate had 0.75±0.17 RD and Het 
had 0.58±0.20 RD which was not significantly different compared to WT (p=0.495). Figure 
4.23 shows a summary of these findings. 
Figure 4.24 Western blot of brain homogenate in WT and Het 
Western blot of brain homogenate from WT (n4) and Het (n4) for (A) Opa1 (B)Preli   
expression with corresponding  actin beneath. 
 
 
Figures 4.24- 4. Show representative 
images of brain sections expressing the 
above proteins. 
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Figure 4.25 Opa1 expression in brain of WT and Het 
Representative images of Opa1 expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibod.y  
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Figure 4.26 VDAC expression in brain of WT and Het 
Representative images of VDAC expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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Figure 4.27 Preli expression in brain of WT and Het 
Representative images of Preli expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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Figure 4.28 Neuroglobin expression in brain of WT and Het 
Representative images of Neuroglobin expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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Figure 4.29 PSD95 expression in brain of WT and Het 
Representative images of PSD95 expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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Figure 4.30 Neurofilament Heavy chain expression in brain of WT and Het 
Representative images of NF H expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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The protein profile for  Het brain showed that there was 46% increase in mitochondrial related 
protein expression compared to WT (p=0.134). Compensatory protein expression was increased 
by 118% which was significantly increased compares to WT (F(5,81) 3.029 p=0.001). Damage 
mediated protein expression was increased by 119% which was also significantly increased 
compared to WT (F(5,58) 7.739 p=0.007). The ratio of compensatory to damage mediated in 
WT brain was 0.76 and 0.77 in Het brain. Figure 4.31 shows a summary of protein profiles for 
both retina and brain. 
 
Figure 4.31 Summary 
of protein profiles in 
retina and brain of WT 
and Het 
Graphs show a summary 
of mitochondrial, 
compensatory and 
damage mediated 
protein expression in 
(A)retina and (B) brain 
of WT and Het. 
 
 
 
4.4.6 Discussion of mitochondrial related protein expression in WT and Het 
Immunohistochemical analysis of mitochondrial function in intact tissue provided an accurate 
investigation platform for a variety of proteins. As ADOA is primarily a retinal disease, the 
laminated structures of the retina provided an excellent substrate for protein localisation. By 
combining retinal and brain histology, a particular profile emerges that lends support to the 
physical phenotypes seen in this mouse model of disease. 
From the analysis it was observed that the mitochondrial profile in the specific layers of Het 
retina showed enhanced activity with the ONL showing a significant 135% increase in activity 
compared to WT. The Het RGC showed the least change with 15% increase compared to WT. 
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The compensation profile of retinal layers in Het showed the ONL had a significant 185% 
increase in protein expression compared to WT. The Het RGC layer had the least increase of 
38% in compensation proteins. 
The damage profile in the retina of Het showed all layers had increased damage mediated 
protein expression. The highest was the INL which had a significant 178% increase compared to 
WT. The RGC showed the least damage with 4% more that WT. 
The expression of PSD95 is negatively correlated with dendritic branching   (Levinson and El-
Husseini 2005; Marshak et al. 2012; Bustos et al. 2014). 
Increased PSD95 expression is considered a compensatory mechanism for reduced pre synaptic 
scaffold proteins (Weisenhaus et al. 2010; Plowey et al. 2014; Li et al. 2015). Neurofilament 
expression is associated with damage mediated cellular response.  Enhanced expression of both 
PSD95 and NF-L have been identified in the substantia nigra of schizophrenia (Mueller et al. 
2004; Kristiansen et al. 2006).   This was also observed in dyskinetic marmoset (Hurley et al. 
2005.) 
The comparative analysis of Het brain and retina with respect to protein expression showed that 
despite its size the retinal tissue exerted a significant increase in compensatory proteins with 
compensation: damage ratio of 0.54. Het brain also had a positive ratio of 0.77. In summary, 
Het retina had 22% less damage mediated protein expression and subsequently had 25% less 
compensatory protein expression.  
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4.4.7 Summary of Chapter 4: Bioenergetic impairment in Opa1Q285STOP mouse 
4.4.7.1 Significant reduction of mitochondrial size in brain and retina 
Opa1
Q285STOP
 mouse showed a significant increase in the proportion of smaller sized 
mitochondria and a significant reduction in median sized mitochondria compared to WT brain 
and retina. 
4.4.7.2 Enhanced ATP levels  
ATP levels in brain (male Het) and spinal cord (female Het) were significantly increased 
compared to WT. Compared to WT, retinal ATP was not significantly different in Het mice.   
4.4.7.3 Bioenergetic impairment in all CNS tissues examined 
Electron transfer in complex I, II and IV were significantly reduced in brain, spinal cord, retinal   
and skeletal muscle mitochondria of Het mouse. Complex IV activity in Het spinal cord was the 
single tissue that exhibited a 7% increase in complex IV activity which may suggest it was the 
final tissue to preserve electron transport function.  
4.4.7.4 Preservation of electron complex ratios in CNS of Het 
Despite the reduction in bioenergetic activity, the ratio of complex activity was preserved in all 
Het tissue examined. 
4.4.7.5 Compensation for damage mediated protein expression  
Both the retina and brain of Het showed a positive ratio of compensation to damage mediated 
protein expression. There was a significant amount of damage associated to the INL but not to 
the RGC layer.   
The significant increase in smaller fragmented mitochondria in brain and retina of Het mouse 
suggested that despite maintaining ATP values in excess of WT, the bioenergetic deficit was 
resulting in the physiological phenotypes observed. The preservation of electron complex ratios 
was considered to be vitally important. This preservation may have been aided by the increase 
in compensatory protein expression observed in brain and retina of Het mouse. 
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Chapter 5 Antioxidant deficit in Opa1Q285STOP mouse 
5.1 Introduction 
ROS normally exist in balance with antioxidants. A disturbance in the oxidant-antioxidant 
homeostasis can result in the generation of reactive non-radical and radical species that may 
participate in the chain reaction. The essential trigger of the endogenous antioxidant system will 
vary according to the sensitivity of the tissue to ROS. The cellular components that are 
susceptible to ROS damage are unsaturated fatty acids in cell membranes, (Bicknell et al. 2002; 
Tanito et al. 2009; van den Elsen et al. 2013),  proteins which can be denatured  (Kortuem et 
al. 2000; Tezel 2006; Saccà et al. 2013) and nucleic acids (Organisciak et al. 1996; Betzen et al. 
2009; Witte et al. 2013). 
Defence mechanisms against excessive ROS are vital in maintaining normal tissue function in 
healthy cells. In tissue with an existing mitochondrial dysfunction, the presence of excessive 
unregulated ROS may be due to an insufficient response to the amount of ROS or due to a direct 
attack on the antioxidant system itself.  
The need for antioxidants arises from normal cellular respiration. Superoxide anion (O2
-
) is the 
product of a one electron reduction of molecular oxygen. Superoxide (O2
•-
) is the precursor of 
many reactive species. It can generate a more reactive hydroxyl radical (OH

) by reacting with 
transition metals (Fe2
+
) in the Fenton reaction. O2
•-
 and H2O2 can produce OH
•
 in the Haber-
Weiss reaction but the reaction is pH dependant at acidic environment within the lysosomes. 
Hydrogen peroxide (H2O2) is formed from the spontaneous dismutation of O2
-
 or the action of 
superoxide dismutase (SOD) on O2
●-
. Mitochondria can contribute 40% hydrogen peroxide to 
the cellular environment (Boveris et al. 1972; Chance et al. 1979; Zager and Burkhart 1997; 
Kaminsky and Kosenko 2008; Grivennikova et al. 2010). The catalase enzyme is found within 
the peroxisomes of most cells. Catalase performs a functional role in signal transduction 
(Suzuki et al. 1997), and development (Pierce et al. 1991). Catalase eliminates excess H2O2 
thereby breaking the chain of ROS generation. 
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 Brain  Retina
WT 6 WT 4
Het 8 Het 4
SC
WT 7
Het 7
A reduction in antioxidant activity can result in a cumulative ROS production. The late onset 
ADOA disease profile may be associated with ROS production. (Shahrestani et al. 2009; Tang 
et al. 2009; Chen et al. 2012). The aim of this section was to establish if the presence of 
impaired antioxidant response was present in the Opa1
Q285STOP
 mouse model. 
5.1.1 Catalase assay in WT and Het mouse 
5.1.1.1 Experimental design of catalase assay 
The method of Aebi (Aebi 1984) and Beers (Beers and Sizer 1952) was employed to calculate 
the catalytic activity of tissue homogenates (as detailed in Chapter 2 section 2.13). The method 
measured the decomposition of a known concentration of H2O2 using the change in absorption 
at 240nm. A concentration of 10.3mM H2O2 prevents inactivation of catalase and reduces the 
formation of air bubbles due to the liberation of O2 (Beers and Sizer 1952). H2O2 at 
concentrations in excess of 0.1M results in rapid inactivation of catalase (Altomare et al. 1974; 
Claiborne et al. 1979; Arnao et al. 1990; Lardinois 1995). The concentration of H2O2 at 0.3% in 
tissue homogenate is insufficient to significantly alter the function of peroxidase activity 
(Vetrano et al. 2005). Details of test samples are shown in Table 5.1. 
5.1.1.2 Results of catalase assay in WT and Het 
Table 5.1Summary of test samples for analysis of catalase activity in 
WT and Het 
 
In WT brain, the catalase activity was 4.30±0.38 units/mg and Het brain 
was 3.50±0.31 units/mg which was not considered statistically different to WT (p=0.099).  
The catalase activity in spinal cord homogenate of WT was 3.90±0.54 units/mg and Het spinal 
cord was 1.70±0.25 units/mg which was significantly reduced compared to WT (F(5,18) 10.902 
p=0.001).  
Catalase activity in WT retinal homogenate was 3.70±0.51 units/mg and 2.10±0.35 units/mg in 
Het retina which was significantly reduced compared to WT retina (F(3,10) 9.156  p=0.007) 
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The kinetics of the catalase reactions are presented in Figure 5.1 and a graph representing the 
results is shown in Figure 5.2. 
 
Figure 5.1Kinetics of H2O2 decomposition in tissue homogenate of WT and Het 
Representative kinetics of the decomposition of H2O2 in the presence of 80g homogenate from 
both WT and Het brain (A), spinal cord (B) and retina (C).  
 
Figure 5.2Catalase activity in WT and Het 
homogenate 
Graph showing the mean ±SD of catalase 
activity per mg of protein in tissue 
homogenate from WT and Het brain, spinal 
cord (SC) and retina(Ret). 
 
  
5.1.1.3 Discussion of catalase activity in WT and Het mouse 
Brain homogenate of Het showed no significant difference in catalase activity compared to WT 
brain. Het spinal cord had a 56% reduction in catalase activity compared to WT which was 
significantly different (p=0.001). There was a 43% reduction in retinal catalase activity which 
was significantly reduced when compared to WT retinal homogenate (p=0.007).   
This suggested that Het spinal cord had the least protection against H202 damage, and that Het 
retinal tissue was also more vulnerable to H202 mediated damage.  
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The significance of this reduction in tissues which both require myelin in order to function 
might suggest that reduction of catalase may induce demyelination in susceptible tissues (Guy et 
al. 1989; Spanevello et al. 2009; Goecks et al. 2012).  
Genetic factors that control the amount of catalase production do so by altering the rate of 
catalase degradation and not the rate of synthesis (Rechcigl and Heston 1967). The activity of 
glutathione peroxidase has a higher affinity for H2O2 than that of catalase (Hirrlinger et al. 
2002). With respect to the tissue specific activity of catalase in spinal cord homogenate, the 
combined activities of both glutathione peroxidase and catalase are required in the control of 
spinal cord oxidative damage  (Baud et al. 2004). 
The spinal cord is highly susceptible to oxidative stress (Uttara et al. 2009; Jia et al. 2012). The 
intrinsic difference in the mitochondria of spinal cord compared to brain is a reduced threshold 
for Ca
2+
-induced mitochondrial permeability transition (mPT) (Brown et al. 2006; Morota et al. 
2007). The mPT is a disruption in the proton motive force. The mPT pore acts as a voltage and 
calcium sensor between the inner and outer mitochondrial membrane (Martin et al. 2011; 
Bernardi 2013). Disruption to the mPT alters Ca
2+
 within the mitochondrial matrix resulting in 
mitochondrial depolarisation. The mPT is under the influence of complex I derived reactive 
oxygen species (Batandier et al. 2004). As the bioenergetic activity of complex I was 
significantly reduced in Het spinal cord mitochondria this will result in a reduction of ROS 
mediated signalling and altered spinal cord mPT. Increased cytoplasmic Ca
2+
 initiates 
excitotoxicity (Ankarcrona et al. 1995; Dutta and Trapp 2011) which triggers a cascade of 
mitophagic signals (Celsi et al. 2009; Perez-Pinzon et al. 2012).  
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5.1.2 SOD analysis in Opa1Q285STOP mouse 
5.1.2.1 Experimental design of SOD analysis 
The antioxidant activity of SOD was analysed in tissue homogenate of WT and Het at 15 
months. The tissues analysed were brain, spinal cord and retina. The total SOD activity was 
determined and with the use of specific inhibitors of MnSOD and CuZnSOD, the activity of 
mitochondrial and cytoplasmic SOD examined by the percentage inhibition of formazan 
formation.  
Tissue homogenates from brain, spinal cord and retina were processed as described in Chapter 2 
(Methods). Protein assays were performed and homogenate diluted to 1mg/ml. Each sample was 
run in triplicate with a standard curve for each run.  For specific analysis of MnSOD, CuZnSOD 
was inhibited with potassium cyanide (1mM). For analysis of CuZnSOD activity, MnSOD was 
inhibited with 2% SDS.  
5.1.2.2 Results of SOD analysis in WT and Het 
Table 5.2 Summary of sample numbers for SOD analysis in WT 
and Het 
 
 
Figure 5.3 shows the kinetic assays. Table 5.3 shows a summary of SOD analysis in WT and 
Het.  and Figure 5.4 shows a representative graph of these findings. Calculation of line fittings 
for SOD activity is shown in Appendix J. 
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Figure 5.3 Kinetics of formazan inhibition as a function of SOD in WT and Het  
 
Representative kinetics of 
formazan formation in the 
absence of SOD and the 
inhibition of formazan 
formation in the presence of 
WT and Het homogenate from 
brain, spinal cord (SC) and 
retina (Ret). Total SOD 
activity was measured without 
any inhibitors.  CuZnSOD 
activity was determined by   
inhibition of MnSOD with 2% 
SDS.  MnSOD activity was 
determined by inhibition of 
CuZnSOD with 1mM KCN. 
 
 
 
 
Table 5.3 Summary of SOD activity in 
tissue homogenate of WT and Het 
Table shows a summary of total SOD, 
MnSOD and CuZnSOD activity in WT and 
Het brain, spinal cord (SC) and retinal 
(Ret) homogenate. The statistical difference 
(p value) between groups is shown. 
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fold SOD CuZn MnSOD Non-SOD Ave
Brain 1.4 3.3 3.0 405.0 103.2
SC 51.0 14.0 33.7 1.4 25.0
Ret 0.8 0.4 1.3 0.3 0.7
Ave 17.7 5.9 12.7 135.6
 
Figure 5.4 SOD units of activity in tissue homogenate of WT and Het 
Graphs showing the mean ±SD SOD activity in tissue homogenate of 15 month WT and Het 
Brain, spinal cord (SC) and retina(Ret) showing (A) Total SOD activity  (B)CuZnSOD activity 
(C)MnSOD activity.  
 
The mean fold reduction of SOD activity in Het brain homogenate was 2.6 compared to WT 
brain. CuZnSOD activity was reduced 3.3 fold and MnSOD activity reduced 3.0 fold. 
Het spinal cord homogenate had the highest fold reduction of 33 compared to WT. CuZnSOD 
activity was reduced 14 fold and MnSOD activity reduced 34 fold. 
Het retinal homogenate had 0.8 fold reduction in SOD activity compared to WT. CuZnSOD 
activity was reduced 0.4 fold and MnSOD activity reduced 1.3 fold. Table 5.4 summarises these 
findings. 
Table 5.4 Fold changes of SOD activities in Het CNS 
 
Tissue specific fold changes in Het 
homogenate compared to WT showed 
spinal cord had the highest reduction of 
all tissues tested. 
 
 
 
A
0
20
40
60
WT Het WT Het WT Het
Brain SC Ret
T
o
ta
l S
O
D
 U
n
it
s/
m
g *** *** **
0.0
0.5
1.0
1.5
2.0
2.5
WT Het WT Het WT Het
Brain SC Ret
M
n
 S
O
D
 U
n
it
s/
m
g *** *** *
CB
0
2
4
6
8
10
WT Het WT Het WT Het
Brain SC Ret
C
u
Z
n
 S
O
D
 U
n
it
s/
m
g
** ***
Total SOD p F CuZn p F MnSOD p F
Brain WT(6) Het(6) WT:Het 0.001 F(5,12) 13.076 WT:Het 0.004 F(5,12)257.8 WT:Het 0.001 F(5,12)48.76
SC WT(7) Het(7) WT:Het 0.001 F(5,12)853.093 WT:Het 0.001 F(5,12)15.42 WT:Het 0.001 F(5,12)22.60
Ret WT(6) Het(6) WT:Het 0.003 F(5,12) 78.006 WT:Het 0.299 F(5,12)10.84 WT:Het 0.029 F(5,12)3.74
*p<0.05**p<0.010***p<0.001 ±SD
Chapter 5 Antioxidant deficit in Opa1
Q285STOP 
mouse 
 
165 
 
The percentage inhibition of formazan formation in tissue homogenate represented the total 
SOD activity in WT and Het. The combined percentage inhibition of CuZnSOD and MnSOD 
should have equalled the total SOD activity. In WT brain, there was less than 1%±1 non-SOD 
activity, Het brain homogenate had 23%±3 non-SOD activity which was significantly increased 
compared to WT (F(5,30) 25.624  p=0.001). WT spinal cord homogenate had 14%±4 non-SOD 
and Het had 35%±1 which was significantly increased compared to WT (F(5,20) 19.228 
p=0.001). There was no statistical difference in non-SOD activity between WT 15%±3 and Het 
21%±2 (p=0.109). Figure 5.5 summarises these findings. 
 
Figure 5.5 Percentage inhibition of formazan formation in WT and Het homogenate 
Graph shows the mean± SD of percentage inhibition of formazan formation due to non-SOD 
activity in WT and Het brain spinal cord (SC) and retina (Ret).The table shows the percentage 
inhibition of formazan formation due to total SOD, CuZn SOD and MnSOD in brain, SC and 
retina and the non-SOD activity calculated from these data.  
 
Het spinal cord homogenate had significantly greater reduction in total SOD activity compared 
to Het brain (F(8,39) 853.864 p=0.001) and to Het retinal homogenate (p=0.001). CuZnSOD 
activity in Het spinal cord homogenate was significantly reduced compared to CuZnSOD 
activity in Het brain homogenate (F8,39) 85.864 p=0.001) but not compared to Het retinal 
homogenate (p=0.313). Het MnSOD activity in spinal cord homogenate was significantly 
reduced compared to brain homogenate (F(8,39) 853.864 p=0.007) but not compared to Het 
retinal homogenate (p=0.167). Non SOD activity in Het spinal cord homogenate was 
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SOD CuZn MnSOD Non-SOD
SC>B 94% 95% 99% 51%
SC:B 0.001 0.001 0.007 0.006
SC>R 60% 65% 98% 66%
SC:R 0.001 0.313 0.167 0.001
significantly greater compared to Het brain homogenate (F(2,17)8.763 p-0.006) and compared 
to Het retinal homogenate (p=0.001). Table 5.5 summarises these findings. 
Table 5.5 Summary of SOD activity in Het spinal cord 
 
Table shows a summary of SOD activity in Het 
spinal cord homogenate compared to Het brain 
and retinal homogenate. The statistical difference 
between groups is shown. 
 
5.1.2.3 Discussion of SOD analysis in WT and Het 
Het tissue homogenate demonstrated a significant reduction in SOD activity compared to WT 
homogenate. Within the tissues tested Het spinal cord activity was significantly reduced 
compared to Het brain and Het retina. Although all tissues of the Het CNS showed impaired 
antioxidant activity, spinal cord appeared to have significantly more dysfunction. The combined 
reduction in threshold for Ca
2+
 induced mPT opening in spinal cord mitochondria with reduced 
mitochondrial fusion renders the spinal cord more susceptible to oxidative stress. Reduced SOD 
activity permits the accumulation of O2
-
  which results in oxidative stress. Lipid peroxidation of 
polyunsaturated fats (PUFA) in the mitochondrial membrane reduces fluidity and function. This 
further impairs electron transport. The influx of calcium into the mitochondrial matrix initiates a 
cardiolipin Ca
2+
  dependant dissociation of complex II  resulting in apoptotic induction (Hwang 
et al. 2014). Mitochondria with reduced membrane potential cannot restore or maintain 
sufficient proton motive force to generate ATP. In sufficient numbers, they will trigger 
mitophagy which will ultimately result in cell death.  
Het mouse was observed to have gait anomalies which are associated with spinal cord 
neuropathy (Gupta et al. 2012; Guo et al. 2013). The reduction of cytoplasmic CuZnSOD has 
been associated with impaired neurotransmitter release and reduced skeletal muscle strength 
(Shi et al. 2014). This was observed in rotarod testing, wire hang, and tight rope testing.   
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5.1.3 Protein analysis of antioxidant SOD expression 
IHC was performed as previously described. 
5.1.3.1 IHC of retina and brain for MnSOD expression 
IHC was performed on retinal and brain sections of WT and Het to determine the protein 
expression of MnSOD. Table 5.6 shows a summary of SOD expression in the retinal layers of 
WT and Het. Figure shows a graph of representative AFU in retinal layers. 
Table 5.6 MnSOD expression in retinal layers of WT and Het 
 
Table shows the mean ±SEM of MnSOD expression in retinal layers and brain of WT and Het 
 
 
Figure 5.6 MnSOD expression in retina and brain  of WT and Het 
Graph show the mean ±SEM AFU of MnSOD expression in (A)retina and (B) Brain  of 
WT and Het. 
 
Het retinal layers showed a significant 68% reduction of MnSOD expression in the OPL 
(F(5,17) 1.889 p=0.032) and 54% reduction in the RGC layer (F(5,17) 1.582 p=0.040). Het 
brain had 81% reduction which was significant compared to WT  (F(5,32) 6.913 p=0.001).  
PRL ONL OPL INL IPL GCL
MnSOD WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 228.1 250.5 218.1 349.2 170.2 129.8 163.3 259.3 180.9 90.41 71.34 64.78
SEM 52.27 38.15 99.93 38.98 54.2 20.76 81.32 21.29 80.56 34.99 36.4 23.16
WT:Het 0.651 0.653 0.020 0.606 0.886 0.002
F F ( 5,16) 8.912F (5,16)11.416 F (5,16) 10.444F (5,16)4.028 F (5,16) 2.850 F (5,16) 8.476
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MnSOD PRL ONL OPL INL IPL GCL
WT 4 0.185 0.112 0.032 0.850 0.827 0.040
Het 5
F(5,16) 8.91 11.4 10.4 4 2.85 8.47
*p<0.05**p<0.010***<p0.001 ±SEM
n MnSOD p
WT 8 WT:Het 0.001
Het 7 F(5,32) 6.913
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5.1.3.2 Western blotting of brain homogenate in WT and Het 
Western blotting of WT and Het  brain homogenate for MnSOD showed WT had an RD of 
1.0±0.21 and Het had 0.73±0.02 which was significantly reduced compared to WT (F(3,36) 
6.199 p= 0.021). Figure 5.7 shows a summary of these data. 
Figure5.7 Western 
blotting of brain 
homogenate in WT and 
Het 
Western blot of brain 
homogenate from WT 
(n4) and Het (n4) for 
MnSOD. 
 
Figure 5.8 shows representative images of retinal expression of MnSOD and Figure 5.9 shows 
MnSOD expression in brain of WT and Het. 
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Figure 5.8 MnSOD expression in retinal sections of WT and Het 
Representative images of MnSOD  expression in WT and Het retina (A-B) showing 
RGC regions for (C) WT and (D) Het (indicated by arrows). (E) Control sections for 
WT and (F) Het were processed without the primary antibody. 
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Figure 5.9 MnSOD expression in brain  sections of WT and Het 
Representative images of MnSOD expression in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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5.1.4 Nitrated protein deposition in WT and Het 
5.1.4.1 Introduction to nitrated protein deposition 
Protein nitration results from the interaction of secondary oxidants derived from peroxynitrite 
(ONOO
-
) with tyrosine containing proteins. Peroxynitrite anion protonation to ONOOH gives 
rise to tyrosine nitrating agents. This reaction is initiated by a one electron oxidation of tyrosine 
to tyrosyl radical. The susceptibility of tyrosine to nitration depends on the accessibility of the 
residue. Nitrated proteins are associated with other retinal disorders including glaucoma 
(Feilchenfeld et al. 2008), diabetic retinopathy (Kowluru 2003; Beauchamp et al. 2004; Kanwar 
et al. 2007) and age related macular degeneration (AMD) (Zhou et al. 2010). The incidence of 
increased protein nitration in the presence of reduced SOD activity has been established (Sasaki 
et al. 2000; Moreno et al. 2011; Miyamoto et al. 2014).  
Clearance of nitrated proteins with denitrase has been demonstrated as an inducible factor in 
eliminating nitrated proteins (Kamisaki et al. 1998; Irie et al. 2003; Deeb et al. 2013). If 
denitration was initiated before nitration was extensive, the denitration of proteins could permit 
the restoration of their function. (Sadowska-Bartosz et al. 2014). 
3’Nitrotyrosine antibody was used for the detection of nitration (Franze et al. 2004; Khan et al. 
2006) in brain and retinal sections.  
5.1.4.2 Results of 3 nitrotyrosine deposition in retina and brain of WT and Het 
Table 5.7 shows a summary of 3 nitrotyrosine deposition in retinal layers of WT and Het. 
Figure 5.10 shows a graph of this data. 
Table 5.7 Nitrotyrosine deposition in retina and brain of WT and Het 
 
Table shows the mean ±SEM of 3 nitrotyrosine deposition in retinal layers and in brain of WT 
and Het. Statistical difference between groups is represented by p value. 
 
PRL ONL OPL INL IPL GCL
3Nitro WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6 WT5 Het6
Ave 245.4 381.3 318 131.8 344.9 119.1 244.9 227.2 847.5 800 497.7 228.8
SEM 47.57 20.21 31.72 90.69 41.43 32.28 56.74 75.88 224.9 14.84 85.14 4.403
WT:Het 0.048 0.001 0.84 0.032 0.547 0.023
F F ( 5,20) 2.732F (5,20) 10.786F (5,20) 0.774 F (5,20)1.842 F (5,20) 1.040 F (5,20)3.443
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Figure 5.10 3 Nitrotyrosine deposition in retinal layers and brain of WT and Het 
Graphs show the mean ±SEM of AFU for nitrotyrosine deposition in (A) retinal layers 
(B) brain of WT and Het. 
 
There was a mean 74% increase in 3 nitrotyrosine in the retinal layers of Het. The ONL showed 
s significant 348% increase (F(5,12) 2.548 p=0.009) compared to WT. There was 210% 
increase in the INL(F(5,12) 1.415 p=0.010),  177% in the  IPL(F(5,12) 1.402 p=0.014) and  
126%  in the GCL (F(5,12) 4.201 p=0.019). The brain of Het had 197% increase compared to 
WT (F5,25) 7.919 p=0.001). 
Figures 5.11 show representative images of 3 nitrotyrosine deposition in retina of WT and Het 
and Figure 5.12 show representative images of 3 nitrotyrosine deposition in brain. 
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Figure 5.11 3Nitrotyrosine deposition in retina of WT and Het 
Representative images of 3 nitrotyrosine deposition in WT and Het retina (A-B) 
showing RGC regions for (C) WT and (D) Het (indicated by arrows). (E) Control 
sections for WT and (F) Het were processed without the primary antibody. 
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Figure 5.12 3 Nitrotyrosine deposition in brain of WT and Het 
Representative images of 3Nitrotyrosine deposition in WT and Het brain (A-B) with 40x 
magnified regions (C-D). Control sections for WT and Het (E-F) were processed 
without primary antibody. 
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5.1.5 Discussion of antioxidant SOD expression in Het 
The combined percentage reduction of MnSOD expression in Het retina was 38%. The retinal 
MnSOD assay demonstrated a 58% reduction in functional activity. This suggested that 20% of 
the expressed MnSOD was not functionally active. The percentage reduction of MnSOD 
expression in Het brain was 81%. This correlated with the 75% reduction in MnSOD activity in 
Het brain.  
The percentage difference in the deposition of 3 nitrotyrosine between WT and Het was 
compared to the percentage difference in MnSOD expression in retinal layers.  This was then 
used to generate the ratio of MnSOD compensation against 3 nitrotyrosine deposition.  As 
before, a ratio of less than a value of 1 suggested that control factors against nitrotyrosine were 
successfully combatting the damage mediated effects. Figure 5.13 shows this finding. 
Figure 5.13 The ratio of MnSOD to 3 
nitrotyrosine in retinal layers of WT and Het 
Graph shows the ratio of MnSOD expression to 3 
nitrotyrosine deposition in WT and Het retina where 
a value of less than 1 was considered beneficial in 
the control of damage mediated activity. 
 
 
MnSOD competes with nitric oxide for the reaction with O2
-
 and prevents the generation of 
peroxynitrite. MnSOD can be the target of nitration leading to a reduction in its enzymatic 
activity. (MacMillan-Crow and Thompson 1999; Bayir et al. 2007; Surmeli et al. 2010).  Of the 
seven tyrosine residues two are potential targets due to their surface location (Perry et al. 2009; 
Porta et al. 2010). Nitration of Tyr34 results in MnSOD inactivation (Demicheli et al. 2007). 
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5.1.6 Summary of Chapter 5: Antioxidant impairment in Opa1Q285STOP mouse 
There was a significant reduction in antioxidant activity of Opa1
Q285STOP
 mouse tissue 
homogenates compared to WT. 
5.1.6.1 Significant reduction of catalase activity in Opa1Q285STOP mouse 
The antioxidant activity of catalase was significantly reduced in both spinal cord and retina of 
Het mouse homogenate. Catalase activity in Het brain homogenate was not significantly 
different to WT. 
5.1.6.2 Significant reduction of SOD activity in Opa1Q285STOP mouse 
Compared to WT, the total SOD activity was reduced in Het brain, spinal cord and retina. 
Spinal cord homogenate showed the highest tissue specific reduction of all SOD activity. 
MnSOD activity was reduced by greater than 75%. CuZnSOD activity was reduced by more 
than 60%. 
The reduction of antioxidant activity observed in all tissues of Het mouse was considered 
secondary to the bioenergetic deficit as observed in the previous chapter. The reduction in 
catalase activity in the spinal cord and retinal tissue homogenate and not brain suggested that 
there was tissue specific preservation of catalase activity. The reduction of MnSOD in all tissues 
tested  suggested several possible scenarios:  that either there was a reduction in the requirement 
for MnSOD due to the bioenergetic reduction especially in complex I. Or that there was 
insufficient production of MnSOD although it would appear unlikely as the phenotype changes 
which occur at a late stage (more than 10 months)   would more likely manifest at an earlier age. 
Or possibly MnSOD activity was specifically reduced possibly due to the presence of nitration 
to the susceptible tyrosine residues present on the surface of the MnSOD molecule. 
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Chapter 6 Trial of resveratrol in Opa1Q285STOP mouse 
6.1 Introduction 
The objective of the trial was to determine if the administration of resveratrol as an antioxidant 
could alleviate potential ROS induced optic atrophy. The retinal pathology in Opa1
Q285STOP
 
mouse was considered late on-set beginning at 12 months. The efficacy of resveratrol 
administration in other ophthalmic conditions (Kubota et al. 2009; Zheng and Kern 2009; Zheng 
et al. 2009; Zheng et al. 2010a), indicated that resveratrol could gain access through the retinal-
brain barrier. The second objective of the trial was the safety aspect of resveratrol 
administration over a prolonged period of time where the female recipients would be crossed to 
generate the next cohort of study subjects. 
6.2 Other potential therapies 
A range of potential antioxidant therapies were considered. Endogenous antioxidant activity is 
finely balanced with ROS/RNS production in healthy tissue with an ongoing damage limitation 
by repair [DNA] or replacement (oxidised proteins).In 1991, (Sies 1991) defined the term 
oxidative stress as ‘a disturbance in the prooxidant-antioxidant balance in favour of the former 
leading to potential damage’. Summarised are a selection of antioxidant therapies with relevant 
clinical trial results. 
6.2.1 Coenzyme Q10 & synthetic derivative Idebenone 
Coenzyme Q10 (CoQ10) or ubiquinone is a biologically active quinine found in the membranes 
of the endoplasmic reticulum (ER) peroxisomes and the inner mitochondrial membrane. Within 
the electron transport chain, (ETC) electrons pass from complex I NADH and complex II 
succinate to CoQ10 where it functions as an electron carrier from both complexes to complex III. 
CoQ on the inner mitochondrial membrane accepts electrons from reducing equivalents 
generated during fatty acid and glucose metabolism and transfers them to electron acceptors. 
The reduced form of CoQ10H2 in the cell membrane inhibits lipid peroxidation when low-
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density proteins (LDL) and cell membranes are exposed to oxidising conditions ex vivo. The 
formation of oxidised lipids and consumption of  tocopherol are suppressed when CoQ10H2 is 
present. 
The biopharmaceutical kinetics of Idebenone inhibits lipid peroxidation and prevents oxidative 
damage by preserving ATP formation. It is rapidly absorbed with a peak plasma level within 15 
minutes after oral administration and a half-life of between 2.2 0 15 hours. The highest 
concentrations are found in the GI tract, liver and kidney. It is excreted via the renal system 
within 18 hours of administration with no cumulative effects. 
The mode of action of Idebenone can function in either an oxidised or a reduced state. Its effects 
on astroglial cells demonstrate an inhibition of enzymatic metabolism of arachidonic acid by 
cyclooxygenase and lipoxygenase. In its reduced form, Idebenone has a powerful anti-
inflammatory effect within the CNS (Paolino et al. 2004). In vitro experiments in cell culture 
show synaptosomes of rat brain cortex under oxidative injury are protected from ROS within 
the cytosol and mitochondria. (Rauchová et al. 2008) et al., 2006) Oxidative lipid peroxidation 
is reduced and it may confer some protection to mitochondrial cell membranes (Becker et al 
2010). 
6.2.1.1 Reasons for non-selection 
Idebenone although marketed as a substitute for CoQ10 has activities that CoQ10 clearly does 
not possess. It has some antioxidant properties against the products of lipid peroxidation but 
despite extensive clinical trials in various disorders (Friedrich’s ataxia, MELAS, Parkinson’s 
disease) the overall primary outcome –gross motor function, lowering of cerebral lactate and 
increasing plasma CoQ10 levels remains dependant on several factors including age, stage of 
disease process and quantity of does administration. 
6.2.2 Minocyclin 
A tetracycline analogue lacking methyl and hydroxyl groups’ mitocyclin is a highly lipid 
soluble long acting protein inhibitor and inhibitor of 5 lipoxygenase. Minocyclin binds to the 
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30S ribosomal subunit preventing the binding of tRNA to mRNA ribosome complex. 
Metabolised in the liver minocyclin is prescribed in cases of acne.  
The documented toxicity studies include increased I
125
 uptake and thyroid tumour incidence 
(Doerge et al. 1997) retinal pigment epithelial apoptosis via p38 MAPK pathway and p38 
phosphorylation (Hollborn et al. 2010) neurotoxicity including induction of proapoptotic GADD 
45, IFN1 and cytokine induced growth factor  (Krügel et al. 2011)  
6.2.2.1 Reasons for non-selection 
Opa1
Q285STOP 
mouse general health is good. They are mobile well developed and reproduce 
albeit with slightly reduced brood size. The average lifespan exceeds 24 months. Given the 
option of antioxidant treatment with minocyclin and no treatment, the literature provides 
compelling evidence that no treatment would be the healthier option. These mice have an 
extensive mitochondrial haploinsufficiency that puts them in a high-risk category. It is not the 
intention of this therapy to risk their health with an agent that carries an inordinate number of 
documented and potential toxic side effects.  
6.2.3 Cyclosporine 
The use of cyclosporine in the prevention of graft versus host disease exerts specific T helper  
cell immunosuppression.. Cyclosporin binds to cyclophillin which forms a calcineurin 
inhibiting complex normally responsible for transcription of interleukin 2 (IL2).Repeated 
topical application  of cyclosporine for the treatment of keratoconjunctivitis at 0.1% 
concentrations has been reported to induce acute inflammatory reaction on rabbit eye resulting 
in a breakdown of the blood retinal barrier and increased aqueous protein concentration 
(Toshida 1998). 
6.2.3.1 Reasons for non-selection 
The toxicity of cyclosporine includes nephrotoxicity, hypertension, and diabetes and 
haemoylytic uraemia. There is also evidence of its potential carcinogenic properties (Weischer 
et al. 2007) et al. 2007). Documented reports of oxidative and  nitrosative stress with elevated  
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expression of inducible nitric oxide are reported in a variety of organs including renal 
(Josephine et al. 2007) hepatic  (Lee 2010) and neurological (Schröter et al. 2005). 
6.2.4 Memanthine 
Memantine is an amantadine derivative with a moderate-affinity for NMDA receptors. It is a 
non-competitive NMDA receptor antagonist that binds preferentially to NMDA receptor-
operated cation channels. It blocks the effects of excessive levels of glutamate that may lead to 
neuronal dysfunction by acting on glutamatergic neurotransmission.  There is some evidence 
that dysfunction of glutamatergic neurotransmission, manifested as neuronal excitotoxicity, is 
involved in the aetiology of Alzheimer's disease (Cacabelos et al. 1999).  Memantine undergoes 
partial hepatic metabolism. About 48% of administered drug is excreted unchanged in urine. 
Side effects include pain, leg pain, fever, increased appetite, dizziness, confusion, headache, 
hallucinations, and tiredness. Less common side effects include vomiting, anxiety, and 
hypertonia. 
Memantine has the ability to block only the excessive pathological inducing NMDA receptors 
with an uncompetitive mechanism and a fast off rate. With neurodegenerative conditions, the 
existence of extra synaptic NMDA’s causes an increased Ca+2 influx. NADPH oxidase (NOX)  
in the presence of increased Ca+
2
  levels activates neuronal NO synthase (nNOS) to generate 
nitric oxide (NO). Recently Nakamura (Nakamura and Lipton 2011) published a report on the 
role of s-nitrosylation which he states is responsible for protein misfolding in many 
neurodegenerative diseases including Parkinson’s  synuclein protein and Alzheimer’s amyloid 
 and Tau proteins. 
6.2.4.1 Reasons for non-selection 
The safety review by the NDA (pharmaceutical marketing: report location at 
:www.fda.gov/ohrms/dockets/ac/03/briefing/3979B1_04_FDA-Safety%2Review.pdf) published 
an extensive safety report on this agent. The manufacturers (Forest Laboratories Inc.) reported 
the following effects on rodents (both rat and mouse populations) ‘Corneal opacities, obscured 
retinal blood vessels and corneal endothelial vacuolization’. The cause of these clearly 
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damaging effects was due to ‘abnormal local drug storage due to saturated excretion and not 
clinically relative’!  Further rodent exposure to the product reveals cortical neuron vacuolization 
lesions on brains of rat and mouse’ Forest laboratories concluded that these were ‘Olney 
lesions’. Rodent populations being susceptible to increased cortical ablation through necrotic 
cell death on administration of NMDA antagonists. This toxic effect is reported to be the result 
of increased metabolism and is associated with older animals. To date no Olney’s lesions have 
been proven or unproven to occur in human brain primarily because no one is looking for them 
6.3 Resveratrol 
Resveratrol was administered to mice over a 15-month period from time of conception. 
Resveratrol was added to drinking water at a concentration of 219.06M, which was calculated 
as 13.5mg/kg. Concurrent treatment of mice with vehicle was given 0.1% ethanol administered 
in drinking water. In order to mimic the normal housing conditions of these mice, both WT and 
Het mice remained in shared cages. As the long term effects of resveratrol administration over a 
prolonged period were unknown, it was considered imperative to include an age matched WT 
cohort. 
6.3.1 Resveratrol treatment administration 
6.3.2 Selection of product 
The isolation of resveratrol from established plant sources including Japanese knotweed 
requires extensive extraction steps to remove impurities. One impurity is emodin which is a 
naturally occurring product within Japanese knotweed and is known for inducing unwanted side 
effects relating to gastro intestinal disturbances. The specification of any resveratrol product 
required the reporting of emodin content. A most generous gift of resveratrol from Interpharma-
Praha (a subsidiary of the Japanese Otsuka pharmaceutical company]) was made. The product 
included the specification sheet which stated resveratrol at a purity of 98.8% with an emodin 
content of less than 0.01% (Resveratrol specification sheet Appendix B). 
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6.3.3 Selection of dose 
The dose of resveratrol administered was selected on the established NOAEL (No-observed-
adverse-effects-level) which was reported as 22.4mg/kg (Crowell et al. 2004; Horn et al. 2007; 
Edwards et al. 2011). As the mice were to receive resveratrol for a 15 month period and during 
gestation, it was decided to reduce the prescribed dose to 13.56g/kg. This would provide 
219.06m a day. The administration of resveratrol during gestation required embryo-fetal 
toxicity studies. The dose of resveratrol from 20mg/kg up to 100 mg/kg were reported in a 
diversity of animals including rat (Breinholt et al. 2003; Williams et al. 2009) chick (Hancock 
and Miller 2006; Dias et al. 2008) bovine (Klinge et al. 2008) and mouse (Huang et al. 2009; 
Singh et al. 2011). There were no reports of adverse effects on either mother or embryos. Table 
6.1 shows the calculations used to obtain the dose of mg/kg. 
Table 6.1 Dose of resveratrol mg/kg 
 
Table shows the molecular weight and the dose per kg weight calculated by multiplying 
the volume by the dose and dividing by weight in kg 
6.3.4 Route of administration 
The route of administration was considered an imperative part of this trial. Reports of 
administration by intraperitoneal injection were considered inappropriate for a prolonged study. 
Treatment by gavage was also considered inexpedient as the effects of daily handling for the 
purposes of gavage were likely to traumatize the mouse.  The administration of resveratrol in 
water was the most appropriate route. Stock resveratrol was prepared in 1 ml aliquots. The 
molecular weight of resveratrol was 228.24.  Stock resveratrol was prepared by adding 
2.5g/50ml ethanol. This gave 0.05g at a concentration of 219.06mM per ml. One 1ml aliquot 
was added to 1 litre of drinking water which gave 49.99mg of resveratrol containing 219.06M. 
Mice were given resveratrol in drinking water at a dose of 13.57mg/kg  calculated as volume of 
water ingested (5.7ml) multiplied by the dose in mg/ml  0.0499 divided by weight of an average 
MW Stock mM/mlmg/L M /L Vol/ Dose Weight mg/kg
mg/ml  /ml mg/ml /kg
Res 228.2 50 219.07 50 219.07 5.7 0.05 0.021 13.57
Etoh 46.07 0.789 17.13 789 17.13 5.7 0.789 0.021 214.16
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mouse in kg (0.021). Resveratrol was sensitive to light at 366nm so mouse water bottles were 
covered in blue filter, which blocked this wavelength (Lee filters 355). The presence of blue 
filter cover did not alter water consumption in resveratrol treated mice. 
6.3.5 Vehicle treated controls 
For vehicle treated animals, 1ml of 100% ethanol (0.789mg/l) was added to 1 litre of drinking 
water which provided 17mM ethanol. Drinking bottles were covered in green Lee filter to 
maintain consistency in the trial and allow immediate identification of the bottle contents. 
6.3.6 Daily water consumption in C57Bl/6 
The daily consumption of water was measured over a 1 week period using a commercial mouse 
water bottle with a ball bearing which prevented leakage when the cage was moved. The daily 
content of the water bottle was measured using a syringe for accurate analysis. The mean daily 
water intake in both WT and Het mice was 5.7±0.4ml. These findings were in agreement with 
previously published data on water consumption in C57BL/6 mice (Bachmanov et al. 2002). 
Resveratrol could be dissolved in ethanol or DMSO. Ethanol was used as DMSO can impart 
antioxidant properties (Santos et al. 2003; Colucci et al. 2008) which would confound the 
effects of resveratrol. The density of ethanol was 789g/l with a molecular weight of 46.07. The 
alcoholic content of the vehicle was examined. In the UK a unit of alcohol is defined as 10ml of 
pure ethanol or 7.9g/ml .The percentage alcohol by volume (%AbV) of 0.1% in an end volume 
of 5.7ml was 1.75%AbV (Tapson 2004).  
The calorific content of vehicle treatment was considered. There is 230kJoule (55 calories) in 1 
unit of alcohol. Vehicle and res treated mice received 0.131kJ(0.03cal) daily from a volume of 
5.7ml.  
6.3.7 Efficacy, health and safety 
In order for resveratrol to be effective, it was imperative to refresh the contents within 24 hours 
of dispensing. This provided an excellent opportunity to observe the mice for any signs of 
adverse effects. Daily weigh recordings were changed to weekly when it was considered mouse 
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weight was maintaining stability. In the subsequent mice, weekly weighing was continued for 
16 weeks following weaning and continued throughout the duration of the trial at monthly 
intervals from month 4. The reason for selection of 16 weeks was with the female pups, this was 
the age at which they were ready for mating and would be separated from the mum (Appendix 
D contains weekly and monthly growth rates). The efficacy of resveratrol treatment was tested 
in vivo at 12 months of age with SHIRPA, rotarod, narrow beam and tight rope testing. At 15 
months, cognitive function testing was performed. At 15 months of age, mice were culled for 
full tissue retrieval. Growth rates were calculated using the weekly and monthly weight 
recordings. The rate was calculated as the difference between the initial weight at weaning and 
the weight at day 28 which is when mouse reaches his maximum post natal growth (Eisen 
1976).  
6.3.8 Bioavailability of resveratrol 
In order to determine the bioavailability of resveratrol in mice treated over a 15-month period, 
whole blood analysis was analysed by HPLC-UV. 
Measurement of resveratrol was performed with modifications according to Biasutto (Biasutto 
et al. 2010). Whole blood from both resveratrol and control treated mice was collected at time of 
tissue retrieval. Whole blood was collected in pediatric EDTA vials and inverted to permit 
mixing. Blood was stabilized with the addition of freshly prepared ascorbic acid (10mM at 0.1 
vol), and acidified with 0.6M acetic acid at 0.1 vol. Following mixing, 4 volumes of acetone 
was added followed by sonication (or vortexing) for 2 minutes. Blood was centrifuged at 4
o
C 
for 8 minutes at 10,000g. Supernatants were transferred to a fresh tube where acetone was 
evaporated by vacuum centrifugation at room temperature. Samples were precipitated with 
methanol and 20l was applied to a Gemini C18 reverse phase column. Untreated blood 
samples were spiked with known quantities of resveratrol to determine the yield of recovered 
product. 
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6.3.8.1 Reasons for selection 
Resveratrol has an excellent safety record with no documented side effects.  The dose required 
to exert any toxicological effect was a staggering 3000mg/kg (13.14mMol/kg) –over 3.5 
thousand times the recommended dose. The side effects produced nephrotoxicity as resveratrol 
is eliminated via urine, dehydration, dyspnoea, rough coat, diarrhoea, anaemia and in male rat 
leukocytosis. Mice were given resveratrol at a concentration of 219.06mM in their drinking 
water. Vehicle treated mice were given ethanol at a concentration of 17mM. Mice were 
examined thoroughly for any adverse effects including gastro intestinal disturbances that might 
indicate the presence of emodin at greater than acceptable concentration. The bottled water 
containing resveratrol required replacement at 24 hour intervals which also provided an 
opportunity to examine the mice for signs of stress. The trial design is available in Appendix C. 
6.3.9 Solubility of resveratrol  
The solubility of resveratrol in water was less than 3% (Kristl et al. 2009). Stock resveratrol was 
prepared in 1ml aliquots in 100% ethanol. This was added to one litre of tap water and used to 
fill mouse drinking bottles. The addition of the ethanol base product to tap water could 
potentially cause precipitation. This potential precipitation was investigated. 
6.3.9.1 Spectrophotometric analysis of resveratrol 
Stock resveratrol at 50mg/ml was diluted to 0.05mg/ml in either 100% ethanol which 
represented complete dissolution or cold tap water. This was mixed by inversion. Trans 
resveratrol can photoisomerise to Cis resveratrol when exposed to UV. The absorption 
coefficient of Trans resveratrol at 304nm is 33400 M
-1
 cm
-1
 (Pinto et al. 1999). The expected 
absorbance of 219.06M of resveratrol at 304mm wavelength was calculated from the 
absorption coefficient of 33400 M
-1
 cm
-1
 was 7.316. The product was further diluted to permit 
spectroscope analysis at 200-450nm. 
6.3.9.2 Results of resveratrol solubility 
The absorbance of resveratrol at 304nm wavelength in 100% ethanol was 0.918. The 
absorbance of resveratrol in 0.1% ethanol was 0.903.  The concentration of resveratrol in 100% 
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               Trans res             Cis res
A(304) e33400 M-1 cm-1 A(286) e33400 M-1 cm-1
 x DF 8  x DF 8
100% EtoH 0.918 219.880 0.031 7.425
0.1% EtoH 0.903 216.287 0.018 4.311
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ethanol was calculated as 27.48M and with the dilution factor (times 8) gave a final 
concentration of 219.8M. The concentration of resveratrol in 0.1% ethanol was calculated as 
27.03M and adjusted with the dilution factor was 216.28M. The presence of Cis resveratrol 
was observed at 286nm wavelength. Resveratrol in 100% ethanol had an absorbance of 0.031 
which was 7.425M. Resveratrol in 0.1% ethanol contained 4.311M Cis resveratrol with an 
absorbance of 0.018 at 286nm. In order to reduce precipitation, the tap water was allowed to 
reach room temperature (RT) and the readings repeated. Trans resveratrol in 0.1% ethanol and 
water at RT had an absorbance of 0.912 at 304nm which was 218.44M. Cis resveratrol 
absorbance at 286nm was 0.022 which was 5.26M. Figure 6.1 shows the absorbance spectra of 
resveratrol. 
 
Figure 6.1 Absorbance spectra of resveratrol in ethanol 
and tap water 
Absorbance of Trans resveratrol in 100% ethanol at 
wavelength of 304nm was 0.918. In 0.1% ethanol the 
absorbance was 0.903. In 0.1% ethanol (RT) the 
absorbance was 0.912. The absorbance of Cis resveratrol 
in 100% ethanol at wavelength of 286nm was 0.031. In 
0.1% ethanol the absorbance was 0.018. In 0.1% ethanol 
(RT) the absorbance was 0.022. 
 
6.3.9.3 Discussion of resveratrol solubility 
The addition of resveratrol to cold tap water caused 1.6% precipitation. By allowing the tap 
water to reach room temperature there was a reduction to 0.65%. Stock drinking water was 
allowed to stand at room temperature prior to dispensing. 
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6.4 Health monitoring of mice on resveratrol trial 
6.4.1 Introduction 
Throughout the trial, the health and safety of the mice was paramount.  The general health of 
Opa1
Q285STOP
 mouse was good with a satisfactory breeding record. As this therapy was designed 
to improve their mitochondrial health, any deviation from normal mouse behaviour while 
receiving resveratrol or vehicle may have required withdrawal from the trial. In the original 
cohort, one mouse was removed from the trial due to gastro intestinal disturbance. As it 
transpired, this was not due to resveratrol as he continued to have occasional upsets throughout 
without any change in body weight. A second female mouse was lost to trauma at seven 
months. Shredded nesting material became wrapped around her hind limb resulting in extensive 
ischemia. This mouse would have required limb amputation under general anaesthetic. Due to 
her immediate distress she was culled. 
6.4.1.1 Weight monitoring 
The weight of the mice was recorded throughout the trial. With all participants, weight was 
recorded weekly for a minimum of sixteen weeks. Thereafter weights were recorded monthly.  
Mouse reaches its maximum post natal growth rate at about half its mature asymptotic weight 
(Eisen 1976). There is an increase from birth to 28 days followed by an eventual stabilization 
which is dependent on sex, diet and environment (Cheek and Holt 1963). 
As mouse weights were recorded weekly for the first 16 weeks post weaning, the growth rate 
was calculated for the first 4 weeks following weaning. Weight monitoring continued 
throughout the trial at monthly intervals to 15 months. 
Any variation in monthly weight would indicate that the chronic administration of resveratrol or 
vehicle was having an adverse effect (Appendix D contains weekly and monthly weight rates 
for all animals tested). Body weight and brain weight are reported in grams (g). Cardiac weight 
is reported as a ratio of body weight. 
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n Body Brain Cardiac
weight(g) weight(g) Ratio
F Het 25 26.9 ± 4.0 0.48 ± 0.05 0.64 ± 0.10
rFHet 22 28.8 ± 2.8 0.42 ± 0.07 0.62 ±0.10
vFHet 11 28.2 ± 3.3 0.45 ±0.02 0.55 ±0.09
FHet:rFHet 0.135 0.025 0.505
FHet:vFHet 0.401 0.263 0.035
rFHet:vFHet 0.656 0.458 0.112
F(11,191) 9.866 2.725 1.935
S sMHet 14 32.6±1.0 0.49±0.03 0.60±0.03
O srMHet 4 34.5±1.5 0.42±0.06 0.62±0.04
H L sMHet:srMHet 0.385 0.385 0.820
O O sMHet:gMHet 0.247 0.015 0.129
U srMHet:grMHet 0.450 0.829 0.962
S G F(9,57) 1.043 1.037 2.565
I R gMHet 9 30.7±1.2 0.42±0.04 0.68±0.04
N O grMHet 7 32.7±1.4 0.44±0.04 0.61±0.05
G U gvMHet 7 32.7±1.4 0.45±0.05 0.72±0.05
P gMHet:grMHet 0.308 0.672 0.275
gMHet:gvMHet 0.308 0.653 0.452
grMHet:gvMHet 0.998 0.981 0.083
F(9,57) 1.043 1.037 2.565
r=resveratrol  v=vehicle  s=solitary housed  g=group housed
6.4.1.2 Results of weight monitoring 
Res treated female WT (n13) growth rate was 1.57±0.35. Vehicle treated female WT (n6) 
growth rate was 1.08±0.37 which was not significantly different to res WT female (p=0.747). 
Res treated Het female (n16) growth rate was 1.28±0.49. Vehicle treated Het female (n11) 
growth rate was 1.16±0.54 which was not significantly different to female res Het(p=0.801). 
Resveratrol treated male WT (n9) rate was 1.70±0.68/g. Vehicle treated male WT (n6) rate was 
1.75±0.61 which was not significantly different to res WT male (p=0.182). Male res Het (n8) 
growth rate was 1.77±0.61. Veh treated male Het (n7) growth rate was 2.0±0.55 which was not 
significantly different compared to res male Het (p=0.135). 
At 15 months, full tissue retrieval was performed and mouse body, brain and cardiac weight was 
documented. Table 6.2 shows the mean weight ±SD in all untreated, res and veh treated male 
and female Het. Male Het populations have been analysed according to housing conditions as 
was previously seen solitary housed mouse brain weight was increased and cardiac weight ratio 
reduced. There were no solitary housed veh treated male Het mice. The statistical significance 
between groups is shown with the percentage difference between untreated and treated Het.  
Table 6.2 Body brain & Cardiac weight ratio 
in Het res & veh Het 
Body, brain and cardiac weight ratio in 
untreated female and male Het compared to res 
treated Het showing a significant difference in 
female res treated brain weight compared to 
untreated (p=0.025). Compared to untreated 
male Het, res treated male Het was not 
significantly different in any weight measures. 
Compared to untreated males, veh treated Het 
male was not significantly different in any 
weight measures.  
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6.4.1.3 Discussion of weight in res treated Het at 15 months 
The brain weight in res treated female Het population weighed 17% less than untreated female 
Het. Veh female Het brain weight was 10% less than untreated female Het which suggested that 
resveratrol was responsible for at least 7% reduction in brain weight. Solitary housed res treated 
male Het Male brain weight was reduced by 14% compared to solitary housed male Het. Group 
housed res treated male Het brain weighed 6% more than group housed male Het. Veh treated 
group housed male Het brain weight was increased by 7% compared to untreated male Het. 
The cardiac weight ratio in res treated females was reduced by 4%. Veh treated female cardiac 
weight ratio was significantly reduced by 13% compared to untreated female Het (p=0.035). 
Cardiac weight ratio in solitary housed male res treated Het had a 3% increase compared to 
solitary housed untreated male Het. Group housed res treated males had a 10% reduction in 
cardiac weight ratio compared to group housed male Het. Veh treated group housed male Het 
had a 7% increase in cardiac weight ratio compared to untreated group housed male Het.   
6.5 Neuromuscular dysfunction in res treated Opa1Q285STOP mouse 
6.5.1 Introduction 
Studies of the neuromuscular and cognitive function in the untreated Het mouse at 12 months 
clearly demonstrated impaired musculoskeletal function. SHIRPA analysis revealed extensive 
aberrations in all but the sensory function. As many of these tests were observational in method, 
the reduced visual acuity of Het mouse did not bias findings.  
It was the intention to repeat these phenotypic analyses to determine the effect of resveratrol 
after a 12 month administration period. 
6.5.2 SHIRPA analysis in res treated Opa1Q285STOP mouse 
For SHIRPA analysis eight resveratrol treated Het mice were analysed with 10 untreated Het 
mice. The test was performed as described in Chapter 3.2.  Essentially, different functional 
abilities were scored depending on whether the animal was in the arena under observation or 
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SHIRPA
Het 8 rHet 6
FHet 5 rFHet 3
MHet 3 rMHet 3
whether performing physical tasks. The raw data from SHIRPA analysis of res treated Het 
mouse is shown in Appendix G. 
For lower motor function there were a total of eleven independent tests, for cerebrospinal 
function, a total of 12 tests, sensory function had 7 tests, neuropsychiatric had eight tests and 
autonomic had 17 independent tests. Results are shown as the mean direct score (SD±1). 
6.5.2.1 Results of SHIRPA analysis in res treated Het mouse 
Table 6.3 Summary of test numbers for SHIRPA analysis in 
untreated and res Het 
 
The results for SHIRPA analysis are shown in Figure 6.2 where untreated WT has been 
included on the graph for comparison only. Appendix G contains the raw data for SHIRPA. 
 
Figure 6.2 SHIRPA analysis in untreated and treated Opa1
Q285STOP 
mouse 
Graphs showing Observational SHIRPA analysis in untreated (n8) and res treated (n6) Het 
mice. 
6.5.2.2 Discussion of SHIRPA in res treated Het 
The functional impairment of untreated Het mouse was established at an earlier time. Any 
improvement in the five functional activities tested was not observed in resveratrol treated Het. 
In res Het mouse, lower motor function was significantly reduced by 60% in male res Het 
(F(3,11)4.684 p=0.004) compared to untreated male Het. 
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A:Lower Motor B:Cerebrospinal C:Sensory D:Neuropsychiatric E:Autonomic
FHet rFHet MHet rMHet FHet rFHet MHet rMHet FHet rFHet MHet rMHet FHet rFHet MHet rMHet FHet rFHet MHet rMHet
Ave 0.57 0.63 0.46 0.73 0.60 0.67 0.53 0.69 0.17 0.24 0.02 0.14 0.61 0.80 0.60 0.50 0.41 0.41 0.33 0.41
SEM 0.07 0.06 0.06 0.06 0.08 0.07 0.12 0.07 0.10 0.06 0.00 0.06 0.06 0.05 0.04 0.05 0.06 0.05 0.07 0.05
n A B C D E
FHet 5 FHet:rFHet 0.403 0.465 0.820 0.021 0.084
rFHet 3 MHet:rMHet 0.004 0.163 0.504 0.235 0.606
MHet 3 F(3,11) 4.684 F(3,11) 0.948 F(3,11) 2.178 F(3,11) 4.570 F(3,11) 4.570
rMHet 3 *p<0.05**p<0.010***p<0.001 ±SD
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   Rotarod Analysis
F Het 13 M Het 15
rFHet 7 rMHet 6
vFHet 5 vMHet 0
sMHet 5 gMHet 10
srMHet 3 grMHet 3
s:solitary g:group  r:res v :veh
Neuropsychiatric function in res Het female showed a significant 32%  increase (F3,11) 4.570 
p=0.021) compared to untreated female Het. 
The results of SHIRPA indicated that resveratrol was exerting an adverse effect in the lower 
motor function of male res Het and in the neuropsychiatric function of female res Het. These 
findings would be confirmed using other phenotypic testing. 
6.5.3 Rotarod analysis in res treated Opa1Q285STOP mouse 
 
Table 6.4 Summary of test numbers for rotarod analysis in 
untreated res and veh Het 
 
Untreated female Het latency was 84±4 seconds. Latency in 
resveratrol treated Het females was 62±6 seconds which was significantly reduced when 
compared to female Het (F (4,41) 1.867 p=0.021). Vehicle treated female Het latency was 62±2 
seconds which was significantly reduced compared to untreated female Het (F (4,41) 1.867 
p=0.040).Untreated male Het latency was 71±5 seconds Latency in male res Het mouse was 
72±5 seconds which did not differ significantly to untreated male Het (p=0.848). Figure 6.3 A 
shows a summary of rotarod latency to fall in res treated Het mouse. 
As previously examined, housing conditions influenced the latency to fall in male mice. Latency 
to fall in untreated solitary housed male Het mice was 109±14 seconds Latency in res treated 
solitary housed male Het mice was 64±13 seconds which was significantly reduced compared to 
untreated solitary housed male Het (F (3,17) 1.992 p=0.001). Latency in untreated group housed  
Het males was 35±7 seconds. Res treated group housed Het male latency was 72±6 seconds 
which was significantly increased compared to untreated (F (3,17) 1.992  p=0.001). Figure 6.3 
B shows a summary of these findings. 
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sMHet 5 sMHet:srMHet 0.001
srMHet 3 sMHet:gMHet 0.001
gMHet 10 gMHet:grMHet 0.001
grMHet 3 srMHet:grMHet 0.126
F(3.17) 1.992 ±SD
s:solitary g:group r:res  v:veh
n Latency p
FHet 13 FHet:rFHet 0.021
rFHet 7 FHet:vFHet 0.040
vFHet 5 rFHet:vFHet 0.870
MHet 15 MHet:rMHet 0.848
rMHet 6 F(4.41) 1.867 ±SD
 
Figure 6.3 Rotarod latency 
in untreated and treated Het 
mouse 
 Graph shows mean ±SD 
(A)Latency to fall in untreated  
and treated female and male 
Het mice. (B) Housing 
conditions in solitary and 
group housed untreated and 
treated male Het. 
 
6.5.3.1 Discussion of rotarod in res treated Het mouse 
There was a reduction in latency to fall in the resveratrol treated Het mice. Female Het mice 
showed a reduction of 18% compared to untreated female Het mice. Male res treated Het mice 
had less than 4% reduction compared to untreated Het males. Housing conditions did not appear 
to have a significant effect on resveratrol treated males unlike untreated males who performed 
significantly better as solitary housed animals. Vehicle treated female Het mice had a significant 
23% reduction in latency compared to untreated female Het mice. There was no significant 
difference between the res and vehicle treated female Het mice. Whether the reduction in 
latencies was due to the ethanol content was investigated further. 
The effects of body weight were considered; Untreated female Het who weighed less than 28g 
had a latency of 87±5 seconds. Res treated female Het weighing less than 28g had a latency of 
63±5 seconds which was significantly reduced compared to untreated female Het (F7,370) 
5.716 p=0.002). Latency in untreated Het males who weighed less than 34g was 80±3 seconds 
and latency in res Het males weighing less than 34g was 67±6 seconds which was not 
significantly different to untreated Het (p=0.077). 
6.5.4 Narrow beam testing in res treated Opa1Q285STOP mouse 
The narrow beam test was performed as previously described in Chapter 3.2. Mice were placed 
at one end of an elevated gradually narrowing beam and on completing the distance of 60cm 
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Beam/Rope
F WT 5 M WT 5
F Het 7 M Het 8
rFHet 4 rMHet 4
vFHet 3 vMHet 0
returned to their home cage. The test measured mouse gait and spatial awareness. The initial test 
was designed to measure the distance travelled on the beam, however as previously identified, 
Het mice had initiation issues where no travel down the beam was observed. It was decided to 
continue with this test measure as any improvement could be rapidly detected. 
6.5.4.1 Results of narrow beam test in res treated Het mouse 
 
Table 6.5 Summary of test numbers for rope and beam in 
untreated, res and veh Het 
 
 
Figure 6.4 A shows a summary of the initiation time on the narrow beam in untreated, res and 
veh treated female and male Het mice. 
6.5.5 Tight rope test in res treated Opa1Q285STOP mouse 
The tight rope test was performed as described in Chapter 3.2.3. Mice were placed at the mid-
point of an extended rope and supported until they had obtained purchase. The distance 
travelled from the mid-point was not in excess of 30cm. The test was designed to test 
symmetrical coordination and balance. The test measured the distance travelled on the rope. 
6.5.5.1 Results of tight rope test in res treated Het mouse 
Figure 6.4 B shows of the distance travelled on the tight rope in untreated, res and veh treated 
female and male Het mice. 
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Figure 6.4 Beam initiation and rope distance testing in untreated and treated Het mice 
Graph of means ±SD (A) narrow beam time to initiation travel in seconds which was 
significantly reduced in both res and veh Het compared to untreated and (B) distance 
travelled in cm on tight rope in untreated, res and veh treated Het.  
 
6.5.5.2 Discussion of narrow beam and tight rope in res treated Het mouse 
Resveratrol treated Het mice appeared to excel at tests where the usual Het trepidation resulted 
in reduced performance scores. In the narrow beam test, the time to initiate travel on the narrow 
beam was reduced by 79% compared to untreated Het. Initiation time in veh Het had was 
reduced by 53% compared to untreated Het. The distance travelled along the beam in both  res 
and veh Het was also significantly increased compared to untreated Het. 
In the tight rope test, the distance travelled by the resveratrol treated Het mice was 4.1 fold 
further compared to untreated Het. Veh treated female Het were also significantly different 
compared to untreated Het (p=0.027).  
The narrow beam test was designed as a spontaneous response to escape requiring spatial 
awareness and some coordination as the beam narrowed the result reflected the true nature of 
the problems inherent in the Het population. These difficulties appeared to have been overcome 
in the resveratrol treated Het mice because there appeared to be little hesitation at performing 
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the task. Res treated Het mouse fear response appeared to be reduced thus permitting a quicker 
response to the task.  
The tight rope test differed from the narrow beam test in that the ability to move along the rope 
in order to return to the home cage required skill and stamina. It also required an ability to 
determine the logic of travel along a rope 1cm in diameter. The untreated Het population 
travelled for 24 ±2.2seconds on top of the rope yet only covered 4.2±1.0 cm in distance. The 
untreated Het population failed to cover more distance because their ability to gain balance was 
impaired. In most instances, once on top of the rope several Het mice simply froze in position 
anticipating their rescue within the test time of one minute. 
The resveratrol treated Het mice spent 17.3 ±5.3 seconds travelling on top of the rope and 
covered a significant 21.8±2.5cm (F(4,21) 4.764 p=0.001). Although they were curious about 
their environment, the test procedure did not lend itself to hesitation. More significant was the 
distance of 21.8±2.5 cm given that the full length of the rope was 30cm. The reduced fear 
response in res treated Het resulted in a significant distance travelled in a shorter period of time. 
6.5.6 Res Het mouse learning in training trials 
The ability to learn from previous tests was shown to be impaired in the Het population. This 
was demonstrated by the use of improved rotarod latency over a three day period where the 
skills learnt on the first day of testing are applied on the second day, and those of the second day 
are applied on the third day of testing. The gradual increase or decrease in latency can be seen 
over the three day test period where the initial value changes incrementally. Negative values 
denote a reduction in score from the initial to the final value. 
6.5.6.1 Results of mouse learning in res treated Het mouse 
Female Het mice (n=12) had a learning score of 0.20±0.12. Female res Het (n=7) mice scored –
0.160 ±0.03 which was not significantly different compared to untreated female Het (p=0.124). 
Female vehicle treated Het (n=5) mice had a learning score of -0.160 ±0.010 which was not 
significantly different to untreated female Het (p=0.177).  Male Het mice (n=14) scored -0.195 
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T Maze
Het 16 rHet 9
F Het 8 rFHet 5
M Het 8 rMHet 4
vFHet 4 vMHet 3
±0.021 and res Het males (n=6) scored -0.210 ±0.030 which when compared to untreated Het 
males was not statistically significant (p=0.968).  
Housing conditions did not influence learning ability in untreated and treated Het. There was no 
significant difference in learning skills between solitary housed (p=0.572) and group housed 
(p=0.761) in both untreated and res treated mice.  
6.6 Cognitive dysfunction in res treated Opa1Q285STOP mouse 
6.6.1 Introduction 
Concerns with the findings of reduced SHIRPA scores for neuropsychiatric and autonomic 
function combined with poor rotarod performance in the resveratrol treated Het population 
suggested that resveratrol appeared to be having a detrimental effect in the Het population. The 
cognitive function tests performed were the T maze test and novel object recognition as 
described in Chapter 3 section 2.2. 
6.6.2 T maze analysis in res treated Opa1Q285STOP mouse 
As before, the investigation ratio and discrimination ratio were calculated from the combination 
of  time spent in the novel arm  divided by the time in both the original and novel arm 
(investigation ratio) and the time  spent in the novel arm minus time in original arm divided by 
time in both novel and original arm (discrimination ratio).  
A summary of mouse test numbers is shown in Table 6.6.  All mice were within 14 days of their 
15 month date of birth. 
6.6.2.1 Results of T maze testing in res treated Het mouse 
 
Table 6.6 Summary of test numbers for T maze analysis in Het res 
and veh Het 
 
The time taken to locate the novel arm was 23 ±4 seconds in untreated Het mice. This was 
reduced to 15±2 seconds in res Het mice which was significantly reduced compared to untreated 
Chapter 6 Trial of resveratrol in Opa1
Q285STOP
 mouse 
 
197 
 
0
10
20
30
40
WT Het rHet vHet WT Het rHet  vHet WT Het rHet  vHet
To novel In novel In original
T
im
e 
(s
ec
)
**
*
*
*
n Time to p In  Novel p In original p
Het 18 Het:rHet 0.021 Het:rHet 0.030 Het:rHet 0.028
rHet 7 Het:vHet 0.008 Het:vHet 0.137 Het:vHet 0.987
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Het (F (2.29) 4.639 p=0.021). Vehicle treated Het mice time to the novel arm was 12±1 seconds 
which was statistically different to untreated Het (p=0.008). The time spent exploring the novel 
arm was 20±2 seconds in Het mice and 27±2 seconds in res treated Het mice which was 
significantly more than untreated Het (F(2,29) 3.939 p=0.030). Veh Het spent 25 ±2 seconds in 
the novel arm which was not significantly different to untreated Het (p=0.137). The time spent 
in the original arm was 14±2/sec in untreated Het, 12 ±2 seconds in res treated and14±2 seconds 
in vehicle treated Het mice. Res treated Het time in original arm was statistically reduced 
compared to untreated Het mice (F(2,29) 1.864 p=0.028). The time spent by veh Het was not 
statistically different to untreated Het (p=0.987). Figure 6.5 shows a summary of this data. 
Figure 6.5 Parameters of T 
maze testing in untreated 
and treated Het mouse 
Graph showing the mean 
±SD of T maze testing 
parameters in untreated, res 
treated and veh treated Het 
was analysed by measuring: 
Het time to locate novel arm, 
Time spent in novel arm and 
Time spent in original arm in 
a series of seven consecutive 
tests. 
 
From the above data, the investigation ratio (IR) was determined.  In untreated Het mice the IR 
was 0.49 ±0.04. Res Het IR was 0.65 ±0.03 and in vehicle treated Het was 0.63 ±0.02.There 
was a statistical difference between untreated and res treated Het IR (F (2,29) 2.418 p=0.006). 
There was no statistical difference between untreated and veh treated Het mice (p=0.144).  
The discrimination ratio (DR) in untreated Het was 0.14±0.06.In res treated Het the DR was 
0.34 ±0.06 and in veh treated Het the DR was 0.26±0.05. There was a statistical difference 
between untreated and res treated Het (F(2,29) 6.708 p=0.002). There was no significant 
different between untreated and veh treated Het(p=0.096). Figure 6.6 shows a summary of this. 
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Figure 6.6 T Maze IR and DR in untreated 
and  treated Het mouse 
Graph showing the (A) IR and (B) DR in T maze 
testing of untreated Het, res and veh Het. 
 
 
 
 
6.6.2.2 Discussion of T maze testing in res treated Het mouse 
The IR in res treated Het was increased by 55% compared to untreated Het and veh treated IR 
was increased by 63%. This suggested that res and veh treated Het were less anxious and 
prepared to investigate their surroundings. The DR in res Het mice was significantly increased 
compared to untreated Het by 36%. The increase in veh treated Het DR was not statistically 
significant but represented a 30% increase compared to untreated Het.   
The learning trend in res treated Het mouse was examined with respect to serial repeat testing. 
The mean score in untreated Het mouse was 0.14 ±0.09.  Res Het score was 0.34±0.13 which 
was significantly increased compared to untreated Het mouse (F(2,29) 7.304  p-0.001). Veh Het 
score was 0.26 ±0.14 which was also significantly increased compared to untreated Het (F2,29) 
7.304 p=0.001). Figure 6.7 shows a summary of these findings. 
Figure 6.7 T Maze Learning trend in Het, res and veh treated Het 
The learning score for T maze 
in untreated Het was 
significantly reduced 
compared to both res and veh 
treated Het.  
The trend showed untreated 
Het slow decline with recovery 
for no more than three 
consecutive tests. Both res and 
veh treated Het showed no 
decline in trend. 
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6.6.3 Novel object recognition in res treated Opa1Q285STOP mouse 
Novel object recognition (NOR) testing was performed as previously described in Chapter 3 
section 3.3. A summary of test numbers is shown in Table 6.7.    
6.6.3.1 Results of NOR in res treated Het mouse 
Table 6.7 Summary of test numbers for NOR in untreated, res 
and veh Het. 
 
The time spent with the novel item in the Het group was13 ±2 
seconds. In the res Het group this was 12±2 seconds and 15±4 seconds in the vehicle group. 
There was no statistical difference between untreated Het and res Het (p=0.588) or untreated 
Het and vehicle treated Het mice (p=0.583). The time spent with the original item in untreated 
Het mice was 10±2 seconds and 7±2 seconds in res Het mice which was not significantly 
different compared to untreated Het (p=0.085) Vehicle treated Het mice spent 5 ±2 seconds with 
the original object which was not significantly different compared to untreated Het (p=0.112). 
These data are presented in Figure 6.8. 
Figure 6.8 Parameters of NOR 
testing in untreated and treated 
Het mouse 
Graph showing mean ±SD of the 
parameters used to investigate 
novel object recognition. Time to 
locate novel object, time spent with 
novel object and time spent with 
the original object in Het, res and 
veh Het treated mice.  
 
 
The IR in untreated Het mice was 0.49±0.05. The res treated Het mice had an IR score of 
0.58±0.09 which was not statistically significant compared to untreated Het (p=0.067). The IR 
in vehicle treated Het mice was 0.67±0.12 which was also not statistically significant (p=0.069) 
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The DR in untreated Het mice was 0.13 ±0.09. The res Het mice scored 0.29±0.16 which was 
not statistically significant compared to untreated Het (p=0.078). The DR in vehicle treated Het 
mice was 0.50±0.15 which was statistically significant compared to untreated Het (F(2,30) 
2.254 p=0.024). This is shown in Figure 6.9. 
 
Figure 6.9 NOR IR and DR in resveratrol 
treated Het mouse 
Graph showing (A) investigation and (B) 
discrimination ratio of NOR in untreated, res 
treated and veh Het treated Het 
 
 
6.6.3.2 Discussion of NOR in res treated Het mouse 
There was very little variation between the untreated Het mice and resveratrol treated Het mice. 
There was a 18% increase in IR seen in res Het  and veh Het showed a 37% increase compared 
to untreated Het. The DR in res treated Het mice showed a 123% increase compared to 
untreated Het DR. The vehicle treated Het mice showed an increased DR of 285% compared to 
untreated Het mice. However, despite this improvement, it did not alter the learning pattern in 
res Het mice. There was no statistical difference in the correct choice between untreated and res 
treated Het mice. The average correct score in untreated Het mouse was 0.46±0.08.This was 
0.441±0.65) in res Het. (p=0.475) and 38±0.11 in vehicle treated (p=0.419). Finally, the objects 
used in NOR testing did not demonstrate any statistical significant difference in the time spent 
with each item.  This suggested that there was no preferential treatment towards any objects or 
no specific influence discrimination of particular items used in novel object recognition. 
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6.7 Bioenergetic impairment of res treated Opa1Q285STOP mouse 
6.7.1 Introduction 
Resveratrol enhances mitochondrial biogenesis via the activation of the energy sensor AMP-
activated kinase (AMPK) (Baur and Sinclair 2006; Lagouge et al. 2006; Chung et al. 2010; Um 
et al. 2010). As a result, increased AMPK activation increases fatty acid oxidation and 
mitochondrial biogenesis. Whether mitochondrial biogenesis is mediated by indirect activation 
of sirtuins or whether AMPK is a direct target of resveratrol remains to be clarified (Chung et 
al. 2010; Pacholec et al. 2010). Increased biogenesis may result in increased ATP production 
and it was intended to measure endogenous ATP in brain and retinal homogenate, however 
following some very ambiguous results it was discovered that resveratrol inhibits the activity of 
luciferase firefly (Bakhtiarova et al. 2006).  As previous analysis demonstrated that the Het 
mouse appeared not to have compromised levels of ATP, it was decided to continue to electron 
transport analysis. 
6.7.1.1 Bioavailability of resveratrol 
Whole blood samples were prepared as described in Chapter 2 section 20.2.  HPLC UV was 
performed on whole blood samples from mice who had been treated with resveratrol or vehicle 
for a total of 15 months. The level of back ground was reported to be too high to estimate the 
presence of resveratrol. This was possibly due to the quality of reagents used in the preparation 
process. 
6.7.2 Analysis of electron transfer in Opa1Q285STOP mouse 
6.7.3 Introduction 
Electron transfer assays were performed as described in Chapter 4 section 4.3. Briefly, a series 
of experiments were performed where a minimum of three individual WT, Het, res WT, res Het, 
veh WT and veh Het tissues were tested simultaneously. In order to maximise the number of 
experimental tests, each mouse contributed several organs for combined analysis. The tests 
performed were on the activity of complex I oxidation of NADH by mitochondria which was 
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analysed by fluorescence spectrophotometer, complex II succinate dehydrogenase (SDH) 
analysed by the  reduction of DCPIP in the presence of succinate at 600nm using a UV 
spectrophotometer and complex IV oxidation of  reduced cytochrome c followed at 550nm. The 
presence of residual succinate from storage buffer had no significant effect in complex I 
analysis which is shown in Appendix K. The kinetic reactions for electron complex analysis are 
in Appendix L and the calculations for line fitting are in Appendix M. Summaries for sample 
numbers in each analysis are shown in the table preceding results. 
6.7.3.1 Results of complex I oxidation of NADH  
Complex 1 activity was measured in brain, spinal cord, retina and muscle mitochondria. 
 
Table 6.8 Summary of test samples for complex I analysis in 
untreated ,res and veh Het 
 
Isolated mitochondria from Het brain oxidised 108±6 nmol/mg Res 
treated Het brain oxidised 166±7 nmol/mg which was significantly increased compared to 
untreated Het (F(2,21) 25.123 p=0.002). Vehicle treated Het brain oxidised 43±4 nmol/mg 
which was significantly reduced compared to untreated Het (F(2.21) 197.42 p=0.001).  
Complex I activity in untreated Het spinal cord oxidised 82±9 nmol/mg and res Het spinal cord 
mitochondria oxidised 48±9 nmol/mg which was significantly reduced compared to untreated 
Het (F(2.24) 18.191 p=0.008).Veh Het spinal cord oxidised 78±19 nmol/mg which was not 
significantly different  to untreated Het(p=0.548). 
Het retinal mitochondrial oxidised 52±17 nmol/mg Res Het retina oxidised 94±38 nmol/mg 
which was not statistically different compared to untreated Het (p=0.057). Veh Het oxidised 
59±28 nmol/mg NADH which was not significantly different to untreated Het (p=0.828).   
Complex I activity in Het muscle oxidised 95 ±10nmol/mg res Het muscle oxidised 63 ±11 
nmol/mg which was significantly reduced compared to untreated Het (F(2,9) 16.72 p=0.014). 
CI BrainCI Retina
Het 9 Het 9
rHet 8 rHet 6
vHet 5 vHet 6
CI SC  CI Mus
Het 10 Het 5
rHet 9 rHet 4
vHet 8 vHet 3
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Veh Het oxidised 56±2 nmol/mg which was significantly reduced (p=0.001) compared to 
untreated Het. 
6.7.3.2 Results of complex II succinate dehydrogenase 
 
Table 6.9 Summary of test samples for complex II in untreated, 
res and veh Het 
 
Complex II activity in untreated Het brain mitochondria reduced 20 
±6 mol/mg. Res Het brain reduced 31±6mol/mg. which was 
significantly reduced compared to untreated Het (F(2,17) 185.152 p=0.012). Veh Het brain 
reduced 77±2mol/mg which was significantly increased compared to untreated Het (p=0.001). 
Spinal cord in untreated Het reduced 19±2mol/mg. per mg, res Het reduced 26±7 mol/mg. 
which was significantly increased compared to untreated Het (F(2,17) 5.032 p=0.023). Veh Het 
SC reduced 17±11mol/mg. which was not significantly different (p=0.527) compared to 
untreated Het.  
Retinal complex II activity in untreated Het reduced 58±14mol/mg. Res treated retinal 
mitochondrial reduced 21±6mol/mg. which was significantly reduced compared to untreated 
Het (F(2,18) 47.199 p=0.001). Veh treated Het retinal mitochondria reduced 102±5mol/mg. 
which was significantly increased compared to untreated Het (p=0.001).  
Complex II in untreated Het muscle mitochondria reduced 25±6mol/mg., res Het reduced 
17±5 mol/mg which was not significantly different compared to untreated Het  (p=0.146) and 
veh Het reduced 16±4mol/mg which was not statistically different compared to untreated Het 
(p=0.148).  
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6.7.3.3 Results of complex IV oxidation of cytochrome c 
 
Table 6.10 Summary of test samples for complex IV analysis in 
untreated res and veh Het 
 
Untreated Het brain mitochondria oxidised 2.80±0.13 mol/mg Res 
Het oxidised 1.45±0.51 mol/mg which was significantly reduced compared to untreated Het 
(F(2,18) 40.212 p=0.001). Veh Het oxidised 1.30±0.01 mol/mg which was also significantly 
reduced compared to untreated Het (p=0.001). 
Het spinal cord mitochondria oxidised 2.68±0.11mol/mg Res Het spinal cord mitochondria 
oxidised 1.48±0.08 mol/mg which was significantly reduced  compared to untreated Het 
(F(2,21) 4.7478 p=0.001), and veh Het oxidised 1.50±0.05 mol/mg which was also 
significantly reduced  compared to untreated Het (p=0.001).  
Retinal oxidation in untreated Het was 0.96±0.14 mol/mg. Res Het retinal mitochondria 
oxidised 2.52±0.43 mol/mg which was significantly increased compared to untreated Het 
(F(2,17) 15.120 p=0.001), and veh Het oxidised 1.92 ±0.98 mol/mg which was also 
significantly increased  compared to untreated Het (p=0.010). 
Muscle mitochondria oxidation in untreated Het was 1.63±0.04 mol/mg Res Het oxidised 
1.89±0.16 mol/mg which was not significantly different to untreated Het (p=0.172), and veh 
Het muscle oxidised 1.01±0.62 mol/mg which was significantly reduced compared to 
untreated Het (F(2,9) 13.572 p=0.007).  
Figure 6.10 - 6.12 shows a graphical representation of the data. 
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Figure 6.10 Complex I NADH oxidation in untreated and treated Het mitochondria 
Graphs of mean ±SD of complex I oxidation of NADH in untreated, res and veh treated Het 
brain, spinal cord (SC) retina (Ret) and skeletal muscle (Mus) mitochondria. The graph shows 
complex I oxidation of NADH nmol/mg in 30g mitochondria/ml 
 
 
Figure 6.11 Complex II reduction of DCPIP in untreated and treated Het mitochondria 
Graphs of mean ±SD complex II reduction of DCPIP in untreated, res and veh Het 
mitochondria from brain, spinal cord (SC) retina (Ret) and skeletal muscle (Mus) mitochondria. 
The graph shows the reduction of DCPIP mol/mg in 50g mitochondrial protein. 
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Figure 6.12 Complex IV oxidation of cyto c in untreated and treated Het mitochondria 
Graphs of mean ±SD complex IV oxidation of reduced cytochrome c in untreated, res and veh 
treated Het mitochondria from brain, spinal cord (SC) retina (Ret) and skeletal muscle (Mus) 
mitochondria. The graph shows reduced cytochrome c mol/mg in 50g of mitochondrial 
protein. 
 
The ratio of complex activity in each tissue was examined. Previous examination of complex 
ratios in the CNS of untreated WT demonstrated that the ratio of complex I was highest in 
spinal cord mitochondria. The ratio of complex II was highest in retinal mitochondria and the 
ratio of complex IV was highest in brain mitochondria. Untreated Het maintained these ratios. 
Table 6.11 shows a summary of the ratio of each complex for brain, spinal cord and retinal 
mitochondria with the statistical difference between groups. 
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Table 6.11 Ratio of complex activity in untreated res and veh Het mitochondria 
 
Table shows the ratio of complex activity according to tissue type. Compared to 
untreated Het the ratio of complex I activity was reduced in res Het spinal cord. The 
ratio of Complex II activity was increased in all res Het tissues. Complex IV ratio was 
reduced in res Het brain and spinal cord mitochondria and increased in retinal 
mitochondria. Compared to untreated Het, veh Het had a reduction in complex I ratio 
in brain. The ratio of Complex II activity was reduced in spinal cord and enhanced in 
retinal mitochondria. Compared to untreated Het, veh Het ratio of complex IV was 
reduced in brain and increased in retinal mitochondria.  
 
In res Het spinal cord, the ratio of complex I activity was significantly reduced by 52% 
(F(2,68)4.432 p=0.001) compared to untreated Het. The ratio of complex II activity in res Het 
retina was significantly reduced by 53% compared to untreated Het (F(2,48) 45.389 p=0.001). 
Compared to untreated Het, the ratio of complex IV activity was significantly reduced in res Het 
brain by 30% (F(2,46) 38.685 p=0.001) and in spinal cord by 33% (p=0.001).  
Compared to untreated Het, veh Het complex I ratio was increased by 33% in spinal cord 
mitochondria and the correct ratio was maintained (p=0.775). The ratio of complex II activity in 
veh Het retina was reduced by 13% (F(2,48) 45.389 p=0.011) but the correct ratio was 
maintained. The ratio of complex IV activity in veh Het brain was reduced by 30% F(2.46) 
38.685 p=0.001). 
Brain Spinal cord Retina
Het rHet vHet Het rHet vHet Het rHet vHet
CI 45±5 54±4 25±3 33±6 16±1 44±10 22±6 30±4 31±8
Het:rHet 0.909 0.001 0.781
Het:vHet 0.001 0.775 0.736
rHet:vHet 0.002 0.003 0.946
F(2,68)4.432
CII 21±5 39±5 39±2 19±6 33±5 9±1 60±1 28±7 52±2
Het:rHet 0.001 0.001 0.001
Het:vHet 0.001 0.004 0.011
rHet:vHet 0.816 0.001 0.001
F(2,48) 45.389
CIV 43±4 30±3 30±0.9 42±6 33±6 34±4 15±2 37±19 36±5
Het:rHet 0.001 0.001 0.001
Het:vHet 0.001 0.052 0.001
rHet:vHet 0.531 0.126 0.268
F(2, 46) 38.685
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rHet Brain SC Ret Mus Ave ETC
CI 46 -45 71 -26 11
CII 49 34 -64 -34 -4
CIV -48 -45 161 16 21
Ave 16 -19 56 -15
vHet Brain SC Ret Mus Ave ETC
CI -62 -10 7 -44 -27
CII 276 -10 75 -921 -145
CIV -53 -44 99 -38 -9
Ave 54 -21 60 -334
 
6.7.3.4 Discussion of ETC activity in res treated Opa1Q285STOP mouse 
The percentage change in res and veh treated Het were compared to untreated Het mice. Table 
6.12 shows a summary of the percentage changes compared to untreated Het.  
Table 6.12 Percentage change of complex activity in res and veh Het mitochondria 
 
The table shows the percentage change in 
individual complex activity in brain, spinal 
cord retinal and skeletal muscle 
mitochondria compared to untreated Het 
mitochondria. The average percent change 
in bioenergetic activity for tissue types is 
also shown. 
 
Tissue specific alternations in mitochondrial electron transport activity were calculated from the 
total change in complexes I, II and IV compared to untreated Het. In res Het treated 
mitochondria, both brain and retina showed an increase in ETC activity compared to untreated 
Het. Both spinal cord and skeletal muscle mitochondria showed a reduction in bioenergetic 
activity. Veh Het showed enhanced activity in brain and retinal mitochondria and reduced 
activity in spinal cord and skeletal muscle mitochondria compared to untreated Het. 
If the ratio of individual complex activity in untreated Het was established as a means of 
mitohormesis (Tapia 2006; Ristow and Zarse 2010; Bouitbir et al. 2012; Ristow 2014), then by 
comparing the ratio of bioenergetic activity in res and veh treated Het to untreated WT would 
demonstrate any improvement in tissue specific activity.  
The ratio of complex I activity was highest in untreated WT spinal cord mitochondria. 
Compared to untreated WT, the difference in ratio of complex I activity in spinal cord 
mitochondria of untreated Het was 13% which was not significantly different to untreated WT 
(p=0.578). Res Het had 58% reduction in the ratio of complex I activity in spinal cord 
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Het rHet vHet
CI(SC) %  -13 -58 16
: WT p= 0.578 0.009 0.462
F(2,68)2.144
CII(Ret) %  7 -50 -7
: WT p= 0.706 0.001 0.260
F(2,48) 45.389
CIV(B) %  5 -27 -27
: WT p= 0.822 0.001 0.001
F(2, 46) 38.685
mitochondria which was significantly reduced (F(2,68) 2.144 p=0.009). Veh Het had a 16% 
increase in the ratio of complex I activity in spinal cord mitochondria compared to untreated 
WT which was not significantly different (p=0.462). 
The ratio of complex II activity was highest in untreated WT retinal mitochondria. Compared to 
WT, the difference in ratio of complex II activity in Het retinal mitochondria was enhanced by 
7% and was not  significantly different to WT (p=0.706). The ratio of complex II activity in res 
Het retinal mitochondria was reduced by 50% compared to WT which was statistically 
significant (F2,48) 45.389 p=0.001).  Veh Het ratio of complex II activity in retinal 
mitochondria was reduced by 7% which was not significantly different compared to WT 
(p=0.260). 
The ratio of complex IV activity was highest in untreated WT brain mitochondria. Compared to 
WT, complex IV ratio in untreated Het brain mitochondria was enhanced by 5% which was not 
significantly different to WT (p=0.822). Res Het brain mitochondrial ratio of complex IV 
activity was significantly reduced by 27% compared to WT (F(2.46) 38.685 p=0.001). Veh Het 
ratio of complex IV activity in brain mitochondria was also significantly reduced by 27% which 
was significantly different to WT brain (p=0.001). Table 6.13 shows a summary of the ratio of 
complex activity compared to untreated WT. 
 
Table 6.13 Ratio of complex activity compared to 
untreated WT 
The table shows the percentage difference in the ratio 
of complex I activity in spinal cord mitochondria, 
complex II activity in retinal mitochondria and 
complex IV activity in brain mitochondria compared to 
untreated WT. The statistical significance between 
groups is represented by the p value. 
 
Untreated Het mitochondria maintained the correct tissue specific ratios of activity in complex I, 
II and IV.  Veh Het maintained the correct tissue specific ratios of activity for complex I and 
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complex II but showed a significant reduction in complex IV activity for brain. Res Het 
mitochondria showed the tissue specific ratios of all complex activities were not preserved. 
If the ratio of individual complex activity for specific tissues reflects the functional ability to 
maintain a healthy mitochondrial environment, then resveratrol conferred no advantages to Het 
function. The possibility of correcting the ratio of complexes by mixing of the mitochondrial 
matrix content is reduced in Het but not absent. As Het CNS mitochondria maintained the 
correct ratios of complexes and veh Het maintained both complex I and II suggests the presence 
of ethanol was responsible for the reduction of complex IV in treated Het brain mitochondria. 
Resveratrol alone was responsible for the altered complex I and complex II ratios. 
The effects of 0.1% ethanol were not anticipated to yield effects but vehicle treated Het 
demonstrated significant differences compared to untreated Het. The administration of a low 
dose over a prolonged period clearly produced effects that were either eliminated or exaggerated 
by the combined administration of resveratrol with 0.1% ethanol. Figure 6.13 shows the effects 
of resveratrol minus the ethanol effect for both tissue specific and ETC supercomplex activity. 
For example, complex I activity in veh Het brain mitochondria showed a 61% reduction in 
activity compared to untreated Het. Res Het brain mitochondria showed a 45% increase in 
activity. The effects of ethanol (61% reduction) were subtracted from 45% increase to get the 
actual effects of resveratrol minus the effect of ethanol.  This was applied to all ETC activity to 
determine a more exact tissue specific effect of resveratrol. 
Res Het complex 1 activity was enhanced by 39% compared to untreated Het. Complex II was 
reduced by 80% and complex IV was enhanced by 30%. Tissue specific mitochondrial changes 
were seen in brain with 39% reduction in activity, spinal cord had 3% increase, retina had 4% 
reduction and skeletal muscle showed a 25% increase compared to untreated Het. 
The effects of resveratrol have been reported to cause a reduction in complex I and complex II 
activity at a concentration of 10mg/kg in rats (Sassi et al. 2014), which was not as a result of 
Ca2+ dysregulation but the accumulation of ‘compounds’ in mitochondria. These ‘compounds’ 
are most likely H202 generated by the dismutation of superoxide by the enhanced presence of 
Chapter 6 Trial of resveratrol in Opa1
Q285STOP 
mouse 
 
211 
 
-100
-80
-60
-40
-20
0
20
40
P
e
rc
e
n
t 
 
H
e
t
Brain        SC        Ret
C1          C2     C4
r-v Het ETC
r-vHet Tissue
C1 C2
39 -80
C4
30 r-vHet
 Brain Retina
-39 -4
 SC
3 r-vHet
MnSOD. Opa1 regulation of calcium Mitochondria act as store houses for calcium and the 
presence of a fusion mutation renders mitochondria more susceptible to mitophagy. 
Figure 6.13 Changes in specific complexes and tissue 
in res treated Het 
Graph showing the tissue specific and complex specific 
effects of resveratrol in Het mouse. The tissue specific 
bioenergetics in res Het brain were reduced by 39%, 
spinal cord and retinal mitochondria were unchanged. 
Skeletal muscle were increased by 25%.  Complex I 
activity was increased by 39%, complex IV by 30% and 
complex II reduced by 80%. 
 
Loss of mitochondria results in a local cellular increase in calcium. This progressive rise in local 
calcium concentration can induce autophagy (Pinton et al. 2008).  Retinal ganglion cells are 
dependent on calcium clearance during development . (Dayanithi et al. 2010). Calcium 
dysregulation has been associated with Dominant optic atrophy  (Lenaers et al. 2009; Fülöp et 
al. 2011; Kushnareva et al. 2013) and  other neurological disorders including Parkinson’s 
disease    (Büeler 2010; Chu 2010; Zhu and Chu 2010; Buhlman et al. 2014) . 
 The dose specific activity of resveratrol has been reported in cell culture (Guo et al. 2011; 
Carpéné et al. 2014; Martins et al. 2014; Meira Martins et al. 2014). Because of the variability 
in bioavailability of resveratrol, it is not always possible to determine what concentration is 
available to specific cell populations.  There are reports that female recipients derive less benefit 
from resveratrol administration (Liesa et al. 2009; Yao et al. 2011). This is possibly due to the 
presence of estrogen receptors which compete for binding with resveratrol (Araújo et al. 2008; 
Chakraborty et al. 2013). Astrocytes respond to estrogen with enhanced expression of both 
fusion and fission genes (Liesa et al. 2009).If resveratrol was capable of reducing the already 
limited availability of Opa1 in Het mice, it was anticipated that this would have produced 
serious side effects and possible loss of animals. 
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6.7.4 Mitochondrial related protein expression in res treated Het 
6.7.4.1 Introduction 
As described in Chapter 4 section 4.4, localization of protein in specific tissue can support some 
of the previous findings. Western blotting of retinal homogenates was performed on untreated 
Het (n5) and resveratrol treated Het (n6) tissues. Immunohistology was performed using a range 
of antibodies as previously described on untreated Het (n4), res Het (n4) and veh Het (n4) 
retinal sections. Western blotting was performed on untreated Het (n4) and res Het (n4) brain 
homogenate and sections of brain were analysed using the same panel of antibodies used for 
retinal sections. 
6.7.5 Results of mitochondrial related protein expression in res treated Het 
Table 6.14 shows a summary of the mitochondrial related protein expression of Opa1, VDAC 
and Preli in the retina of untreated Het res and veh Het.  Figure 6.14 shows the mean AFU for 
(A)Opa1, (B) VDAC and (C) Preli  expression in untreated, res and veh Het retina. 
Table 6.14 Mitochondrial related proteins Opa1, VDAC and Preli in res treated Het 
 
Table shows the mean (±SEM) of retinal mitochondrial expression of (A) Opa1 (B) 
VDAC (C) Preli in untreated, res and veh treated Het. The statistical difference between 
groups is represented by p value. 
 
A PRL ONL OPL INL IPL GCL
Opa1 Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 96.4 235 188 98.8 131 164 130 185 217 71.1 93.4 160 89 101 162 77.7 52.6 146
SEM 26.8 72.3 84.6 37.6 24.7 53.6 26.3 61.6 75.8 11.9 36.1 50.3 29.2 23.7 72.1 10.3 12.4 23.5
Het:rHet 0.603 0.959 0.539 0.818 0.877 0.557
Het:vHet 0.691 0.524 0.030 0.004 0.014 0.017
F F ( 5,16) 2.285 F (5,15) 4.390 F (5,15) 2.751 F (5,15)5.463 F (5,15) 9.729 F (5,15) 15.056
B PRL ONL OPL INL IPL GCL
VDAC Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 555 422 269 944 403 311 526 221 250 890 351 339 747 244 268 798 390 349
SEM 88 72.8 70.7 23.5 116 76 81.9 72.3 84.4 66.1 61.4 66.4 67.6 34.7 89.8 65.8 44.1 79.6
Het:rHet 0.374 0.012 0.698 0.004 0.665 0.228
Het:vHet 0.008 0.952 0.016 0.001 0.074 0.461
F F ( 5,15) 10.470 F (5,15) 1.380 F (5,15) 6.747 F (5,15)1.028 F (5,15)1.146 F (5,15)0.441
C PRL ONL OPL INL IPL GCL
Preli Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 255 380 368 186 88 109 144 182 196 120 96 162 215 178 284 99 171 236
SEM 71 52 73 113 85 66 58 34 53 43 33 94 106 31 131 30 16 104
Het:rHet 0.252 0.780 0.723 0.228 0.342 0.591
Het:vHet 0.447 0.075 0.875 0.152 0.461 0.943
F F ( 5,21) 21.466 F (5,21) 1.843 F (5,15) 5.851 F (5,15)4.645 F (5,15) 1.132 F (5,15) 3.626
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Figure 6.14 Mitochondrial 
related AFU in untreated, res 
and veh Het retina 
Graph shows the mean ±SEM of 
(A) Opa1 expression (B) VDAC 
and (C) Preli in Het, res Het and 
veh Het retinal layers. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.15 shows a summary of the Neuroglobin, PSD95 and NF L expression in  Preli in the 
retina of untreated Het res and veh Het.  Figure 6.15 shows the mean AFU for (D) Neuroglobin, 
(E) PSD95 and (F) Neurofilament expression in untreated, res and veh Het retina. 
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Het 6 Het:rHet 0.641 0.080 0.864 0.031 0.966 0.965
rHet 7 Het:vHet 0.348 0.372 0.275 0.138 0.255 0.138
vHet 6 rHet:vHet 0.651 0.380 0.383 0.453 0.302 0.174
*p<0.05**p<0.010***p<0.001 ±SEM
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Table 6.15 Mitochondrial related Neuroglobin, PSD95 and NF in res treated Het 
 
Table shows the mean (±SEM) of retinal mitochondrial expression of (D) Neuroglobin 
(E) PSD95(F)Neurofilament L in untreated, res and veh treated Het. The statistical 
difference between groups is represented by p value. 
 
 
Figure 6.15 Mitochondrial related 
AFU in res treated Het 
 
Graphs show the mean ±SEM AFU 
of (D)Neuroglobin in Het, res Het 
and veh Het retinal layers. 
 
 
 
 
 
D PRL ONL OPL INL IPL GCL
Neuro Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 250.5 214.3 176.4 349.2 181.4 267.1 129.8 85.71 134.2 259.3 94.48 151.1 90.41 95.08 223.1 64.78 66.7 129.3
SEM 38.15 30.29 97.47 38.98 5.215 69.44 20.76 13.97 70.63 21.29 27.37 29.79 34.99 42.04 150.6 23.16 10.76 40.57
Het:rHet 0.454 0.457 0.508 0.781 0.537 0.410
Het:vHet 0.776 0.102 0.341 0.223 0.090 0.928
F F ( 5,20) 1.530 F (5,20) 0.784 F (5,20) 0.969 F (5,20)0.896 F (5,20) 1.654 F (5,20) 0.838
E PRL ONL OPL INL IPL GCL
PSD95 Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 267 252 250 162 352 256 239 230 215 82.8 174 131 211 125 167 92.9 75.7 63.9
SEM 24.2 58.5 62 32 115 18.7 2.26 71.5 13.7 11.2 70.7 42.5 15.8 75.4 38.8 15.6 36.5 11.7
Het:rHet 0.654 0.347 0.347 0.850 0.293 0.446
Het:vHet 0.041 0.050 0.049 0.113 0.028 0.115
F F ( 5,28) 1.900 F (5,28) 1.176 F (5,28) 4.913 F (5,28)2.091 F (5,28)2.78 F (5,28) 1.762
F PRL ONL OPL INL IPL GCL
NF L Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 128 291 143 168 281 121 182 506 185 140 242 291 173 318 124 405 602 341
SEM 56.5 39.5 25.8 54.8 89 48.3 70.4 76.5 81.6 42 81.1 173 54.7 24.9 55.8 105 28.5 97.5
Het:rHet 0.029 0.023 0.011 0.002 0.001 0.890
Het:vHet 0.938 0.369 0.556 0.040 0.820 0.263
F F ( 5,23) 8.530 F (5,23) 1.280 F (5,23) 4.219 F (5,23)3.493 F (5,23) 7.706 F (5,23) 2.512
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…Figure 6.15 
Graphs show the mean ±SEM AFU 
of (E)PSD95 and (F) NF L in Het, 
res Het and veh Het retinal layers. 
 
 
 
 
 
 
 
 
 
There was no significant difference observed in Opa1 expression between untreated and res 
treated Het. There was a significant difference observed in VDAC expression between untreated 
and res treated Het. Res Het had a significant 54% reduction in VDAC expression in the ONL 
(F(5,12) 5.9998 p=0.006), OPL (F(5,12) 2.784 p=0.028), INL (F(5,12) 9.494 p=0.001, IPL 
(F(5,12) 7.013 p=0.001) and GCL (F(5,12) 2.250 p=0.045). This reduction in VDAC expression 
was also observed in veh Het who had a 60% reduction compared to untreated Het. 
Compensatory protein expression of preli and neuroglobin were not statistically different in res 
and veh Het compared to untreated Het. 
Damage mediated protein expression of PSD95 was not significantly different in res and veh 
Het compared to untreated Het. Neurofilament light chain expression was increased by 87% in 
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res Het retina. Res Het PRL has a significant 127% increase (F(5,12) 1.246 p=0.004). There was 
a 178% increase in NFl in the OPL (F(5,12)6.922 p=0.002) and 83% increase in the IPL 
(F(5,12) 5.823 p=0.038). 
By combining the AFU of Opa1, VDAC and Preli a mitochondrial specific profile was 
obtained. The combined Preli, Neuroglobin and VDAC expression were combined to obtain 
compensatory proteins and PSD95 and neurofilament combined to obtain a damage mediated 
profile. The purposes of this was to determine if there was a particular region within the retinal 
layers that showed enhanced activity compared to untreated Het retina. Table 6.16 summarises 
these results. Figure 6.16 summarises these findings. 
Table 6.16 Protein profiles in untreated res and veh Het retina 
 
Table shows the mean (±SEM) of (A) mitochondrial  (B) compensation and (C) damage 
mediated protein expression in retinal layers of untreated res and veh Het. Statistical 
difference between groups is represented by the  p value. 
 
 
 
A PRL ONL OPL INL IPL GCL
Mito Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 297 345 275 387 207 194 254 196 220 336 179 220 336 174 237 302 204 243
SEM 26.8 72.3 84.6 37.6 24.7 53.6 26.3 61.6 75.8 11.9 36.1 50.3 29.2 23.7 72.1 10.3 12.4 23.5
Het:rHet 0.514 0.108 0.423 0.109 0.054 0.331
Het:vHet 0.765 0.086 0.461 0.232 0.233 0.556
rHet:vHet 0.355 0.910 0.741 0.382 0.457 0.706
F F ( 5,16) 2.285 F (5,15) 4.390 F (5,15) 2.751 F (5,15)5.463 F (5,15) 9.729 F (5,15) 15.056
PRL ONL OPL INL IPL GCL
B Comp Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 348 338 271 453 224 245 245 163 193 395 180 217 357 172 258 294 209 237
SEM 88 72.8 70.7 23.5 116 76 81.9 72.3 84.4 66.1 61.4 66.4 67.6 34.7 89.8 65.8 44.1 79.6
Het:rHet 0.881 0.023 0.156 0.015 0.030 0.380
Het:vHet 0.222 0.026 0.337 0.043 0.236 0.559
rHet:vHet 0.329 0.965 0.364 0.697 0.355 0.789
F F ( 5,15) 10.470 F (5,15) 1.380 F (5,15) 6.747 F (5,15)1.028 F (5,15)1.146 F (5,15)0.441
PRL ONL OPL INL IPL GCL
C Damage Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet Het rHet vHet
Ave 197 271 196 164 316 188 210 367 199 111 207 211 192 221 145 248 338 202
SEM 71 52 73 113 85 66 58 34 53 43 33 94 106 31 131 30 16 104
Het:rHet 0.117 0.038 0.027 0.166 0.375 0.489
Het:vHet 0.987 0.741 0.877 0.152 0.501 0.717
rHet:vHet #### 0.076 0.019 0.960 0.278 0.293
F F ( 5,21) 21.466 F (5,21) 1.843 F (5,15) 5.851 F (5,15)4.645 F (5,15) 1.132 F (5,15) 3.626
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Figure 6.16 Protein profiles in 
untreated res and veh Het 
Graphs showing  the mean ±SEM 
AFU of (A) mitochondrial (B) 
compensation and (C) damage 
mediated expression in retinal 
sections of untreated res and veh 
Het. 
 
 
 
 
 
 
 
 
 
 
There was no significant difference in any retinal layer for mitocondrial specific proteins in 
untreated res and veh Het. Compensatory protein expression in res Het was significantly 
reduced in the ONL (p=0.023)  and INL (p=0.015). Veh Het also had a significant reduction of 
compensatory proteins in the ONL (p=0.026) and INL (p=0.043). Damage mediated protein 
expression was significantly increased in res Het ONL (p=0.038) and OPL (p=0.027). Veh Het 
damage mediated protein profile was not significantly different compared to untreated Het. 
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 The ratio of compensatory to damage mediated protein expression was examined as before. A 
value of less then 1 was considered a positive measure in controlling damage mediated protein 
expression. Fiigure 6.17  summarises these findings. 
 
 
Figure 6.17 Ratio of compensation to damage in 
untreated and treated Het  
Line graph shows the ratio of compensatory 
protein expression to damage mediated protein 
expression in retinal layers of untreated res and 
veh Het. Untreated WT is included for reference. 
 
 
 Res treated Het ONL and OPL appeared to be more compromised with respect to increased 
damage mediated protein expression. Both res and veh showed reduced compensatory protein 
expression. Res Het only showed enhanced damage mediated protein expression. 
6.7.6 Western blotting of retinal homogenate  
Western blotting of Het and res Het retinal homogenate was analysed for Opa1, neuroglobin and 
preli expression. Western blotting for Opa1 expression in retinal protein homogenate in 
untreated Het had 0.92±0.11 and res treated Het retina had 0.54 ±0.1 which was significantly 
reduced compared to untreated Het (F(3,12) 7.895 p=0.005). Neuroglobin expression of retinal 
homogenate from untreated Het had 0.82±0.19 and res Het retina had 0.92±0.18 which was not 
significantly different to untreated Het (p=0.484). Western blotting for preli expression in 
retinal homogenate of untreated Het was 0.57±0.16. Res treated Het retina had 0.42±0.0.2 
which was significantly reduced compared to untreated Het (F(3,12) 5.115 p=0.032). Figure 
6.18 (A-D) shows representative bands from Western blot gels. 
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Figure 6.18 Western 
blotting of retinal 
homogenate in 
untreated and res Het 
Images show 
representative bands 
from Western blotting of 
retinal homogenate from 
untreated Het (n4) and 
res treated Het (n4) for 
(A) Opa1 (B), 
neuroglobin (C) preli. 
Lower bands show  
actin as a loading 
control. 
 
 
 
 
 
Western blot results demonstrated that preli had two isoforms 28kDa and 31kDa in untreated 
Het retina.  Res Het retina appeared to have reduced 31kDa sized band. Neuroglobin had two 
isoforms 17kDa and 20kDa. Res Het retina appeared to have both isoforms in equal proportion. 
Untreated Het had a higher proportion of 17kDa only. 
Figures 6.19- 6.24. Show representative images of retinal protein expression in untreated, res 
and veh Het. 
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Figure 6.19 Opa1 protein expression in untreated res and veh  treated Het retina 
Representative images of Opa1  expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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Figure 6.20 VDAC protein expression in untreated res and veh  treated Het retina 
Representative images of VDAC expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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Figure 6.21 Preli protein expression in untreated res and veh  treated Het retina 
Representative images of Preli  expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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Figure 6.22 Neuroglobin protein expression in untreated res and veh  treated Het retina 
Representative images of Neuroglobin  expression in Het (A), res Het (B) and veh Het 
(C) retinal sections. Negative control sections (omission of primary antibody) for Het 
(D), res Het (E) and veh Het (F) are shown. 
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Figure 6.23 PSD95 protein expression in untreated res and veh  treated Het retina 
Representative images of PSD95  expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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Figure 6.24 NF l protein expression in untreated res and veh  treated Het retina 
Representative images of NFL expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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6.7.7 Mitochondrial protein expression in brain of untreated and treated Het 
Table 6.17 shows a summary of the results of brain IHC for all antibodies tested in tissue 
sections from untreated, res and veh Het. Figure 6.25 shows graphs representing the mean 
±SEM AFU of these data.  
Table 6.17 Results of protein expression in brain of untreated res and veh  Het 
 
Table shows the mean 
(±SEM) of mitochondrial 
(A) Opa1 (B) VDAC 
(C)Neuroglobin (D)Preli 
€PSD95 and (F) NF H  in 
brain of untreated, res and 
veh Het. The statistical 
difference between groups 
is represented by the  p 
value. 
 
 
 
 
Figure 6.25 Protein expression in 
brain of untreated res and veh 
Het. 
Graphs show the mean ± SEM AFU 
of (A) Opa1, VDAC, Preli (B) 
neuroglobin, PSD95, NF H in brain 
sections of untreated res and veh 
Het. 
 
Compared to untreated Het, Opa1 expression was unchanged in res Het (p=0.582) and in veh 
Het (p=0.159). VDAC expression was reduced by 41% in res Het which was significantly 
different compared to untreated Het (F(5,24) 2.223 p=0.005). Veh Het had a 32% reduction 
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which was also significantly different compared to untreated Het (p=0.017). Preli expression in 
untreated Het was not significantly different in res Het (p=0.813) or veh Het (p=0.723). 
Compared to untreated Het, Neuroglobin expression was significantly reduced by 86% in res 
Het brain(F(5,19) 5.086 p=0.001), and was not statistically different to untreated Het in veh Het 
brain (p=0.054). Compared to untreated Het, PSD95 expression in res Het had a significant 
909% increase (F5,27) 15.381 p=0.001). Veh Het was not significantly different to untreated 
Het(p=0.761).  Neurofilament expression was unchanged in res Het brain (p=0.635), but veh 
Het showed a significant 88% reduction (F(5,25) 6.683 p=0.001). 
6.7.8 Western blotting of untreated and res Het brain homogenate 
Western blotting of Het and res Het brain homogenate was analysed for Opa1, neuroglobin and 
VDAC expression. Western blotting of brain homogenate for Opa1 protein showed untreated 
Het had 0.983±0.105 RD and res treated Het brain had 0.930±0.10 RD which was not 
significantly different to untreated Het (p=0.446). Western blotting in untreated Het brain for 
neuroglobin had 0.95±0.15 RD. Res treated Het brain had 0.93±0.07 which was not statistically 
different compared to untreated Het (p=0.076). Western blot of brain homogenate for VDAC 
expression in untreated Het brain was 0.836±0.070 RD. Res treated Het brain had 0.735±0.082 
which was not significantly different compared to untreated Het (p=0.372). Figure 6.26 shows 
representative bands from Western blot gels. 
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Figure 6.26 Western blotting of brain 
homogenate in untreated and res Het 
Western blots show representative bands 
from  brain homogenate of untreated Het 
(n4) and res treated Het (n4) for (A) 
Opa1, (B) neuroglobin and (C) VDAC. 
Lower bands show  actin as a loading 
control. 
 
 
 
 
 
The ratio of compensation to damage 
mediated protein expression  in brain was examined. In untreated Het the ratio was 0.77. In res 
treated Het the ratio was 2.26. Veh Het ratio was 0.40. This suggested that res Het was not 
compensating for an excess of damage mediated protein expression. 
Figures 6.27- 6.6.32 show representative images of IHC in brain for all the antibody staining 
reported. 
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Figure 6.27 Opa1 expression in brain of untreated res and veh Het 
Representative images of Opa1 expression in (A) untreated Het (B) res Het and (C) veh 
Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  were 
processed without primary antibody. 
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Figure 6.28 VDAC expression in brain of untreated res and veh Het 
Representative images of VDAC expression in (A) untreated Het (B) res Het and (C) 
veh Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  
were processed without primary antibody. 
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D Het Control Het merge Het Hoechst
E res Het Control res Het merge res Het Hoechst
F veh Het Control veh Het merge veh Het Hoechst
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Figure 6.29 Preli  expression in brain of untreated res and veh Het 
Representative images of Preli  expression in (A) untreated Het (B) res Het and (C) veh 
Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  were 
processed without primary antibody. 
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Figure 6.30 Neuroglobin  expression in brain of untreated res and veh Het 
Representative images of Neuroglobin  expression in (A) untreated Het (B) res Het and 
(C) veh Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  
were processed without primary antibody. 
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Figure 6.31 PSD95 expression in brain of untreated res and veh Het 
Representative images of PSD95  expression in (A) untreated Het (B) res Het and (C) 
veh Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  
were processed without primary antibody. 
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Figure 6.32 NF h expression in brain of untreated res and veh Het 
Representative images of NF h  expression in (A) untreated Het (B) res Het and (C) veh 
Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  were 
processed without primary antibody. 
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Het PRL ONL OPL INL IPL GCL Ave
Mito 29 135 21 92 80 15 62
Comp 44 185 35 150 125 38 96
Dam 95 62 131 178 64 4.2 89
resHet PRL ONL OPL INL IPL GCL Ave
Mito 49 25 -7 2 -7 -22 7
Comp 40 41 -10 14 8 -2 15
Dam 168 213 303 418 89 42 206
vehHet PRL ONL OPL INL IPL GCL Ave
Mito 19 18 5 26 27 -7 14
Comp 12 43 6 37 62 11 29
Dam 94 86 119 428 24 -15 123
Brain Mito Comp Dam Ret Mito Comp Dam
Het 46 118 119 Het 55 89 63
rHet 24 26 274 rHet 23 16 150
vHet 26 26 -35 vHet 14 26 65
6.7.9 Discussion of mitochondrial protein expression in res treated brain and retina 
The percent difference observed in retinal layers was examined for each protein profile in res 
and veh Het sections.  In order to determine the extent of change, all the data was compared to 
untreated WT as this was the standard to which any potential therapy aspired to.  Table 6.18 
shows a summary of the percentage difference in untreated res and veh Het retinal layers 
compared to untreated WT. 
Table 6.18 Percentage change in retinal protein expression compared to WT 
 
Table shows the percentage change observed in retinal 
layers of protein expression in untreated res and veh 
Het retina. The percentage change in the whole retina 
and brain is included. 
 
 
 
Compared to untreated WT, mitochondrial specific proteins of untreated Het had a 63% 
increase. The ONL had the highest increase with 135% and the GCL had the least with 15%. 
Compensation protein expression was increased by an average 96%.  The ONL showed the 
highest increase with 185% and the OPL with the least of 35%. Damage mediated protein 
expression was increased by 89%. The INL had the highest percent increase with 178%. The 
GCL had the least damage with 4% increase. 
Res Het had an average of 7% increase in mitochondrial proteins. This was observed in the PRL 
only. The GCL had the highest reduction of mitochondrial proteins with a 22% loss compared 
to untreated WT. Compensation protein expression in res Het has an average 15% increase. The 
ONL had the highest with 41% and the GCL had the least with a 2% reduction. Damage 
mediated protein expression was increased by 206% in res Het retina. The INL had the highest 
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increase with 418%. The GCL had the least increase in damage protein expression with a 42% 
increase.  
Vehicle treated Het retina had an average 14% increase in mitochondrial protein expression 
compared to WT. The INL had the highest increase with 26%. The GCL had a reduction of 7%. 
Compensation protein expression in veh Het showed a 29% increase in expression with the IPL 
showing the highest increase with 62%.The OPL had the least percent change with 6% increase. 
Damage mediated protein expression in veh Het had a 123%increase in expression. The INL 
had the highest with 428% increase and the GCL showed a 15% reduction compared to 
untreated WT.  
The mean percentage change in retina and brain is shown in Figure 6.33. It demonstrates that res 
treated Het had increased damage mediated protein expression with reduced compensation in 
both brain and retina. As vehicle treated Het protein profile showed, there was a substantial 
reduction in compensatory protein expression but without the increased damage protein 
expression suggesting that veh Het may have less oxidative stress. 
 
Figure 6.33 Protein profiles of untreated res and veh Het brain and retina 
Graphs show the mean± SEM AFU of mitochondrial, compensation and damage 
mediated protein expression in (A) retina and (B) brain of untreated , res and veh Het. 
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The effects of resveratrol minus vehicle demonstrated that compared to untreated Het, 
mitochondrial protein in brain was unchanged, damage mediated proteins increased by 141%  
and compensation proteins reduced by 1%.  Retinal mitochondrial protein in res Het showed a 
7% increase in mitochondrial related protein expression with a 51% increase in damage proteins 
and a reduction of 6% in compensation proteins. The ratio of compensation to damage mediated 
proteins was lost in both tissues. 
Cultured glioblastoma (glioma stem cell) in the presence of resveratrol increased the expression 
of neurofilament  (Sato et al. 2013).  There are reports of antioxidant activity and the reduction 
of neurofilament expression suggesting that protection was conferred on cultures cells following 
damage. Ladostigil was observed to confer protection in aged rats (Weinreb et al. 2007). Direct 
application of antioxidant therapy as an intravitreal injection attenuated retinal degeneration 
with respect to protein expression.   Epigallocatechin gallate, the active ingredient of green tea 
reduced the expression of sodium nitroprusside induced neurofilament in photoreceptor (Zhang 
and Osborne 2006).  Dietary supplementation in canine age related neurodegeneration reduced 
neurofilament expression (Opii et al. 2008). 
PSD95 expression in Alzheimer’s  hippocampal neuronal cell culture reduced the expression of 
PSD95 which supports the findings reported Rege. Pre-treatment of rats with resveratrol protect 
them against morphine induced neuroinflammation with reduced PSD95 expression (Tsai et al. 
2012). Treatment of a mouse model of Alzheimer’s disease reduced the expression of PSD 95  
(Porquet et al. 2013). 
Resveratrol appeared to have specific adverse effects within the retina where there was a 
significant increase in damage mediated protein expression without the potentially protective 
effect of compensatory proteins. This was possibly due to the enhanced H202 mediated damage   
initiated by increased MnSOD activity. 
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 Brain SC  Retina
Het 8 Het 7 Het 4
rHet 6 rHet 3 rHet 3
vHet 6 vHet 3 vHet 0
 
6.8 Endogenous antioxidants in res treated Opa1Q285STOP mouse 
6.8.1 Catalase activity in res treated Het  
Catalase activity in untreated Het showed a reduction in spinal cord and retina of 40% and 30% 
respectively. Brain catalase was reduced by 8%.  The effects of resveratrol on catalase activity 
in Het brain, spinal cord and retina were examined. 
6.8.1.1 Results of catalase activity in res treated Het 
For catalase analysis the assay was performed as described in Chapter C5 section 1.2. 
 
Table 6.19 Summary of test samples for catalase activity in 
untreated res and veh Het 
 
The catalase activity in untreated Het brain homogenate  had 3.50±0.31 units/mg. Res Het brain 
homogenate had 4.60±0.34 units/mg which was not significantly different to untreated Het 
(p=0.077). Catalase activity in veh Het brain homogenate had 1.70±0.34 units/mg. which was 
statistically reduced compared to untreated Het brain (F(5,31) 7.995  p=0.001).  
The catalase activity in spinal cord homogenate of untreated Het had 1.70±0.25 units/mg. Res 
Het had 2.20±0.40 units/mg which was not statistically different to untreated Het (p=0.278) and 
veh Het had 2.70±0.12 units/mg which was significantly increased compared to untreated Het 
(F5,18) 10.902 p=0.043).  
The catalase activity in untreated Het retinal homogenate was 2.10 ±0.35 units/mg and res Het 
(n3) had 1.0 ±0.12 units/mg which was significantly reduced compared to untreated Het 
(F(3,10) 9.156  p=0.007). 
The kinetic reactions of the catalase assay are shown in Figure 6.34 and a graphical 
representation of catalase activity in shown in Figure 6.35. 
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Figure 6.34 Kinetics of  H2O2 decomposition in Het, res and veh treated Het 
Representative kinetics of H202 decomposition in the presence of 80g tissue homogenates from 
WT, Het, res Het and veh Het brain  (A) Brain, spinal cord (B) and retina (C). 
 
Figure 6.35 Catalase activity in tissue 
homogenate of untreated and treated 
Het. 
Graph showing the mean ±SD catalase 
activity per mg tissue homogenate from  
Het, res Het and veh Het brain, spinal 
cord (SC) and retina (Ret).  
 
 
 
6.8.1.2 Discussion of catalase activity in res treated Het 
The catalase activity in res Het brain homogenate was enhanced by 23% compared to untreated 
Het. Res spinal cord homogenate was enhanced by 29% compared to untreated Het. Retinal 
catalase activity was reduced by 52% compared to untreated Het. 
Catalase activity in veh Het brain homogenate showed a 74% reduction compared to untreated 
Het. Veh Het spinal cord homogenate had a 29% increase compared to untreated Het. 
Catalase activity in retinal homogenate of res Het was reduced by 53% compared to untreated 
Het and 73% compared to untreated WT. Untreated Het retinal catalase activity was reduced by 
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 Brain SC  Retina
WT 6 WT 4 WT 6
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10.34 22.66 14.12 0.63 30.71 31.41 1.59 1.23 0.76
0.15 1.57 1.51 0.12 1.19 1.61 0.54 0.46 0.02
Het:rHet 0.001 0.001 0.385
Het:vHet 0.001 0.001 0.108
rHet:vHet0.001 0.001 0.353
F(5,12) 32.430 F(5,12)105.37 F(5,1)8.912
MnSOD Het rHet vHet Het rHet vHet Het rHet vHet
0.409 2.651 0.651 0.007 0.201 0.016 0.164 0.256 0.074
0.049 0.533 0.125 0.001 0.017 0.002 0.097 0.108 0.004
Het:rHet 0.001 0.001 0.340
Het:vHet 0.494 0.712 0.448
rHet:vHet0.001 0.001 0.131
F(5,12) 48.676 F(5,12)22.619 F(5,1)3.743
CuZnSOD Het rHet vHet Het rHet vHet Het rHet vHet
1.645 1.788 1.466 0.132 0.792 0.162 0.247 0.069 0.082
0.219 0.134 0.057 0.013 0.137 0.008 0.080 0.017 0.008
Het:rHet 0.478 0.013 0.002
Het:vHet 0.377 0.771 0.029
rHet:vHet0.125 0.053 0.804
F(5,12) 257.825 F(5,12)15.439 F(5,1)10.892
43% compared to WT, however the further 29% reduction in res Het treated retina would 
suggest that resveratrol has exerted a negative influence on H2O2 decomposition. 
6.8.2 SOD activity in res treated Opa1Q285STOP mouse 
6.8.2.1 Introduction to SOD assay in res treated Het 
An increase in MnSOD  activity with administration of resveratrol has been well publicised 
(Robb et al. 2008a; Robb et al. 2008b; Danz et al. 2009; Ryan et al. 2010; Mojica-Villegas et al. 
2014; Robb and Stuart 2014) The SOD assay was performed as previously described. 
6.8.2.2 Results of SOD assay in res treated Het 
Table 6.20 Summary of test samples for SOD analysis 
in untreated, res and veh Het 
  
 
Table 6.21 shows a summary of SOD activity in untreated Het, res and veh Het brain, spinal 
cord and retinal homogenate for total SOD, MnSOD and CuZnSOD. The kinetic reactions of 
the SOD assay are in Appendix N and the calculations for line fittings used are in Appendix O. 
Figure 6.36 shows graphical representations of these data. 
Table 6.21 Summary of SOD analysis in 
untreated, res and veh Het 
Table shows a summary of total SOD, MnSOD 
and CuZnSOD activity in Het, res and veh Het 
brain, spinal cord (SC) and retinal (Ret) 
homogenate. The statistical difference (p value) 
between groups is shown with the percentage 
change compared to untreated Het. 
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Figure 6.36 SOD units of activity in tissue 
homogenate of untreated and treated Het. 
 
(A)Graph showing the mean  ±SD of total SOD 
activity of Het, res Het and veh Het in brain, 
spinal cord (SC) and retinal (Ret) homogenate. 
 
 
 
(B) Graph showing the mean  ±SD of MnSOD 
activity in tissue homogenate brain, spinal cord 
(SC) and retina (Ret) in untreated Het, res Het and 
veh Het. 
 
 
 
(C)Graph showing the mean ±SD of CuZnSOD 
activity in untreated Het, res Het and veh Het 
brain, spinal cord (SC) and retina (Ret). 
 (p=0.004). 
  
  
 
6.8.2.3 Discussion of SOD activity in res treated Het 
Due to the profound reduction in untreated Het spinal cord SOD activity, the average percent 
changes observed in res and veh Het were examined according to tissue type homogenate.  
Compered to untreated Het, brain homogenate in res Het had a 225% increase in SOD activity. 
This was due to the 548% increase in MnSOD activity. Res Het spinal cord homogenate showed 
a 2681% increase in SOD activity compared to untreated Het. MnSOD activity was increased 
2780% and CuZnSOD activity was increased 498%. Retinal homogenate in res Het showed a 
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reduction of 13% compared to untreated Het. CuZnSOD activity was reduced by 72%.  MnSOD 
activity was increased by 56%.  
Compared to untreated Het, veh Het brain homogenate had a 28% increase in SOD activity. 
Spinal cord homogenate had a 1674% increase in SOD activity compared to untreated Het.  
Retinal homogenate in veh Het had a 58% reduction in SOD activity compared to untreated Het. 
On examining the original data where the inhibition of formazan formation results in a change 
in absorbance, the percentage inhibition with the combined MnSOD and CuZnSOD should have 
been equal to the percent inhibition obtained with total SOD. In untreated Het brain there was 
23%±6 non-SOD activity. In res Het there was 7%±4 non-SOD which was significantly reduced 
compared to untreated Het (F(5,30) 25.624 p=0.001). Veh Het brain homogenate had 25%±5 
non-SOD activity which was not significantly different compared to untreated Het (p=0.672). 
Spinal cord homogenate in untreated Het had 35%±2 non-SOD activity , res Het had 7%±2 non-
SOD which was significantly reduced compared to untreated Het (F5,20) 19.228 p=0.001). Veh 
Het had 49%±2 non SOD activity which was significantly increased compared to untreated Het 
(p=0.030). Retinal homogenate in untreated Het  had 21%±2  non-SOD activity. Res Het had 
23±5 which was not significantly different compared to untreated Het (p=0.536). Veh Het had 
23%±1 which was  not significantly different  compared to untreated Het (p=0.603). Figure 6.37 
summarises this observation. 
 
Figure 6.37 Non-SOD inhibition of 
formazan formation in Het 
homogenates 
Graph showing the mean ±SEM of non-
SOD activity in untreated, res and veh Het 
tissue homogenate. Res Het brain and 
spinal cord homogenate had significantly 
less non SOD activity compared to 
untreated Het. Veh Het spinal cord 
homogenate had a significantly higher 
percentage of non-SOD activity compared 
to untreated Het. 
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6.8.3 Antioxidant index in res treated Opa1Q285STOP mouse 
As discussed in Chapter 5 Section 5.1.3, the combined changes observed in catalase activity and 
SOD were used to establish an antioxidant profile specific for tissue type. In res treated Het 
brain AO index was 171.  This was due to the increase in brain MnSOD. Spinal cord AO index 
in res Het was 1089.  Retinal AO index in res Het was reduced to minus 23 due to a reduction in 
all but MnSOD activity. The tissue specific AO profile index in res Het was 715. Vehicle 
treated Het brain AO index was 5. Spinal cord AO index was 51 and retinal AO index was 
reduced to minus 61 due to the combined reduction of all AO activity observed. The tissue 
specific AO profile index in veh Het was minus 408. 
The effect of vehicle treatment was obtained by subtracting the fold changes observed in veh 
Het antioxidant activity. The effects of resveratrol on the antioxidant status of Het showed a 7% 
reduction of catalase activity compared to untreated Het. CuZnSOD activity was increased by 
163% and MnSOD activity increased 1066%. Res treated Het brain had an AO index of 145, 
spinal cord had an AO of 751 and retinal AO index was 21. The AO index of res Het was 306. 
Figure 6.38 shows a summary of this. 
Figure 6.38 AO profile in res treated Het  
Line graph representing the percent changes in res 
treated Het compared to untreated Het (represented 
by blue line). All res Het homogenates showed an 
increase in AO activity. Spinal cord had the highest 
increase of 751%. Antioxidant activity showed 
catalase activity was marginally reduced, 
CuZnSOD activity increased 163% and MnSOD 
activity was increased 10.85 fold compared to 
untreated Het. 
 
6.8.4 MnSOD protein expression in res treated Opa1Q285SSTOP mouse 
6.8.4.1 Introduction 
As described previously immunohistology was performed using MnSOD antibody on untreated 
Het (n4), res Het (n4) and veh Het (n4) retina and brain sections. Western blotting was 
performed on untreated Het (n4) and res Het (n4) retinal  and brain homogenate.  
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6.8.5 Results of MnSOD protein expression in untreated res and veh Het retina 
Table 6.22 shows a summary of the MnSOD expression in the retina of untreated Het res and 
veh Het.  Figure 6.39 (A) shows the mean AFU for MnSOD expression in untreated, res and 
veh Het retina. Figure 6.39 (B) shows the mean AFU for MnSOD expression in untreated, res 
and veh Het brain. 
Table 6.22 Summary of MnSOD protein expression in untreated and treated Het retina 
 
Table shows the mean (±SEM) of retinal mitochondrial expression of MnSOD in 
untreated, res and veh treated Het. The statistical difference between groups is 
represented by p value. 
 
IHC of brain in untreated Het had 558±92AFU. Res treated Het had 1806±351 which was 
significantly increased compared to Het (F(5,32) 6.913 p=0.006). Veh Het had 789±87 which 
was not significantly different to untreated Het. Figure 6.39 (B) shows this data. 
 
Figure 6.39 MnSOD 
expression in 
untreated, res and 
veh Het retina and 
brain 
Graph shows the 
mean ±SEM of 
MnSOD expression in 
Het, res Het and veh 
Het  (A)retinal layers 
and (B) Brain. 
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Western blotting of brain homogenate in untreated Het had 0.86±0.12 and res Het had 
0.95±0.21 (p=0.229). Retinal homogenate in untreated Het had 1.06±0.09 and res Het had 
1.60±0.11 which was significantly increased compared to Het (F(3,12) 1.591 p=0.003). Figure 
6.40 shows representative bands from Western blotting. 
Figure 6.40 MnSOD protein in brain and 
retinal homogenate of untreated and res 
Het 
Images show representative bands from 
Western blotting of (A) brain and (B) retinal 
homogenate from untreated Het (n4) and res 
treated Het (n4) for MnSOD. Lower bands 
show  actin as a loading control. 
 
Figures 6.41 and 6.42 show representative images of MnSOD expression in retina and brain 
from untreated res and veh Het. 
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Figure 6.41 MnSOD expression in untreated res and veh treated retina 
Representative images of MnSOD expression in Het (A), res Het (B) and veh Het (C) 
retinal sections. Negative control sections (omission of primary antibody) for Het (D), 
res Het (E) and veh Het (F) are shown. 
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Figure 6.42 MnSOD expression in untreated res and veh treated brain 
Representative images of MnSOD expression in (A) untreated Het (B) res Het and (C) 
veh Het  brain.  Control sections for (D) untreated Het (E) res Het and (F) veh Het  
were processed without primary antibody. 
 
 
 
A Het MnSOD Het merge Het Hoechst
B res Het MnSOD res Het merge res Het Hoechst
C veh Het MnSOD veh Het merge veh Het Hoechst
D Het Control Het merge Het Hoechst
E res Het Control res Het merge res Het Hoechst
F veh Het Control veh Het merge veh Het Hoechst
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6.8.5.1 Discussion of SOD activity in res treated Het 
6.8.5.1.1 MnSOD expression in retina 
Res Het retinal tissue showed a mean 35% increase in retinal layers. Western blotting showed a 
48% increase compared to untreated Het. The res Het retinal homogenate MnSOD assay 
showed a 56% increase compared to untreated Het. This suggested that all the available 
MnSOD was functional. Veh Het retinal MnSOD expression was reduced by 47% compared to 
untreated Het. The MnSOD assay showed a reduction of 56% compared to untreated Het. This 
suggested that 9% of MnSOD in veh Het was non-functional. 
6.8.5.1.2 MnSOD expression in brain 
MnSOD activity was investigated by IHC and Western blotting where there was a significant 
increase in protein expression compared to untreated Het. Previously, MnSOD activity was 
examined in brain homogenate where it showed a 570% increase in activity. The increase in 
protein deposition combined with increased dismutation suggested that the surplus MnSOD was 
functional. Veh Het MnSOD expression was increased by 41% compared to untreated Het.  
MnSOD activity in the inhibition of formazan showed veh Het had 63% more activity compared 
to untreated Het. This suggested that the expressed MnSOD was functional. 
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6.8.6 3 Nitrotyrosine deposition in untreated res and veh Het retina 
Table 6.23 shows a summary of 3 nitrotyrosine deposition in the retinal layers of untreated res 
and veh Het. 
Table 6.23 3Nitrotyrosine deposition in retinal layers of untreated res and veh Het 
 
Table shows the mean (±SEM) of 3 Nitrotyrosine deposition in retinal layers of 
untreated res and veh Het. Statistical difference between groups is represented by the  p 
value. 
3 nitrotyrosine deposition was examined in brain sections. Untreated Het had 1561±275 AFU. 
Res Het had 477±98 which was significantly reduced (F(5,30) 7.919 p=0.001).  Veh Het had 
286±44 which was also significantly reduced (p=0.001). Figure 6.43 shows a summary of 3 
nitrotyrosine deposition in retina (A) and brain (B) of untreated res and veh Het. 
 
Figure 6.43 3 Nitrotyrosine deposition in untreated res and veh Het 
Graph shows the mean ±SEM of 3 nitrotyrosine deposition   in Het, res Het and veh Het  
(A)retinal layers and (B) brain. 
Figures 6.44 show representative images of 3 nitrotyrosine deposition in retinal l sections and 
Figure 6.45 shows same in brain sections expression in retina and brain from untreated res and 
veh Het. 
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Figure 6.44 3 Nitrotyrosine deposition in untreated res and veh Het retina 
Representative images of 3 nitrotyrosine deposition in Het (A), res Het (B) and veh Het 
(C) retinal sections. Negative control sections (omission of primary antibody) for Het 
(D), res Het (E) and veh Het (F) are shown. 
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Figure 6.453 Nitrotyrosine deposition in untreated res and veh Het brain 
Representative images of 3 nitrotyrosine deposition in (A) untreated Het (B) res Het 
and (C) veh Het brain.  Control sections for (D) untreated Het (E) res Het and (F) veh 
Het  were processed without primary antibody. 
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The presence of 3 Nitrotyrosine was significantly reduced in res Het compared to untreated Het. 
In the INL there was a significant 73% reduction (F(5,12) 1.415 p=0.048) which was not 
present in veh Het INL (p=0.196). Res Het IPL showed a 69% reduction of 3 Nitrotyrosine 
deposition which was also significant (F(5,12) 1.402 p=0.047) and was not present in the veh 
Het IPL (p=0.249). The GCL of res Het had a 77% reduction in the presence of nitrotyrosine 
(F(5,12) 4.201 p=0.001) . This was also present in veh Het with a  66% reduction (p=0.004). 
3 Nitrotyrosine deposition was significantly reduced in brain of both res and veh Het. Res Het 
had a 70% reduction (F(5,30) 7.919 p=0.001) and veh Het had 81% less 3Nitrotyrosine 
compared to untreated Het. 
The ratio of 3 Nitrotyrosine to MnSOD was examined in the retinal layers. The ratios obtained 
were compared to WT.  The mean ratio in WT was 0.31. Untreated Het had a ratio of 1.03. Res 
Het ratio was 0.45 and veh Het ratio was 1.75. This meant that although the deposition of 3 
Nitrotyrosine in veh Het may not have been significantly more compared to untreated Het, the 
combined reduction of MnSOD resulted in significantly more oxidative stress. The ratio in WT 
brain was 0.31. Untreated Het brain was 1.03. res Het ratio was 0.45 and veh Het 1.75. Figure 
6.46 summarises these data. 
 
Figure 6.46 Ratio of MnSOD to 3 
Nitrotyrosine in res retina and brain 
Line graph showing the ratio of 
MnSOD to 3 nitrotyrosine in 
untreated, res and veh retinal layers 
and brain. The percentage difference 
compared to untreated WT is shown. 
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6.8.7 Summary of Chapter 6: Trial of resveratrol in Opa1Q285STOP mouse 
Brain weight was significantly reduced in res treated female Het mice. Cardiac weight ratio was 
also significantly reduced.  
6.8.7.1 Neuromuscular anomalies in res treated Opa1Q285STOP mouse 
There was a significant reduction in neuromuscular function as seen in rotarod testing. This was 
seen in female resveratrol and vehicle treated female Het mice. Resveratrol treated male Het 
showed no housing dependent change in rotarod performance. Resveratrol treated Het mice 
appeared to have reduced fear conditioning which was evident in rope and beam testing. There 
was no significant difference in learning skills in res treated Het mice.  
6.8.7.2 Cognitive function in Opa1Q285STOP mouse 
Spontaneous alternation testing of resveratrol treated Het demonstrated a significant increase in 
investigation and discrimination ratio which was not observed in vehicle treated Het.  Novel 
object recognition testing did not reveal any significant difference between untreated and 
resveratrol treated Het mice. 
6.8.7.3 Bioenergetic impairment in res treated Opa1Q285STOP mouse 
Resveratrol treated Het showed a significant increase in complex I activity by 24% at the 
expense of complex II. Complex IV activity was increased by 40% compared to untreated Het.  
CNS specific effects were observed in all tissues examined with the brain showing the greatest 
reduction in ETC activity.  
6.8.7.4 Antioxidant activity in res treated Opa1Q285STOP mouse 
Resveratrol treated Het had a significant increase in MnSOD activity which had a potential 
negative influence on catalase activity.  Res Het spinal cord showed the greatest enhancement to 
AO activity.   The combined changes in antioxidant activity in a reduced catalase environment 
may be detrimental to mitochondrial survival.  
6.8.7.5 Protein profile expression in Opa1Q285STOP mouse 
Resveratrol treated tissues showed an increase in mitochondrial related protein expression in 
both brain and retina. Retina specifically showed enhanced damage mediated protein 
expression. Both brain and retina showed significantly reduced compensatory protein 
expression compared to untreated Het. 
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The effects of resveratrol administration were compounded by the presence of ethanol which 
itself resulted in alterations of both In Vivo and In Vitro measured parameters. There were no 
significant improvement in neuromuscular function or cognitive performance save for an 
enhanced fear response. This would be considered disadvantageous to any mouse as it is likely 
to result in a reduced life span.  Bioenergetic changes resulted in enhanced activity but the 
specific ratios of activity were significantly disturbed in the res Het mouse for complex II 
(retina) which was also observed in veh Het. The ratio for complex IV activity in Het spinal 
cord was significantly disturbed in the res treated but not the veh treated Het mice. This 
suggested that resveratrol was enhancing the electron transport function at a cost to the 
mitochondria of the spinal cord and resulting periphery. Enhanced MnSOD activity in the res 
Het mitochondria was possibly responsible for enhancing the concentration of H2O2 but in the 
presence of reduced catalase activity would prove detrimental to mitochondrial function.  
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Chapter 7 Paradoxical effects of resveratrol in WT C57BL/6  
7.1 Introduction 
The resveratrol study was a three-armed trial. The inclusion of wild type (WT) mouse was 
incorporated with vehicle treated WT to extend a comprehensive analysis of the effects of resveratrol. 
Resveratrol was given to a total of 26 WT mice (14 female and 12 male). For the vehicle arm of the 
trial, a total of 12 WT were treated (6 female and 6 male). The resveratrol treated and vehicle treated 
WT mice were housed with Het cage mates and testing conditions for all experiments were performed 
concurrent with Het treated. As all previous techniques have been described in the previous chapters, 
all that remains are the results of the data collected. All resveratrol treated WT are called res WT and 
vehicle treated WT as veh WT. Mice were given resveratrol at a concentration of 219.06mM in their 
drinking water. Vehicle treated mice were given ethanol at a concentration of 17mM. Mice were 
examined thoroughly for any adverse effects including gastro intestinal disturbances that might 
indicate the presence of emodin at greater than acceptable concentration. The bottled water containing 
resveratrol required replacement at 24 hour intervals which also provided an opportunity to examine 
the mice for signs of stress. The trial design is available in Appendix C. 
7.2 Health monitoring in res treated WT 
7.2.1 Introduction 
The health and safety of all participants on the resveratrol trial was paramount. Monitoring of weight 
was considered an excellent indicator of general health. The weekly post weaned weights of res treated 
WT was discussed in Chapter 6 section 6.2.1.2. The monthly weight checks continued to 15 months. 
7.2.1.1 Results of weight monitoring at 15 months 
All female mice treated and untreated were housed in groups. Male untreated and treated were kept as 
group housed where possible. Individual housed males were either isolated for breeding purposes or 
because of in cage harassment. Where possible the assailants were removed to solitary quarters. 
Weights were analysed according to housing conditions in male mice only. Both untreated and res 
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n Body weight Brain weight Cardiac ratio
(g) (g)
FWT 25 27.7 ±1.7 0.59 ± 0.18 0.62 ± 0.14
rFWT 13 32.2 ± 5.9 0.42 ±0.05 0.55 ± 0.08
vFWT 6 28.7 ± 3.1 0.42 ±0.03 0.71 ± 0.33
FWT:rFWT 0.001 0.001 0.050
FWT:vFWT 0.525 0.009 0.180
rFWT:vFWT 0.057 0.421 0.006
F(11,191) 9.866 2.725 1.935
S sMWT 4 34.0 ±2.6 0.490±0.08 0.52±0.08
O srMWT 6 34.8 ±1.5 0.438±0.05 0.60±0.05
H L sMWT:srMWT 0.786 0.963 0.343
O O sMWT:gMWT 0.624 0.909 0.012
U srWT:grMWT 0.251 0.015 0.129
S G F(9,57) 1.043 1.037 2.565
I R gMWT 7 32.5±1.2 0.48±0.04 0.66±0.03
N O grMWT 6 37.3±1.5 0.43±0.05 0.54±0.03
G U gvMWT 6 35.3±1.5 0.40±0.05 0.71±0.05
P gMWT:grMWT 0.017 0.288 0.046
gMWT:gvMWT 0.163 0.257 0.336
rgMWT:gvMWT 0.358 0.755 0.340
F(9,57) 1.043 1.037 2.565
r=resveratrol  v=vehicle   s=solitary housed  g=group housed
treated males were both solitary and group housed. Veh treated male WT were housed in group cages 
only. Table 7.1 summarises the results showing the percentage difference between treated and 
untreated WT and the statistical p value.  
 Table 7.1 Body brain and cardiac weight 
ratio in untreated, res and veh WT 
 
Table showing weights in untreated, res and 
veh treated female and male WT at 15 months. 
The statistical p value is shown between 
groups.  
 
  
 
 
 
7.2.1.2 Discussion of weight at 15 months 
In the WT population there was a significant 16% increase in res treated female WT weight compared 
to untreated females(F(15,150) 6.471 p=0.001). Veh treated female Het had a 3% increase which 
suggested resveratrol was responsible for 13% of this increase. Both res treated and veh treated 
females showed a significant reduction in brain weight of 29% in res WT (F(15,150) 2.400 (p=0.001) 
and 28% in veh WT (p=0.009) compared to untreated female WT. Res treated females had a 
significant 13% reduction in cardiac weight ratio (F(15,150) 1.805 (p=0.025) compared to untreated 
females. Veh treated females had a 13% increase in cardiac weight ratio compared to untreated female 
WT which was not statistically significant (p=0.180). There was no significant difference observed 
between the solitary housed untreated and solitary housed res treated male WT. Solitary housed 
untreated male WT and group housed untreated male WT differed significantly in cardiac weight ratio 
(F(15,150) 1.805 (p=0.012) with group housed male WT showing a 28% increase. Solitary housed res 
treated male WT differed significantly to group housed res treated male WT in brain weight (F15,150) 
2.400 (p=0.015) where solitary housed had a 11% increase compared to group housed.  Group housed 
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male res treated weight was significantly increased by 15% compared to group housed male WT 
(F15,150) 6.471(p=0.017). Veh treated group housed males showed a non-significant 9% increase in 
weight compared to untreated group housed male WT (p=0.163). Group housed male brain weight was 
reduced by a significant 19% (F(15,150) 2.400 p=0.049) compared to untreated male WT. 
Resveratrol has been reported as showing no significant effect in body or organ weights mouse when 
administered at a concentration of 3g/kg in CD-1 mouse strain  (Kyselova et al. 2003). Dietary 
induced increased body weight and abdominal fat volume have been reduced with the addition of 
resveratrol (Baek et al. 2014). Resveratrol offers resistance to high fat induced obesity and insulin 
resistance (Lagouge et al. 2006; Jeon et al. 2014). The current literature supports the anti-obesity 
effects of resveratrol in multiple species including primates (Jimenez-Gomez et al. 2013; Roberts et al. 
2014), pig (Azorín-Ortuño et al. 2011),rat (Beaudoin et al. 2013; Nagao et al. 2013), mouse (Hogan et 
al. 2010; Kim et al. 2011) and even zebra fish  (Pardal et al. 2014). The doses range from 3mg/kg to 
200mg/kg. The only significant difference was the duration of therapy. Most studies ranged from two 
weeks to 16 weeks.  
The average brain weight in mouse is reported as 450g but C57Bl/6 brain weight is heavier than other 
lab mice (Wahlsten et al. 2006).  Any loss of weight can impact metabolic constraints and there exists 
functional correlates between brain weight and function (Williams et al. 1998). 
The cardiovascular protection conferred by resveratrol is presumed to be by mechanism including 
reduced platelet aggregation, improved endothelial function, and the reduction of myocardial fibrosis 
(Petrovski et al. 2011; Magyar et al. 2012; Hao et al. 2013; Soner and Sahin 2014). The application of 
cardiac weight as an indirect function of left ventricular hypertrophy suggests that a bulky muscle 
mass doesn’t equate to function. This would suggest that resveratrol provided cardio protection to the 
res treated WT where the presence of ethanol could have adverse effects. 
7.3 Neuromuscular impairment in res treated WT 
7.3.1 SHIRPA analysis in res treated WT 
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   Rotarod Analysis
F WT 11 M WT 8
rFWT 6 rMWT 5
vFWT 3 vMWT 0
sMWT 4 gMWT 5
rsMWT 3 rgMWT 3
s:solitary g:group  r:res v :veh
SHIRPA analysis was performed on six untreated WT and six res WT.  There were three males and 
three females in each group. Observations were made in the viewing jar, above the arena and in the 
arena. The total number of observations for each mouse was lower motor function was 11, 
cerebrospinal function 12, sensory 7, neuropsychiatric 8 and autonomic 17. 
7.3.1.1 Results of SHIRPA in res treated WT 
For lower motor function WT scored 0.06±0.03 and res WT scored 0.03±0.01(p=0.074). 
Cerebrospinal function in WT was 0.11±0.05 and res WT was 0.08±0.02 (p=0.161). Sensory function 
in WT was 0.04±0.01. res WT sensory function was 0.11±0.02 (p=0.053). Neuropsychiatric function 
was 0.13±0.03 in WT and 0.14±0.04 in res WT (p=0.074). Autonomic function in WT was 0.06±0.03 
and in res WT was 0.03±0.03 (p=0.055). (Appendix G contains raw data for SHIRPA analysis of res 
WT). 
7.3.1.2 Discussion of SHIRPA in res treated WT 
Analysis of lower motor function score showed a reduction of 52% compared to untreated WT. 
Cerebrospinal function score was less than 25% compared to untreated WT. The score in sensory 
function was increased by 200%. The result from three different observational recordings (in the 
viewing jar, in the arena and above the arena) was not statistically significant. Neuropsychiatric 
function score was reduced by 14% and autonomic function score reduced by 42% compared to 
untreated WT. 
7.3.1.3 Rotarod analysis in res treated WT 
Analysis of motor function and coordination was performed in res WT and veh WT. The number of 
animals tested is summarised in Table 7.2. 
7.3.1.4 Results of rotarod in res treated WT 
 
Table 7.2 Summary of test numbers for rotarod in WT res and veh 
WT 
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**
A B
n Rotarod p n Housing p
FWT 10 FWT:rFWT 0.002 sMWT 5 sMWT:srMWT 0.003
rFWT 6 FWT:vFWT 0.024 gMWT 5 sMWT:gMWT 0.006
vFWT 5 rFWT:vFWT 0.785 srMWT 5 gMWT:grMWT 0.488
MWT 7 MWT:rMWT 0.520 grMWT 6 rsMWT:grMWT 0.839
rMWT 7 F (4,28) 6.098 ±SD F(3,12) 3.897
*p<0.05**p<0.010***p<0.001 s:solitary    g:group   r:resveratrol
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Latency to fall in untreated female WT was 110±4 seconds.  In res WT latency was 74±4 seconds 
which was significantly reduced compared to untreated WT (F(4,28) 6.098 p=0.002). Veh WT female 
latency was 87±7 seconds which was also significantly different to untreated WT F(4,28) 6.098 
p=0.024). Male WT latency was 64±5 seconds. Res treated WT male latency was 60±3 seconds which 
was not significantly different to untreated WT (p=0.520). There was no significant difference in male 
res treated WT where housing conditions were previously seen to affect the performance of rotarod. 
Solitary housed male WT latency was 104±2 seconds and solitary housed res treated male WT latency 
was 58±5 seconds which was significantly reduced compared to untreated WT (F(3,12) 3.897 
p=0.003). Untreated group housed male WT latency was 50±7 seconds and group housed res treated 
male WT latency was 60±3 seconds which was not significantly different to untreated male WT 
(p=0.488). Figure 7.1 shows a graphical representation of this data. 
The effect of weight on latency to fall was considered. Untreated  female WT who weighed less than 
30g had a latency of 117±4 seconds. Res treated female WT who weighed less than 30g had a latency 
of 84±5 seconds which was significantly reduced compared to untreated female WT (F(7,262) 17.943 
p=0.002). Latency in untreated male WT who weighed less than 34g was 76±5 seconds and latency in 
res treated male WT who weighed less than 34g was 58±5 seconds which was significantly reduced 
compared to untreated male WT (p=0.036). 
Figure 7.1 Latency to fall in 
untreated, res and veh WT 
(A)Graphs show the mean ±SD of 
latency to fall from rotarod in 
female and male untreated res and 
veh treated WT. (B) Graph shows 
the mean ±SD of housing 
conditions and latency in 
untreated and res treated male 
WT. 
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WT 10 WT:rWT 0.004 WT 10 WT:rWT 0.024
rWT 8 WT:vWT 0.380 rWT 8 WT:vWT 0.019
vWT 3 rWT:vWT 0.010 vWT 3 rWT:vWT 0.070
F(2,16) 7.966 ±SD F(2,16) 6.680 ±SD
7.3.1.5 Discussion of rotarod in res treated WT 
In female res WT there was a reduction of 33% in latency compared to untreated WT. Veh treated 
female WT showed a 21% reduction compared to untreated WT. Solitary housed res treated male WT 
had a 45% reduction in latency to fall and group housed res treated male WT had an increase of 18% 
compared to group housed  untreated male WT. 
7.3.1.6 Results of narrow beam and in res treated WT 
 
Table 7.3 Summary of test numbers for beam and rope in WT 
 
In untreated WT, beam initiation was 4.8±1.2 seconds. In res WT initiation was 25±6 seconds. There 
was a significant increase in initiation time between untreated WT and res WT (F(2,16) 7.966 
p=0.004).  Vehicle treated WT beam initiation was 12±3 seconds which was not significantly different 
compared to untreated WT (p=0.380). Figure 7.2 A shows these data. 
7.3.1.7 Results of tight rope testing in res treated WT 
In the tightrope test, the distance travelled by untreated WT was 8.4±1.1/cm. The distance travelled by 
res WT was 4.1±1.6/cm which was significantly reduced compared to untreated WT (F(2.16) 6.680 
p=0.024). Veh WT travelled 4.3 ±0.3/cm which was significantly reduced compared to untreated WT 
(p=0.019). Figure 7.2B shows this data. 
 
Figure 7.2 Beam initiation and tight 
rope distance in untreated res and veh 
WT 
Graph showing mean ±SD of (A)narrow 
beam initiation to travel/seconds in 
untreated WT, res WT and veh WT. (B) 
Tightrope distance travelled/cm  in 
untreated WT, res treated WT and veh WT. 
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7.3.1.8 Discussion of narrow beam and tight rope testing in res treated WT 
In the narrow beam test the time to initiate travel down the beam was increased by 440% in the res 
WT population. The initiation time in res WT females was increased by1680% compared to untreated 
female WT. Veh treated WT female initiation was increased by 488%. The male res treated WT 
initiation time was increased by 93% compared to untreated male WT.  
In the tight rope test, the distance travelled by res female WT was reduced by 15% compared to 
untreated female WT and male res WT reduced by 79% compared to untreated male WT. Veh female 
had a 63% increase in distance travelled compared to untreated female WT.  
7.3.1.9 Fear conditioning in res treated WT and Het 
An increase in narrow beam initiation time was considered a symptom of anxiety in untreated Het 
mice. Res treated Het female initiation was 80% less than res treated female WT. Res treated Het male 
initiation was 26% less than res treated WT.  This suggested that res treated WT mice were more 
disturbed by the narrow beam test compared to res treated Het. Res treated female WT initiation time 
was a mere 18% better than untreated female Het. Res treated male WT initiation time was 364% 
faster than untreated male Het. 
Res treated female Het had a 192% increase in distance travelled compared to res treated WT. Res 
treated male Het had a 1162% increase in distance travelled compared to res treated male WT. This 
suggested that resveratrol had exerted significantly different effects  in the functioning brain of WT 
and Het. A clear reduction in fear conditioning in the res Het mice was not evident in res treated WT. 
7.3.1.10 Learning skills in res treated WT 
Learning skills were calculated as previously described. Essentially the ability to learn over a three day 
time period, the skills required to retain a position on the rotarod. This was a combination of modified 
body positioning with the incremental revs per minute and maintaining a simultaneous forward gait 
movement with both hind and fore paws. Also concentration on the task as distraction resulted in 
losing the pace of the rotarod. 
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7.3.1.11 Results of learning skills in res treated WT 
The learning skills in untreated female WT mice were 056 ±0.15. Resveratrol treated female WT 
learning score was 0.26±0.1 which was not significantly different compared to untreated WT 
(p=0.245). Female Veh WT scored 0.10 ±0.18 which was not significantly different compared to 
untreated WT (p=0.166).The learning score in untreated male WT was 0.34±0.18.Res treated male 
WT learning score was 0.20±0.02 which was not statistically significant (p=0.654).  
7.3.1.12 Discussion of learning skills in res treated WT 
There was a 54% reduction in learning in female res treated WT compared to untreated female WT. 
Vehicle treated female WT had a 82% reduction in learning compared to untreated WT. Male res 
treated learning was reduced by 41% compared to untreated WT. Housing conditions did not influence 
learning abilities in res treated male WT. Solitary housed res WT were not significantly different 
compared to res treated group housed male WT (p=0.327). 
 
7.4 Cognitive impairment in res treated WT 
7.4.1 Introduction 
Cognitive function was examined in res treated WT consecutively with untreated WT and vehicle 
treated WT to explore the activity of resveratrol on hippocampal dependent learning and memory. 
Investigations comprised of T maze spontaneous alternation and novel object recognition test. These 
tests were performed in mice at 15 months of age. 
7.4.2 T Maze testing in res treated WT 
For spontaneous alternation testing, T maze analysis in untreated, res treated and veh treated WT was 
performed. Spontaneous alternation in a two armed T maze was used to identify spatial anomalies in 
the res treated WT population. The time in seconds to locate the novel arm, time spent in the novel 
arm and time spent in the original arm were collated to generate the investigation (IR), and 
discrimination ratio (DR). The sample numbers are summarised in tables preceding the results. 
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T Maze
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n To novel p In Novel p In original p
WT 13 WT:rWT 0.037 WT:rWT 0.015 WT:rWT 0.059
rWT 8 WT:vWT 0.540 WT:vWT 0.153 WT:vWT 0.674
vWT 4 rWT:vWT 0.061 rWT:vWT 0.447 rWT:vWT 0.644
F(2,22)6.124 F(2,22)5.913 F(2,22)3.249
7.4.2.1 Results of T maze testing in res treated WT 
 
Table 7.4 Summary of test numbers for T maze in untreated res and 
veh WT 
 
The time to explore the novel arm in untreated WT was 11 ±2 seconds and in res WT was 19 ±4 
seconds which was significantly increased compared to untreated WT (F(2,22) 6.124 p=0.037).  Veh 
treated WT took 7±2 seconds which was not statistically different to untreated WT (p=0.540). 
The time spent in the novel arm in untreated WT was 29±3 seconds. In res treated WT it was 22±3 
seconds which was statistically reduced compared to untreated WT (F(2,22)5.913 p=0.015). Vehicle 
treated WT spent 20±3 seconds in the novel arm which was also significantly reduced compared to 
untreated WT (p=0.015). 
Time spent in the original arm in untreated WT was 12±2seconds and 18±3 seconds in res treated WT 
which was not significantly different to untreated WT (p=0.059). Vehicle WT spent 12±2 seconds in 
the original arm which was not significantly different to untreated WT (p=0.674).Figure 7.3 shows a 
summary of these findings. 
 
Figure 7.3 T Maze test parameters in 
untreated and treated WT 
Graph showing the mean ±SD time in seconds 
of T maze testing parameters measured in 
untreated, res and veh treated WT. Time to 
novel arm, time spent in novel arm and time 
spent in original arm. 
 
 
The IR in untreated WT was 0.66±0.05. In res WT the IR was 0.57±0.03 which was not significantly 
different to untreated WT (p=0.174). The IR in veh WT was 0.59±0.02 which was not significantly 
different to untreated WT (p=0.776). 
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WT 13 WT:rWT 0.174 WT:rWT 0.004
rWT 8 WT:vWT 0.776 WT:vWT 0.268
vWT 4 rWT:vWT 0.576 rWT:vWT 0.351
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The DR in untreated WT was 0.39±0.05. Res WT DR was 0.15±0.01 which was significantly reduced 
compared to untreated WT (F(2,22 ) 25.448 p=0.004).  The DR of veh WT was 0.26 ±0.02 which was 
not significantly different compared to WT (p=0.268). Figure 7.4 shows the IR and DR of T maze 
testing. 
 
Figure 7.4 T maze IR and DR in untreated res 
and veh WT 
Graph showing the mean ±SD (A) investigation 
and (B) discrimination ratio for T maze testing in 
untreated, res and veh treated WT.  
 
7.4.2.2 Discussion of T maze testing in res 
treated WT 
In T maze analysis, res WT took 72% longer to explore the novel arm compared to untreated WT 
which was considered statistically different (p0.037). Veh WT took 35% less time than untreated WT. 
The time spent in the novel arm was reduced in res WT mice by 23% (p=0.015)  and by 30% in the 
veh treated group(p=0.015). The time spent in the original arm in res WT was increased by 49% 
compared to untreated WT. Veh WT time in original arm was the same as untreated WT. The IR of res 
WT was reduced by 21% compared to untreated WT. Veh WT IR was increased by 6%.  The DR in 
res WT was reduced by 14% (p=0.004) whereas in veh WT it was reduced by 11% compared to 
untreated WT. 
7.4.3 Novel object recognition testing in res treated WT 
For novel object recognition testing untreated WT (n9), res WT (n6) and vehicle treated WT (n3) 
performed the object recognition task with a total of seven novel items. The same testing parameters 
were applied. The IR and DR were obtained as previously described. 
7.4.3.1 Results of NOR testing in res treated WT 
 
Table 7.5 Summary of test numbers for NOR testing in WT 
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n To novel p In Novel p In original p
WT 11 WT:rWT 0.001 WT:rWT 0.001 WT:rWT 0.950
rWT 8 WT:vWT 0.011 WT:vWT 0.024 WT:vWT 0.418
vWT 4 rWT:vWT 0.562 rWT:vWT 0.840 rWT:vWT 0.435
F(2,20) 3.512 F(2,20) 6.454 F(2,20) 0.933
 
Time to novel object was significantly increased in res WT compared to untreated WT (F2,20) 3.512 
p=0.001). Time to novel in veh WT was also significantly increased (p=0.011). The time spent with 
the novel object was 22±2 seconds in untreated WT, 15±2 seconds in res WT which was significantly 
reduced compared to untreated WT (F(2,20) 6.454 p=0.001). Veh WT time with novel object was also 
significantly reduced to 12±1 seconds (p=0.024).  
Time spent with the original object in untreated WT was 7±1 seconds. Res WT also spent 6.6±1.8 
seconds which was not significantly different compared to untreated WT (p=0.960). Veh WT spent 
3.2±0.9 seconds which was not statistically significant compare to untreated WT (p=0.418). Figure 7.5 
shows a summary of these finding. 
 
Figure 7.5 NOR test parameters untreated 
and treated WT   
Graph showing the mean ±SD time in seconds 
for the testing parameters used in novel object 
recognition testing The time to novel object, time 
with novel object and time with original object in 
untreated res and veh WT. 
 
The IR in untreated WT was 0.71±0.05. IR in res WT was 0.57±0.1 which was not statistically 
different compared to untreated WT (p=0.144).  The IR in veh WT was 0.72±0.07 which was not 
statistically different compared to untreated WT (p=0.706). 
The DR in untreated WT was 0.51±0.09. In res treated WT the DR was 0.30±0.09 which was 
significantly reduced compared to untreated WT (F(2,20) 3.372 p=0.013). Veh WT DR was 0.53±0.11 
which was not significantly different to untreated WT (p=0.942). Figure 7.6 shows the IR and DR of 
NOR in res treated WT. 
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Figure 7.6 NOR IR and DR in untreated, res 
and veh WT   
Graph showing the mean ±SD of  NOR  
(A)investigation ratio and (B)discrimination 
ratio in untreated WT, res WT and veh WT for 
NOR testing. 
 
 
7.4.3.2 Discussion of NOR in res treated WT 
In NOR, the time to novel object was increased by 120% in res WT which was significantly different 
compared to untreated WT (p=0.001) and by 69% in veh WT (p=0.011). The time with the novel 
object was reduced by 33% in res WT (p=0.001) and by 47% in veh WT. The time with the original 
item was unchanged in res WT but reduced by 51% in veh WT. The IR in res WT was reduced by 
20% and in veh WT was unchanged compared to untreated WT. The DR in res WT was reduced by 
41% and in veh WT was increased by 4%. The preference for particular objects was examined.  
The time spent with individual items demonstrated preference which was considered noteworthy as 
untreated WT had shown particular behavioural traits in response to items that were considered normal 
exploratory behavioural traits. In the untreated WT, the time spent with silicone was 22±5/sec. Res 
WT spent 7±4/sec which was significantly reduced (F(2,20) 2.677 p=0.010).  Veh WT spent 8±1/sec 
which was also significantly reduced (p=0.024). Untreated WT spent 23±5/sec with wood. Res WT 
spent 10±6/sec which was significantly reduced (F(2,20) 14.28 p=0.008). Veh WT spent 8±0.8/sec 
which was also significantly reduced (p=0.011). Untreated WT spent 31±2 /sec with fabric. Veh 
treated WT spent 9±0.8/sec which was significantly reduced compared to untreated WT F(2,20) 3.327 
p=0.024). Untreated WT spent 15±4sec with glass. Res WT spent 6±3/sec which was significantly 
reduced compared to untreated WT (F(2,20) 4.02 p=0.044).Figure 7.7 attempts to demonstrate these 
findings. 
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Figure 7.7 Preference in NOR testing 
Line graph showing both the preference for 
specific objects (mean (±SD) time with 
novel/sec) and the trend in test participation 
in NOR testing. Compared to untreated WT, 
res WT spent a significantly less time with 
silicone (p=0.010), wood (p=0.008) and 
glass (p=0.044).  Compared to untreated 
WT, veh WT spent a significantly less time 
with silicone (p=0.024), wood (p=0.011) and 
fabric (p=0.024). 
 
 
While some items were less favourable (resin and slate), this did not deter untreated WT from 
continuing to investigate on each successive test. In res WT, the reduced IR can be seen as a 
significant reduction in time spent with novel objects. The trend showed a decline in test participation 
from the 2
nd
 test.  Vehicle treated WT followed a similar but more exaggerated trend in time spent 
with novel objects. The time spent with a less favourable object (slate) although not statistically 
significant (p=0.249) suggested the discrimination in veh WT was disturbed. The time spent with 
fabric which was increased in all tested mice was significantly reduced in veh WT.  
7.5 Bioenergetic dysfunction in res treated WT   
7.5.1 Introduction 
The activity of the electron transport system was examined in the res WT population using 
mitochondrial extractions from brain, spinal cord, and retinal and gastrocnemius skeletal muscle. The 
number of tests performed for each complex is summarised in a table preceding each section. The 
methods used have been described elsewhere. The presence of residual succinate in complex I activity 
showed no significant effect. This is summarised in Appendix P. The kinetic reactions of ETC are 
shown in Appendix Q and the calculations for line fitting are shown in Appendix R. 
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CI B CI SC CII B CII SC CIV B CIV SC
WT 8 WT 10 WT 8 WT 10 WT 9 WT 10
rWT 7 rWT 9 rWT 8 rWT 6 rWT 8 rWT 8
vWT 5 vWT 8 vWT 7 vWT 6 vWT 5 vWT 5
CI Ret CI Mus CII Ret CII Mus CIV Ret CIV Mus
WT 9 WT 4 WT 9 WT 4 WT 8 WT 4
rWT 6 rWT 3 rWT 6 rWT 4 rWT 6 rWT 3
vWT 6 vWT 3 vWT 6 vWT 3 vWT 6 vWT 3
7.5.1.1 Results of Bioenergetic assays in res treated WT 
 
Table  7.5 shows a summary of test 
numbers for bioenergetic assays.  
 
Table 7.6 shows a summary of complex I, complex II and complex IV activity in brain, spinal cord 
retina and skeletal muscle of untreated WT, res and veh WT. 
Table 7.6 Bioenergetics of WT, res and veh WT 
 
 
Table shows a summary of bioenergetic analysis of complex I, complex II and complex IV activity in 
isolated mitochondria of untreated, res and veh WT brain spinal cord (SC) retina (Ret) and skeletal 
muscle (Mus). The statistical difference between groups is represented by p value.  
 
 
 
 
Brain SC Ret Mus
CI WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
nMol/mg/ml262±33134±7 43±4 341±17 73±9 300±28288±14131±3304±22154±17172±10 94±4
WT:rWT 0.002 0.008 0.057 0.014
WT:vWT 0.001 0.548 0.828 0.001
rWT:vWT 0.001 0.054 0.025 0.153
F(2,17)9.987 F(2,24)65.876 F(2,18)7.790 F(2,9)9.987
CII WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Mol/mg/min 50±4 32±2 60±3 54±2 14±1 33±2 128±9 61±2 117±6 39±6 28±5 17±2
WT:rWT 0.012 0.023 0.001 0.146
WT:vWT 0.001 0.527 0.001 0.148
rWT:vWT 0.001 0.007 0.001 0.914
F(2,20)12.650 F(2,17)7.880 F(2,20)12.650 F(2,9)4.411
CIV WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Mol/mg/min3.6±0.11.9±0.1.8±0.092.5±0.10.9±0.1.8±0.082.4±0.092.3±0.13.0±0.2.5±0.061.4±0.051.3±0.1
WT:rWT 0.001 0.001 0.001 0.172
WT:vWT 0.001 0.001 0.010 0.007
rWT:vWT 0.552 0.926 0.113 0.001
F(2,19)8.616 F(2,20)31.193 F(2,17)9.694 F(2,9)8.616
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Figures 7.8 A–C shows a graphical representation of the ETC activity in WT, res and veh treated 
mouse. 
Figure 7.8 Complex 1 activity in res WT 
mouse 
 (A) Graphs of mean ±SD complex I 
oxidation of NADH in isolated 
mitochondria from untreated, res and veh 
treated WT brain, spinal cord (SC), retina 
(Ret) and skeletal muscle (Mus). 
 
 
(B) Graphs of mean ±SD Complex II 
reduction of DCPIP in 50g/ml isolated 
mitochondria from WT, res and veh WT 
brain, spinal cord (SC), retina (Ret) and 
skeletal muscle (Mus). 
 
 
(C) Graphs of mean ±SD Complex IV 
oxidation of reduced cytochrome c in 
isolated mitochondria from WT, res WT 
and veh WT in brain, spinal cord (SC), 
retina (Ret) and skeletal muscle (Mus). 
 
 
The ratio of individual complex activity was examined in the mitochondrial from the CNS. As 
previously observed, untreated WT showed the highest ratio of activity for complex I in spinal cord, 
for complex II in retina and complex IV in brain. Table 7.7shows the ratio for individual complexes in 
the CNS in untreated, res and veh treated WT.   
Chapter 7 Paradoxical effects of resveratrol in C57Bl/6 
 
270 
 
Brain SC Ret Mus
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
CI    Ave 29 43 33 38 22 33 33 35 34 25 25 33
SEM 8 5 5 7 5 8 7 6 4 1 2 2
WT:rWT 0.180 0.064 0.937 0.002
WT:vWT 0.793 0.551 0.789 0.002
rWT:vWT 0.341 0.270 0.955 0.002
F(2,65)53.749
CII   Ave 21 30 30 23 14 16 56 56 54 2 25 33
SEM 3 5 3 5 2 2 10 3 2 4 4 4
WT:rWT 0.063 0.012 0.538 0.995
WT:vWT 0.077 0.179 0.178 0.150
rWT:vWT 0.993 0.302 0.470 0.150
F(2,61)5.219
CIV  Ave 41 38 26 30 18 27 29 44 47 25 34 36
SEM 6 7 2 5 4 4 2 5 6 2 2 2
WT:rWT 0.257 0.001 0.001 0.002
WT:vWT 0.001 0.200 0.001 0.001
rWT:vWT 0.009 0.044 0.587 0.123
F(2,62)16.734
Table 7.7 Ratio of complex 
activity in untreated res 
and veh WT 
The table shows the ratio of 
complex I, complex II and 
complex IV activity in brain, 
spinal cord and retinal 
mitochondria in untreated 
res and veh WT. 
 
 
 
 
Untreated WT demonstrated that complex I activity was highest in spinal cord mitochondria, complex 
II activity was highest in retinal mitochondria and complex IV activity was highest in brain 
mitochondria. Res WT ratio in spinal cord mitochondria was not significantly different to untreated 
WT (p=0.064).The ratio of complex II activity in res WT retinal mitochondria was not significantly 
different to untreated WT (p=0.538). The ratio of complex IV activity in res WT brain was not 
significantly different to untreated WT (p=0.257). The ratio of complex I activity in veh treated WT 
spinal cord was not significantly different to untreated WT (p=0.551). The ratio of complex II activity 
in veh WT retinal mitochondria was not significantly different to untreated WT (p=0.178). The ratio of 
complex IV activity in veh WT brain mitochondria was significantly reduced compared to untreated 
WT (F(2,62) 16.734 p=0.001). 
7.5.1.2 Discussion of ETC activity in res treated WT 
Tissue specific reductions in ETC activity were examined in res and veh WT. 
Res WT brain mitochondria had a reduction of 41% in ETC activity compared to untreated WT. All 
complexes tested were reduced: Complex I had a 49% reduction, complex II had a 36% reduction and 
complex IV showed a 39% reduction. 
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rWT Brain SC Ret Mus Ave ETC
CI -49 -78 -60 11 -44
CII -36 -75 -52 -28 -48
CIV -39 -62 -3 -44 -37
Ave -41 -72 -38 -20
vWT Brain SC Ret Mus Ave ETC
CI 12 -12 6 -40 -8
CII 20 -40 -9 -56 -21
CIV -45 -30 28 -49 -24
Ave -4 -27 8 -48
The bioenergetic activity in res WT SC mitochondria had a 72% reduction in ETC activity compared 
to untreated WT. Complex I activity was reduced by 78%, complex II reduced by 75% and complex 
IV reduced by 62%  compared to untreated WT.  
Res treated retinal mitochondria had a 38% reduction in electron transfer activity compared to 
untreated WT. Complex I was reduced by 60%, complex II was reduced by 52% and complex IV was 
reduced by 3%. 
Skeletal muscle in res WT had a 20% reduction in bioenergetic activity compared to untreated WT. 
Complex I was enhanced by 11%, complex II was reduced by 48% and complex IV was reduced by 
37%. 
Veh treated WT brain mitochondria had a 4% reduction in electron transport. Complex I was enhanced 
by 12%, complex II was enhanced by 20% and complex IV was reduced by 45%. Veh WT spinal cord 
mitochondria had a 27% reduction in activity compared to untreated WT. Complex I was reduced by 
12%, complex II was reduced by 40% and complex IV was reduced by 30%. Veh WT retinal 
mitochondria were enhanced by 8% compared to untreated WT. Complex I was increased by 6%, 
complex II was reduced by 9% and complex IV was increased by 28%. Skeletal muscle in veh WT 
had a 48% reduction in bioenergetic activity compared to untreated WT. Complex I was reduced by 
40%, complex II reduced by 56% and complex IV reduced by 49%.Table 7.8 shows a summary of 
these findings. 
Table 7.8 Percentage changes in res and veh 
treated WT mitochondria 
Table showing the percentage change in bioenergetic 
activity in res and veh WT compared to untreated 
WT. Res WT had a 44% reduction in complex I 
activity, 48% reduction in complex II and 67% 
reduction in complex IV. Veh WT had a 8% reduction 
of complex I, 21% reduction in complex II and 24% 
reduction in complex IV. 
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The effects of 0.1% ethanol over a 15 month time period had a negative impact on electron transport 
compounded by the addition of resveratrol. The percent reduction in ETC activity seen in the vehicle 
treated brain, SC retina and skeletal muscle was subtracted from the percent change observed in res 
treated WT. This represented the effects of resveratrol only in WT mouse in this trial.  
Tissue specific changes due to resveratrol were examined.  
Brain mitochondria showed a 37% reduction in activity. This was observed in both complex I with a 
61% and complex II with 56% reductions. Complex IV showed a marginal 6% increase. Res WT 
spinal cord mitochondria had 45% reduction in bioenergetic activity. Complex I was reduced by 67%, 
complex II reduced by 35% and complex IV was reduced by 32%.  Retinal mitochondria in res WT 
showed a 46% reduction in electron transport compared to untreated WT. Complex I was reduced by 
65%, complex II was reduced by 43% and complex IV was reduced by 30%. Skeletal muscle in res 
WT showed a 28% increase in bioenergetic activity compared to untreated WT. Complex I was 
reduced  by 35%, complex II was reduced by 27% and complex IV reduced by 13%. Figure 7.9 shows 
a graphical representation of these data. 
Figure 7.9 Resveratrol specific bioenergetic effects in WT mouse 
Graph representing the tissue specific and complex specific changes in 
res treated WT compared to untreated WT (represented by green line). 
The mitochondrial tissue specific changes showed that all CNS 
mitochondria had reduced activity. Skeletal muscle showed a 28% 
increase in activity. Complex specific activities showed that complex I 
was reduced 35%, complex II reduced 45%  and complex IV reduced 
by 46%. 
 
 
Resveratrol may have had a positive impact on the bioenergetic function of skeletal muscle in res 
treated WT, unfortunately this was not evident during rotarod testing. Resveratrol appeared to have an 
adverse effect in the CNS on all complexes notably in the retinal and spinal cord mitochondria with a 
combined reduction of 46% activity.  
Chapter 7 Paradoxical effects of resveratrol in C57Bl/6 
 
273 
 
7.5.2 Results of mitochondrial related protein expression 
Table 7.9 shows a summary of mitochondrial Opa1, VDAC and Preli expression in retinal layers of 
untreated, res and veh WT. Figure 7.10 shows a graphical representation of this data. Table 7.10 
summarises Neuroglobin, PSD95 and neurofilament expression and Figure 7.11 shows graphs 
representing this data. 
Table 7.9 Mitochondrial protein expression in retina of untreated and treated WT 
 
Table shows the mean ±SEM of retinal mitochondrial expression of (A)Opa1 (B) VDAC (C) 
Preli in untreated, res and veh treated WT. The statistical difference between groups is 
represented by p value. 
 
 
 
 
 
 
 
 
 
 
A Opa1 PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 192 302 203 256 330 199 258 487 336 224 255 243 281 298 255 187 203 142
SEM 39.3 50.4 36.2 52.6 56.8 42.5 73 94.4 36.8 79.2 36.4 18 41.8 21.5 4.46 30.5 28 33.3
WT:rWT 0.546 0.789 0.215 0.204 0.281 0.197
WT:vWT 0.213 0.780 0.840 0.974 0.070 0.251
F F ( 5,16) 2.285 F (5,15) 4.390 F (5,15) 2.751 F (5,15)5.463 F (5,15) 9.729 F (5,15) 15.056
B VDAC PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 91.9 185 144 273 466 130 184 245 102 215 429 179 181 366 108 404 435 224
SEM 15.9 56.4 6.18 25.1 197 0.44 19.6 118 7.21 26.5 134 13.3 25.7 136 3.94 30.6 247 7.2
WT:rWT 0.062 0.242 0.001 0.814 0.354 0.782
WT:vWT 0.001 0.425 0.006 0.746 0.309 0.648
F F ( 5,15) 10.470 F (5,15) 1.380 F (5,15) 6.747 F (5,15)1.028 F (5,15)1.146 F (5,15)0.441
C Preli PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 366 240 262 17 19 69 194 113 172 110 119 56 122 130 62 213 128 36
SEM 120 84 73 4 1 12 63 14 48 16 9 8 37 44 20 61 29 15
WT:rWT 0.282 0.001 0.016 0.102 0.219 0.614
WT:vWT 0.080 0.750 0.041 0.729 0.511 0.592
F F ( 5,28) 1.900 F (5,28) 1.176 F (5,28) 4.913 F (5,28)2.091 F (5,28)2.78 F (5,28) 5.075
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A
Opa1 PRL ONL OPL INL IPL GCL
WT:rWT 0.229 0.358 0.045 0.659 0.778 0.685
WT:vWT 0.902 0.436 0.460 0.791 0.677 0.266
rWT:vWT 0.227 0.092 0.168 0.859 0.488 0.139
±SEM *p<0.05**p<0.010***p<0.001
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Figure 7.10 Mitochondrial related protein 
expression in untreated, res and veh WT retina 
(A)Graph shows the mean ±SEM of Opa1 expression 
in WT, res WT and veh WT retinal layers. 
 
 
 
 
 (B)Graph shows the mean ±SEM of VDAC 
expression in WT, res WT and veh WT retinal layers. 
 
 
 
 
 
(C)Graph shows the mean ±SEM of VDAC 
expression in WT, res WT and veh WT retinal layers. 
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PSD95 PRL ONL OPL INL IPL GCL
WT:rWT 0.172 0.031 0.073 0.019 0.026 0.018
WT:vWT 0.351 0.763 0.794 0.712 0.806 0.882
rWT:vWT 0.639 0.054 0.115 0.037 0.041 0.013
±SEM *p<0.05**p<0.010***p<0.001
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Neuro PRL ONL OPL INL IPL GCL
WT:rWT 0.379 0.934 0.864 0.530 0.894 0.317
WT:vWT 0.354 0.753 0.275 0.566 0.383 0.932
rWT:vWT 0.964 0.828 0.383 0.959 0.486 0.388
±SEM *p<0.05**p<0.010***p<0.001
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Table 7.10 Mitochondrial related proteins expression in untreated and treated WT 
 
Table shows the mean ±SEM of (D) neuroglobin (E) PSD95 and (F) NF l expression in retinal 
layers of untreated, res and veh treated WT. The statistical difference between groups is 
represented by p value. 
Figure 7.11 Mitochondrial related proteins 
expression in untreated and treated WT 
(D) Graphs shows the mean ±SEM of 
Neuroglobin  in WT, res WT and veh WT 
retinal layers. 
 
 
 
(E) Graphs shows the mean ±SEM of PSD95 
in WT, res WT and veh WT retinal layers. 
D Neuro PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 228.1 158.4 154.5 218.1 210.7 189.4 170.2 158.6 96.18 163.3 119 123 180.9 165.8 80.36 71.34 113.9 75.07
SEM 52.27 2.327 28.11 99.93 20.05 34.19 54.2 40.82 27.34 81.32 30.8 31.49 80.56 36.4 7.807 36.4 10.7 17.84
WT:rWT 0.408 0.817 0.562 0.962 0.405 0.452
WT:vWT 0.240 0.814 0.732 0.892 0.402 0.652
F F ( 5,20) 1.530 F (5,20) 0.784 F (5,20) 0.969 F (5,20)0.896 F (5,20) 1.654 F (5,20) 0.838
E PSD95 PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 90.5 189 156 37.8 269 66.9 84.4 237 105 24.5 209 50.3 40.3 228 58.8 34 189 25.4
SEM 10.2 3.57 48.8 10.3 66.7 28.8 24.6 65.7 58 11.3 53.3 22.4 18.1 59.1 31.8 26.4 67.9 11
WT:rWT 0.064 0.958 0.987 0.905 0.822 0.351
WT:vWT 0.028 0.847 0.558 0.574 0.043 0.809
F F ( 5,15) 18.664 F (5,21) 1.843 F (5,15) 5.851 F (5,15)4.645 F (5,15) 1.132 F (5,15) 3.626
F NF L PRL ONL OPL INL IPL GCL
WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 112 67.6 153 165 77.1 196 99.2 102 257 57.1 72.4 162 195 94.7 358 443 #### 424
SEM 13.2 6.61 23.8 87.1 2.09 47.8 3.55 34.2 34.9 11.7 22.9 17.7 28.3 32.3 53.8 37.6 67.6 113
WT:rWT 0.128 0.536 0.041 0.278 0.311 0.003
WT:vWT 0.001 0.745 0.036 0.149 0.001 0.299
F F ( 5,23) 8.530 F (5,23) 1.280 F (5,23) 4.219 F (5,23)3.493 F (5,23) 7.706 F (5,23) 2.512
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F
NF H PRL ONL OPL INL IPL GCL
WT:rWT 0.351 0.337 0.973 0.895 0.132 0.071
WT:vWT 0.378 0.731 0.076 0.380 0.021 0.782
rWT:vWT 0.075 0.201 0.081 0.453 0.001 0.092
±SEM *p<0.05**p<0.010***p<0.001
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(F) Graphs shows the mean ±SEM of NFl A 
in WT, res WT and veh WT retinal layers. 
 
 
 
 
 
Res treated WT had a significant 89% increase in Opa1 expression in the OPL (F (5,13) 3.085 
p=0.045). Opa1 expression in all other res treated WT retinal layers was not significantly different 
compared to untreated WT. Veh WT Opa1 expression was unchanged compared to untreated 
WT.VDAC expression There was no significantly difference in protein expression of VDAC, Preli or 
Neuroglobin in  res or veh treated WT compared to untreated WT. 
Compared to untreated WT res WT had a significant increase in PSD95 expression in the ONL 
(F(5,12) 3.404) p=0.031), INL (F(5,12) 2.248 p=0.019) IPL (F(5,12) 2.214 p=0.026), and GCL 
(F(5,12) 2.431 p=0.018). These findings were not present in veh treated WT. Neurofilament 
expression in res treated WT was not significantly different compared to untreated WT. Veh WT had a 
significant 184% increase of NF l expression in the IPL (F5,12)5.823 p=0.021). 
7.5.2.1 Western blotting of res treated retinal homogenate 
Opa1 expression in retinal homogenate of untreated WT retinal homogenate had 1.04±0.11 RD. Opa1 
expression in res treated WT retina had 0.57±0.16 which was statistically reduced compared to 
untreated WT (F(3,12) 11.110 p=0004). Retinal expression of neuroglobin showed untreated WT had 
0.61±0.27RD. Res treated WT had 0.44±0.16RD which was not statistically significant compared to 
untreated (p=0.128). Preli expression in retinal homogenate of  untreated WT had 0.91±0.21 RD. Res 
WT retinal homogenate had 0.52±0.07 RD which was significantly reduced compared to untreated 
WT (F(3,12) 5.115 p=0.009).Figure 7.12 shows representative bands from Western blot for this data. 
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Figure7.12 Western blotting of 
untreated and res treated WT retinal 
homogenate 
Representative bands from Western 
blotting of retinal homogenate from 
untreated WT(n4) and res treated WT(n4) 
for (A)Opa1 (B), neuroglobin (C) and 
preli. Graphs show the mean ±SEM RD of 
proteins Lower bands show  actin as a 
loading control. 
 
 
 
 
Figures 7.13-7.18 show representative images of protein expression in untreated, res and veh WT 
retinal sections. Control sections are shown are processed sections omitting the use of the primary 
antibody. 
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Figure 7.13 Opa1 expression in retina of untreated, res and veh treated WT 
Representative images of Opa1expression in WT (A), res WT (B) and veh WT (C) retinal 
sections. Negative control sections (omission of primary antibody) for WT (D), res WT (E) and 
veh WT (F) are shown. 
 
 
A WT Opa1 WT merge WT Hoechst
B res WT Opa1 res WT merge res  WT Hoechst
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F veh WTControl veh WT merge veh WT  Hoechst
PRL IS
ONL
GCL
PRL IS
ONL
GCL
PRL IS
ONL
GCL
PRL IS
ONL
GCL
PRL IS
ONL
GCL
PRL IS
ONL
GCL
Chapter 7 Paradoxical effects of resveratrol in C57Bl/6 
 
279 
 
 
Figure 7.14 VDAC expression in retina of untreated, res and veh treated WT 
Representative images of VDAC expression in WT (A), res WT (B) and veh WT (C) retinal 
sections. Negative control sections (omission of primary antibody) for WT (D), res WT (E) and 
veh WT (F) are shown. 
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Figure 7.15 Preli expression in retina of untreated, res and veh treated WT 
Representative images of Preli expression in WT (A), res WT (B) and veh WT (C) retinal 
sections. Negative control sections (omission of primary antibody) for WT (D), res WT (E) and 
veh WT (F) are shown. 
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Figure 7.16 Neuroglobin expression in retina of untreated, res and veh treated WT 
Representative images of Neuroglobin expression in WT (A), res WT (B) and veh WT (C) 
retinal sections. Negative control sections (omission of primary antibody) for WT (D), res WT 
(E) and veh WT (F) are shown. 
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Figure 7.17 PSD 95 expression in retina of untreated, res and veh treated WT 
Representative images of PSD95 expression in WT (A), res WT (B) and veh WT (C) retinal 
sections. Negative control sections (omission of primary antibody) for WT (D), res WT (E) and 
veh WT (F) are shown. 
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Figure 7.18 NF L expression in retina of untreated, res and veh treated WT 
Representative images of Neurofilament L expression in WT (A), res WT (B) and veh WT (C) 
retinal sections. Negative control sections (omission of primary antibody) for WT (D), res WT 
(E) and veh WT (F) are shown. 
 
The combined AFU from Opa1, VDAC and Preli expression generated the mitochondrial profile. 
Compensatory proteins were combined AFU of VDAC, and neuroglobin, and damage mediated 
A WT NF L WT merge WT Hoechst
B res WT NF L res WTmerge res WT Hoechst
C veh WT NF L veh WT merge veh WT Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
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Mito PRL ONL OPL INL IPL GCL
WT:rWT 0.546 0.355 0.194 0.438 0.446 0.664
WT:vWT 0.883 0.448 0.759 0.865 0.466 0.568
rWT:vWT 0.466 0.104 0.119 0.357 0.506 0.328
±SEM *p<0.05**p<0.010***p<0.001
protein expression was the combined AFU of PSD95 and NF L. Table 7.11 summarises these findings 
and Figure 7.19 shows a graphical representation of the data. 
Table 7.11 Summary of retinal protein profile in untreated and treated WT 
 
Table shows the mean (±SEM) of (A) mitochondrial (B) compensation and (C) damage 
mediated protein expression in retinal layers of untreated WT, res and veh WT. Statistical 
difference between groups is represented by the p value. 
 
Figure 7.19 Protein profiles in untreated res 
and veh treated WT 
Graphs showing the mean ±SEM AFU of (A) 
mitochondrial related protein expression in retinal 
sections of untreated res and veh treated WT. 
 
 
 
 
 
PRL ONL OPL INL IPL GCL
A            Mito WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 176 215 167 246 335 176 201 297 178 197 268 181 211 277 148 206 251 147
SEM 20.0 29.0 21.0 40.0 29.0 29.0 21.0 28.0 20.0 33.0 28.0 21.0 27.0 39.0 21.0 40.0 38.0 29.0
WT(5):rWT(4) 0.546 0.355 0.194 0.438 0.446 0.664
WT(5):vWT(3) 0.883 0.448 0.759 0.865 0.466 0.568
rWT(4):vWT(3) 0.466 0.104 0.119 0.357 0.506 0.238
F(5,15) 2.285 4.39 2.751 5.436 9.729 15.06
 B          Comp WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 232 242 203 166 272 133 210 281 203 175 268 159 187 265 142 263 256 134
SEM 18.0 24.0 21.0 13.0 16.0 28.0 18.0 12.0 15.0 24.0 18.0 15.0 13.0 25.0 26.0 16.0 20.0 18.0
WT(5):rWT(4) 0.888 0.340 0.329 0.337 0.350 0.944
WT(5):vWT(3) 0.677 0.765 0.723 0.867 0.586 0.202
rWT(4):vWT(3) 0.697 0.765 0.923 0.273 0.152 0.239
F(5,15) 1.047 1.38 6.747 1.028 1.146 0.441
C        Damage WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT WT rWT vWT
Ave 101 128 155 102 173 131 92 169 181 41 141 106 117 161 209 238 202 225
SEM 19.0 14.0 15.0 20.0 17.0 12.0 16.0 20.0 19.0 20.0 15 16 13 18 12.0 12.0 18.0 15.0
WT(5):rWT(4) 0.559 0.315 0.025 0.005 0.529 0.775
WT(5):vWT(3) 0.253 0.670 0.019 0.015 0.195 0.915
rWT(4):vWT(3) 0.570 0.558 0.865 0.608 0.495 0.858
F(5,21) 21.47 1.843 5.831 4.645 1.132 3.626
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Dam PRL ONL OPL INL IPL GCL
WT:rWT 0.559 0.315 0.025 0.005 0.529 0.775
WT:vWT 0.253 0.670 0.019 0.015 0.195 0.915
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…Figure 7.19  
(B) Graphs showing the mean ±SEM AFU of 
compensation mediated protein expression in retinal 
sections of untreated res and veh treated WT. 
 
 
(C) Graphs showing the mean ±SEM AFU of 
damage mediated expression in retinal sections of 
untreated res and veh treated WT. 
 
 
There was no significant difference observed in 
mitochondrial or compensatory protein expression between untreated WT and res or veh treated WT. 
Res treated WT had a significant 84% increase in damage mediated protein expression in the OPL 
(F(5,48) 3.380 p=0.025). Veh treated WT had a 19% increase in damage mediated protein expression 
in the OPL which was significantly increased compared to untreated WT (p=0.019). Res WT had a 
244% increase in damage mediated protein expression the INL (F(5,45) 6.662 p=0.005). Veh WT had 
a 159% increase which was also significant compared to untreated WT (p=0.015). 
7.5.3 Mitochondrial protein expression in brain of untreated and treated WT 
Table 7.12 shows a summary of mitochondrial related protein expression in brain of untreated res and 
veh treated WT. Figure 7.20 shows graphs representing this data. 
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*** ***A B
A Opa1 WT(n5) rWT(n4) vWT(n3) D Preli WT(n5) rWT(n4) vWT(n3)
Ave 619.9 1024 612.8 Ave 542.4 1308 1007
SEM 119.6 278.8 208.7 SEM 107.6 270.7 206.2
WT:rWT 0.223 WT:rWT 0.874
WT:vWT 0.982 WT:vWT
rWT:vWT 0.21 rWT:vWT 0.321
F(5,30) 4.527 F(5,30) 4.627
B VDAC WT(n5) rWT(n4) vWT(n3) E PSD95 WT(n5) rWT(n4) vWT(n3)
Ave 542.4 1308 1007 Ave 623 2056 781.1
107.6 270.7 206.2 93.35 401.6
WT:rWT 0.012 WT:rWT 0.267
WT:vWT 0.112 WT:vWT 0.53
rWT:vWT 0.348 rWT:vWT 0.651
F(5,18) 2.870 F(5,39) 2.983
C Neuro WT(n5) rWT(n4) vWT(n3) F NF H WT(n5) rWT(n4) vWT(n3)
Ave 390 179.5 272.3 Ave 524.5 884.4 158.1
128.7 42.4 65.3 SEM 176 138.4 44.14
WT:rWT 0.001 WT:rWT 0.182
WT:vWT 575 WT:vWT 0.301
rWT:vWT 0.001 rWT:vWT 0.774
F(5,17) 2.454 F(5,17) 7.832
Table 7.12 Mitochondrial protein 
expression in brain of untreated and 
treated WT 
Table shows the mean ±SEM of 
mitochondrial (A) Opa1,(B)VDAC, (C)Preli, 
(D)Neuroglobin, (E)PSD95 and (F)NF H 
protein expression in brain of untreated, res 
and veh WT. The statistical difference 
between groups is represented by the p 
value. 
 
 
 
Figure 7.20 Protein expression in brain of 
untreated res and veh WT 
Graphs show the mean ± SEM AFU of (A) 
Opa1, VDAC and Preli  (B) Neuroglobin, 
PSD95 and NF H in brain sections of 
untreated res and veh WT. 
 
 
These was no statistical difference observed between untreated and res or veh treated WT for Opa1 or 
VDAC expression. Res treated WT brain had a significant increase in Preli expression compared to 
untreated WT (p=0.012) which was not observed in veh treatd WT. PSD95 expression was increased 
by 230% in res treated WTwhich was signitficanllt different 
7.5.3.1 Western blotting of untreated and res WT brain homogenate 
Brain homogenate was examined for Opa1, neuroglobin and VDAC expression in untreated and res 
treated WT. Western blotting of brain homogenate for Opa1 protein expression in untreated WT brain 
was 0.99 ±0.1 RD. Res treated WT had 0.94±0.10 which was not significantly different to WT 
(p=0.813). Western blotting for neuroglobin expression in untreated brain was 1.0±0.16 RD. Res 
treated brain had 0.91±0.12RD which was not significantly different to untreated (p=0.693). Western 
blotting of brain homogenate for VDAC expression in untreated WT brain showed 0.88±0.13 RD. Res 
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treated WT brain had 0.83±0.23 which was not significantly different to untreated WT  (p=0.153). 
Figure  7.21 shows these data. 
 
Figure 7.21 Western blotting of 
untreated and res treated WT brain 
homogenate 
Figure shows representative bands from 
Western blotting of brain homogenate 
from untreated WT (n4) and res treated 
WT (n4) for(A) Opa1 (B) neuroglobin 
and  (C) VDAC Lower bands show  
actin as a loading control. Graphs 
represent the mean ±SEM of RD. 
 
 
 
 
 
Figures 7.22-7.27 show representative images of protein expression in untreated, res and veh WT 
retinal sections. Control sections are shown are processed sections omitting the use of the primary 
antibody. 
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Figure 7.22 Opa1 expression in untreated res and veh WT brain 
Representative images of Opa1 expression in (A) untreated WT (B) res WT and (C) veh WT 
brain.  Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
 
A WT Opa1 WT merge WT Hoechst
B res WT Opa1 res WT merge res  WT Hoechst
C veh WT Opa1 veh WT merge veh WT Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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Figure 7.23 VDAC expression in untreated res and veh WT brain 
Representative images of VDAC expression in (A) untreated WT (B) res WT and (C) veh WT 
brain.  Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
A WT VDAC WT merge WT Hoechst
B res WT VDAC res WT merge res WT Hoechst
C veh WTVDAC vehWTt merge veh WTHoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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Figure 7.24Preli expression in untreated res and veh WT brain 
Representative images of Preli expression in (A) untreated WT (B) res WT and (C) veh WT 
brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
 
A WT Preli WTmerge WT Hoechst
B res WT Preli res WTmerge res WT Hoechst
C veh WT Preli veh WT merge veh WT Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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Figure 7.25 Neuroglobin expression in untreated res and veh WT brain 
Representative images of Neuroglobin expression in (A) untreated WT (B) res WT and (C) veh 
WT brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
 
A WT  Neuroglobin WT merge WT  Hoechst
B res WT Neuro res WT merge res WT Hoechst
C veh WT  Neuro veh WT merge veh WT Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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Figure 7.26 PSD95 expression in untreated res and veh WT brain 
Representative images of PSD95expression in (A) untreated WT (B) res WT and (C) veh WT 
brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
A WT PSD95 WT merge WT  Hoechst
B res WT PSD95 res WTmerge res WT  Hoechst
C veh WT PSD95 veh WT merge vehWT  Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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Figure 7.27 NF H expression in untreated res and veh WT brain 
Representative images of NF H expression in (A) untreated WT (B) res WT and (C) veh WT 
brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
A WT NF L WT merge WT Hoechst
B res WT NF L res WTmerge res WT Hoechst
C veh WT NF L veh WT merge veh WT Hoechst
D WT Control WT merge WT Hoechst
E res WT  Control res WT merge res WT  Hoechst
F veh WTControl veh WT merge veh WT  Hoechst
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n Ret Mito Comp Dam
WT 30 WT:rWT 0.211 0.514 0.136
rWT 27 WT:vWT 0.645 0.069 0.097
vWT 27 rWT:vWT 0.096 0.016 0.867
*p<0.05 **p<0.010***p<0.001 ±SEM
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Brain Mito Comp Dam
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B
C:D 1: PRL ONL OPL INL IPL GCL Brain
WT 0.44 0.61 0.44 0.23 0.63 0.90 0.76
rWT 0.53 0.64 0.60 0.53 0.61 0.79 1.89
% WT 22 5 38 125 -3 -13 147
vWT 0.76 0.98 0.89 0.67 1.47 1.68 1.15
% WT 75 62 104 185 135 86 51
Retina Mito Comp Dam
WT rWT vWT WT rWT vWT WT rWT vWT
Ave 303 319 225 158 211 125 129 178 191
SEM 28 28 22 23 25 24 20 19 20
WT:rWT 0.211 0.514 0.136
WT:vWT 0.645 0.069 0.097
WT:vWT 0.096 0.016 0.867
F(5,369)7.522 F(5,414)2.399 F(5,425)5.581
Brain Mito Comp Dam
WT rWT vWT WT rWT vWT WT rWT vWT
Ave 600 107 663 523 785 575 400 1484 666
SEM 79 132 61 10 131 108 82 158 93
WT:rWT 0.033 0.165 0.001
WT:vWT 0.745 0.781 0.340
WT:vWT 0.071 0.293 0.006
F(5,75)2.411 F(5,68)5.957 F(5,75)2.573
The combined AFU of mitochondrial, compensation and damage mediated proteins are summarised in 
Table7.13.  Figure 7.28 shows the  summary of profiles in both retina and brain. 
 
Table 7.13 Summary of protein profile of 
retina and brain in untreated and 
treated WT 
Table shows the mean ±SEM of 
mitochondrial, compensatory and damage 
mediated protein expression in retina and 
brain of untreated res and veh treated WT. 
The statistical difference between groups is 
represented by the  p value. 
 
 
Figure 7.28 Protein profiles in retina and 
brain of untreated and treated WT 
Graphs show the mean ± SEM AFU of 
mitochondrial, compensatory and damage 
mediated protein expression of (A)retina 
and (B) brain  of untreated, res and veh 
treated WT. 
 
Although there was no significant 
difference seen in retinal compensatory protein expression, the ratio of compensatory to damage 
mediated expression was considered. Table 7.14 shows the ratios of compensation to damage protein 
expression.  
Table 7.14 Ratio compensation: damage protein expression in untreated and treated WT 
 
Ratio of compensation to damage protein 
expression where a value of less than 1 indicates 
control of oxidative stress. 
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7.5.4 Discussion of mitochondrial related protein expression in res WT 
Res treated retinal protein expression showed a 5% increase compared to untreated Wt. There was a 
34% increase in compensatory protein expression and a 38% increase in damage mediated protein 
expression. The ratio of damage to compensation was 0.84, which suggested that oxidative stress was 
under control. Res treated brain showed a 71% increase in mitochondrial related protein expression. 
There was a 50% increase in compensatory proteins and a 271% increase in damage mediated proteins 
expression. Res WT brain had a damage to compensation ratio of 1.89 which suggested that the extent 
of damage was not under controlled.  
Veh treated WT retina had a reduction of 11% mitochondrial protein expression compared to untreated 
WT. Compensation protein expression was reduced by 21% and damage mediated proteins expression 
increased by 48%. The ratio of damage to compensation proteins was 1.53, which suggested that the 
retinal environment was under considerable oxidative stress. Veh treated WT brain has 11% increase 
in mitochondrial proteins expression and a 10% increase in compensation proteins. There was a 67% 
increase in damage mediated protein expression. This meant the damage to compensation ratio was 
1.16. Figure 7.29 summarises the effects of resveratrol minus ethanol on retinal and brain proteins. 
Figure 7.29 Effects of resveratrol on protein 
expression in retina and brain of WT 
Line graph shows the percentage change in protein 
expression compared to untreated WT (represented by 
green line) in res minus ethanol WT retina and brain. 
 
These findings suggested that resveratrol did not cause 
any change to the mitochondrial environment of WT retina. The ratio of damage to compensation 
proteins suggested that oxidative stress was controlled. Res WT brain showed that the mitochondria 
were under considerable stress with a significant increase in damage mediated proteins expression and 
inadequate compensation protein expression to control for this. 
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 Brain SC  Retina
WT 6 WT 7 WT 4
rWT 6 rWT 3 rWT 3
vWT 6 vWT 3 vWT 0
 
7.6 Endogenous antioxidants in res treated WT 
7.6.1 Introduction to catalase activity in res treated WT 
Catalase activity was examined as described in brain and spinal cord of res WT and veh WT mouse. 
For catalase activity in the retina, due to the homogenate requirement, veh WT mice were not 
analysed. Results are presented as units/mg homogenate protein. 
7.6.1.1 Results of catalase activity in res treated WT 
 
Table 7.15 Test numbers for catalase activity in untreated res and 
veh WT homogenate 
 
Catalase activity in brain homogenate of untreated WT, res WT and veh WT were analysed for the 
ability to decompose a known concentration of H2O2. The catalase activity in untreated WT brain 
homogenate had 4.30±0.38 units/mg. Res WT brain had 3.20±0.70 units/mg which was significantly 
reduced compared to untreated WT F(5,31) 7.995 p=0.042). Veh WT brain homogenate had 2.80±0.34 
units/mg which was significantly reduced compared to untreated WT (p=0.006). 
The catalase activity in spinal cord homogenate of untreated WT had 3.90±0.54 units/mg. Res WT had 
4.0±0.18units/mg which was not significantly different compared to untreated WT (p=0.761), and veh 
WT had 3.60±0.18 units/mg which was not significantly different compared to untreated WT 
(p=0.499).  
Catalase activity in retinal homogenate from untreated WT had 3.70±0.51 units/mg. Res WT had 
2.60±0.10 units/mg which was not statistically different compared to untreated WT (p=0.055).  
Figure 7.30 shows the kinetics of catalase activity and Figure 7.31 shows a graphical representation of 
the data. 
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Figure 7.30 Kinetics of H2O2 decomposition in res treated WT mouse 
Representative kinetics showing the decomposition of H202 in the presence of brain (A) spinal cord (B) 
and retinal (C) homogenate from untreated WT, res WT and veh WT. 
 
 
Figure 7.31 Catalase activity in res treated WT 
Graph of mean ±SD catalase activity units/mg in 80g 
homogenate of untreated, res and veh treated WT brain, 
spinal cord (SC) and retina (Ret). 
 
 
7.6.1.2 Discussion of catalase activity n res WT 
Catalase activity in res treated WT showed a significant 26% reduction in brain homogenate compared 
to untreated WT. Catalase activity in res treated retinal homogenate was reduced by 30% compared to 
untreated WT. Res treated spinal cord was essentially unchanged compared to untreated WT. 
Veh treated WT brain homogenate showed a significant 35% (p=0.006) reduction in catalase activity 
compared to untreated WT. Veh treated WT spinal cord homogenate was unchanged compared to 
untreated WT. 
This suggested that resveratrol had enhanced the catalytic activity in brain homogenate by 9% despite 
the presence of 0.1% ethanol. 
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 Brain SC  Retina
WT 6 WT 7 WT 6
rWT 6 rWT 3 rWT 6
vWT 6 vWT 3 vWT 3
Brain SC Ret
Total SOD WT rWT vWT WT rWT vWT WT rWT vWT
24.77 22.66 20.32 32.87 39.87 37.19 2.93 2.89 0.96
3.15 1.57 0.61 5.77 2.15 1.97 1.04 0.90 0.04
WT:rWT 0.146 0.007 0.981
WT:vWT 0.007 0.077 0.001
rWT:vWT 0.112 0.006 0.001
F(5,12) 13.076 F(5,12)853.093 F(5,12) 78.006
MnSOD WT rWT vWT WT rWT vWT WT rWT vWT
1.64 5.03 2.63 0.16 0.24 0.04 0.38 0.45 0.13
0.06 0.82 0.27 0.08 0.01 0.01 0.21 0.25 0.01
WT:rWT 0.001 0.001 0.340
WT:vWT 0.494 0.712 0.448
rWT:vWT 0.001 0.001 0.131
F(5,12) 13.076 F(5,12)853.093 F(5,12) 78.006
CuZnSOD WT rWT vWT WT rWT vWT WT rWT vWT
7.15 4.25 4.03 1.29 1.88 0.24 0.33 0.19 0.17
0.37 0.27 0.26 0.65 0.31 0.02 0.08 0.11 0.00
WT:rWT 0.001 0.033 0.021
WT:vWT 0.001 0.258 0.027
rWT:vWT 0.282 0.001 0.594
F(5,12) 13.076 F(5,12)853.093 F(5,12) 78.006
 It would appear that in WT, resveratrol successfully combatted the adverse effects of ethanol on 
catalase function specifically in brain. Retinal catalase activity in res treated WT may have been 
reduced indirectly through the actions of MnSOD.   
7.6.2 SOD analysis in res treated WT 
SOD activity was analysed in res WT and veh WT mouse as previously described. Brain, spinal cord 
and retinal homogenate were analysed for total SOD activity, CuZn and MnSOD activity with the use 
of specific inhibitors for each sub type. 
7.6.2.1 Results of SOD analysis in res treated WT 
Table 7.16 Test numbers for SOD analysis in untreated res and 
veh WT homogenate 
 
Table 7.17 shows a summary of SOD activity in untreated WT, res and veh WT brain, spinal cord and 
retinal homogenate for total SOD, MnSOD and CuZnSOD activity. The kinetic reactions of SOD are 
shown in Appendix S and the calculations for line fittings are shown in Appendix T. Figure 7.32 
shows a graphical representation of the data. 
Table 7.17 Summary of analysis of SOD activity in untreated res and veh WT 
 
 
Table shows a summary of total SOD, MnSOD 
and CuZnSOD activity in WT, res and veh WT 
brain, spinal cord (SC) and retinal (Ret) 
homogenate. The statistical difference (p 
value) between groups is shown. 
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Figure 7.32 SOD activity in WT res and veh WT homogenate 
 
(A)Graph showing the mean ±SD of total SOD activity 
of homogenate in untreated WT, res and veh WT brain 
spinal cord (SC) and retina (Ret). 
 
  
 
 
(B) Graph showing the mean ±SD of MnSOD activity in 
untreated WT, res WT and veh WT brain spinal cord 
(SC) and retina (Ret) tissue homogenate. 
 
 
 
 
 
(C) Graph showing the mean ±SD of CuZnSOD activity 
units/mg in brain, spinal cord (SC) and retina (Ret) of 
untreated WT, res and veh WT. 
 
 
 
 
 
 
 
 
 
7.6.2.2 Discussion of SOD analysis in res treated WT 
Compared to untreated WT, the activity of CuZnSOD was reduced by 12% in res WT. Res WT brain 
homogenate had a 40% reduction and retinal homogenate had a 42% reduction compared to untreated 
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WT. CuZnSOD was increased by 46% in res WT spinal cord homogenate compared to untreated WT. 
MnSOD activity was increased by 84% compared to untreated WT. Res WT brain homogenate had a 
208% increase, spinal cord had 55% increase and retinal homogenate a 16% increase.   
Compared to untreated WT, veh WT showed a 59% reduction of CuZnSOD. Veh WT brain 
homogenate had a 44% reduction, spinal cord had 82% reduction and retinal homogenate had a 50% 
reduction. MnSOD activity in veh WT had a 27% reduction compared to untreated WT. Veh WT brain 
homogenate had a 60% increase, spinal cord had 74% reduction and retinal homogenate had 66% 
reduction.  
In the assay of inhibition of formazan formation, the combined percentage inhibition of CuZnSOD and 
MnSOD should equal the total SOD inhibition. Any inhibition of formazan formation not directly due 
to either CuZnSOD or MnSOD was called non-SOD.  WT brain homogenate had 1%±2.0 non-SOD. 
Res WT had -11%±8 which was significantly different to untreated WT (F5,30) 25.624 p=0.006). Veh 
WT had 3%±2 which was not significantly different to untreated WT (p=0.416). Untreated WT spinal 
cord homogenate had 14%±4 non-SOD. Res WT had 1±0.94 non-SOD which was significantly 
different to untreated WT (F(5,20) 19.228 p=0.013). Veh WT had 37%±1 non-SOD activity which 
was significantly more than untreated WT (F(5,20) 19.228 p=0.001). Retinal homogenate in untreated 
WT had 15%±6 non-SOD. Res WT had 18%±5 which was not significantly different compared to 
untreated WT (p=0.372). Veh WT had 16%±1 non-SOD activity which was  not significantly different 
to  untreated WT (p=0. 842). Figure 7.33 shows a summary of these data. 
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Figure 7.33 Inhibition of formazan 
formation by non-SOD activity. 
Inhibition of formazan formation that was 
not due to MnSOD or CuZnSOD was called 
non-SOD. Non-SOD activity in veh treated 
WT was significantly increased in brain, 
spinal cord (SC) and retina (Ret) compared 
to untreated WT and res WT. 
 
 
7.6.3 Antioxidant profile for res treated WT 
The antioxidant ‘index’ (AO index) was obtained by taking the percentage increase or decrease in the 
combined SOD and catalase activity for each tissue. A negative value was considered indicative of 
oxidative stress.  
In res WT the tissue specific AO profile was 23. Res WT brain homogenate profile was 53 which 
represented the combined percent reductions in catalase and CuZnSOD with the increased MnSOD 
activity. Res WT spinal cord profile was 36 which represented the percent increase in catalase, CuZn 
SOD and MnSOD. Retina had a profile of -17 due to the reduction of catalase and CuZnSOD.  
The antioxidant activity in res WT compared to untreated WT had 9% reduction of catalase activity, 
12% reduction of CuZnSOD and 93% increase in MnSOD.   
Veh WT tissue specific AO profile was -34. Compared to untreated WT, veh WT brain had an 
antioxidant reduction of 4%. Spinal cord was reduced by 54% and retina was reduced by 58%. 
Catalase activity was reduced by 17%. CuZnSOD was reduced by 59% and MnSOD by 27%.  
When res treated WT values were corrected for ethanol, the AO profile index for res WT increased to 
63. Res WT brain AO activity was increased by 57% compared to untreated WT, res WT spinal cord 
was increased by 90% and res WT retinal homogenate was  increased by 43%.  Catalase activity was 
increased by 25%, CuZnSOD activity was increased by 46% and MnSOD activity increased by 119%. 
Figure 7.34 shows a summary of this profile. 
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Figure 7.34 AO profile in res treated WT 
Line graph representing the percentage changes in res treated 
WT compared to untreated WT (represented by green line). 
Compared to untreated WT, the AO activity in all tissues was 
increased. The AO activity of catalase increased by 25%, 
CuZnSOD activity was increased by 46% and MnSOD increased 
by 119%. 
 
 
The enhanced MnSOD activity observed in all tissues possibly served to exhaust circulating catalase. 
The reduction of retinal catalase in res treated WT may have been induced by the excessive H202 
production initiated by an excess MnSOD. The increase of MnSOD activity seen in both WT and Het 
resveratrol treated mice clearly had profound effects within the mitochondria. The strategy for coping 
with excess H202 was not challenged with an excess catalase response in either genotype suggesting 
that the duration of therapy exceeded any potentially useful benefit resveratrol may have conferred. 
7.6.4 MnSOD protein expression in res treated WT 
7.6.4.1 Introduction to MnSOD protein in res treated WT 
IHC was performed on retinal and brain sections of untreated, res and veh WT as previously 
described.. A minimum of four independent WT, res treated WT and vehicle treated WT were used. 
Western blotting was performed on tissue homogenate of brain and retina from untreated WT and res 
WT only 
7.6.5 Results of MnSOD expression in res treated WT 
7.6.5.1 MnSOD expression in res treated WT retina and brain  
Table 7.18 shows a summary of MnSOD expression in the retinal layers and brain of untreated res and 
veh WT. Figure 7.35 shows a graph of this data. 
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Table 7.18 MnSOD expression in untreated and treated WT retina and brain 
 
Table shows the mean ±SEM MnSOD expression in retinal layers of WT, res and veh WT. The 
statistical difference between groups is represented by the p value. 
 
Figure 7.35 MnSOD expression in untreated and treated retinal layers and brain 
Graph shows the mean ±SEM of MnSOD expression in WT, res and veh WT (A) retinal layers 
and (B) brain. 
 
7.6.5.2 Western blotting of retinal and brain homogenate in WT and res WT  
MnSOD expression  in untreated WT  brain homogenate had 1.03±0.25 RD. Res treated WT brain had 
1.49±0.130 which was significantly increased compared to untreated WT (F(3,18) 9.181 p=0.017). 
.MnSOD expression in retinal homogenate of untreated WT had 1.12±0.04 RD and res treated WT 
retina had 1.20±0.20 which was not significantly different compared to untreated WT (p=0.709). 
Figure 7.36 shows a summary of  these data. 
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Figure 7.36 MnSOD 
expression in brain and retinal 
homogenate of WT and res 
WT 
Representative bands from 
Western blotting of (A) brain and 
(B) retinal homogenate from 
untreated WT(n4) and res 
treated WT(n4) for MnSOD 
.Graphs show the mean ±SEM 
RD of proteins Lower bands 
show  actin as a loading 
control. 
 
Figures 7.37 show representative images of MnSOD expression in untreated, res and veh WT retinal 
sections. Control sections are shown are processed sections omitting the use of the primary antibody. 
Figure 7.38 shows representative images of MnSOD expression in brain sections as above. 
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Figure 7.37 MnSOD  expression in retina of untreated, res and veh treated WT 
Representative images of MnSOD expression in WT (A), res WT (B) and veh WT (C) retinal 
sections. Negative control sections (omission of primary antibody) for WT (D), res WT (E) and 
veh WT (F) are shown. 
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Figure 7.38 MnSOD expression in untreated res and veh WT brain 
Representative images of MnSOD expression in (A) untreated WT (B) res WT and (C) veh WT 
brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were processed 
without primary antibody. 
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7.6.5.3 Discussion of mitochondrial related protein expression in res WT 
7.6.5.3.1 MnSOD in retina of res and veh treated WT 
MnSOD protein expression was examined in the retinal layers of untreated res and veh treated WT. 
Compared to untreated WT, res WT had a significant 107% increase in the PRL (F(5,17) 35.531 
p=0.001), 124% increase in the ONL (F5,17) 15.534 p=0.008), 85% increase in the OPL (F(5,17) 
7.631 p=0.015), 75% increase in the INL (F(5,17) 11.515 p=0.016). There was no significant 
difference observed in the IPL (p=0.261) or GCL (p=0.259).  The average increase of  MnSOD 
expression in res WT was 73%.  
Veh treated WT retina had a significant 52% reduction in the PRL (F(5,17) 35.531 p=0.029). All other 
retinal layers were not statistically different to untreated WT but showed a reduction in MnSOD 
expression. The mean percentage reduction was 49%. 
The activity of MnSOD in retinal homogenate of res WT showed a 16% increase compared to 
untreated WT, which suggested that 57% of the mean increase in protein expression was not 
functional. Veh treated WT had a 66% reduction in MnSOD activity with a 49% reduction in protein 
expression which suggested that 17% of the expressed SOD was not active. 
7.6.5.3.2 MnSOD activity in brain of res and veh WT 
MnSOD protein expression in res WT brain was increased by a significant 68% (F(5,32) 6.913 p0.014. 
compared to untreated WT. Western blotting showed that res WT had a significant 45% increase in 
expression (p=0.017). The MnSOD activity in brain homogenate of res WT showed an increase in 
excess of 200% compared to untreated WT. This suggested that the quantification of protein 
expression by IHC has limitations.  
MnSOD expression in Veh treated WT was not significantly different to untreated WT however did 
show a 31% reduction (p=0.162).  
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7.6.6 3 Nitrotyrosine deposition in retina and brain of res treated WT 
The presence of 3 nitrotyrosine deposition in the retina and brain of untreated res and veh treated WT 
was examined using IHC. Table7.19 shows a summary of 3 Nitrotyrosine deposition in the retinal 
layers and brain of untreated res and veh WT. Figure 7.39 (A) shows a graph of retinal data and Figure 
7.39 (B) shows a graph of brain. 
Table 7.19 3Nitrotyrosine deposition in res treated WT retina and brain 
 
Table shows the mean ±SEM 3 nitrotyrosine deposition in retinal layers of WT, res and veh 
WT. The statistical difference between groups is represented by the p value. 
 
Figure 7.39 3 Nitrotyrosine deposition in untreated res and veh WT 
Graph shows the mean ±SEM of 3 Nitrotyrosine deposition in WT, res and veh WT (A) retinal layers 
and (B) brain. 
Figures 7.40 shows representative images of 3 Nitrotyrosine in retina and Figure 7.41 show brain of 
untreated, res and veh treated WT. 
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Figure 7.40 3 Nitrotyrosine deposition in retina of untreated, res and veh treated WT 
Representative images of 3 Nitrotyrosine deposition in WT (A), res WT (B) and veh WT (C) 
retinal sections. Negative control sections (omission of primary antibody) for WT (D), res WT 
(E) and veh WT (F) are shown. 
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Figure 7.41 3 Nitrotyrosine deposition in untreated res and veh WT brain 
Representative images of 3 Nitrotyrosine deposition in (A) untreated WT (B) res WT and (C) 
veh WT brain. Control sections for (D) untreated WT (E) res WT and (F) veh WT were 
processed without primary antibody. 
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Compared to untreated WT, res WT had a significant 818% increase of 3 nitrotyrosine in the ONL 
(F(5,12) 8.011 p=0.007) which was not observed in veh WT. There was a significant 200% increase in 
the IPL of res WT (F(5,12) 5.221 p=0.031). This was also observed in the IPL of veh treated WT 
(p=0.032).  3Nitrotyrosine deposition in brain of res and veh treated WT was not significantly 
different to untreated WT. 
The ratio of 3 Nitrotyrosine deposition to MnSOD expression was examined. Res treated WT 
maintained a ratio where the score did not exceed a value of 1 indicating that the excess of MnSOD 
expression was keeping nitration reduced. Veh treated WT showed values in excess of 1 in the PRL, 
INL and IPL. This suggested that the reduction in MnSOD expression was influencing the nitration of 
retinal proteins .Figure 7.42 summarises these findings.  
 
Figure 7.42 Ratio of MnSOD to 3 
Nitrotyrosine expression in untreated res and 
veh WT 
Line graph showing the ratio of MnSOD to 3 
Nitrotyrosine expression in (A)retinal layers 
and (B)brain of untreated res and veh treated 
WT. The table insert shows the percentage 
difference between groups. 
 
7.6.7 Discussion of 3 nitrotyrosine deposition in res treated WT 
Res treated WT had a mean 212% increase in 3 nitrotyrosine deposition in the retina compared to 
untreated WT. Despite this the ratio of MnSOD to 3 nitrotyrosine was comparable to the values 
observed in untreated WT. This would suggest that resveratrol did not prevent the deposition of 
nitrotyrosine. Res treated brain had a 69% increase in nitrotyrosine compared to untreated WT.  
Veh treated WT had  an  increase of 143% in 3 nitrotyrosine deposition compared to untreated WT. 
Because of the reduction in MnSOD expression, the ratio to nitrotyrosine exceeded untreated WT 
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values in the PRL, INL and IPL. Nitrotyrosine deposition in veh treated WT brain was reduced by 
70% compared to untreated WT. 
7.6.8 Summary of Chapter 7: Resveratrol administration in C57BL/6 mouse 
7.6.8.1 Reduced organ weight and lower motor function in res WT 
Compared to untreated female WT, female resveratrol treated WT mice had a significant increase in 
body weight, with a reduction in brain weight and cardiac weight ratio. Lower motor function was 
reduced in female WT. 
7.6.8.2 Cognitive impairment in res treated WT 
Compared to untreated WT, res WT cognitive function was impaired in T maze testing with a 
significant reduction in discrimination ratio. NOR demonstrated a reduced IR and DR in res  WT not 
observed in veh WT. Despite their reduced fear response, discrimination was reduced. 
7.6.8.3 Bioenergetic dysfunction in res treated WT 
In resveratrol treated WT C57Bl/3 mouse, all complexes of the ETC tested were impaired. Complex I 
activity showed the greatest reduction of 63%. Tissue specific ETC impairment was highest in res WT 
spinal cord with 77% reduction in ETC activity. The ratio of complex activity was preserved in res 
WT. 
7.6.8.4 Antioxidant activity in res treated WT 
The antioxidant activity in res WT was enhanced by the administration of resveratrol. Despite the 
enhanced activity of MnSOD, the tissue specific reduction of both catalase and CuZnSOD resulted in 
oxidative stress most notably in the spinal cord. 
7.6.8.5 Protein expression profile in res treated WT 
Resveratrol treated mitochondrial related protein expression in WT brain was increased but was 
combined with increased damage mediated protein expression. There was an insufficient 
compensatory protein response to this damage. expression. Resveratrol treated retina showed an 
enhanced protein and compensatory protein expression. 
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The administration of resveratrol did not confer any identified advantage to C57Bl/6 mouse.  
The reduced neuromuscular activity seen on In Vivo testing was compounded by the increase in 
body weight.  Bioenergetic activity in res treated WT was reduced to the level of untreated Het. 
The antioxidant status was unbalanced with the increase in MnSOD there was a reduction in 
spinal cord CuZn SOD and catalase activity.  Despite the increase in mitochondrial related 
proteins, the ratio was unbalanced favouring damage mediated protein expression over 
compensatory in res WT brain. 
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Chapter 8 Discussion of Opa1Q285STOP mouse model 
8.1 Spectrum of phenotypic anomalies in Opa1Q285STOP mouse 
The physical abilities of Opa1
Q285STOP
 mouse were tested at 12 months of age. This was at the 
onset of ophthalmic deterioration. However, it would appear that Opa1
Q285STOP 
mouse had 
several impaired neuromuscular and cognitive mechanisms as determined by a variety of tests.  
Other physical impairments not before associated with this mouse model were neuropsychiatric 
function associated with reduced exploratory behaviour, prolonged extended freeze in novel 
environments, extended latency to investigate – all of which are associated with depressive 
states. The Opa1
Q285STOP
 mouse model appeared to lack the adaptive stimuli specific response to 
his environment. Figure 8.1 shows some of the anomalies associated with Het neuromuscular 
function.  
 
Figure 8.1 Opa1
Q285STOP
 
mouse on the tight rope 
Opa1
Q285STOP
 mouse on the 
tightrope demonstrating 
reduced lower motor 
function –note the lack of 
hind paw grip and nail use 
on front right paw. Reduced 
autonomic function – note 
the lack of prehensile tail. 
 
Impaired cognitive function was identified which related to region specific impairment in Het 
brain. . T maze tested the functional activity of the hippocampus and specifically the dorsal 
hippocampus where spatial reference memory acquisition is located. (Bannerman et al. 1995). 
The anterior hippocampus is located in close proximity to the amygdala which controls 
behaviour in anxiogenic conditions. Anxiety as a tonic response to aversion depends on the 
anterior hippocampus but fear is controlled by the amygdala. Dorsal hippocampal spatial 
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reference is influenced by the anterior hippocampal response. The anterior hippocampal 
response is modulated by stress (Kim et al. 2001). The IR of T maze demonstrated female Het 
mice specifically had enhanced anterior hippocampal dysfunction. Dorsal hippocampal 
discrimination in both male and female Het mice was impaired. 
Novel object recognition examined the function of the perirhinal cortex (Murray et al. 2007; 
Kim et al. 2014).  By employing objects made from different substrates, the false positive effect 
was avoided, (Kivisaari et al. 2013). The perirhinal cortex facilitates the recognition of objects 
through the combined inputs and outputs to other structures including the entorhinal cortex 
(Clark et al. 2000), involving olfactory association, insular cortex (Bermudez-Rattoni et al. 
2005) via somatosensory inputs, the cingulate cortex (Aggleton et al. 1997; Ennaceur et al. 
1997), which  plays a role in attention and memory retrieval (Leech and Sharp 2014) and the 
para hippocampal gyrus responsible for environmental recognition including topographical cues 
(Epstein and Kanwisher 1998). Functional perirhinal activity was impaired specifically in male 
Het mice with a significant reduction in IR. Somatosensory deficit was also evident in male Het 
mice with a significantly reduced DR. Figure 8.2 shows a map of Opa1
Q285STOP 
mouse brain with 
specific regions of impaired function in specific pathways identified in cognitive testing. 
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Figure 8.2 Impaired cognitive 
function in Opa1
Q285STOP
 
mouse  
Brain specific regions in 
Opa1
Q285STOP
 mouse brain 
showed impaired function as 
demonstrated by cognitive 
function analysis. The combined 
parameters of T maze and NOR 
are applied where applicable. 
Untreated Het response to novel 
showed heightened stress 
response (amygdala) influencing 
hippocampal spatial reference 
and acquisition. Perirhinal 
cortex activity dependent on 
combined cingulate, insular and 
entorhinal cortex inputs specific 
to NOR testing was impaired. 
 
 
 
8.1.1 Spectrum of human phenotypic anomalies with ADOA Plus syndrome 
ADOA Plus humans have neuromuscular and neurological involvement. The presence of MS 
like symptoms have been reported with cerebellar ataxia and spastic paraplegia (Verny et al. 
2008; Milea et al. 2010; Yu-Wai-Man et al. 2010; Marelli et al. 2011; Pretegiani et al. 2011; 
Liskova et al. 2013). Symptoms can be indistinguishable from other degenerative diseases such 
as hereditary spastic paraplegia (Finsterer et al. 2012; Klebe et al. 2012; Kumar et al. 2013) , 
multiple sclerosis (Verny et al. 2008; Yu-Wai-Man et al. 2010) and Alzheimer’s disease (Wang 
et al. 2009). 
Reduced neuronal plasticity in mitochondrial associated disorders can cause phenotypic 
behavioural patterns. Mood disorder like phenotypes may be associated with the accumulation 
of mitochondrial mutations (Kasahara et al. 2006). There is also the significant association 
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between neuron-specific mitochondrial mutations and mood disorder phenotypes (Kato 2001; 
Kasahara et al. 2006). Suboptimal  mitochondrial function can be found in human depressive 
states (Morava and Kozicz 2013) which would agree with the SHIRPA neuropsychiatric 
functional assessment in Opa1
Q285STOP
 mouse. 
8.2 Spectrum of bioenergetic anomalies in Opa1Q285STOP mouse 
The reduction in cognitive function may be due to a decline in the brain reserves of ATP when 
functioning under stressful conditions. Male Het mouse showed enhanced ATP levels compared 
to WT.  Opa1
Q285STOP
 mouse showed a significant increase in the proportion of smaller sized 
mitochondria. This may indicate that the threshold for mitophagy onset differs in Het mouse. 
Mitophagy is initiated when small sized mitochondria with a reduced m present. The m 
of Het mitochondria did not differ to WT so despite the reduction in size, these mitochondria 
were functional. However the precise location of mitochondria within brain is significant for the  
limits of bioenergetic threshold. Non synaptic brain mitochondria can withstand a 72% 
reduction in complex I activity before there are significant changes in ATP orm. In synaptic 
mitochondria, the threshold is reduced to 25% (Davey et al. 1997; Davey et al. 1998). As the 
ATP determination assays were performed on a complete half of brain, partial length spinal cord 
and whole retina, specific regional differences in ATP would not have been detected. The 
reduction of m. in synaptic mitochondria may be a protective mechanism against the 
generation of ROS. ROS production requires a minimum mitochondrial membrane potential of -
350mVm (Korshunov et al. 1997). 
The bioenergetic deficits observed in Het mouse were 54% for complex I, complex II 32% and 
complex IV 5%.  The tissue specificity of this dysfunction revealed that retinal mitochondria 
had the highest percentage reduction in activity with 77% reduction for complex I and 58% for 
complex IV. However on examination of the ratio of ETC, it was observed that complex II 
activity has the highest activity in the retinal mitochondria with 55%. Complex I activity has 
38% activity in the spinal cord and complex IV has 40% activity in the brain. Het retained these 
ratios albeit at a reduced rate. 
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As complex I is the proximal component of the ETC, it is responsible for transfer of electrons to 
ubiquinone. By passing electrons from the mitochondrial matrix to the inner membrane space, it 
also maintains the mitochondrial electron gradient m. A reduction in complex I activity 
should therefore result in reduced ATP synthesis and a reduced m.  As this was not so in 
Het, an alternate mechanism is proposed: As a Another preventative mechanism for ROS 
generation is the presence of  intermembrane cytochrome c peroxide (Gilmour et al. 1994). 
Intermembrane cytochrome c can bypass the superoxide producing electron chain by the 
external NADH-cytochrome b5 reductase in the outer membrane and can oxidize superoxide to 
oxygen preventing the formation of H2O2 (Figure 8.3).  When cytochrome c is released, electron 
transport in the complexes is inhibited due to limitations on cytochrome c oxygenase 
(Kuznetsov et al. 2004). Cytochrome c release into the cytosol forms a complex with Apaf-1, 
(Vaux 1997),  which in turn triggers a cascade of apoptotic signals. If the imminent cession of 
electron transport can be by-passed through a cytosolic cytochrome c substrate, this will reduce 
complex I mediated ROS generation (La Piana et al. 1998; Skulachev 1998).  It also gives 
complex 4 the task of maintaining the m. This mechanism would appear to be operational in 
Opa1
Q285STOP
 mouse. It provides a rational for normal ATP levels and essentially normal m 
observed in brain and retinal mitochondrial isolates. Figure 8.3 shows a schematic of the 
proposed function of intermembrane cytochrome c. 
Figure 8.3 Mitochondria maintain 
function following cytochrome c release 
Intermembrane cytochrome c can pass 
electrons directly to complex 4 thereby 
reducing complex 1 mediated ROS. 
Complex 4 becomes responsible for 
maintaining m. 
 
 
The activity of employing intermembrane cytochrome c to pass electrons directly to complex IV 
may have tissue specific restrictions. The retinal phenotype of Opa1
Q285STOP 
mouse is age related 
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with symptoms beginning from 12 months. As mouse maturation rate is 25 times faster (Flurkey 
et al. 2007b, a) than human at this age, the presentation of advanced pathologies may not be 
surprising. Figure 8.4 shows the mouse aging process in relation to human aging with 
maturation rate equivalents. 
 
Figure 8.4 Representative 
mouse age range in 
C57BL/6 with human age 
equivalents 
Mouse age in months and 
its relation to human age in 
years. As mouse maturation 
is 25 times faster than 
human at 12 months, the 
accelerated pathology of 
OPA1 mutation can be 
expected. 
 
The preservation of complex ratios in Het CNS might explain how faced with significant 
reductions in bioenergetic activity Het mouse remained in good health. The preservation of 
ratios in complexes II and IV might suggest that complex I mediated impairment acts as the 
trigger mechanism for altering the threshold of the other components in the chain.  The 
provision of a voluntary running saucer may have provided a mitochondrial advantage to middle 
aged Het mouse (Iqbal et al. 2013; Fealy et al. 2014; Zhang et al. 2014). The modest fat content 
of mouse diet also conferred advantages to maintaining mitohormesis (Bosma 2014; Feillet-
Coudray et al. 2014). Table 8.1 shows a summary of the ratios of individual complexes and the 
tissues they were associated with. 
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CI B SC Ret
WT 29 38 33
Het 45 33 22
CII B SC Ret
WT 21 23 56
Het 21 19 60
CIV B SC Ret
WT 41 30 29
Het 43 42 15
Table 8.1 Ratios of complex activity and tissue  association 
Table shows a summary of the ratio of individual complexes in each 
tissue. Complex I activity was highest in spinal cord, complex II was 
highest in retina and complex IV was highest in brain. 
 
 
 
8.2.1 Spectrum of human bioenergetic anomalies in ADOA Plus syndrome 
Bioenergetic analysis in human ADOA has been performed on isolated lymphocytes where 
patients with normal vision showed an increased complex II and III activity with increased 
complex IV proteins. Reduced OPA1 impairs ETC efficiency, but compensation through 
increased distal complexes activity may preserve mitochondrial ATP production in patients who 
maintain normal vision (Van Bergen et al. 2011). Cell culture of human skeletal muscle biopsy 
showed a deficiency in complex I mediated bioenergetics (Lodi et al. 2004). This was in 
agreement with findings. Fibroblasts from ADOA individuals showed reduced complex I  
activity and demonstrated the association between Opa1 and complexes I, II and III but not IV 
(Zanna et al. 2008). 
8.3 Resveratrol therapy in Opa1Q285STOP mouse 
The administration of resveratrol to Opa1
Q285STOP
 mouse from conception to 15 months revealed   
a reduction of brain and cardiac weight ratio in female Het. This further compounded 
neuromuscular testing as weight can have a significant impact on performance. SHIRPA 
analysis revealed that sensory function in res Het was significantly more impaired compared to 
untreated Het. Resveratrol treated Het mice demonstrated a reduced fear response and thus 
showed enhanced cognitive function through investigation and discrimination ratios compared 
to untreated Het mice. 
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8.3.1 Spectrum of bioenergetic dysfunction in res treated Opa1Q285STOP compared to WT 
The administration of resveratrol to Het mouse restored the activity of complex I to 20% higher 
than that of WT. Complex IV activity was 10% higher than that of untreated WT but complex II 
mediated activity was 47% less than WT. Untreated Het complex II activity was reduced by 
59% therefore resveratrol did not confer any advantage. As previously discussed, untreated Het 
maintained the correct ratio of bioenergetic activity, notably the retinal mitochondria showed 
over 60% complex II specific activity. This was also observed in veh Het retinal mitochondria.  
Therefore the findings of SHIRPA in res Het were confirmed. The bioenergetic activity in 
retinal mitochondria of res Het favoured complex IV activity. This clearly did not confer any 
functional advantage as res Het sensory function was over 500% higher than untreated Het.  
The antioxidant activity in res treated Het was examined. Mitochondrial MnSOD showed a 
significant 83% higher activity compared to untreated WT. Considering that untreated Het had a 
76% reduction; this greatly enhanced activity can be expected to generate a significant amount 
of ROS.  Figure 8.5 shows the mitochondrial environment of WT, Het and res Het 
demonstrating the significant ROS enhanced environment initiated by resveratrol. 
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Figure 8.5Schematic of the 
mitochondrial environment in WT 
and Het 
WT (A) production of excess 
superoxide (O2

) from complexes I 
and III are dismutated by MnSOD. 
This results in the production of 
H2O2 and O2. Catalase decomposes 
H2O2 to H2O and 02. Het (B) shows 
reduced superoxide production due 
to reduced activity of complex I (and 
potentially complex III). The 
reduced MnSOD can dismutate a 
modest amount of O2

 to H2O2 and 
O2. Reduced catalase decomposes 
some H2O2 but the remainder allows 
further generation of radicals with 
transition metals (Fenton reaction). 
(C) Res Het has excess MnSOD 
which dismutates O2

 rapidly 
producing an excess of H2O2. 
Resveratrol did not enhance 
catalase activity, thus allowing a 
higher concentration of H2O2 in Het 
mitochondria that previously found 
to generate even more radicals. 
8.3.1.1 Resveratrol induced mitochondrial alterations in res Het mouse 
The dose dependency of resveratrol is critical. Specific dose response effects of resveratrol  in 
isolated cell populations  have been performed  (Hofer et al. 2014).  At concentrations of 75M 
and less, resveratrol enhanced the production of complex I, complex II and complex VI. It also 
increased the concentration of VDAC and TIM22 import channel. At concentrations of 100M 
and higher, the reverse effects were observed. In the presence of resveratrol at a concentration 
of 50M, neuronal cell response to stress resulted in increased mTOR phosphorylation and 
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increased AMPK activation.  Resveratrol increased the electron transfer supercomplex rather 
than individual complexes (Hofer et al., 2014). 
Cytochrome P450 is mono oxygenaase that catalyses several reactions involved in drug 
metabolism. CYP3A4 is a member of the cytochrome P450 family. It localises to the ER and its 
expression is induced by glucocorticoids. Mitochondrial P450 employ adrenodoxin reductase to 
transfer electrons from NADPH to P450.  Resveratrol inhibits CYP3A4 which could potentially 
increase the bioavailability and toxicity of other drugs (Piver et al. 2001; Regev-Shoshani et al. 
2004).This may explain the effects of 0.1% ethanol content in resveratrol therapy. 
Resveratrol has antioxidant properties which include the ability to scavenge O2

 and metal 
induced radicals (Martinez and Moreno 2000; Leonard et al. 2003; Losa 2003; Yen et al. 2003). 
Resveratrol  also exhibits pro oxidant effects including lipoperoxidation (Martins et al. 2013), 
and DNA damage (Rahman et al. 1990). Resveratrol had been reported to reduce catalase 
activity in rats (Skrajnowska et al. 2013). In isolated cardiomyocytes, catalase activity was 
reduced in the presence of H2O2  (Movahed et al. 2012). This suggested that resveratrol was 
unable to initiate up regulation of catalase production in the face of increased H2O2. 
The resveratrol induced increase in MnSOD activity has been established (Robb et al. 2008a; 
Robb and Stuart 2014). More recently, the effects of resveratrol on the expression level of 
CuZnSOD mRNA and catalase mRNA demonstrated significant inhibitory activity (Yang et al. 
2013).  
The pathogenic effects of excess H2O2 can have further downstream effects. The transient 
receptor potential canonicals (TRPC) are cationic channels consisting of two subfamilies 
divided on their structure. The activation of TRPC5 is H2O2 dependent and modulated by 
catalase. Catalase provides a protective role in brain mitochondrial function    (Nazıroğlu 2012).  
The presence of H2O2 activates TRPC which responds by opening a non-specific cation channel 
leading to increased calcium influx. The oxidative stress induced calcium stimulated 
mitochondrial uptake is modulated by catalase.  TRPC5 is also implicated in hippocampal 
neurite outgrowth  (Strübing et al. 2001) and the associated AHN (adult hippocampal 
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neurogenesis)  (Greka et al. 2003). TRPC5 in the amygdala is also responsible for fear 
conditioning  (Riccio et al. 2009) and regulates the inborn fear response behaviour.  This 
behavioural response was noted to be reduced in resveratrol treated Het population who 
performed tight rope and narrow beam tests.  Resveratrol has been identified as an inhibitor of 
TRPC5 which is independent of  its antioxidant capabilities   (Naylor et al. 2011). At 
concentrations of between 4-30M, resveratrol inhibited TRPC5 in a sustained fashion. By 
either increasing catalase production or reducing H2O2, the detrimental effects observed in res 
treated Het physical phenotype began to explain themselves. 
8.4 Spectrum of phenotypic anomalies in C57Bl/6 WT mouse 
If a very brief summary of res WT mouse phenotype was required, it would be accurate to say 
that C57Bl/6 WT exhibited almost identical In Vivo and In Vitro pathologies. There were some 
significant differences in res WT which included a substantial increase in body weight 
combined with a significant reduction in brain weight and cardiac weight ratio. Their In Vivo 
neuromuscular performance was not significantly different compared to untreated Het with 
reduced latency on rotarod which allowing for body weight suggested impaired neuromuscular 
function. They also exhibited a reduced fear response but not to the extent as res Het as the 
percentage reduction compared to untreated WT was statistically higher than that of res Het. 
8.4.1 Spectrum of bioenergetic dysfunction in C57Bl/6 WT 
Res treated WT bioenergetic profile for complex I activity showed a 63% reduction in activity 
compared to untreated WT. Untreated Het had a 64% reduction. Complex II activity was 
reduced by 44% in res WT and 59% in untreated Het. Complex IV activity was reduced by 18% 
in res WT and 22% in untreated Het.  The only important interpretation from this data that can 
be inferred is that res WT mitochondria were doing whatever was necessary to maintain 
function in a deleterious environment. As is happened to be identical to untreated Het was not a 
coincidence.  
Clearly untreated Het are compensating for impaired fusion from the time of conception. Het 
mouse has a normal possibly extended lifespan (personal observation) despite their reduced 
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mitochondrial fusion abilities. As this is a congenital mutation, it is possible that compensatory 
changes are initiated as part of a postnatal adaptation mechanism (Escobar et al. 2013). 
Despite the bioenergetic dysfunction observed in res WT, the ratio of complex II activity was 
preserved in retinal mitochondria. The ratio of complex I was not preserved for spinal cord but 
for brain. The ratio of complex IV was not preserved for brain but retina. This alteration in 
complex mediated tissue specific activity is possibly why their neuromuscular performances 
were impaired.   
Resveratrol has been reported to have an adverse effect in hippocampal neurogenesis. 
Administration of resveratrol  and adverse hippocampal neurogenesis  was first reported in 
2012(Park et al. 2012). At a concentration of 10mg/kg, the activation of AMPK results in 
reduced proliferation and survival of neural progenitor cells in the dentate gyrus of the 
hippocampus Reduced brain derived neurotrophic factor (BDNF) in the hippocampus of mice 
results in impaired neurogenesis (Lee et al. 2002; Duan et al. 2003). Resveratrol reduced BDPF 
in a dose dependent manner.  Resveratrol down regulates phosphorylated  cyclic AMP (cAMP) 
response element binding protein  (pCREB)  (Kim et al. 2010). The requirement of pCREB in 
spatial learning and memory is well established (Nagakura et al. 2002; Martel et al. 2006; Porte 
et al. 2008). Resveratrol activates SIRT1 whether directly or indirectly. Enhanced SIRT1 
activity can impair and prevent adult neural precursors from differentiating into neurons 
(Saharan et al. 2013). This suggests SIRT1 is a negative regulator of neuronal differentiation. 
There are two regions in brain that are capable of generating new neurons – the subventrical 
zone and the dentate gyrus (Spalding et al. 2013). Many factors affect adult hippocampal 
neurogenesis (AHN) including environmental enrichment (Kempermann et al. 1997; van Praag 
et al. 1999). Aging, stress and anxiety all have detrimental effects (Prickaerts et al. 2004; 
Mirescu and Gould 2006). Given that the untreated Het population had identical bioenergetic 
dysfunction compared to res treated WT, it would appear the provision of a running saucer 
provided more beneficial support to Opa1
Q285STOP
 mouse than the administration of resveratrol 
(Nishijima et al. 2013). Figure 8.6 summarises the percentage difference observed in untreated 
Het, res Het and res WT when compared to untreated WT. 
Chapter 8 Discussion of Opa1
Q285STOP 
mouse model 
 
326 
 
 
Figure 8.6 Summary of Untreated, res and WT treated mitochondrial profiles 
This flow chart shows line graphs of the percentage difference observed in untreated 
Het, res Het & WT when compared to untreated WT. (A) shows the results of 
neuromuscular testing SHIRPA, rotarod, tight rope and narrow beam. (B) shows 
bioenergetic activity. (C) shows antioxidant activity. (D) shows the protein expression 
profiles in retina and brain. 
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8.5 Conclusions on resveratrol as a therapy for Opa1Q285STOP mouse 
With the benefit of hindsight, the potential to augment the effects of resveratrol delivered as an 
ethanol based therapy with P450 (CYP3A4) inhibition (Piver et al. 2001; Lu et al. 2013), would 
now appear perilous in the face of fusion deficiency. The bioavailability of resveratrol following 
ingestion is dependent on the availability of sulfatases. Resveratrol is metabolised into 
glucuronides and sulfates of resveratrol. Steroid sulfatases decongugate resveratrol sulfates at 
the required time or location. Meanwhile, resveratrol can be transported as a stable sulfate 
conjugated complex in plasma (Patel et al. 2013). This now suggests that resveratrol may have a 
cumulative effect.   
Administration from before the age of retinal phenotype onset (~10 months) may prove more 
instrumental in preservation of mitochondrial bioenergetics. However, resveratrol does not have 
a role in the therapy of any retinal disease. Complex II activity is highest in the retinal 
mitochondria. Resveratrol specifically reduced the activity of complex II in both WT and Het 
mice. Therefore it must be considered that it offers no advantage to Opa1
Q285STOP
 mouse. 
8.6 Implications for novel therapy in Opa1Q285STOP mouse 
Opa1
Q285STOP
 mouse model of ADOA represents a late onset ‘Plus’ model of disease. From 12 
months, mouse vision deteriorates with respect to retinal function. The reason for this 
deterioration must be found in the mitochondria that serve a more immediate purpose. A 
reduction in mitochondrial fusion would be expected to result in reduced m. However if the 
population of mitochondria are physically small, the m threshold may be simultaneously 
reduced. This will influence mitophagy which targets mitochondria specifically with reduced 
m. Reduced complex I activity may be a preventative measure against ROS induced 
mitochondrial damage. Utilizing intermembrane cytochrome c also reduces the potential for 
ROS.  With advanced age the mechanisms maintaining Opa1
Q285STOP
 mitochondrial function 
becomes impaired.  
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In Opa1
Q285STOP
 mouse, the age related reduction of cytochrome c may occur prematurely. At 10 
months, the reproductive life span of mouse is at an end and the natural cycle of events dictates 
that mouse has no more to contribute to the gene pool. 
Therefore the pathology associated with Opa1 reduction might be targeted directly. Cardiolipin 
is responsible for holding the electron transport chain as a supercomplex (Zhang et al. 2002a; 
Mileykovskaya and Dowhan 2014). Cardiolipin is an anionic phospholipid found in micro 
domains of the IMM (Ardail et al. 1990). Preli provides the phosphatidic acid required for 
cardiolipin synthesis. It bonds non covalently to cytochrome c (Tyurin et al. 2007). The space 
between complexes III and IV is 6nm (Kurisu et al. 2001). Cardiolipin occupies the space 
between the supercomplexes to facilitate transfer of electrons. A reduction in cardiolipin results 
in alternations between the individual complex spacing and specifically results in complex 4 
depletion (Ostrander et al. 2001; Bazán et al. 2013). 
The Opa1: cardiolipin interaction enhances GTP hydrolysis  (Ban et al. 2010).  Lipid binding, 
GTP hydrolysis and membrane tubulation are key events in fusion. If the availability of Opa1 
protein is reduced, the possibility exists that cardiolipin is reduced. Figure 8.7 shows a 
hypothetical schematic of Opa1 and cardiolipin interaction in WT and in Opa1
Q285STOP 
mouse.  
As Opa1
Q285STOP
 mouse ages, the number of available mitochondria with a WT copy of the 
OPA1 gene is reduced. Cardiolipin levels reach a threshold where complex IV formation 
becomes compromised and phenotypic changes become evident. If the complex IV subunit of 
the supercomplex is not present in sufficient quantity, then therapy designed to maximise its 
electron transfer ability may force it beyond a recoverable state. 
 
 
Chapter 8 Discussion of Opa1
Q285STOP 
mouse model 
 
329 
 
 
Figure 8.7 Opa1 Cardiolipin interaction 
(A)Cardiolipin and Opa1 interact at the IMS enhancing GTP hydrolysis. Cardiolipin 
bonds non- covalently to cytochrome c assisting Opa1 in its segregation within cristae. 
Cardiolipin is responsible for complex IV assembly to a functional unit. (B)Reduced 
Opa1 combined with reduced cardiolipin resulting in poorly sequestered cytochrome c. 
Complex IV non assembly resulting in reduced membrane potential all trigger 
mitophagy in high ATP dependent cells.  
8.6.1 A novel therapy for OpaQ285STOP mouse 
Mitochondrial specific therapies designed at correcting a cardiolipin imbalance are available 
(Zhao et al. 2004). A peptide drug SS-31 is a Szeto-Schiller (SS) peptide that specifically targets 
the inner mitochondrial membrane.  It selectively binds to cardiolipin through hydrophobic 
interaction and prevents the conversion of cytochrome c to peroxidase. SS-31 peptide has 
antioxidant properties  in the form of a dimethyltyrosine residue (Szeto 2006). SS-31 has been 
used in ischemia-reperfusion injury (Cho et al. 2007), protection against neurodegeneration 
(Yang et al. 2009) and the prevention of insulin resistance. An improvement in the age related  
effects of skeletal muscle have been observed in  27 month old mouse following 1 injection  
(Siegel et al. 2013). Vehicle treated mice were given saline ! 
By considering the many functions of Opa1, addressing the possible cause of reduced ETC 
function in late onset ADOA may be more beneficial than targeting individual complexes. The 
generation of ROS in Opa1
Q285STOP
 mouse with a profound complex I reduction is a 
misconception (Ian Holt personal communication). 
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8.7 Conclusions on a mitochondrial profile of Opa1Q285STOP  mouse 
This study attempted to address some of the unanswered questions regarding the disease profile 
in a mouse model of ADOA. It identified a range of disorders particular to the CNS whose 
effects were identified in the musculoskeletal, neurological, and neuropsychiatric systems. It 
examined aspects of the differences between the sexes. It also considered ‘environmental’ 
conditions, which affected the tolerance for Opa1 mutation. In view of this extended profile, 
Opa1
Q285STOP
 mouse model may be considered a ‘plus’ model of the disease. 
The findings supported a bioenergetic deficit as the likely cause of disease onset. The ATP 
content was not reduced. The ratio of complex II activity was highest in retinal mitochondria 
and complex II supports less equivalents of ATP production. Although there were deficits in the 
antioxidant system, these were homogenous across the range of tissues examined thus not 
indicative of a tissue-targeted disorder. The administration of resveratrol disrupted the in-built 
compensatory mechanisms that appear to be inherent in Opa1
Q285STOP
 mouse model. It altered 
the ratio of individual complex activity in specific tissues. Resveratrol did not appear to confer 
any mitochondrial advantage to Opa1
Q285STOP 
mouse when administered from conception to 15 
months but more importantly resveratrol did not appear to damage Opa1
Q285STOP
 mouse. There 
was no change in the lifespan of treated Het compared to untreated Het. The retinal specific 
disruption of complex ratio activity indicates that resveratrol is not suitable therapy for retinal 
disorders. 
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Appendix  A Lux readings from Redwood animal house 
 
 
Lux readings converted from candela m
2 
including wavelength spectrum of triphosphor 
tubes 3000k 18w warm white in place. All mouse cages were located in the same room. 
Top cages were not used due to the increase in lux. All other locations where mouse 
procedures were performed were also measured. 
 
 
 
 
 
 
Equation  Ev=IvD2measuring distance D (m) 
From Candela (Iv ) To Lux (Ev) 
OPTOM 2.61
Mouse bench 7.6 7.4 7.51 3.38 3.29 3.34 3.33
Tissue bench 40.9 42.6 48.5 18.18 18.93 21.56 19.55
Redwood
Res RackRow 1 56.5 49.7 54.4 Row 1 25.11 22.09 24.18 23.79
Row 2 14.6 23.8 24.4 Row 2 6.49 10.58 10.84 9.3
Row 3 7.2 8.5 18.5 Row 3 3.2 3.78 8.22 5.06
Row 4 5.8 4.8 15.4 Row 4 2.58 2.13 6.84 3.85
Row 5 6.8 4.8 13.5 Row 5 3.02 2.13 6 3.71
Row 6 6.4 5.4 8 Row 6 2.84 2.4 3.56 2.93
Row 7 6.2 4.8 8.3 Row 7 2.76 2.13 3.69 2.86
Stock rackRow 1 39.4 17.4 31 Row 1 17.51 7.73 13.78 13
Row 2 9.4 18.3 23 Row 2 4.13 8.13 10.22 7.49
Row 3 8.5 6.3 7.6 Row 3 3.78 2.8 3.38 3.32
Row 4 5.5 4.9 6.5 Row 4 2.44 2.18 2.89 2.5
Row 5 6.3 3.6 9.6 Row 5 2.8 1.6 4.27 2.89
Row 6 8.3 3.6 5 Row 6 3.69 1.6 2.22 2.5
Row 7 7 2.3 6.11 Row 7 3.11 1.02 2.72 2.28
Double rackRow 1 21.8 16.1 Row 1 9.69 7.16 8.42
Row 2 17.4 6.8 Row 2 7.73 3.02 5.37
Row 3 12.3 6.5 Row 3 5.47 2.89 4.18
Row 4 11.25 9.3 Row 4 5 4.13 4.56
Row 5 8.8 7.5 Row 5 3.91 3.33 3.62
Row 6 7.8 6.8 Row 6 3.47 3.02 3.24
Row 7 6.5 5.4 Row 7 2.89 2.4 2.64
Room 78.9 30.7 44.6 118.4 35.07 13.64 19.82 52.62 30.28
(door open)
Room 72.6 22.2 38.1 45.7 32.27 9.87 16.93 20.31 19.84
(door shut)
Anteroom 149 163 163 66.0 72.2 72.4 29.3 59.98
Rotarod Room 106.4 108.6 107.5 47.29 48.27 21.02 38.86
Large cages
Res cages
Stock cages
Lux readings Mouse room Redwood
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Appendix  B Resveratrol Specification Sheet 
 
A copy of the original specification number R05 for resveratrol HP (high purity) 
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Appendix  C Resveratrol Trial Design 
 
Resveratrol three  armed trial consisted of untreated WT and Het, resveratrol treated 
WT and Het and vehicle treated WT and Het. There was a  total of 34 untreated WT and 
47 untreated Het. There was 26 res treated WT and 27 res treated Het. There was 12 
veh treated WT and 19 veh treated Het.  
 
 
 
 
Resveratrol 13.56mg/kg (219.06M)  or       Vehicle (ethanol 0.1% 17mM)                     
Resveratrol Trial  Design
               Vehicle
Ethanol 0.1%(17mM)
WT 12
F WT 6
M WT 6
Het 19
F Het 11
M Het 8
3 Armed trial
Mode of   Delivery: Drinking  water
     No Treatment
WT 34
F WT 24
M WT 10
Het 47
F Het 24
M Het 23
      Resveratrol 
13.5mg/Kg(219.06M)
WT 26
F WT 14
M WT 12
Het 27
F Het 16
M Het 11
               Vehicle
Ethanol 0.1%(17mM)
WT 12
F WT 6
M WT 6
Het 19
F Het 11
M Het 8
Vol/ml Dose Weight mg/kg
mg/ml  /kg
5.7 0.05 0.021 13.57
Vol/ml Dose Weight mg/kg
mg/ml  /kg
5.7 0.789 0.021 214.2
Breeding
Res Tx F WT F Het M WTM Het Total
Aug 2011 3 3 1 2 9
Oct 2011 4 4 4 4 16
Dec 2011 2 2 1 1 6
Mar 2012 2 5 2 0 9
Total 40
Breeding
Veh Tx F WT F Het M WTM Het Total
Aug 2011 0 2 0 1 3
Oct 2011 2 2 0 0 4
Dec 2011 1 2 0 0 3
Mar 2012 3 5 6 7 21
Total 31
      Resveratrol 
13.5mg/Kg(219M) 
WT 26
F WT 14
M WT 12
Het 27
F Het 16
M Het 11
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Appendix  D Weight monitoring in untreated, res & veh WT and Het  
 
Health monitoring in trial mice. Mice were weighed weekly  from time of weaning to 16 
weeks. Weight monitoring continued from week 16 on a monthly basis until 15 months. 
Untreated WT and Het males and females were included for comparative data 
collection. 
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Appendix  E SHIRPA Test Protocol  
 
SHIRPA primary screening protocol where specific functional analysis pertained to 
multiple test observations throughout the testing procedure. 
 
 
 
  
Muscle and lower motor neurone function
Body position Spontaneous activity Locomotor activity
Gait \tail elevation Limb position
Positional passivity Visual placing Abdominal tone
Wire maneuver Limb tone Urination/defacation
Righting reflex Passivity
Motor performance Balance and coordination
Spinocerebellar function
Body position Locomotor activity Gait
Tail elevation Limb position Visual placing
Grip strength Body tone Limb tone
Abdominal tone Righting reflex Motor performance
Balance and coordination
Sensory function
Transfer arousal Gait Limb position
Touch escape Visual placing Pinna reflex
Corneal reflex Toe pinch Righting reflex
Analgesic
Neuropsychiatric function
Body position Spontaneous activity Bizarre behaviour
Transfer arousal Locomotor activity Food and water
Startle response Touch escape Positional passivity
Body tone Righting reflex Cataplexy
Fear Irritability Aggression
Anxiety Vocalisation Prepulse inhibition
Learning and memory
Autonomic function
Palpebral closure Piloerrection Startle response
Tail elevation Skin color Salivation
Temperature Food water intake Respiration rate
Heart rate Urination Defacation
Tests contributing to assessment of Opa1 Q
285STOP
 mouse phenotype
Primary screen

Behavioural observation profile

Secondary Screen

Locomotor activity
Balance and coordination
Histology
Biochemistry
Tertiary screen

Anxiety
Learning and memory
Prepulse inhibition
Rogers  1997
SHIRPA Testing protocol
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Appendix  F SHIRPA  WT & Het 12 months  
Raw data for un treated WT & Het 
 
SHIRPA raw data in resveratrol treated WT and Het at 12 months. WT consisted of 
three males and three females. Het consisted of three males and five females.  Different 
observations of mouse behaviour were categorized in one of five ‘functions’ designed to 
identify anomalous behaviour in more than one category. SHIRPA score 
 
 
Mouse ID 2005 2019 2024 2008 2023 2026 2009 2025 2028 2010 2011 2012 2006 2004 2007
Genotype WT WT WT WT WT WT Het Het Het Het Het Het Het Het Het
DOB 18.07.11 15.07.11 18.07.11 09.07.11 18.07.11 18.07.11 09.07.11 18.07.11 18.07.11 09.07.11 09.07.11 09.07.11 18.07.11 18.07.11 18.07.11
Sex M M M F F F F F F F F F M M M
Housing Solo Pair Pair Group Group Group Group Group Group Group Group Group Group Group Group
Weight 35g 46g 37g 27g 26g 29g 24g 29g 29g 26g 29g 24g 32g 29g 32g
Date 30.09.12 30.09.12 29.09.12 30.09.12 30.09.12 29.09.12 29.09.12 29.09.12 29.09.12 29.09.12 29.09.12 29.09.12 30.09.12 29.09.12 29.09.12
Viewing Jar Score Spin mouse
A B Body position Inactive 0 0 0 0 0 0
Active 1 1 1 1 1 1 1 1 1
Hyperactive 2 2 2
D E Coat Well groomed 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Piloerection 1 1 1
Color Deep blackBrown Grey fleckDeep blackDeep blackDeep black Deep blackDeep blackDeep blackDeep black Grey fleckGrey fleck
B D E Defecation Present 0 0 0 0 0 0 0 0 0
Absent 1 1 1 1 1 1 1 1
B D E Urination Present 0 0 0 0 0 0 0 0 0
Absent 1 1 1 1 1 1 1 1
A D E Tremor Absent 0 0 0 0 0 0 0 0
Present 1 1 1 1 1 1 1 1 1
C E Palpebral closureEyes open 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Eyes closed 1
C E Lacrimation Absent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Present 1
Arena
A B D Transfer ArousalExtended freeze0 0
Brief freeze 1 1 1 1 1 1 1 1 1 1
Immediate move2 2 2 2 2 2
A B Gait Fluid 0 0 0 0 0 0 0 0 0 0 0
Other 1 1 1 1 1 1
A B E Tail elevation Dragging 0 0 0 0 0 0
Horizontal 1 1 1 1 1 1 1 (to Left) 1 1 1 1
Straub tail 2
A B E Pelvic elevation Less than 5mm0 0 0 0 0 0 0 0 0 0 0 0
more than 5mm1 1 1 1 1
2
C D E Startle response None 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
(Backward flip of pinnae)Preyer flick 1 1
C D E Touch escape No response 0 0 0 0 0 0 0 0 0 0 0
Response 1 1 1 1 1 1
Flees prior to 2
Above Arena
A B E Position Tail hold 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Scruff hold 1
supine 2
no struggle 3
A B E Trunk curl Absent 0 0 0 0 0 0 0 0 0 0 0
Present 1 1 1 1 1 1
A B E   Limb grasping Absent 0 0 0 0 0 0 0 0 0 0 0 0
Present 1 1 1 1 1
A B E Pinna reflex Present 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Absent 1 1
C E Corneal reflex Present 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Absent 1
A B E Contact righting Present 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Absent 1 1 1
C E Evidence biting None 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Attempted 1
C D Vocalisation None 0 0 0 0 0 0 0 0 0 0 0 0
Vocal 1 1 1 1 1
SHIRPA WT & Het 12 months
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Appendix  G SHIRPA  res treated WT & Het 12 months  
Raw data for resveratrol treated WT & Het 
 
Different observations of mouse behavior were categorized in one of five ‘functions’ 
designed to identify anomalous behavior in more than one category. In both res WT and 
res Het there were three males and three females. The individual SHIRPA scores  of 6 
resveratrol treated WT and 6 resveratrol treated Het mice are shown 
  
Mouse ID 2085 2086 2072 2075 2076 2065 2083 2070 2073 2074 2072 2066
Genotype WT WT WT WT WT WT Het Het Het Het Het Het
DOB 22.10.1122.09.1121.09.1121.09.119.09.1121.09.11 21.09.119.09.1121.09.1121.10.119.09.1121.10.11
Sex M M M F F F M M M F F F
Housing G G G G G G G G G G G G
Weight 32g 42g 35g 26g 25g 32g 34g 32g 31g 32g 26g 24g
Date 01.12.1201.12.1201.12.1201.12.1201.12.1201.12.12 01.12.1201.12.1201.12.1201.12.1201.12.1201.12.12
Viewing Jar
A B Body positionInactive 0 0 0 0 0 0
Active 1 1 1 1
Hyperactive 2 2
D E Coat Well groomed 0 0 0 0 0 0 0 0 0 0 0 0
Piloerection
Color flecked greydeep bl Bl Bl Brown flecked greyBl Br deep bl brown Br
B D E Defecation Present 0 0 0 0 0
Absent 1 1 1 1 1 1 1
B D E Urination Present 0 0 0 0 0 0 0
Absent 1 1 1 1 1
A D E Tremor Absent 0 0 0 0 0 0
Present 1 1 1 1 1 1
C E Palpebral closureEyes open 0 0 0 0 0 0 0
Eyes closed
C E Lacrimation Absent 0 0 0 0 0 0 0 0 0 0 0 0
Present
Arena
A B D Transfer ArousalExtended freeze 0 0 0 0
Brief freeze 1 1 1 1 1
Immediate move 2 2 2
A B Gait Fluid 0 0 0 0 0 0 1 1 Heel walk1 rear legs out0 0
Other
A B E Tail elevationDragging 0 0 0 0 0 0 0 0 0
Horizontal 1 1 1
Straub tail
A B E Pelvic elevationLess than 5mm 0 0 0 0 0 0 0 0 0
more than 5mm 1 1 1
C D E Startle responseNone 0 0 0 0 0 0 0
(Backward flip of pinnae)Preyer flick 1 1 1 1 1
C D E Touch escapeNo response 0 0 0 0 0 0
Response 1 1 1 1 1 1
Flees prior to
Above Arena
A B E Position Tail hold 0 0 0 0 0 0 0 0 0
Scruff hold 1 1 1
supine
no struggle
A B E Trunk curl Absent 0 0 0 0 0 0 0 0 0
Present 1 1 1
A B E   Limb graspingAbsent 0 0 0 0 0 0 0 0
Present 1 1 1 1
A B E Pinna reflexPresent 0 0 0 0 0 0 0 0 0 0 0 0
Absent
C E Corneal reflexPresent 0 0 0 0 0 0 0 0 0 0 0 0
Absent
A B E Contact rightingPresent 0 0 0 0 0 0 0 0 0 0 0 0
Absent
C E Evidence bitingNone 0 0 0 0 0 0 0 0 0 0 0 0
Attempted
C D VocalisationNone 0 0 0 0 0 0 0
Vocal 1 1 1 1 1
SHIRPA res WT & res Het 12 months
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Appendix  H Succinate content in complex 1 assay WT and Het 
 
Individual histograms of succinate concentration with line graphs of rate of NADH 
oxidation in isolated mitochondria from WT and Het brain (A), spinal cord (B) retina 
(C) and skeletal muscle (D). Mitochondria were suspended in storage buffer for a 
maximum time of 30 minutes at 4
o
C prior to assay for complex I. These graphs showed 
that the succinate content did not adversely affect the assay of complex I activity 
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Appendix  I  ETC substrate oxidation  WT and Het 
Calculation of substrate oxidation from line fittings 
 
Calculation of substrate oxidation in isolated mitochondria of WT and Het. From line 
fitting (A)Complex I oxidation of NADH using the absorption coefficient of NADH at 
340nm  6200 M
-1
 x cm
-1
at 460nm wavelength. (B) Complex II reduction of DCPIP using 
the absorption coefficient of  22 x 10
3
 M
-1
- cm 
-1
 at 600nm wavelength. (C) Complex IV 
oxidation of reduced cytochrome c using the absorption coefficient of  21.1 x10
3 
M
-1
 cm
-
1
 at 550nm wavelength. 
 
 
 
A: Complex I B: Complex II C: Complex IV
Complex I Brain Complex II Brain Complex IV Brain
Equation for linear regression I/A=At+B Equation for linear regression I/A=At+B Equation for exponential decay  A550(t)=A0
exp(-kt)
+A
WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT yo a b Het yo a b
1976 0.549 611.0 1970 0.360 607.5 2017 0.062 0.350 1956 0.022 0.359 1969 0.210 0.503 0.589 1977 0.367 0.408 1.000
1991 0.699 617.5 1977 0.387 598.0 1991 0.062 0.360 1977 0.031 0.366 1976 0.317 0.460 1.164 2001 0.365 0.408 1.000
1995 1.053 643.3 2001 0.360 605.2 2031 0.063 0.343 2001 0.023 0.361 1991 0.301 0.494 1.160 1970 0.288 0.484 1.161
2005 1.077 646.8 1990 0.424 604.6 1976 0.033 0.351 1955 0.028 0.361 1995 0.301 0.494 1.160 1990 0.364 0.408 0.998
2037 1.077 642.6 1993 0.512 613.6 2042 0.031 0.341 1956 0.033 0.357 2005 0.315 0.462 0.935 1993 0.365 0.434 0.998
1968 0.864 624.3 1999 0.481 615.3 1968 0.060 0.364 2040 0.018 0.352 2037 0.317 0.474 1.179 1999 0.360 0.408 0.998
2041 0.512 613.6 1955 0.392 610.6 2041 0.070 0.371 2039 0.011 0.353 1968 0.294 0.472 0.653 1955 0.354 0.408 0.989
2042 0.505 591.3 1956 0.425 605.9 2042 0.062 0.363 2039 0.018 0.353 2041 0.288 0.457 0.653 1956 0.311 0.484 0.933
2040 0.401 606.7 2042 0.291 0.462 0.653 2040 0.361 0.408 1.000
Complex I SC Complex II SC Complex IV SC
WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT yo a b Het yo a b
1991 1.035 662.7 1977 0.300 605.5 2024 0.060 0.340 2047 0.023 0.345 1976 0.277 0.506 0.735 1993 0.358 0.408 1.001
1976 1.000 643.9 2001 0.368 611.6 2019 0.059 0.356 2022 0.027 0.356 1969 0.359 0.383 0.696 1999 0.358 0.401 1.012
1969 1.000 642.9 1964 0.268 611.1 2026 0.063 0.365 2039 0.012 0.354 1991 0.268 0.519 0.737 2059 0.324 0.482 1.213
1995 1.049 351.3 1990 0.134 604.6 2029 0.064 0.357 2027 0.032 0.362 1995 0.361 0.383 0.696 1960 0.325 0.466 0.986
2005 1.036 631.4 1993 0.369 601.8 2031 0.060 0.342 1960 0.025 0.352 2005 0.269 0.499 0.517 1962 0.361 0.456 0.931
2037 0.852 622.8 1999 0.345 613.2 2008 0.054 0.365 1962 0.017 0.354 2037 0.291 0.494 0.734 2007 0.315 0.441 0.626
2024 0.814 622.4 2000 0.279 586.9 2059 0.012 0.356 2030 0.329 0.448 0.815 2001 0.341 0.456 0.931
2019 1.366 659.7 2022 0.343 618.8 2031 0.274 0.465 0.476 1964 0.321 0.446 0.755
2026 1.097 639.9 2047 0.334 618.9 2008 0.288 0.454 0.531 1977 0.264 0.475 0.426
2029 1.035 634.3 2039 0.426 605.3
Complex I  Retina Complex II Retina Complex IV Retina
WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT yo a b Het yo a b
2003 1.050 653.2 1992 0.165 594.8 2003 0.061 0.349 1962 0.024 0.346 1969 0.097 0.613 0.178 1950 0.537 0.182 0.405
2018 1.035 633.0 1963 0.195 578.9 2018 0.097 0.361 1963 0.493 0.352 2023 -2.196 2.888 0.022 2022 0.490 0.232 0.276
2017 0.814 621.6 1964 0.170 596.4 2017 0.061 0.363 1964 0.493 0.352 1995 0.101 0.616 0.176 1990 0.458 0.277 0.379
1976 0.905 622.0 1977 0.305 605.2 1976 0.096 0.367 1977 0.035 0.344 2005 0.102 0.618 0.176 1993 0.537 0.195 0.365
1975 0.747 605.1 1970 0.161 582.9 1975 0.097 0.363 1970 0.034 0.334 2037 0.563 23.260 0.003 1999 0.458 0.277 0.379
1968 0.816 623.9 2007 0.169 600.6 1968 0.093 0.355 2007 0.049 0.352 1989 0.368 0.384 0.428 2000 0.604 0.112 0.402
1969 0.947 601.8 2002 0.182 606.8 1989 0.093 0.357 2000 0.039 0.352 2029 0.369 0.383 0.431 2001 0.606 0.105 0.405
2023 0.814 633.2 1981 0.226 606.2 2029 0.062 0.357 2001 0.029 0.358 2030 0.351 0.398 0.435 2002 0.602 0.111 0.381
2036 0.707 620.3 1950 0.226 606.2 2030 0.102 0.375 2002 0.038 0.352
Complex I Muscle Complex II Muscle Complex IV Muscle
WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT yo a b Het yo a b
1969 0.457 598.9 1960 0.380 593.1 1969 0.037 0.361 1960 0.032 0.356 1976 0.391 0.356 0.820 1950 0.321 0.396 0.319
1976 0.599 608.2 1962 0.348 598.0 1976 0.065 0.367 1962 0.032 0.355 2008 0.361 0.390 0.653 1960 0.127 0.603 0.240
2008 0.362 594.7 2007 0.348 598.1 2008 0.029 0.353 2007 0.018 0.360 2018 0.379 0.362 0.734 1962 0.345 0.353 0.291
2018 0.905 622.0 2009 0.284 594.3 2018 0.041 0.358 2009 0.025 0.355 1969 0.411 0.348 0.836 2016 0.393 0.335 0.464
1950 0.325 593.5 1950 0.031 0.358 2009 0.238 0.474 0.153
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Appendix  J  SOD inhibition of formazan formation WT and Het. 
 
Percentage of inhibition of formazan formation were calculated from the calculation  
 
where S1 was formazan formation with no inhibition, S2 was sample minus enzyme and 
S3 was diluent only with no enzyme. Specific inhibition of MnSOD or CuZnSOD 
allowed different subtypes to be examined in (A) Brain, (B) spinal cord and (C) retinal 
homogenate of WT and Het.  
 
A: Brain B: Spinal cord C: Retina
Total SOD Brain Total SOD SC Total SOD retina
Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B
WT Slope y= I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c
2062 0.0074 0.0534 2016 0.0128 0.0681 1975 0.0015 0.0599 1962 0.0165 0.0487 2024 0.0141 0.0618 2110 0.0170 0.0628
2046 0.0058 0.0535 2011 0.0126 0.0707 1997 0.0015 0.0618 1955 0.0174 0.0469 2036 0.0144 0.0591 2111 0.0171 0.0619
2042 0.0065 0.0518 2012 0.0126 0.0666 2003 0.0014 0.0340 1964 0.0177 0.0429 2041 0.0145 0.0560 2112 0.0165 0.0879
2026 0.0060 0.0520 2028 0.0130 0.0808 2017 0.0221 0.0676 2009 0.0168 0.0667 1975 0.0146 0.0499 1964 0.0178 0.0598
2029 0.0074 0.0555 2032 0.0128 0.0783 2036 0.0230 0.0773 2010 0.0174 0.0532 2008 0.0138 0.0230 2000 0.0183 0.0597
2030 0.0083 0.0488 2033 0.0133 0.0823 2041 0.0220 0.0853 2011 0.0178 0.0414 2019 0.0152 0.0290 2009 0.0184 0.0509
2042 0.0222 0.0373 2012 0.0176 0.0453
Mn SOD Brain Mn SOD SC Mn SOD Retina
WT Slope y= I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c
2062 0.0105 0.0387 2016 0.0197 0.0555 1975 0.0221 0.0599 1962 0.0325 0.0782 2024 0.0161 0.0583 2110 0.0196 0.0672
2046 0.0132 0.0334 2011 0.0212 0.0417 1997 0.0216 0.0480 1955 0.0314 0.0721 2036 0.0168 0.0747 2111 0.0201 0.0659
2042 0.0108 0.0436 2012 0.0189 0.0474 2003 0.0215 0.0650 1964 0.0315 0.0576 2041 0.0168 0.0654 2112 0.0211 0.0878
2026 0.0134 0.0313 2028 0.0198 0.0324 2017 0.0237 0.0316 2009 0.0304 0.0420 1975 0.0222 0.0499 1964 0.0228 0.0755
2029 0.0134 0.0226 2032 0.0192 0.0367 2036 0.0222 0.0580 2010 0.0302 0.0503 2008 0.0205 0.0607 2000 0.0215 0.0630
2030 0.0132 0.0322 2033 0.0201 0.0339 2041 0.0238 0.0136 2011 0.0306 0.0420 2019 0.0205 0.0663 2009 0.0223 0.0711
2042 0.0239 0.0102 2012 0.0301 0.0503
CuZnSOD Brain CuZnSOD SC CuZnSOD Retina
WT Slope y= I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c WT Slope y=I/c Het Slope y=I/c
2062 0.0240 0.0392 2016 0.0307 0.0350 1975 0.0117 0.0490 1962 0.0149 0.0313 2024 0.0215 0.0340 2110 0.0224 0.0909
2046 0.0247 0.0323 2011 0.0297 0.0391 1997 0.0117 0.0254 1955 0.0132 0.0390 2036 0.0208 0.0597 2111 0.0221 0.0696
2042 0.0236 0.0397 2012 0.0294 0.0358 2003 0.0119 0.0401 1964 0.0149 0.0368 2041 0.0224 0.0729 2112 0.0224 0.0759
2026 0.0236 0.0397 2028 0.0278 0.0361 2017 0.0152 0.0429 2009 0.0184 0.0478 1975 0.0160 0.0475 1964 0.0196 0.0672
2029 0.0237 0.0277 2032 0.0277 0.0391 2036 0.0141 0.0732 2010 0.0185 0.0511 2008 0.0164 0.0517 2000 0.0203 0.0624
2030 0.0250 0.0393 2033 0.0297 0.0391 2041 0.0156 0.0211 2011 0.0188 0.0448 2019 0.0159 0.0379 2009 0.0200 0.0864
2042 0.0154 0.0558 2012 0.0183 0.0477
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Appendix  K Succinate content in complex I assay Het res and veh Het 
 
 
Individual histograms of succinate concentration with line graphs of rate of NADH 
oxidation in isolated mitochondria from Het, res Het and veh  Het brain (A), spinal 
cord (B) retina (C) and skeletal muscle (D). Mitochondria were suspended in storage 
buffer for a maximum time of 30 minutes at 4
o
C prior to assay for complex I. These 
graphs showed that the succinate content did not adversely affect the assay of complex I 
activity 
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Appendix  L Kinetics of ET in isolated mitochondria of Het, res Het and veh Het 
 
 
Representative kinetics of (A) complex I activity in isolated mitochondria of Het, res 
and veh Het at 460nm using fluorescence spectrophotometry.in the presence of 30g/ml 
mitochondria. (B)Complex II succinate dehydrogenase activity in Het, res and veh Het 
was followed at 600nm (C) Complex IV  absorbance of  reduced cytochrome c was 
followed at 550nm in the presence of 30g mitochondrial protein. 
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Appendix  M ETC substrate oxidation Het, res and veh Het 
Calculation of substrate oxidation from line fittings 
 
 
 
Calculation of substrate oxidation in isolated mitochondria of Het, res Het and veh Het.  
From line fitting (A)Complex I oxidation of NADH using the absorption coefficient of 
NADH at 340nm  6200 M
-1
 x cm
-1
at 460nm wavelength. (B) Complex II reduction of 
DCPIP using the absorption coefficient of  22 x 10
3
 M
-1
- cm 
-1
 at 600nm wavelength. 
(C) Complex IV oxidation of reduced cytochrome c using the absorption coefficient of  
21.1 x10
3 
M
-1
 cm
-1
 at 550nm wavelength. 
 
 
 
 
 
A: Complex I B: Complex II C: Complex IV
Complex 1 Brain Complex II  Brain Complex IV  Brain
Equation for linear regression I/A=At+B Equation for linear regression I/A=At+B Equation for exponential decay  A550(t)=A0
exp(-kt)
+A
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het yo a b rHet yo a b vHet yo a b
1970 0.360 607.5 1980 0.638 608.9 1985 0.168 575.0 1956 0.022 0.359 2081 0.035 0.357 2121 0.079 0.371 1977 0.367 0.408 1.000 1980 0.372 0.367 0.593 1985 0.487 0.252 0.887
1977 0.387 598.0 1983 0.639 607.8 1992 0.169 574.5 1977 0.031 0.366 2083 0.350 0.347 2127 0.086 0.365 2001 0.365 0.408 1.000 1983 0.328 0.346 0.446 1992 0.499 0.231 1.350
2001 0.360 605.2 1984 0.554 620.6 2096 0.153 604.8 2001 0.023 0.361 2084 0.035 0.357 2098 0.090 0.349 1970 0.288 0.484 1.161 1984 0.390 0.355 0.606 2096 0.487 0.252 0.886
1990 0.424 604.6 1994 0.638 609.6 2098 0.142 603.0 1955 0.028 0.361 2066 0.031 0.350 2120 0.085 0.364 1990 0.364 0.408 0.998 1994 0.372 0.367 0.593 2098 0.488 0.238 0.889
1993 0.512 613.6 2066 0.643 591.5 2120 0.203 593.2 1956 0.033 0.357 2067 0.031 0.356 1992 0.085 0.367 1993 0.365 0.434 0.998 2066 0.371 0.367 0.593 2120 0.499 0.216 1.348
1999 0.481 615.3 2067 0.725 606.4 2040 0.018 0.352 2074 0.356 0.349 1985 0.084 0.365 1999 0.360 0.408 0.998 2067 0.291 0.416 0.239
1955 0.392 610.6 2074 0.639 610.8 2039 0.011 0.353 1955 0.354 0.408 0.989 2074 0.177 0.536 0.192
1956 0.425 605.9 2039 0.018 0.353 1956 0.311 0.484 0.933
Complex 1 SC Complex II SC Complex IV SC
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het yo a b rHet yo a b vHet yo a b
1977 0.300 605.5 1980 0.158 584.9 1982 0.270 605.0 2047 0.023 0.345 2066 0.039 0.344 2120 0.018 0.344 1993 0.358 0.408 1.001 2071 0.241 0.482 0.248 1992 0.477 0.289 1.290
2001 0.368 611.6 1983 0.152 591.6 1985 0.379 600.5 2022 0.027 0.356 2067 0.021 0.350 2098 0.022 0.351 1999 0.358 0.401 1.012 2074 0.290 0.454 0.342 2096 0.500 0.263 1.374
1964 0.268 611.1 1984 0.183 587.6 1992 0.345 603.1 2039 0.012 0.354 2104 0.030 0.356 2039 0.022 0.350 2059 0.324 0.482 1.213 2083 0.232 0.484 0.237 2132 0.488 0.259 0.888
1990 0.134 604.6 2073 0.184 587.7 2096 0.184 588.0 2027 0.032 0.362 2109 0.029 0.351 2027 0.016 0.351 1960 0.325 0.466 0.986 2084 0.278 0.444 0.241 2133 0.467 0.300 0.903
1993 0.369 601.8 2074 0.202 586.0 2120 0.326 598.2 1960 0.025 0.352 2082 0.031 0.355 2133 0.020 0.350 1962 0.361 0.456 0.931 1980 0.378 0.367 0.546 1982 0.467 0.278 0.902
1999 0.345 613.2 2066 0.229 580.7 2098 0.378 595.9 1962 0.017 0.354 2084 0.021 0.351 2132 0.018 0.348 2007 0.315 0.441 0.626 1983 0.361 0.389 0.589 1985 0.477 0.294 1.279
2000 0.279 586.9 2067 0.153 601.7 2138 0.335 590.1 2059 0.012 0.356 2001 0.341 0.456 0.931
2022 0.343 618.8 2104 0.183 587.4 2143 0.184 588.1 1964 0.321 0.446 0.755
2047 0.334 618.9 2109 0.200 57.3 1977 0.264 0.475 0.426
2039 0.426 605.3
Complex 1 Retina Complex II Retina Complex IV Retina
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het yo a b rHet yo a b vHet yo a b
1992 0.165 594.8 2083 0.338 602.8 2096 0.374 604.2 1962 0.024 0.346 2083 0.018 0.345 2096 0.060 0.359 1950 0.537 0.182 0.405 2072 0.477 0.253 0.623 2138 0.391 0.317 0.177
1963 0.195 578.9 2084 0.304 602.6 2098 0.113 597.6 1963 0.493 0.352 2084 0.016 0.361 2098 0.057 0.352 2022 0.490 0.232 0.276 2074 0.346 0.392 0.554 2143 0.373 0.330 0.163
1964 0.170 596.4 1980 0.393 615.5 1985 0.163 587.0 1964 0.493 0.352 1980 0.011 0.348 1985 0.072 0.347 1990 0.458 0.277 0.379 2066 0.331 0.395 0.372 2127 0.397 2.305 0.277
1977 0.305 605.2 1983 0.284 591.7 1992 0.280 594.1 1977 0.035 0.344 1983 0.008 0.347 1992 0.072 0.370 1993 0.537 0.195 0.365 2067 0.338 0.384 0.305 2128 0.349 0.374 0.246
1970 0.161 582.9 2073 0.284 59.9 2138 0.132 574.4 1970 0.034 0.334 1984 0.002 0.353 2132 0.072 0.345 1999 0.458 0.277 0.379 1984 0.390 0.318 0.176 2120 0.494 0.269 0.378
2007 0.169 600.6 2074 0.555 620.7 2143 0.291 570.0 2007 0.049 0.352 1994 0.012 0.354 2120 0.072 0.358 2000 0.604 0.112 0.402 1994 0.373 0.329 0.163 2132 0.488 0.256 0.886
2002 0.182 606.8 2000 0.039 0.352 2001 0.606 0.105 0.405
1981 0.226 606.2 2001 0.029 0.358 2002 0.602 0.111 0.381
1950 0.226 606.2 2002 0.038 0.352
Complex 1 Muscle Complex II Muscle Complex IV  Muscle
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het yo a b rHet yo a b vHet yo a b
1960 0.380 593.1 2073 0.298 598.6 1982 0.222 549.9 1960 0.032 0.356 2073 0.014 0.353 1982 0.020 0.358 1950 0.321 0.396 0.319 2073 0.369 0.360 0.341 1982 0.378 0.333 0.181
1962 0.348 598.0 2145 0.299 590.5 2121 0.207 597.5 1962 0.032 0.355 2145 0.024 0.359 2121 0.020 0.357 1960 0.127 0.603 0.240 2145 0.366 0.360 0.340 1992 0.334 0.375 0.175
2007 0.348 598.1 2147 0.263 594.9 1992 0.223 591.5 2007 0.018 0.360 2147 0.015 0.355 1992 0.013 0.355 1962 0.345 0.353 0.291 2147 0.362 0.354 0.326 2121 0.385 0.325 0.152
2009 0.284 594.3 2158 0.239 599.9 2009 0.025 0.355 2156 0.022 0.358 2016 0.393 0.335 0.464 2158 0.341 0.378 0.273
1950 0.325 593.5 1950 0.031 0.358 2009 0.238 0.474 0.153
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Appendix  N SOD kinetics in Het, res and veh Het tissue homogenate 
 
Graphs show the kinetic inhibition of formazan formation in the presence of 
tissue homogenate from (A)brain (B) spinal cord  and (C) retina of Het, res Het and 
veh Het. WT and control (no inhibition) is included for reference. SOD subtypes were 
examined using specific inhibitors for MnSOD (2% SDS) and CuZnSOD (5,M KCN) 
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Appendix  O SOD inhibition of formazan formation Het, res and veh Het  
 
Percentage of inhibition of formazan formation were calculated from the calculation  
{[(S1 - S3) - (SS - S2)] / (S1 – S3)} x 100.  
where S1 was formazan formation with no inhibition, S2 was sample minus enzyme and 
S3 was diluent only with no enzyme. Specific inhibition of MnSOD or CuZnSOD 
allowed different subtypes to be examined in (A) Brain, (B) spinal cord and (C) retinal 
homogenate of Het, res Het and veh Het 
 
 
 
 
 
 
 
 
 
A: Brain B: Spinal cord C: Retina
Total SOD Brain Total SOD SC Total SOD retina
Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c
2016 0.0128 0.0681 2074 0.0080 0.0553 2120 0.0108 0.0489 1962 0.0165 0.0487 2073 0.0020 0.0764 2128 0.0021 0.0584 2110 0.0170 0.0628 2105 0.0185 0.0306 2128 0.0184 0.0419
2011 0.0126 0.0707 2081 0.0077 0.0544 2121 0.0095 0.0520 1955 0.0174 0.0469 2105 0.0020 0.0842 2133 0.0023 0.0662 2111 0.0171 0.0619 2107 0.0181 0.0418 2133 0.0186 0.0547
2012 0.0126 0.0666 2083 0.0072 0.0327 2128 0.0106 0.0710 1964 0.0177 0.0429 2107 0.0023 0.0780 2149 0.0019 0.0790 2112 0.0165 0.0879 2109 0.0170 0.0470 2149 0.0185 0.0457
2028 0.0130 0.0808 2145 0.0080 0.0553 2138 0.0108 0.0489 2009 0.0168 0.0667 1964 0.0178 0.0598 2073 0.0188 0.0268
2032 0.0128 0.0783 2147 0.0079 0.0522 2149 0.0102 0.0536 2010 0.0174 0.0532 2000 0.0183 0.0597 2104 0.0195 0.0659
2033 0.0133 0.0823 2157 0.0067 0.0453 2150 0.0110 0.0534 2011 0.0178 0.0414 2009 0.0184 0.0509 2067 0.0193 0.0654
2012 0.0176 0.0453
Mn SOD Brain Mn SOD SC Mn SOD Retina
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c
2016 0.0197 0.0555 2074 0.0216 0.0263 2120 0.0230 0.0150 1962 0.0325 0.0782 2073 0.0221 0.0844 2128 0.0316 0.0430 2110 0.0196 0.0672 2105 0.0134 0.0457 2128 0.0192 0.0920
2011 0.0212 0.0417 2081 0.0230 0.0250 2121 0.0225 0.0153 1955 0.0314 0.0721 2105 0.0231 0.0558 2133 0.0322 0.0403 2111 0.0201 0.0659 2107 0.0143 0.0520 2133 0.0220 0.0859
2012 0.0189 0.0474 2083 0.0220 0.0306 2128 0.0220 0.0156 1964 0.0315 0.0576 2107 0.0280 0.0309 2149 0.0333 0.0404 2112 0.0211 0.0878 2109 0.0137 0.0490 2149 0.0200 0.0719
2028 0.0198 0.0324 2145 0.0222 0.0258 2138 0.0223 0.0145 2009 0.0304 0.0420 1964 0.0228 0.0755 2073 0.0152 0.0630
2032 0.0192 0.0367 2147 0.0220 0.0308 2149 0.0220 0.0158 2010 0.0302 0.0503 2000 0.0215 0.0630 2104 0.0160 0.0520
2033 0.0201 0.0339 2157 0.0229 0.0255 2150 0.0229 0.0155 2011 0.0306 0.0420 2009 0.0223 0.0711 2067 0.0151 0.0543
2012 0.0301 0.0503
CuZnSOD Brain CuZnSOD SC CuZnSOD Retina
Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c Het Slope y=I/c rHet Slope y=I/c vHet Slope y=I/c
2016 0.0307 0.0350 2074 0.0187 0.0312 2120 0.0278 0.0315 1962 0.0149 0.0313 2073 0.0151 0.0452 2128 0.0233 0.0361 2110 0.0224 0.0909 2105 0.0284 0.0554 2128 0.0278 0.0699
2011 0.0297 0.0391 2081 0.2160 0.0306 2121 0.0279 0.0241 1955 0.0132 0.0390 2105 0.0164 0.0528 2133 0.0231 0.0524 2111 0.0221 0.0696 2107 0.0277 0.0183 2133 0.0286 0.0811
2012 0.0294 0.0358 2083 0.0174 0.0319 2128 0.2930 0.0261 1964 0.0149 0.0368 2107 0.0158 0.0390 2149 0.0239 0.0673 2112 0.0224 0.0759 2109 0.0285 0.0318 2149 0.0285 0.0618
2028 0.0278 0.0361 2145 0.0199 0.0404 2138 0.0307 0.0324 2009 0.0184 0.0478 1964 0.0196 0.0672 2073 0.0276 0.0587
2032 0.0277 0.0391 2147 0.0178 0.0375 2149 0.0298 0.0305 2010 0.0185 0.0511 2000 0.0203 0.0624 2104 0.0280 0.0332
2033 0.0297 0.0391 2157 0.0222 0.0424 2150 0.0310 0.0355 2011 0.0188 0.0448 2009 0.0200 0.0864 2067 0.0288 0.0687
2012 0.0183 0.0477
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Appendix  P Succinate content in complex I assay of WT, res and veh WT 
 
 
Individual histograms of succinate concentration with line graphs of rate of NADH 
oxidation in isolated mitochondria from WT, res WT and veh  WT brain (A), spinal cord 
(B) retina (C) and skeletal muscle (D). Mitochondria were suspended in storage buffer 
for a maximum time of 30 minutes at 4
o
C prior to assay for complex I. These graphs 
showed that the succinate content did not adversely affect the assay of complex I 
activity 
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Appendix  Q Kinetics of ET in isolated mitochondria of WT, res and veh WT 
 
Representative kinetics of (A) complex I activity in isolated mitochondria of  WT, res 
and veh WT at 460nm using fluorescence spectrophotometry.in the presence of 30g/ml 
mitochondria. (B)Complex II succinate dehydrogenase activity in Het, res and veh Het 
was followed at 600nm (C) Complex IV  absorbance of  reduced cytochrome c was 
followed at 550nm in the presence of 30g mitochondrial protein. 
 
 
 
 
 
 
0
200
400
600
800
0 100 200 300
A
F
U
Time (s)
CI Brain A
I/A=At + B
0
200
400
600
800
0 100 200 300
A
F
U
Time (s)
CI  Muscle
I/A=At + B
0
200
400
600
800
0 100 200 300
A
F
U
Time (s)
CI Retina
I/A=At + B
0
200
400
600
800
0 100 200 300
A
F
U
Time (s)
CI   SC
I/A=At + B
WT Veh WTRes WT
0.0
0.2
0.4
0.6
0.8
-50 50 150 250A
b
s
o
rb
a
n
c
e
 5
5
0
n
m
Time( s)
C C4Brain 
A550(t) = A0
exp(-kt) + A∞ 0.0
0.2
0.4
0.6
0.8
-30 70 170 270
A
b
s
o
rb
a
n
c
e
 5
5
0
n
m
Time (s)
C4   Muscle
A550(t) = A0
exp(-kt) + A∞
0.0
0.2
0.4
0.6
0.8
-30 70 170 270
A
b
s
o
rb
a
n
c
e
 5
5
0
n
m
Time (s)
C4 Retina
A550(t) = A0
exp(-kt) + A∞
0.0
0.2
0.4
0.6
0.8
-30 70 170 270
A
b
s
o
rb
a
n
c
e
 5
5
0
n
m
Time (s)
C4   SC
A550(t) = A0
exp(-kt) + A∞
0.0
0.1
0.2
0.3
0.4
0.5
0 100 200 300
A
b
so
rb
an
ce
 6
0
0
n
m
Time (s)
C2 Muscle
I/A=At + B
0.0
0.1
0.2
0.3
0.4
0.5
0 100 200 300
A
b
so
rb
an
ce
 6
0
0
n
m
Time (s)
C2   SC
I/A=At + B
0.0
0.1
0.2
0.3
0.4
0.5
0 100 200 300
A
b
so
rb
an
ce
 6
0
0
n
m
Time (s)
C2  Brain 
B
I/A=At + B
0.0
0.1
0.2
0.3
0.4
0.5
-100 100 300
A
b
so
rb
an
ce
 6
0
0
n
m
Time (s)
C2 Retina
I/A=At + B
Appendix 
 
348 
 
 
Appendix  R ETC substrate oxidation WT, res and veh WT 
Calculation of substrate oxidation from line fittings 
 
 
Calculation of substrate oxidation in isolated mitochondria of WT res WT and veh WT.  
From line fitting (A)Complex I oxidation of NADH using the absorption coefficient of 
NADH at 340nm  6200 M
-1
 x cm
-1
at 460nm wavelength. (B) Complex II reduction of 
DCPIP using the absorption coefficient of  22 x 10
3
 M
-1
- cm 
-1
 at 600nm wavelength. 
(C) Complex IV oxidation of reduced cytochrome c using the absorption coefficient of  
21.1 x10
3 
M
-1
 cm
-1
 at 550nm wavelength. 
 
 
 
 
 
 
A: Complex I B: Complex II C: Complex IV
Complex I Brain Complex II  Brain Complex IV Brain
Equation for linear regression I/A=At+B Equation for linear regression I/A=At+B Equation for exponential decay  A550(t)=A0
exp(-kt)
+A
WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT yo a b rWT yo a b vWT yo a b
1976 0.549 611.0 1986 0.500 609.6 1995 0.844 597.1 2017 0.062 0.350 1986 0.039 0.352 2131 0.080 0.367 1969 0.210 0.503 0.589 1986 0.287 0.440 0.375 2095 0.446 0.318 0.958
1991 0.699 617.5 1987 0.320 567.3 2097 1.000 617.1 1991 0.062 0.360 1987 0.039 0.354 2130 0.065 0.365 1976 0.317 0.460 1.164 1987 0.316 0.408 0.374 2097 0.434 0.291 0.903
1995 1.053 643.3 1988 0.413 593.7 2119 0.981 604.1 2031 0.063 0.343 1988 0.028 0.349 2119 0.057 0.359 1991 0.301 0.494 1.160 2061 0.319 0.404 0.385 2119 0.428 0.308 0.959
2005 1.077 646.8 1972 0.411 608.0 2125 0.981 607.1 1976 0.033 0.351 2061 0.028 0.350 2125 0.065 0.356 1995 0.301 0.494 1.160 1972 0.308 0.406 0.363 2125 0.497 0.249 1.211
2037 1.077 642.6 2075 0.350 594.4 2126 0.635 597.0 2042 0.031 0.341 2065 0.043 0.358 2095 0.068 0.366 2005 0.315 0.462 0.935 2062 0.326 0.404 0.432 2126 0.444 0.324 1.321
1968 0.864 624.3 2061 0.440 593.8 1968 0.060 0.364 2075 0.035 0.347 2126 0.065 0.368 2037 0.317 0.474 1.179 2065 0.239 0.483 0.303
2041 0.512 613.6 2065 0.405 610.9 2041 0.070 0.371 1968 0.294 0.472 0.653
2042 0.505 591.3 2042 0.062 0.363 2041 0.288 0.457 0.653
Complex I SC Complex II SC Complex IV  SC
WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT yo a b rWT yo a b vWT yo a b
1991 1.035 662.7 1986 0.162 603.5 2095 0.536 599.8 2024 0.060 0.340 2069 0.012 0.346 2126 0.033 0.360 1976 0.277 0.506 0.735 2069 0.271 0.447 0.178 2119 0.497 0.244 1.211
1976 1.000 643.9 1987 0.214 599.2 2097 0.694 616.6 2019 0.059 0.356 2072 0.013 0.355 2130 0.033 0.359 1969 0.359 0.383 0.696 2076 0.274 0.453 0.245 2125 0.435 0.346 1.322
1969 1.000 642.9 1988 0.218 596.2 2119 0.948 608.8 2026 0.063 0.365 2103 0.019 0.351 2139 0.048 0.355 1991 0.268 0.519 0.737 2110 0.274 0.453 0.245 2131 0.446 0.308 0.959
1995 1.049 351.3 2075 0.316 596.2 2125 0.980 609.1 2029 0.064 0.357 2108 0.195 0.352 2144 0.032 0.356 1995 0.361 0.383 0.696 2114 0.259 0.461 0.236 2152 0.445 0.291 0.658
2005 1.036 631.4 2076 0.214 598.1 2126 1.284 596.9 2031 0.060 0.342 2110 0.012 0.350 2131 0.039 0.351 2005 0.269 0.499 0.517 2115 0.215 0.513 0.189 2095 0.446 0.318 0.958
2037 0.852 622.8 2069 0.162 602.7 2130 0.882 604.1 2008 0.054 0.365 2114 0.015 0.349 2152 0.031 0.342 2037 0.291 0.494 0.734 1986 0.270 0.448 0.177 2097 0.446 0.318 0.958
2024 0.814 622.4 2072 0.142 594.6 2139 0.954 617.6 2030 0.329 0.448 0.815 1987 0.371 0.338 0.246
2019 1.366 659.7 2103 0.355 596.6 2144 0.980 593.1 2031 0.274 0.465 0.476 1988 0.322 0.397 0.302
2026 1.097 639.9 2108 0.213 583.9 2008 0.288 0.454 0.531
2029 1.035 634.3
Complex 1 Retina Complex II Retina Complex IV Retina
WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT yo a b rWT yo a b vWT yo a b
2003 1.050 653.2 2085 0.413 593.2 2131 0.859 578.3 2003 0.061 0.349 2085 0.043 0.344 2131 0.087 0.373 1969 0.097 0.613 0.178 2069 0.412 0.329 0.479 2119 0.444 0.286 0.475
2018 1.035 633.0 2086 0.440 593.8 2130 0.928 592.5 2018 0.097 0.361 2086 0.035 0.353 2130 0.069 0.348 2023 0.196 2.888 0.022 2065 0.208 0.509 0.190 2125 0.299 0.430 0.264
2017 0.814 621.6 2072 0.314 609.0 2097 1.094 621.4 2017 0.061 0.363 1972 0.043 0.354 2097 0.082 0.366 1995 0.101 0.616 0.176 2061 0.310 0.410 0.253 2126 0.296 0.424 0.247
1976 0.905 622.0 1986 0.222 601.9 2095 1.087 624.5 1976 0.096 0.367 1986 0.039 0.358 2095 0.072 0.347 2005 0.102 0.618 0.176 1972 0.319 0.400 0.279 2139 0.330 0.378 0.244
1975 0.747 605.1 2065 0.400 612.0 2119 0.693 616.6 1975 0.097 0.363 2075 0.041 0.363 2152 0.065 0.355 2037 0.563 #### 0.003 2076 0.292 0.430 0.264 2152 0.446 0.308 0.961
1968 0.816 623.9 2069 0.320 569.6 2125 0.855 571.7 1968 0.093 0.355 2076 0.043 0.348 2154 0.087 0.367 1989 0.368 0.384 0.428 2075 0.336 0.351 0.218 2154 0.445 0.301 0.659
1969 0.947 601.8 1989 0.093 0.357 2029 0.369 0.383 0.431
2023 0.814 633.2 2029 0.062 0.357 2030 0.351 0.398 0.435
2036 0.707 620.3 2030 0.102 0.375
Complex 1 Muscle Complex II Muscle Complex IV  Muscle
WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT Slope y=I/c rWT Slope y=I/c vWT Slope y=I/c WT yo a b rWT yo a b vWT yo a b
1969 0.457 598.9 1987 0.366 598.8 2095 0.290 576.9 1969 0.037 0.361 1987 0.021 0.359 2095 0.014 0.358 1976 0.391 0.356 0.820 1987 0.358 0.355 0.321 2095 0.370 0.348 0.285
1976 0.599 608.2 2146 0.356 599.3 2119 0.296 585.3 1976 0.065 0.367 2146 0.024 0.360 2119 0.021 0.358 2008 0.361 0.390 0.653 2148 0.397 0.327 0.344 2119 0.348 0.375 0.286
2008 0.362 594.7 2148 0.360 588.0 2125 0.262 591.7 2008 0.029 0.353 2148 0.047 0.363 2125 0.022 0.357 2018 0.379 0.362 0.734 2146 0.364 0.355 0.318 2125 0.408 0.310 0.222
2018 0.905 622.0 2159 0.364 593.5 2018 0.041 0.358 2159 0.031 0.362 1969 0.411 0.348 0.836
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Appendix  S SOD kinetics in WT, res and veh WT tissue homogenate 
 
Graphs show the kinetic inhibition of formazan formation in the presence of 
tissue homogenate from (A)brain (B) spinal cord  and (C) retina of WT, res WT and 
veh WT. Control (no inhibition) is included for reference. SOD subtypes were examined 
using specific inhibitors for MnSOD (2% SDS) and CuZnSOD (5,M KCN) 
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Appendix  T SOD inhibition of formazan formation in WT, res and veh WT  
 
 
Percentage of inhibition of formazan formation were calculated from the calculation  
{[(S1 - S3) - (SS - S2)] / (S1 – S3)} x 100.  
where S1 was formazan formation with no inhibition, S2 was sample minus enzyme and 
S3 was diluent only with no enzyme. Specific inhibition of MnSOD or CuZnSOD 
allowed different subtypes to be examined in (A) Brain, (B) spinal cord and (C) retinal 
homogenate of WT, res WT and veh WT 
 
 
 
 
 
 
 
 
B: Spinal cord C: RetinaA: Brain
Total SOD Brain Total SOD SC Total SOD retina
Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B Equation for linear regression I/A=A t+B
WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c
2062 0.0074 0.0534 2061 0.0074 0.0458 2130 0.0080 0.0540 1975 0.0015 0.0599 1988 0.0012 0.0656 2119 0.0017 0.0658 2024 0.0141 0.0618 2110 0.0145 0.0493 2144 0.0177 0.0494
2046 0.0058 0.0535 2065 0.0073 0.0566 2131 0.0076 0.0590 1997 0.0015 0.0618 2061 0.0015 0.0770 2152 0.0016 0.0750 2036 0.0144 0.0591 2114 0.0142 0.0432 2152 0.0173 0.0563
2042 0.0065 0.0518 2069 0.0066 0.0535 2139 0.0078 0.0565 2003 0.0014 0.0340 2065 0.0014 0.0731 2154 0.0016 0.0550 2041 0.0145 0.0560 2115 0.0132 0.0316 2154 0.0175 0.0566
2026 0.0060 0.0520 2146 0.0094 0.0555 2119 0.0080 0.0540 2017 0.0221 0.0676 1975 0.0146 0.0499 1986 0.0148 0.0686
2029 0.0074 0.0555 2148 0.0082 0.0497 2125 0.0076 0.0590 2036 0.0230 0.0773 2008 0.0138 0.0230 1987 0.0148 0.0708
2030 0.0083 0.0488 2155 0.0090 0.0525 2126 0.0090 0.0571 2041 0.0220 0.0853 2019 0.0152 0.0290 1988 0.0154 0.0493
2042 0.0222 0.0373
Mn SOD Brain Mn SOD SC Mn SOD Retina
WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c
2062 0.0105 0.0387 2061 0.0153 0.0231 2130 0.0153 0.0231 1975 0.0221 0.0599 1988 0.0215 0.0559 2119 0.0293 0.0339 2024 0.0161 0.0583 2110 0.0159 0.0529 2144 0.0164 0.0684
2046 0.0132 0.0334 2065 0.0154 0.0237 2131 0.0149 0.0218 1997 0.0216 0.0480 2061 0.0228 0.0323 2152 0.0280 0.0380 2036 0.0168 0.0747 2114 0.0160 0.0475 2152 0.0160 0.0516
2042 0.0108 0.0436 2069 0.0149 0.0218 2139 0.0154 0.0371 2003 0.0215 0.0650 2065 0.0215 0.0759 2154 0.0292 0.0739 2041 0.0168 0.0654 2115 0.0160 0.0633 2154 0.0188 0.0941
2026 0.0134 0.0313 2146 0.0149 0.0214 2119 0.0229 0.0155 2017 0.0237 0.0316 1975 0.0222 0.0499 1986 0.0143 0.0705
2029 0.0134 0.0226 2148 0.0166 0.0245 2125 0.0217 0.0156 2036 0.0222 0.0580 2008 0.0205 0.0607 1987 0.0151 0.0520
2030 0.0132 0.0322 2155 0.0145 0.0296 2126 0.0223 0.0125 2041 0.0238 0.0136 2019 0.0205 0.0663 1988 0.0146 0.0725
2042 0.0239 0.0102
CuZnSOD Brain CuZnSOD SC CuZnSOD Retina
WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c WT Slope y= I/c rWT Slope y= I/c vWT Slope y= I/c
2062 0.0240 0.0392 2061 0.0129 0.0318 2130 0.0207 0.0259 1975 0.0117 0.0490 1988 0.0117 0.0502 2119 0.0217 0.0578 2024 0.0215 0.0340 2110 0.0324 0.0582 2144 0.0251 0.0604
2046 0.0247 0.0323 2065 0.0168 0.0349 2131 0.0196 0.0312 1997 0.0117 0.0254 2061 0.0129 0.0373 2152 0.0214 0.0646 2036 0.0208 0.0597 2114 0.0326 0.0607 2152 0.0250 0.0654
2042 0.0236 0.0397 2069 0.0163 0.0309 2139 0.0185 0.0364 2003 0.0119 0.0401 2065 0.0116 0.0538 2154 0.0222 0.0520 2041 0.0224 0.0729 2115 0.0326 0.0392 2154 0.0252 0.0248
2026 0.0236 0.0397 2146 0.0192 0.0431 2119 0.0244 0.0113 2017 0.0152 0.0429 1975 0.0160 0.0475 1986 0.0296 0.0866
2029 0.0237 0.0277 2148 0.0187 0.0312 2125 0.0228 0.0137 2036 0.0141 0.0732 2008 0.0164 0.0517 1987 0.0276 0.0747
2030 0.0250 0.0393 2155 0.0192 0.0375 2126 0.0244 0.0073 2041 0.0156 0.0211 2019 0.0159 0.0379 1988 0.0254 0.0797
2042 0.0154 0.0558
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Appendix  U Positive Control sections for IHC 
 
Control sections for mitochondrial specific protein expression in mouse tissue. Each 
positive control has a tissue matched negative control. (A): MnSOD expression in male 
C57Bl/6 brain at 3 months showing mitochondrial staining clustered around Hoechst 
stained nucleus. (B): Opa1 expression in hepatocytes showing high density staining. 
(C): VDAC staining in kidney nephron. Negative tissue controls (D)Brain (E)Liver(F) 
Kidney 
 
A Brain MnSOD  merge Brain  Hoechst
B Liver Opa1 merge Liver Hoechst
C VDAC Kidney merge Kidney  Hoechst
D Brain MnSOD  merge Brain  Hoechst
E Liver Opa1 merge Liver Hoechst
F VDAC Kidney merge Kidney  Hoechst
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Positive Control sections for IHC 
 
Control sections for compensatory protein expression in mouse tissue. (A): Preli 
expression in aortic arch of C57Bl/6 at 3 months. mitochondria of mouse olfactory 
bulb. (B): Neuroglobin expression retinal section of C57Bl/6 3 months (C): VDAC 
expression in spleen Opa1
Q285STOP
 mouse at  3 months .Negative tissue controls 
(D)Cardiac (E)Retina (F) spleen 
 
A Aorta Preli  merge Aorta Hoechst
B Retina Neuroglobin merge Retina Hoechst
C VDAC spleen merge Spleen Hoechst
D Cardiac Preli merge Cardiac Hoechst
E Retina Neuroglobin   merge Retina Hoechst
F VDAC Spleen  merge Spleen Hoechst
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Positive Control sections for IHC 
 
Control sections for damaged mediated protein expression. (A) PSD95 expression : 
expression in cerebellum of Python Het (Drp1)brain. (B): Neurofilament heavy chain 
expression in olfactory bulb of Python Het brain. (C): 3nitrotyrosine deposition in the 
glomerulus of 12 month C57Bl/6 WT. Negative control sections (D) Python Brain (E) 
Python Brain (F) Renal 
 
A Brain PSD 95 merge Brain Hoechst
B Brain NF H merge Brain Hoechst
C Renal 3 Nitrotyrosine merge Renal Hoechst
D Brain PSD 95 merge Brain Hoechst
E Brain NF H merge Brain Hoechst
F Renal  3 nitrotyrosine merge Renal Hoechst
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Appendix  V Retinal IHC counts Het res & veh Het 
Average counts in retinal layers Het, res and veh Het 
 
The average of a minimum of three independent experiments for expression of proteins 
as listed for Het, res Het and veh Het. Average AUF in retinal layers of untreated Het, 
res and veh treated Het: Opa1, MnSOD, VDAC, Neuroglobin, Preli, PSD95, NFL and 3 
Nitrotyrosine. 
 
 
 
 
 
 
 
 
IHC Retinal layers  Het
Opa1 Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 96.4 98.8 130 71.1 89 77.7 Ave 235 131 185 93.4 101 52.6 Ave 188 164 217 160 162 146
SEM 26.8 37.6 26.3 11.9 29.2 10.3 SEM 72.3 24.7 61.6 36.1 23.7 12.4 SEM 84.6 53.6 75.8 50.3 72.1 23.5
MnSOD Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 381.3 131.8 119.1 227.2 800 228.8 Ave 332.8 146.4 263.4 172.4 524.9 246.9 Ave 161.9 101.2 150.1 121.3 291.7 170.4
SEM 20.21 90.69 32.28 75.88 14.84 4.403 SEM 92.62 60.95 80.97 56.4 172.3 86.99 SEM 46.38 19.74 43.82 45.36 92.73 73.54
VDAC Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 555 944 526 890 747 798 Ave 422 403 221 351 244 390 Ave 269 311 250 339 268 349
SEM 88 23.5 81.9 66.1 67.6 65.8 SEM 72.8 116 72.3 61.4 34.7 44.1 SEM 70.7 76 84.4 66.4 89.8 79.6
Neuro Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 250.5 349.2 129.8 259.3 90.41 64.78 Ave 214.3 181.4 85.71 94.48 95.08 66.7 Ave 176.4 267.1 134.2 151.1 223.1 129.3
SEM 38.15 38.98 20.76 21.29 34.99 23.16 SEM 30.29 5.215 13.97 27.37 42.04 10.76 SEM 97.47 69.44 70.63 29.79 150.6 40.57
Preli Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 255 186 144 120 215 99 Ave 380 88 182 96 178 171 Ave 368 109 196 162 284 236
SEM 71 113 58 43 106 30 SEM 52 85 34 33 31 16 SEM 73 66 53 94 131 104
PSD95 Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 267 162 239 82.8 211 92.9 Ave 252 352 230 174 125 75.7 Ave 250 256 215 131 167 63.9
SEM 24.2 32 2.26 11.2 15.8 15.6 SEM 58.5 115 71.5 70.7 75.4 36.5 SEM 62 18.7 13.7 42.5 38.8 11.7
NF L Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 128 168 182 140 173 405 Ave 291 281 506 242 318 602 Ave 143 121 185 291 124 341
SEM 56.5 54.8 70.4 42 54.7 105 SEM 39.5 89 76.5 81.1 24.9 28.5 SEM 25.8 48.3 81.6 173 55.8 97.5
3 Nitro Het PRL ONL OPL INL IPL GCL rHet PRL ONL OPL INL IPL GCL vHet PRL ONL OPL INL IPL GCL
Ave 215 167 240 213 468 522 Ave 220 164 100 50.4 100 63.2 Ave 186 136 148 112 267 124
SEM 28.1 113 54.9 62.3 132 101 SEM 110 81.2 55.9 21.5 67.2 40.2 SEM 29.9 45.2 26.7 37.2 77.3 52.4
IHC Retinal layers  res Het IHC Retinal layers  veh Het
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Retinal IHC counts WT, res & veh WT 
Average counts in retinal layers WT, res and veh WT 
 
The average of a minimum of three independent experiments for expression of proteins 
as listed for WT, res WT and veh WT. Average AUF in retinal layers of untreated WT, 
res and veh WT:  Opa1, MnSOD, VDAC, Neuroglobin, Preli, PSD95, NFL and 3 
Nitrotyrosine. 
 
 
 
 
 
 
 
IHC Retinal layers WT
Opa1 WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 192 256 258 224 281 187 Ave 302 330 487 255 298 203 Ave 203 199 336 243 255 142
SEM 39.3 52.6 73 79.2 41.8 30.5 SEM 50.4 56.8 94.4 36.4 21.5 28 SEM 36.2 42.5 36.8 18 4.46 33.3
MnSOD WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 757.2 605.5 767.2 627.3 1745 939.4 316.8 324.2 274.8 215.7 388.7 268.8 306.6 219.1 262 228.2 537.2 470.2
SEM 129.6 118.5 56.31 60.44 416.3 141.4 127.4 153.8 133.3 106.2 198.1 133.8 24.43 42.9 28.78 8.806 76.19 163.8
VDAC WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 91.9 273 184 215 181 404 Ave 185 466 245 429 366 435 Ave 144 130 102 179 108 224
SEM 15.9 25.1 19.6 26.5 25.7 30.6 SEM 56.4 197 118 134 136 247 SEM 6.18 0.44 7.21 13.3 3.94 7.2
Neuro WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 228.1 218.1 170.2 163.3 180.9 71.34 Ave 158.4 210.7 158.6 119 165.8 113.9 Ave 154.5 189.4 96.18 123 80.36 75.07
SEM 52.27 99.93 54.2 81.32 80.56 36.4 SEM 2.327 20.05 40.82 30.8 36.4 10.7 SEM 28.11 34.19 27.34 31.49 7.807 17.84
Preli WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 366 17 194 110 122 213 Ave 240 19 113 119 130 128 Ave 262 69 172 56 62 36
SEM 120 4 63 16 37 61 SEM 84 1 14 9 44 29 SEM 73 12 48 8 20 15
PSD95 WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 90.5 37.8 84.4 24.5 40.3 34 Ave 189 269 237 209 228 189 Ave 156 66.9 105 50.3 58.8 25.4
SEM 10.2 10.3 24.6 11.3 18.1 26.4 SEM 3.57 66.7 65.7 53.3 59.1 67.9 SEM 48.8 28.8 58 22.4 31.8 11
NF L WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 112 165 99.2 57.1 195 443 Ave 67.6 77.1 102 72.4 94.7 215 Ave 153 196 257 162 358 424
SEM 13.2 87.1 3.55 11.7 28.3 37.6 SEM 6.61 2.09 34.2 22.9 32.3 67.6 SEM 23.8 47.8 34.9 17.7 53.8 113
3 Nitro WT PRL ONL OPL INL IPL GCL rWT PRL ONL OPL INL IPL GCL vWT PRL ONL OPL INL IPL GCL
Ave 82.6 157 99.2 174 210 220 Ave 280 257 156 84.6 338 155 Ave 275 140 235 175 435 172
SEM 30.2 52.9 48.1 64.1 104 96 SEM 33.2 35.9 12.5 16.9 66.5 29.1 SEM 84.8 33.8 67.5 47.4 137 57.8
IHC Retinal layers res WT IHC Retinal layers veh WT
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Brain IHC counts WT, res & veh WT, Het res Het & veh Het 
Average counts in brain sections of WT, Het, res WT, res Het, veh WT, and veh Het 
 
The average of a minimum of three independent experiments for expression of proteins 
as listed for WT, res WT and veh WT, Het,  res Het and veh Het . Average AUF in 
brain: Opa1, MnSOD, VDAC, Neuroglobin, Preli, PSD95, NFL and 3 Nitrotyrosine. 
 
 
IHC Brain
WT res & veh WT Het, res & veh Het
Opa1 Opa1
WT rWT vWT Het rHet vHet
Ave 619.9 1024 612.8 Ave 419.1 589.4 471.4
SEM 119.6 278.8 208.7 SEM 80.2 211.4 126.7
MnSOD MnSOD
WT rWT vWT Het rHet vHet
Ave 2983 4000 2055 Ave 557.8 1806 788.8
SEM 789 466 222 SEM 92 351 87.3
VDAC VDAC
WT rWT vWT Het rHet vHet
Ave 542.4 1308 1007 Ave 1016 939.7 901.4
SEM 107.6 270.7 206.2 SEM 299.8 220 40.36
Neuroglobin Neuroglobin
WT rWT vWT Het rHet vHet
Ave 390 179.5 272.3 Ave 969 159.9 542.5
SEM 128.7 42.4 65.3 SEM 195 51.9 177.8
Preli Preli
WT rWT vWT Het rHet vHet
Ave 542.4 1308 1007 Ave 1016 939.7 901.4
SEM 107.6 270.7 206.2 SEM 299.8 220 40.36
PSD95 PSD95
WT rWT vWT Het rHet vHet
Ave 623 2056 781.1 Ave 164.4 1660 259.2
SEM 93.35 401.6 173.7 SEM 36.66 52.48 88.36
NF NF
WT rWT vWT Het rHet vHet
Ave 177.8 624.9 521.5 Ave 1469 1135 265.5
SEM 37.8 57.19 153.9 SEM 305.9 295.2 126.9
3Nitro 3Nitro
WT rWT vWT Het rHet vHet
Ave 524.5 884.4 158.1 Ave 1561 476.7 286.2
SEM 176 138.4 44.14 SEM 275.4 98.04 43.55
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Appendix  W Statistical analysis of data presented  
 
Summary of statistical analysis performed on data from SHIRPA, rotarod, 
narrowbeam and tight rope testing in untreated and treated WT and Het. 
 
 
Rotarod Latency to fall
RM  ANOVA (3,41) 3.168
M WT F Het M Het
F WT 0.001 0.004 0.001
M WT 0.948
F Het 0.053
M Het
Rotarod Latency:housing
RM ANOVA (3,20) 21.433
sMHet gMWT gMHet
sMWT 0.934 0.013 0.001
sMHet 0.001 0.020
gMWT 0.989
gMHet
Narrowbeam Initiation
ANOVA (3,22)6.361
M WT F Het M Het
F WT 0.297 0.001 0.031
M WT 0.001 0.001
F Het 0.530
M Het
Tight rope Distance
ANOVA (3,22)13.833
M WT F Het M Het
F WT 0.369 0.106 0.519
M WT 0.086 0.026
F Het 0.867
M Het
T Maze To novel arm
 ANOVA (3,20) 1.145
M WT F Het M Het
F WT 0.719 0.001 0.064
M WT 0.001 0.020
F Het 0.001
M Het
T Maze  In novel arm
 ANOVA (3,20) 9.651
M WT F Het M Het
F WT 0.019 0.001 0.001
M WT 0.048 0.530
F Het 0.087
M Het
T Maze in Original arm
 ANOVA (3,20) 1.279
M WT F Het M Het
F WT 0.659 0.741 0.340
M WT 0.878 0.221
F Het 0.199
M Het
T Maze IR
 ANOVA (3,20) 1.592
M WT F Het M Het
F WT 0.805 0.006 0.136
M WT 0.144 0.144
F Het 0.033
M Het
T Maze DR
 ANOVA (3,20) 4.744
M WT F Het M Het
F WT 0.726 0.002 0.032
M WT 0.130 0.096
F Het 0.835
M Het
NOR To Novel object
ANOVA (3,23) 7.443
M WT F Het M Het
F WT 0.914 0.001 0.001
M WT 0.001 0.001
F Het 0.899
M Het
NOR with Novel object
ANOVA (3,23) 4.094
M WT F Het M Het
F WT 0.024 0.024 0.116
M WT 0.001 0.004
F Het 0.710
M Het
NOR with Originalobject
ANOVA (3,23) 2.616
M WT F Het M Het
F WT 0.880 0.883 0.012
M WT 0.933 0.021
F Het 0.002
M Het
NOR IR
ANOVA (3,23) 5.033
M WT F Het M Het
F WT 0.106 0.005 0.045
M WT 0.090 0.004
F Het 0.403
M Het
NOR DR
ANOVA (3,23) 7.370
M WT F Het M Het
F WT 0.352 0.004 0.001
M WT 0.046 0.002
F Het 0.015
M Het
WT & Het : Rotarod Beam, Rope, T Maze, NOR
Statistical Testing Parameters
1 Shapiro Wilk Normality of Distribution   (sig. <0.05)
2 Levene's parametric T Test Variance  (Levene's sig. <0.05,  2 tailed sig. >0.05)
3 ANOVA (parametric) means of more than 2 groups  (with post hoc)
4 Post hoc: Tukey (equal group size) Dunnett (unequal group size)
5 Mann-Whitney U test  (non parametric) Asymp.(2 tailed) <0.05*
6 Kruskal-Wallis H test (non parametric)
*Bonferroni Adjustment (sig.0.05/no. T tests performed)
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Summary of statistical analysis of thermal function, body, brain and cardiac weight 
ratio, mitochondrial size and ATP in untreated and treated WT and Het. 
 
 
 
 
Thermal Head
Head ANOVA (3,26)38.542
yHet oWT oHet
yWT 0.001 0.321 0.001
yHet 0.001 0.797
oWT 0.004
oHet
Thermal Flank
Flank ANOVA (3,26)2.077
yHet oWT oHet
yWT 0.112 0.112 0.030
yHet 0.009 0.130
oWT 0.130
oHet
Thermal Tail
Tail ANOVA (3,26)2.502
yHet oWT oHet
yWT 0.024 0.371 0.006
yHet 0.005 0.439
oWT 0.287
oHet
Weight/enrichment Body
ANOVA (6,71) 12.283
M WT F Het M Het
eFHet 0.914 0.009 0.001
eM WT 0.001 0.001 0.001
eM Het 0.008
Weight/enrichment Brain
ANOVA (6,71) 1.369
M WT F Het M Het
eFHet 0.001 0.020 0.001
eM WT 0.846 0.001 0.001
eM Het 0.534
Weight/enrichment Cardiac
ANOVA (6,71) 1.681
M WT F Het M Het
eFHet 0.001 0.009 0.001
eM WT 0.287 0.001 0.001
eM Het 0.004
Weight/Housing Body
ANOVA (6,71) 12.283
gM WT sM Het g MHet
sMWT 0.624 0.634
sMHet 0.247
gMWT 0.317
g Mhet
Weight/Housing Brain
ANOVA (6,71) 12.283
gM WT sM Het g MHet
sMWT 0.009 0.963
sMHet 0.015
gMWT 0.288
g MHet
Weight/Housing Cardiac
ANOVA (6,71) 12.283
gM WT sM Het g MHet
sMWT 0.012 0.343
sMHet 0.129
gMWT 0.317 0.779
g MHet
WT & Het : Thermal, Body, Brain, Cardiac weight  enrichment
ATP Brain ANOVA (3,13) 1.869
M WT F Het M Het
F WT 0.520 0.859
M WT 0.349
F Het 0.279
M Het
ATP SC ANOVA (3,14) 1.633
M WT F Het M Het
F WT 0.464 0.218
M WT 0.737
F Het 0.375
M Het
ATP Ret ANOVA (3,14) 1.633
M WT F Het M Het
F WT 0.049 0.171
M WT 0.969
F Het 0.001
M Het
ATP All ANOVA (5,45) 7.036
B Het SC Het Ret Het
B WT 0.335
SC WT 0.551
Ret WT 0.258
Mito Size Brain
ANOVA (5,12) 26.391
Min Med Max
Het min 0.007
Het med 0.007
Het max 0.855
Mito Size Retina
ANOVA (5,12) 26.391
Min Med Max
Het min 0.009
Het med 0.048
Het max 0.971
Mito   Brain
ANOVA (3,12) 26.391
WT WT WT
Het 0.110
Het 0.254
Het 0.226
Mito Retina
ANOVA (3,12) 26.391
WT WT WT
Het 0.120
Het 0.329
Het 0.560
WT & Het : Mito size, , ATP
SHIRPA  ANOVA
LMF WT:Het 0.015 F(3,23) 40.673
CSF WT:Het 0.001 F(3,23) 24.738
Sen WT:Het 0.204 F(3,23) 13.354
Npsy WT:Het 0.001 F(3,23) 15.348
Auto WT:Het 0.001 F(3,23) 33.889
View WT:Het 0.001  F(3,40) 6.971
In arena WT:Het 0.001  F(3,40) 6.971
Above WT:Het 0.057  F(3,40) 6.971
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Summary of statistical analysis of electron transfer in complex I, complex II and 
complex IV , and antioxidant SOD and Catalase in untreated and treated WT and Het. 
 
 
 
ETC: CI Brain
ANOVA(7,55) 22.123
WT Het
WT 0.001
Het
ETC: CI SC
ANOVA(7,55) 89.435
WT Het
WT 0.001
Het
ETC: CI Ret
ANOVA(7,55) 60.655
WT Het
WT 0.001
Het
ETC: CI Muscle
ANOVA(7,55) 66.350
WT Het
WT 0.004
Het
ETC: CII  Brain
ANOVA(7,48) 55.804
WT Het
WT 0.001
Het
ETC: CII SC
ANOVA(7,48) 54.260
WT Het
WT 0.001
Het
ETC: CII Ret
ANOVA(7,48) 45.570
WT Het
WT 0.001
Het
ETC: CII Muscle
ANOVA(7,48)4.374
WT Het
WT 0.025
Het
ETC: CIV  Brain
ANOVA(7,53) 27.562
WT Het
WT 0.017
Het
ETC: CIV SC
ANOVA(7,53) 42.356
WT Het
WT 0.203
Het
ETC: CIV Ret
ANOVA(7,53) 8.631
WT Het
WT 0.001
Het
ETC: CIV Muscle
ANOVA(7,53) 13.864
WT Het
WT 0.001
Het
ETC: Ratio  CI
ANOVA(5,48) 2.144
Het Het Het
Brain WT 0.017
SC WT 0.685
Ret WT 0.597
ETC: Ratio  CII
ANOVA(5,40) 45.389
Het Het Het
Brain WT 0.675
SC WT 0.626
Ret WT 0.779
ETC: Ratio  CIV
ANOVA(5,46) 38.685
Het Het Het
Brain WT 0.278
SC WT 0.001
Ret WT 0.001
ETC: Ratio  Skeletal Muscle
ANOVA(5,17) 11.87
Het Het Het
C I WT 0.022
C II WT 0.036
C IV WT 0.255
WT & Het : ETC CI, CII, CIV Brain, SC, Retina & Muscle
Total SOD
 Brain  SC Ret
F(5,12)32.4 F(5,12)105.3 F(5,12)8.8
Het Het Het
WT 0.001 WT 0.001 WT 0.003
MnSOD
 Brain  SC Ret
F(5,12)48.7 F(5,12)22.6 F(5,12)3.74
Het Het Het
WT 0.001 WT 0.001 WT 0.029
CuZnSOD
 Brain  SC Ret
F(5,12)3257.8F(5,12)15.4 F(5,12)10.8
Het Het Het
WT 0.004 WT 0.001 WT 0.299
Non SOD
 Brain  SC Ret
F(5,28)23.3 F(5,20)19.78 F(5,24)1.60
Het Het Het
WT 0.001 WT 0.001 WT 0.109
Catalase 
 Brain  SC Ret
F(5,31) 7.995 F(5,18) 10.902F(3,10) 9.156
Het Het Het
WT 0.099 WT 0.001 WT 0.007
WT & Het : SOD & Catalase Brain, SC Retina
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Summary of statistical analysis antioxidant activity IHC retina and brain   in untreated 
and treated WT and Het. 
 
 
 
Brain  AFU Retina  AFU
ANOVA (5,75)2.411 ANOVA (5,369)7.500
Mito Mito
WT Het WT Het
Het 0.134 Het 0.024
Brain  AFU Retina  AFU
ANOVA (5,68)5.957 ANOVA (5,414)2.39
Comp Comp
WT Het WT Het
Het 0.001 Het 0.001
Brain  AFU Retina  AFU
ANOVA  (5,75)2.573 ANOVA  (5,425)5.581
Dam Dam
WT Het WT Het
Het 0.007 Het 0.023
Brain AFUOpa1   VDAC   Preli   
F(5,30) 4.527 2.87 4.57
Het Het Het
WT 0.008 0.005 0.008
MnSOD 3Nitro
F(5,30) 6.91 7.919
Het Het
WT 0.001 0.001
Neuro Psd95 NF h
F(5,30) 4.527 2.454 2.983
Het Het Het
WT 0.008 0.005 0.008
WT & Het : IHC Retina &  Brain
Opa1   Ret AFU
ANOVA (5,15) 3.865 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.241 0.024 0.006 0.177 0.022 0.008
Het
VDAC   Ret AFU
ANOVA (5,15) 2.751Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.005 0.769 0.023 0.008 0.010 0.031
Preli   Ret AFU
ANOVA (5,21) 21.466 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.386 0.520 0.004 0.898 0.027 0.003
Neuroglobin   Ret AFU
ANOVA (5,20) 1.530 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.384 0.722 0.701 0.634 0.846 0.503
PSD 95  Ret AFU
ANOVA (5,28) 1.900 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.314 0.292 0.750 0.272 0.122 0.346
NF L  Ret AFU
ANOVA (5,23) 8.530 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.020 0.536 0.059 0.452 0.740 0.038
MnSOD Ret AFU
ANOVA (5,16) 8.916Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.651 0.653 0.020 0.606 0.886 0.002
3Nitro  Ret AFU
ANOVA (5,20) 2.732 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.048 0.001 0.840 0.032 0.547 0.023
Mito  Ret AFU
ANOVA (5,69) 5.364 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.366 0.044 0.531 0.090 0.067 0.683
Het
Comp   Ret AFU
ANOVA (5,78) 2.133Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.074 0.002 0.250 0.005 0.014 0.376
Damage   Ret AFU
ANOVA (5,81) 1.741 Post Hoc Tukey
PRL OPL ONL NIL IPL GCL
Mito Het Het Het Het Het Het
WT 0.046 0.370 0.006 0.001 0.110 0.485
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Summary of statistical analysis of Het.  res and veh Het weight, rotarod, beam and 
rope, & cognitive T test and NOR 
  
 
Het, res Het & veh Het  : Weight Rotarod Beam, Rope, T Maze, NOR
Rotarod Latency to fall
RM  ANOVA (9,70) 2.554
rFHet vFHet M Het
F Het 0.001 0.003 0.040
rFHet 0.996 0.893
vFHet 0.998
M Het
rM Het
Rotarod Latency:housing
RM ANOVA (3,32) 2.756
rsMHet gMHet rgMHet
sMHet 0.001 0.003 0.001
rsMHet 0.126
gMHet 0.989
rgMHet
Narrowbeam Initiation
ANOVA (15,80)5.403
rHet vHet
Het 0..001 0.019
rHet 0.256
vHet
Tight rope Distance
ANOVA (15,80)6.704
rHet vHet
Het 0..001 0.294
rHet 0.001
vHet
T Maze To novel arm
 ANOVA (3,34) 4.639
rHet vHet
Het 0.021 0.008
rHet 0.527
vHet
T Maze  In novel arm
 ANOVA (3,34) 3.939
rHet vHet
Het 0.030 0.137
rHet 0.767
vHet
T Maze in Original arm
 ANOVA (3,34) 1.864
rHet vHet
Het 0.028 0.987
rHet 0.108
vHet
T Maze IR
 ANOVA (3,34) 2.418
rHet vHet
Het 0.006 0.144
rHet 0.244
vHet
T Maze DR
 ANOVA (3,34) 6.708
rHet vHet
Het 0.002 0.096
rHet 0.494
vHet
NOR To Novel object
ANOVA (3,36) 8.106
rHet vHet
Het 0.638 0.910
rHet 0.649
vHet
NOR with Novel object
ANOVA (3,36) 4.117
rHet vHet
Het 0.588 0.583
rHet 0.378
vHet
NOR with Originalobject
ANOVA (3,36) 1.606
rHet vHet
Het 0.085 0.112
rHet 0.963
vHet
NOR IR
ANOVA (3,36) 2.254
rHet vHet
Het 0.067 0.069
rHet 0.874
vHet
NOR DR
ANOVA (3,36) 2.254
rHet vHet
Het 0.078 0.024
rHet 0.564
vHet
SHIRPA  ANOVA
LMF Het:rHet 0.951 F(3,23) 40.673
CSF Het:rHet 0.109 F(3,23) 24.738
Sen Het:rHet 0.051 F(3,23) 13.354
Npsy Het:rHet 0.012 F(3,23) 15.348
Auto Het:rHet 0.041 F(3,23) 33.889
Weight/Body
ANOVA (11,161) 9.8
rFHet vF Het
F Het 0.165 0.401
rFHet 0.656
vF Het
Weight Brain
ANOVA (11,161) 2.722
rFHet vF Het
F Het 0.025 0.263
rFHet 0.458
vF Het
Weight/Cardiac
ANOVA (11,161) 1.945
rFHet vF Het
F Het 0.505 0.035
rFHet 0.112
vF Het
Weight/Housing Body
ANOVA (6,71) 12.283
srMHet grMHet
sMHet 0.385 0.450
srMHet 0.450
g MHet 0.308
grMHet
Weight/Housing Brain
ANOVA (6,71) 12.283
srMHet grMHet
sMHet 0.385
srMHet 0.829
g MHet 0.672
grMHet
Weight/Housing Cardiac
ANOVA (6,71) 12.283
srMHet grMHet
sMHet 0.820 0.450
srMHet 0.962
g MHet 0.275
grMHet
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Summary of statistical analysis of Het, res and veh Het ETC, and antioxidant Catalase and SOD 
 
 
Het, res & veh Het  : ETC CI, CII, CIV Brain, SC, Retina & Muscle
ETC: CI Brain
ANOVA(5,38)25.123
rHet vHet
Het 0.002 0.001
rHet 0.001
vHet
ETC: CI SC
ANOVA(5,38)89.435
rHet vHet
Het 0.008 0.548
rHet 0.054
vHet
ETC: CI Ret
ANOVA(5,36)69.424
rHet vHet
Het 0.057 0.828
rHet 0.025
vHet
ETC: CI Muscle
ANOVA(5,17)66.414
rHet vHet
Het 0.014 0.001
rHet 0.153
vHet
ETC: CII  Brain
ANOVA(5,48) 55.804
rHet vHet
Het 0.012 0.001
rHet 0.001
vHet
ETC: CII SC
ANOVA(5,31) 54.260
rHet vHet
Het 0.023 0.527
rHet 0.007
vHet
ETC: CII Ret
ANOVA(5,36) 45.570
rHet vHet
Het 0.001 0.001
rHet 0.001
vHet
ETC: CII Muscle
ANOVA(5,17)4.374
rHet vHet
Het 0.146 0.148
rHet 0.914
vHet
ETC: CIV  Brain
ANOVA(5,35) 27.562
rHet vHet
Het 0.001 0.001
rHet 0.552
vHet
ETC: CIV SC
ANOVA(5,38) 42.356
rHet vHet
Het 0.001 0.001
rHet 0.926
vHet
ETC: CIV Ret
ANOVA(5,34) 8.631
rHet vHet
Het 0.001 0.010
rHet 0.113
vHet
ETC: CIV Muscle
ANOVA(5,16) 13.864
rHet vHet
Het 0.172 0.007
rHet 0.001
vHet
ETC: Ratio  CI
ANOVA(5,48) 2.144
rHet vHet
Brain Het 0.909 0.001
SC Het 0.001 0.775
Ret Het 0.781 0.736
ETC: Ratio  CII
ANOVA(5,40) 45.389
rHet vHet
Brain Het 0.001 0.001
SC Het 0.001 0.004
Ret Het 0.001 0.011
ETC: Ratio  CIV
ANOVA(5,46) 38.685
rHet vHet
Brain Het 0.001 0.001
SC Het 0.001 0.052
Ret Het 0.001 0.001
ETC: Ratio  Skeletal Muscle
ANOVA(5,17) 11.87
rHet vHet
C I Het 0.009 0.462
C II Het 0.001 0.260
C IV Het 0.001 0.001
Total SOD
 Brain  SC Ret
F(5,12)32.4 F(5,12)105.3 F(5,12)8.8
rHet vHet rHet vHet rHet vHet
Het 0.001 0.001 0.001 0.001 0.385 0.108
MnSOD
 Brain  SC Ret
F(5,12)48.7 F(5,12)22.6 F(5,12)3.74
rHet vHet rHet vHet rHet vHet
Het 0.001 0.494 0.001 0.712 0.340 0.448
CuZnSOD
 Brain  SC Ret
F(5,12)3257.8 F(5,12)15.4 F(5,12)10.8
rHet vHet rHet vHet rHet vHet
Het 0.478 0.377 0.013 0.771 0.022 0.029
Non SOD
 Brain  SC Ret
F(5,28)23.3 F(5,20)19.78 F(5,24)1.60
rHet vHet rHet vHet rHet vHet
Het 0.001 0.672 0.001 0.030 0.536 0.603
Catalase 
 Brain  SC Ret
F(5,31) 7.995 F(5,18) 10.902 F(3,10) 9.156
rHet vHet rHet vHet rHet vHet
Het 0.077 0.001 0.278 0.043 0.007
Het, res & veh Het : SOD & Catalase
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Summary of statistical analysis of Het, res and veh Het IHC in retina & brain. Protein 
profiles for  mitochondria, compensation and damage profile in retina and brain. 
 
 
 
 
 
Het, res & veh Het : IHC Retina &  Brain
Mito   Ret AFU ANOVA (5,16) 2.285
PRL OPL ONL IPL INL GCL
Mito rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.514 0.765 0.108 0.086 0.423 0.461 0.109 0.230 0.054 0.233 0.331 0.556
Comp   Ret AFU ANOVA (5,15) 10.47
PRL OPL ONL IPL INL GCL
Mito rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.881 0.222 0.023 0.026 0.156 0.337 0.015 0.043 0.030 0.236 0.380 0.559
Damage  Ret AFU ANOVA (5,21) 21.466
PRL OPL ONL IPL INL GCL
Mito rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.117 0.0.9870.038 0.741 0.027 0.877 0.166 0.152 0.375 0.501 0.489 0.717
Opa1   Ret AFU ANOVA (5,15) 3.865 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.241 0.691 0.959 0.524 0.539 0.030 0.818 0.004 0.877 0.014 0.557 0.017
VDAC   Ret AFU ANOVA (5,15) 10.47Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.374 0.008 0.012 0.952 0.698 0.016 0.004 0.001 0.665 0.074 0.228 0.461
Preli  Ret AFU ANOVA (5,21) 21.466Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.252 0.447 0.780 0.075 0.723 0.875 0.228 0.152 0.342 0.461 0.591 0.943
Neuro Ret AFU ANOVA (5,20) 1.530 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
Mito rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.454 0.776 0.457 0.102 0.508 0.341 0.781 0.223 0.537 0.090 0.410 0.928
PSD 95 Ret AFU ANOVA (5,28) 1.900 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.654 0.041 0.347 0.050 0.347 0.049 0.850 0.113 0.293 0.028 0.446 0.115
NF l Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.029 0.938 0.023 0.369 0.011 0.556 0.002 0.040 0.001 0.820 0.890 0.263
MnSOD Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.727 0.003 0.193 0.193 0.074 0.112 0.540 0.026 0.393 0.006 0.211 0.169
3 Nitro Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL OPL ONL IPL INL GCL
rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet rHet vHet
Het 0.958 0.776 0.979 0.784 0.102 0.266 0.048 0.196 0.047 0.249 0.001 0.004
Western Blot Retina RD
Opa1   NeuroPreli   
F(3,12) 7.895 1.012 5.115
Mito rHet rHet rHet
Het 0.005 0.484 0.032
Western Blot Brain RD
Opa1   NeuroVDAC
F(3,12) 2.267 20.92 1.968
Mito rHet rHet rHet
Het 0.460 0.121 0.672
Brain  AFU Retina  AFU
F(5,75) 2.411 7.5
Mito rHet vHet Mito rHet vHet
Het 0.499 0.535 Het 0.250 0.098
Brain  AFU Retina  AFU
F (8,68) 5.957 2.39
Comp rHet vHet Comp rHet vHet
Het 0.014 0.017 Het 0.001 0.001
Brain  AFU Retina  AFU
F(5,75) 2.573 5.581
Dam rHet vHet Dam rHet vHet
Het 0.019 0.033 Het 0.019 0.033
Brain AFU
Brain AFUOpa1   VDAC   Preli   
F(5,30) 4.527 2.87 4.57
rHet vHet rHet vHet rHet vHet
Het 0.582 0.159 0.005 0.017 0.813 0.723
MnSOD 3Nitro
F(5,30) 6.910 7.919
rHet vHet rHet vHet
Het 0.006 0.745 0.001 0.001
Neuro Psd95 NF h
F(5,30) 4.527 2.454 2.983
rHet vHet rHet vHet rHet vHet
Het 0.001 0.054 0.001 0.761 0.635 0.001
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Summary of statistical analysis of WT res and veh WT Rotarod, Beam, Rope T maze 
and NOR. 
 
 
 
 
WT, res WT & veh WT: Weight Rotarod Beam, Rope, T Maze, NOR
Rotarod Latency to fall
RM  ANOVA (9,70) 2.554
rFWT vFWT rM WT
F WT 0.002 0.024
rFWT 0.785
vFWT
M WT 0.520
rM WT
Rotarod Latency:housing
RM ANOVA (3,32) 2.756
srMWT g MWT grMWT
sMWT 0.003 0.006
srMWT 0.002 0.839
g MWT 0.488
grMWT
Narrowbeam Initiation
ANOVA (15,80)5.403
rWT vWT
WT 0.004 0.380
rWT 0.017
vWT
Tight rope Distance
ANOVA (15,80)6.704
rWT vWT
WT 0.001 0.019
rWT 0.423
vWT
SHIRPA  ANOVA
LMF WT:rWT 0.074 F(3,23) 40.673
CSF WT:rWT 0.161 F(3,23) 24.738
Sen WT:rWT 0.053 F(3,23) 13.354
Npsy WT:rWT 0.074 F(3,23) 15.348
Auto WT:rWT 0.055 F(3,23) 33.889
T Maze To novel arm
 ANOVA (2,19) 4.639
rWT vWT
WT 0.037 0.540
rWT 0.061
vWT
T Maze  In novel arm
 ANOVA (2,19) 3.339
rWT vWT
WT 0.015 0.153
rWT 0.447
vWT
T Maze in Original arm
 ANOVA (2,19) 1.864
rWT vWT
WT 0.059 0.674
rWT 0.644
vWT
T Maze IR
 ANOVA (2,19)2.418
rWT vWT
WT 0.174 0.776
rWT 0.576
vWT
T Maze DR
 ANOVA(2,19) 6.708
rWT vWT
WT 0.004 0.268
rWT 0.351
vWT
NOR To Novel object
ANOVA (2,22) 8.106
rWT vWT
WT 0.001 0.011
rWT 0.562
vWT
NOR with Novel object
ANOVA (2,22) 4.117
rWT vWT
WT 0.010 0.024
rWT 0.840
vWT
NOR with Originalobject
ANOVA (2,22) 1.606
rWT vWT
WT 0.960 0.418
rWT 0.435
vWT
NOR IR
ANOVA (2,22) 2.254
rWT vWT
WT 0.144 0.706
rWT 0.578
vWT
NOR DR
ANOVA (2,22) 2.254
rWT vWT
WT 0.013 0.942
rWT 0.308
vWT
Weight/Body
ANOVA (11,161) 9.8
rFWT vFWT
F WT 0.001 0.525
rFWT 0.057
vFWT
Weight Brain
ANOVA (11,161) 2.722
rFWT vFWT
F WT 0.001 0.009
rFWT 0.421
vFWT
Weight/Cardiac
ANOVA (11,161) 1.945
rFWT vFWT
F WT 0.025 0.180
rFWT 0.006
vFWT
Weight/Housing Body
ANOVA (6,71) 12.283
srMWT grMWT
sMWT 0.786
srMWT 0.251
g MWT 0.017
grMWT
Weight/Housing Brain
ANOVA (6,71) 12.283
srMWT grMWT
sMWT 0.963
srMWT 0.015
g MWT 0.288
grMWT
Weight/Housing Cardiac
ANOVA (6,71) 12.283
srMWT grMWT
sMWT 0.343 0.450
srMWT 0.129
g MWT 0.336
grMWT
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Summary of statistical analysis of ETC in WT, res and veh WT, Antioxidant Catalase 
and SOD. 
  
 
 
 
 
 
ETC: CI Brain
ANOVA(5,38)25.123
rWT vWT
WT 0.002 0.001
rWT 0.001
vWT
ETC: CI SC
ANOVA(5,38)89.435
rWT vWT
WT 0.008 0.548
rWT 0.054
vWT
ETC: CI Ret
ANOVA(5,36)69.424
rWT vWT
WT 0.057 0.828
rWT 0.025
vWT
ETC: CI Muscle
ANOVA(5,17)66.414
rWT vWT
WT 0.014 0.001
rWT 0.153
vWT
ETC: CII  Brain
ANOVA(5,48) 55.804
rWT vWT
WT 0.012 0.001
rWT 0.001
vWT
ETC: CII SC
ANOVA(5,31) 54.260
rWT vWT
WT 0.030 0.527
rWT 0.007
vWT
ETC: CII Ret
ANOVA(5,36) 45.570
rWT vWT
WT 0.001 0.001
rWT 0.001
vWT
ETC: CII Muscle
ANOVA(5,17)4.374
rWT vWT
WT 0.146 0.148
rWT 0.914
vWT
ETC: CIV  Brain
ANOVA(5,35) 27.562
rWT vWT
WT 0.001 0.001
rWT 0.522
vWT
ETC: CIV SC
ANOVA(5,38) 42.356
rWT vWT
WT 0.001 0.001
rWT 0.926
vWT
ETC: CIV Ret
ANOVA(5,34) 8.631
rWT vWT
WT 0.001 0.010
rWT 0.113
vWT
ETC: CIV Muscle
ANOVA(5,16) 13.864
rWT vWT
F WT 0.172 0.007
rFWT 0.001
vFWT
ETC: Ratio  CI
ANOVA(5,48) 2.144
rWT vWT
Brain WT 0.180 0.793
SC WT 0.064 0.551
Ret WT 0.937 0.789
ETC: Ratio  CII
ANOVA(5,40) 45.389
rWT vWT
Brain WT 0.077 0.077
SC WT 0.012 0.179
Ret WT 0.538 0.178
ETC: Ratio  CIV
ANOVA(5,46) 38.685
rWT vWT
Brain WT 0.260 0.001
SC WT 0.001 0.200
Ret WT 0.001 0.001
ETC: Ratio  Skeletal Muscle
ANOVA(5,17) 11.87
rWT vWT
C I WT 0.009 0.462
C II WT 0.001 0.260
C IV WT 0.001 0.001
WT, res & veh WT : ETC CI, CII, CIV Brain, SC, Retina & Muscle 
WT, res & veh WT : SOD & Catalase
Catalase 
 Brain  SC Ret
F(5,31) 7.995 F(5,18) 10.902 F(3,10) 9.156
rWT vWT rWT vWT rWT vWT
WT 0.042 0.006 0.761 0.499 0.055
Total SOD
 Brain  SC Ret
F(5,12)32.4 F(5,12)105.3 F(5,12)8.8
rWT vWT rWT vWT rWT vWT
WT 0.146 0.007 0.007 0.077 0.981 0.004
MnSOD
 Brain  SC Ret
F(5,12)48.7 F(5,12)22.6 F(5,12)3.74
rWT vWT rWT vWT rWT vWT
WT 0.001 0.494 0.001 0.712 0.340 0.448
CuZnSOD
 Brain  SC Ret
F(5,12)3257.8 F(5,12)15.4 F(5,12)10.8
rWT vWT rWT vWT rWT vWT
WT 0.001 0.001 0.033 0.258 0.021 0.027
Non SOD
 Brain  SC Ret
F(5,28)23.3 F(5,20)19.78 F(5,24)1.60
rWT vWT rWT vWT rWT vWT
WT 0.006 0.416 0.013 0.001 0.372 0.842
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Summary of statistical analysis of WT, res and veh WT  IHC in retina & brain. Protein 
profiles for  mitochondria, compensation and damage profile in retina and brain. 
 
 
 
 
 
 
WT res WT & veh WT : IHC Retina &  Brain
Opa1   Ret AFU ANOVA (5,15) 3.865 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.546 0.213 0.789 0.780 0.215 0.840 0.204 0.974 0.281 0.070 0.197 0.251
VDAC   Ret AFU ANOVA (5,15) 10.47Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.062 0.001 0.242 0.425 0.001 0.006 0.814 0.746 0.354 0.309 0.782 0.648
Preli  Ret AFU ANOVA (5,21) 21.466Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.282 0.080 0.001 0.750 0.016 0.041 0.102 0.119 0.219 0.511 0.614 0.592
Neuro Ret AFU ANOVA (5,20) 1.530 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.408 0.240 0.817 0.814 0.562 0.732 0.962 0.732 0.405 0.402 0.452 0.652
PSD 95 Ret AFU ANOVA (5,28) 1.900 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.064 0.028 0.958 0.847 0.987 0.558 0.905 0.574 0.822 0.043 0.351 0.809
NF l Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.128 0.001 0.536 0.745 0.041 0.036 0.278 0.149 0.311 0.001 0.003 0.299
MnSOD Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.002 0.232 0.001 0.168 0.016 0.689 0.152 0.300 0.746 0.244 0.827 0.039
3 Nitro Ret AFU ANOVA (5,23) 8530 Post Hoc Tukey
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.222 0.204 0.007 0.062 0.669 0.136 0.205 0.039 0.031 0.032 0.327 0.449
Mito   Ret AFU ANOVA (5,16) 2.285
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.546 0.883 0.355 0.448 0.194 0.759 0.438 0.865 0.446 0.466 0.664 0.568
Comp   Ret AFU ANOVA (5,15) 10.47
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.888 0.697 0.340 0.765 0.329 0.723 0.337 0.867 0.350 0.586 0.944 0.202
Damage  Ret AFU ANOVA (5,21) 21.466
PRL ONL OPL INL IPL GCL
rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT rWT vWT
WT 0.559 0.253 0.315 0.670 0.025 0.019 0.005 0.015 0.529 0.195 0.775 0.915
Brain AFU
Brain AFUOpa1   VDAC   Preli   
F(5,30) 4.527 2.87 4.57
rWT vWT rWT vWT rWT vWT
WT 0.223 0.982 0.012 0.112 0.874 0.434
MnSOD 3Nitro
F(5,30) 6.910 7.919
rWT vWT rWT vWT
WT 0.014 0.162 0.162 0.181
Neuro Psd95 NF h
F(5,30) 4.527 2.454 2.983
rWT vWT rWT vWT rWT vWT
WT 0.001 0.575 0.267 0.530 0.182 0.301
Brain  AFU Retina  AFU
F(5,75) 2.411 7.5
Mito rWT vWT Mito rWT vWT
WT 0.033 0.745 WT 0.211 0.645
Brain  AFU Retina  AFU
F (8,68) 5.957 2.39
Comp rWT vWT Comp rWT vWT
WT 0.165 0.781 WT 0.511 0.069
Brain  AFU Retina  AFU
F(5,75) 2.573 5.581
Dam rWT vWT Dam rWT vWT
WT 0.001 0.340 WT 0.163 0.097
Western Blot Retina RD
Opa1   NeuroPreli   MnSOD
F(3,12) 7.895 1.012 5.115 6.199
rWT rWT rWT rWT
WT 0.008 0.128 0.128 0.709
Western Blot Brain RD
Opa1   NeuroVDAC MnSOD
F(3,12) 2.267 20.92 1.968 6.199
rWT rWT rWT rWT
WT 0.813 0.693 0.153 0.017
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Appendix  Y Summary of mouse ID and numbers used in this study 
 
 
Total  mouse numbers of 165 used in analysis of Opa1
Q285STOP 
mitochondrial profile. Untreated 
WT 34, untreated Het 47, resveratrol treated WT 26, resveratrol treated Het 27, vehicle treated 
WT 12 and vehicle treated Het 19. 
 
 
UNTREATED WT 34 UNTREATED HET 47 RESVERATROL  WT 26 RESVERATROL HET 27
M WT 10 F WT 24 M Het 23 F Het 24 rMWT 12 rFWT 14 rMHet 11 rFHet 16
1968 +/+ M 1976 +/+ F 1960 +/- M 1950 +/- F 1988 +/+ M 1986 +/+ F* 1980 +/- M 1983 +/- F
1969 +/+ M 1975 +/+ F 1967 +/- M 1955 +/- F 2069 +/+ M 1987 +/+ F 1994 +/- M 1984 +/- F
1995 +/+ M 1989 +/+ F 1981 +/- M 1956 +/- F 2072 +/+ M 1972 +/+ F 2070 +/- M 1998 +/- F
2005 +/+ M 1991 +/+ F 1993 +/- M 1957 +/- F 2084 +/+ M 2061 +/+ F 2073 +/- M 2066 +/- F
2017 +/+ M 1997 +/+ F 1999 +/- M 1959 +/- F 2085 +/+ M 2065 +/+ F 2083 +/- M 2067 +/- F
2018 +/+ M 2003 +/+ F 2000 +/- M 1962 +/- F 2086 +/+ M 2075 +/+ F 2086 +/- M 2074 +/- F
2019 +/+ M 2008 +/+ F 2001 +/- M 1963 +/- F 2110 +/+ M 2076 +/+ F 2109 +/- M 2081 +/- F
2024 +/+ M 2023 +/+ F 2004 +/- M 1964 +/- F 2148 +/+ M 2103 +/+ F 2168 +/- M 2104 +/- F
2030 +/+ M 2026 +/+ F 2006 +/- M 1965 +/- F 2159 +/+ M 2108 +/+ F 2173 +/- M 2107 +/- F
2056 +/+ M 2029 +/+ F 2007 +/- M 1970 +/- F 2169 +/+ M 2114 +/+ F 2174 +/- M 2105 +/- F
2031 +/+ F 2013 +/- M 1977 +/- F 2175 +/+ M 2115 +/+ F 2186 +/- M 2116 +/- F
2036 +/+ F 2014 +/- M 1990 +/- F 2184 +/+ M 2146 +/+ F 2145 +/- F
2037 +/+ F 2015 +/- M 2002 +/- F 2155 +/+ F 2147 +/- F
2041 +/+ F 2016 +/- M 2009 +/- F 2166 +/+ F 2156 +/- F
2042 +/+ F 2022 +/- M 2010 +/- F 2157 +/- F
2046 +/+ F 2027 +/- M 2011 +/- F 2158 +/- F
2050 +/+ F 2032 +/- M 2012 +/- F
2053 +/+ F 2035 +/- M 2025 +/- F
2054 +/+ F 2047 +/- M 2028 +/- F
2058 +/+ F 2051 +/- M 2033 +/- F
2062 +/+ F 2057 +/- M 2039 +/- F
2063 +/+ F 2059 +/- M 2040 +/- F
2064 +/+ F 2136 +/- M 2048 +/- F
2160 +/+ F 2141 +/- F
VEHICLE  WT 12 VEHICLE  HET 19
vMWT 6 vFWT 6 vMHet 8 vFHet 11
2130 +/+ M 2095 +/+ F 1982 +/- M 1985 +/- F
2131 +/+ M 2097 +/+ F 2132 +/- M 1992 +/- F WT 34 Het 47
2144 +/+ M 2119 +/+ F 2133 +/- M 2096 +/- F
2152 +/+ M 2125 +/+ F 2143 +/- M 2098 +/- F resWT 26 resHet 27
2154 +/+ M 2126 +/+ F 2151 +/- M 2120 +/- F
2161 +/+ M 2139 +/+ F 2153 +/- M 2121 +/- F vehWT 12 veh Het 19
2162 +/- M 2127 +/- F
2163 +/- M 2128 +/- F WT 72 Het 93
2138 +/- F
2149 +/- F Total number 165
2150 +/- F
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Appendix  Z Reagents 
 
Buffers reagents and concentrations used for isolation and analysis of mitochondrial 
bioenergetics 
 
 
 
 
Bioenergetic Assays (All buffers pretreated with Chelex overnight)
Mitochondrial Isolation Complex I (stock) Complex II (stock) Complex IV (stock) Cytochrome c reduction
Extraction buffer A PB 20mM pH7.4 PB 20mM pH 7.8 PB 10mMpH7.4
50mM HEPES pH7.5 NADH 100mM Succinate 1M n-Dodecyl-D-maltoside 10mMK2HPO4
1M Mannitol KCN 1M Decylub 40mM 10mMKH2PO4
350mM succrose CoenzymeQ1 40mM KCN 1M Cytochrome c 2mM Sephadex column
5mM EGTA DCPIP 16mM Ascorbate 100mM Add 1ml  2mM Cyto c to
Complex I assay Complex II assay Complex IV assay  :1ml 100mM Ascorbate
Extraction buffer B in 499l PB in 492.5l PB in 540l PB +0.005% nDodIncubate 5 mins RT
100mM MOPS pH 7.5 NADH 100M: 5l stock Succinate10M:50l stockCyto c 100M:30l stock Add to Sephadex column
550mM KCl KCN 1M: 5l stock Decylub100M:12.5lstock Wash with PB
5mM EGTA CQ1 40M: 1l stock KCN 2mM 10l stock Collect fractions (x4)
DCPIP 16M:5l stcok Dilute ~1:20
Storage Buffer Check absorbance
50mM HEPES pH 7.5 Store under Argon -80
o
C
1.25M sucrose
5mM ATP Complex I inhibition Complex II inhibition Complex IV inhibition
0.4mM ADT Rotenone 2mM stock TTFA 100mM stock KCN 200mM stock
25mM sodium succinate in 495l PB in 495l PB in 30l mito
10mM K2HPO4 Rotenone 2M:5l stock TTFE 100M:5l stock KCN20M:3l stock
Reagents SIGMA Reagents SIGMA Reagents SIGMA Reagents SIGMA Reagents SIGMA
Chelex  #95577 NADH  #N8129 DCPIP  #D1878 Cyto c  #C2506 Ascorbate  #95209
Dialysis tubing #D9277 KCN #31252 TTFA  #T27006 SephadexG100 #S6147
EGTA #E3889 CoQ1  #7959 Decylub # D7911
MOPS #M1254 Rotenone  #R8875
HEPES #H3375
Mannitol #M4125
Sucrose #S7903
KCL #P9333
ATP #A7699
ADP # A2754
Succinate #A5247
Potassium Dibasic #P3786
Potassium Monobasic #P5655
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Buffers reagents and concentrations used for analysis of antioxidant activity and protein 
chemistry 
 
Antioxidant assays Protein assays
CAT asssay SOD assay Western Blotting Immunohistochemistry
50mM KH2PO4 WST1+ O2
→formazan RIPA buffer PBS  1l pH 7.4
10.3mM H2O2 O2

xanthine 50mM TrisHCL  pH8.0 137mM NaCl
WST1+ O2
+SOD=↓formazan 150mM NaCl 2.7mM KCl
9.4 M H2O2 stock (30%) B1:formzan no inhibition 1% Igepal 10mM Na2HPO4
in 5ml PB B2: sample blank(no enzyme) 0.5% sodium deoxycholate 2mM KH2PO4
H2O2 10.3mM:5.47l stock B3: reagent blank(no enzyme) 0.1% SDS Sterilise by autoclave
e43.6 M-1 cm-1 SOD standard
Begin with 5mM KCN(CuZn inhibition) Running buffer 1l pH 8.3 PFA 4%pH 7.4 (hood)
H2O2 10.3mM: 5.4l stock 2% SDS(MnSOD inhibition) 125mM Tris Heat to 56
o
C
Check absorbance 240nm 1.25M glycine Continual stirring
A 240nm 0.449 =10.30mM 0.5% SDS Filter sterilise
if req adjust H2O2  content
Check absorbance 240nm Transfer Buffer 1l Blocking agent
48mN Tris HcL Goat serum 10%
Normal saline DNA extraction buffer 39mM Glycine Heat inactivate 56
o
C30min
0.9% NaCL 50mM NaOH 0.037% SDS Aliquot 100l -20oC
1l MQ water 1M Tris HCL pH 6.0 20% Methanol
Sterilise by autoclave
Gel reagents Endogenous Peroxidase
Reagents SIGMA Reagents SIGMA 1.5M Tris pH 8.0 (In safety hood)
Hydrogen peroxide #16911 SOD assay kit #19160 0.5M Tris pH 6.8 H2O2 3%
Catalase #C1345 Sodium hydroxide #306776 10% SDS 1.5ml of stock 30%
Hydrochloric acid #H1758 10% APS 3.5ml PBS
SDS #74255 TEMED 200l/slide
Reagents SIGMA Reagents SIGMA
Igepal # I8896 Paraformaldehyde #P6148
Tris-Glycine #T4904 NGS #G9023
Na deoxycholate # D6750
Methanol #322415
APS #A3678
TEMED #T9281
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